{"docstore/data": {"2be5c252-7555-49ff-bc1c-f643c74108ff": {"__data__": {"id_": "2be5c252-7555-49ff-bc1c-f643c74108ff", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Second Quar ter Results\n5/2/2023\nRevenue of $63.5 billion for the Second Quarter, a 9.9 Percent Increase Year-Over-Year\nSecond  Quarter GAAP Diluted EPS of $2.13 and Adjusted Diluted EPS of $3.50\nAdjusted Diluted EPS Guidance Range Raised to $11.70 to $11.90 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nsecond quarter ended March 31, 2023, revenue increased 9.9 percent year-over-year to $63.5 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.13 for the second quarter of fiscal 2023 compared to\n$2.59 in the prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 8.7 percent to $3.50 in the fiscal second quarter from $3.22 in the prior year second quarter.\n", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2023 Second Quar ter Results\n5/2/2023\nRevenue of $63.5 billion for the Second Quarter, a 9.9 Percent Increase Year-Over-Year\nSecond  Quarter GAAP Diluted EPS of $2.13 and Adjusted Diluted EPS of $3.50\nAdjusted Diluted EPS Guidance Range Raised to $11.70 to $11.90 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nsecond quarter ended March 31, 2023, revenue increased 9.9 percent year-over-year to $63.5 billion. ", "page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1be8a049-344b-4ace-8a28-85686b68389d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bed465940adc0fac679efb7b5d99c81faf46694c0310df3e63aa5f31e58f21b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "abfeb62b-55e3-4b4d-98a6-ff1f7837bd46", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Second Quar ter Results\n5/2/2023\nRevenue of $63.5 billion for the Second Quarter, a 9.9 Percent Increase Year-Over-Year\nSecond  Quarter GAAP Diluted EPS of $2.13 and Adjusted Diluted EPS of $3.50\nAdjusted Diluted EPS Guidance Range Raised to $11.70 to $11.90 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nsecond quarter ended March 31, 2023, revenue increased 9.9 percent year-over-year to $63.5 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.13 for the second quarter of fiscal 2023 compared to\n$2.59 in the prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 8.7 percent to $3.50 in the fiscal second quarter from $3.22 in the prior year second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023. ", "original_text": "On the basis of U.S. "}, "hash": "f9f0094808649b91ffcc99b2518bb99f7ab24fe514eb57031dc3ba32d9009c73", "class_name": "RelatedNodeInfo"}}, "text": "Amerisour ceBer gen R epor ts Fiscal 2023 Second Quar ter Results\n5/2/2023\nRevenue of $63.5 billion for the Second Quarter, a 9.9 Percent Increase Year-Over-Year\nSecond  Quarter GAAP Diluted EPS of $2.13 and Adjusted Diluted EPS of $3.50\nAdjusted Diluted EPS Guidance Range Raised to $11.70 to $11.90 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nsecond quarter ended March 31, 2023, revenue increased 9.9 percent year-over-year to $63.5 billion. ", "start_char_idx": 0, "end_char_idx": 540, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "abfeb62b-55e3-4b4d-98a6-ff1f7837bd46": {"__data__": {"id_": "abfeb62b-55e3-4b4d-98a6-ff1f7837bd46", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Second Quar ter Results\n5/2/2023\nRevenue of $63.5 billion for the Second Quarter, a 9.9 Percent Increase Year-Over-Year\nSecond  Quarter GAAP Diluted EPS of $2.13 and Adjusted Diluted EPS of $3.50\nAdjusted Diluted EPS Guidance Range Raised to $11.70 to $11.90 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nsecond quarter ended March 31, 2023, revenue increased 9.9 percent year-over-year to $63.5 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.13 for the second quarter of fiscal 2023 compared to\n$2.59 in the prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 8.7 percent to $3.50 in the fiscal second quarter from $3.22 in the prior year second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023. ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1be8a049-344b-4ace-8a28-85686b68389d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bed465940adc0fac679efb7b5d99c81faf46694c0310df3e63aa5f31e58f21b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2be5c252-7555-49ff-bc1c-f643c74108ff", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Second Quar ter Results\n5/2/2023\nRevenue of $63.5 billion for the Second Quarter, a 9.9 Percent Increase Year-Over-Year\nSecond  Quarter GAAP Diluted EPS of $2.13 and Adjusted Diluted EPS of $3.50\nAdjusted Diluted EPS Guidance Range Raised to $11.70 to $11.90 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nsecond quarter ended March 31, 2023, revenue increased 9.9 percent year-over-year to $63.5 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.13 for the second quarter of fiscal 2023 compared to\n$2.59 in the prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 8.7 percent to $3.50 in the fiscal second quarter from $3.22 in the prior year second quarter.\n", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2023 Second Quar ter Results\n5/2/2023\nRevenue of $63.5 billion for the Second Quarter, a 9.9 Percent Increase Year-Over-Year\nSecond  Quarter GAAP Diluted EPS of $2.13 and Adjusted Diluted EPS of $3.50\nAdjusted Diluted EPS Guidance Range Raised to $11.70 to $11.90 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nsecond quarter ended March 31, 2023, revenue increased 9.9 percent year-over-year to $63.5 billion. ", "page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df0eb9c0fa17d6f9c6460b4985e4f77eddccefb96744a052cec12b9605e9c364", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d885ad9-2d2e-4f7a-afd9-8b9dabb5c15a", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Second Quar ter Results\n5/2/2023\nRevenue of $63.5 billion for the Second Quarter, a 9.9 Percent Increase Year-Over-Year\nSecond  Quarter GAAP Diluted EPS of $2.13 and Adjusted Diluted EPS of $3.50\nAdjusted Diluted EPS Guidance Range Raised to $11.70 to $11.90 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nsecond quarter ended March 31, 2023, revenue increased 9.9 percent year-over-year to $63.5 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.13 for the second quarter of fiscal 2023 compared to\n$2.59 in the prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 8.7 percent to $3.50 in the fiscal second quarter from $3.22 in the prior year second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations. ", "original_text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.13 for the second quarter of fiscal 2023 compared to\n$2.59 in the prior year second quarter. "}, "hash": "583996d0a7550554fd8ef7fe8035a3ad45ebff3ba4d0a0dae0c2817ec5787488", "class_name": "RelatedNodeInfo"}}, "text": "On the basis of U.S. ", "start_char_idx": 540, "end_char_idx": 561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d885ad9-2d2e-4f7a-afd9-8b9dabb5c15a": {"__data__": {"id_": "7d885ad9-2d2e-4f7a-afd9-8b9dabb5c15a", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Second Quar ter Results\n5/2/2023\nRevenue of $63.5 billion for the Second Quarter, a 9.9 Percent Increase Year-Over-Year\nSecond  Quarter GAAP Diluted EPS of $2.13 and Adjusted Diluted EPS of $3.50\nAdjusted Diluted EPS Guidance Range Raised to $11.70 to $11.90 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nsecond quarter ended March 31, 2023, revenue increased 9.9 percent year-over-year to $63.5 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.13 for the second quarter of fiscal 2023 compared to\n$2.59 in the prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 8.7 percent to $3.50 in the fiscal second quarter from $3.22 in the prior year second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations. ", "original_text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.13 for the second quarter of fiscal 2023 compared to\n$2.59 in the prior year second quarter. ", "page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1be8a049-344b-4ace-8a28-85686b68389d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bed465940adc0fac679efb7b5d99c81faf46694c0310df3e63aa5f31e58f21b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "abfeb62b-55e3-4b4d-98a6-ff1f7837bd46", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Second Quar ter Results\n5/2/2023\nRevenue of $63.5 billion for the Second Quarter, a 9.9 Percent Increase Year-Over-Year\nSecond  Quarter GAAP Diluted EPS of $2.13 and Adjusted Diluted EPS of $3.50\nAdjusted Diluted EPS Guidance Range Raised to $11.70 to $11.90 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nsecond quarter ended March 31, 2023, revenue increased 9.9 percent year-over-year to $63.5 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.13 for the second quarter of fiscal 2023 compared to\n$2.59 in the prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 8.7 percent to $3.50 in the fiscal second quarter from $3.22 in the prior year second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023. ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec4f9774e67fadbed3450a1de7c17fb22a4bc4192ff6a2a41162520dd96333ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32fbe827-672d-4810-9e64-56b2bb44dd85", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Second Quar ter Results\n5/2/2023\nRevenue of $63.5 billion for the Second Quarter, a 9.9 Percent Increase Year-Over-Year\nSecond  Quarter GAAP Diluted EPS of $2.13 and Adjusted Diluted EPS of $3.50\nAdjusted Diluted EPS Guidance Range Raised to $11.70 to $11.90 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nsecond quarter ended March 31, 2023, revenue increased 9.9 percent year-over-year to $63.5 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.13 for the second quarter of fiscal 2023 compared to\n$2.59 in the prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 8.7 percent to $3.50 in the fiscal second quarter from $3.22 in the prior year second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.50 to $11.75 to a range of $11.70 to $11.90.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 8.7 percent to $3.50 in the fiscal second quarter from $3.22 in the prior year second quarter.\n"}, "hash": "36e122e9ca6cc0942e45f1e62fa1410044c2fad6ace8bf80648d11f3e95362ec", "class_name": "RelatedNodeInfo"}}, "text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.13 for the second quarter of fiscal 2023 compared to\n$2.59 in the prior year second quarter. ", "start_char_idx": 561, "end_char_idx": 743, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32fbe827-672d-4810-9e64-56b2bb44dd85": {"__data__": {"id_": "32fbe827-672d-4810-9e64-56b2bb44dd85", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Second Quar ter Results\n5/2/2023\nRevenue of $63.5 billion for the Second Quarter, a 9.9 Percent Increase Year-Over-Year\nSecond  Quarter GAAP Diluted EPS of $2.13 and Adjusted Diluted EPS of $3.50\nAdjusted Diluted EPS Guidance Range Raised to $11.70 to $11.90 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nsecond quarter ended March 31, 2023, revenue increased 9.9 percent year-over-year to $63.5 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.13 for the second quarter of fiscal 2023 compared to\n$2.59 in the prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 8.7 percent to $3.50 in the fiscal second quarter from $3.22 in the prior year second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.50 to $11.75 to a range of $11.70 to $11.90.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 8.7 percent to $3.50 in the fiscal second quarter from $3.22 in the prior year second quarter.\n", "page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1be8a049-344b-4ace-8a28-85686b68389d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bed465940adc0fac679efb7b5d99c81faf46694c0310df3e63aa5f31e58f21b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d885ad9-2d2e-4f7a-afd9-8b9dabb5c15a", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Second Quar ter Results\n5/2/2023\nRevenue of $63.5 billion for the Second Quarter, a 9.9 Percent Increase Year-Over-Year\nSecond  Quarter GAAP Diluted EPS of $2.13 and Adjusted Diluted EPS of $3.50\nAdjusted Diluted EPS Guidance Range Raised to $11.70 to $11.90 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nsecond quarter ended March 31, 2023, revenue increased 9.9 percent year-over-year to $63.5 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.13 for the second quarter of fiscal 2023 compared to\n$2.59 in the prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 8.7 percent to $3.50 in the fiscal second quarter from $3.22 in the prior year second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations. ", "original_text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.13 for the second quarter of fiscal 2023 compared to\n$2.59 in the prior year second quarter. ", "page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bbbd927b8ff10e012458ad9caa6ad4858d9c74c022dad0f824f18a73e14303a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58388f55-3720-4b1c-800a-248f0bc82fb9", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.13 for the second quarter of fiscal 2023 compared to\n$2.59 in the prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 8.7 percent to $3.50 in the fiscal second quarter from $3.22 in the prior year second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.50 to $11.75 to a range of $11.70 to $11.90.\n \u201cIn our second quarter, AmerisourceBergen continued executing to deliver strong financial performance while advancing our\nstrategic priorities and pursuing thoughtful capital deployment, like our recently announced agreement to invest in OneOncology.\n", "original_text": "AmerisourceBergen is updating its outlook for fiscal year 2023. "}, "hash": "35a691032324c50176d5deecdc7588eae365dbe732e012cbf661238ea6e45302", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 8.7 percent to $3.50 in the fiscal second quarter from $3.22 in the prior year second quarter.\n", "start_char_idx": 743, "end_char_idx": 945, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58388f55-3720-4b1c-800a-248f0bc82fb9": {"__data__": {"id_": "58388f55-3720-4b1c-800a-248f0bc82fb9", "embedding": null, "metadata": {"window": "On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.13 for the second quarter of fiscal 2023 compared to\n$2.59 in the prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 8.7 percent to $3.50 in the fiscal second quarter from $3.22 in the prior year second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.50 to $11.75 to a range of $11.70 to $11.90.\n \u201cIn our second quarter, AmerisourceBergen continued executing to deliver strong financial performance while advancing our\nstrategic priorities and pursuing thoughtful capital deployment, like our recently announced agreement to invest in OneOncology.\n", "original_text": "AmerisourceBergen is updating its outlook for fiscal year 2023. ", "page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1be8a049-344b-4ace-8a28-85686b68389d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bed465940adc0fac679efb7b5d99c81faf46694c0310df3e63aa5f31e58f21b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32fbe827-672d-4810-9e64-56b2bb44dd85", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Second Quar ter Results\n5/2/2023\nRevenue of $63.5 billion for the Second Quarter, a 9.9 Percent Increase Year-Over-Year\nSecond  Quarter GAAP Diluted EPS of $2.13 and Adjusted Diluted EPS of $3.50\nAdjusted Diluted EPS Guidance Range Raised to $11.70 to $11.90 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nsecond quarter ended March 31, 2023, revenue increased 9.9 percent year-over-year to $63.5 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.13 for the second quarter of fiscal 2023 compared to\n$2.59 in the prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 8.7 percent to $3.50 in the fiscal second quarter from $3.22 in the prior year second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.50 to $11.75 to a range of $11.70 to $11.90.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 8.7 percent to $3.50 in the fiscal second quarter from $3.22 in the prior year second quarter.\n", "page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2fe399b183cbd33c285a535d60abe9691b62a53cdced35049cd454c6c3c8385", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5cbce75-cbf0-41a8-8ccb-2bbbf0831c30", "node_type": "1", "metadata": {"window": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.13 for the second quarter of fiscal 2023 compared to\n$2.59 in the prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 8.7 percent to $3.50 in the fiscal second quarter from $3.22 in the prior year second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.50 to $11.75 to a range of $11.70 to $11.90.\n \u201cIn our second quarter, AmerisourceBergen continued executing to deliver strong financial performance while advancing our\nstrategic priorities and pursuing thoughtful capital deployment, like our recently announced agreement to invest in OneOncology.\n The fundamental strength and resilience of our business continue to allow us to capitalize on opportunities provided by our\ncapabilities, while focusing on efficiency and advancing innovation across our footprint,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n", "original_text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations. "}, "hash": "49deb07730e7a98f9781f699864bf362fb4b8804ecd4d79be394b10e9bc49ee8", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen is updating its outlook for fiscal year 2023. ", "start_char_idx": 945, "end_char_idx": 1009, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5cbce75-cbf0-41a8-8ccb-2bbbf0831c30": {"__data__": {"id_": "e5cbce75-cbf0-41a8-8ccb-2bbbf0831c30", "embedding": null, "metadata": {"window": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.13 for the second quarter of fiscal 2023 compared to\n$2.59 in the prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 8.7 percent to $3.50 in the fiscal second quarter from $3.22 in the prior year second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.50 to $11.75 to a range of $11.70 to $11.90.\n \u201cIn our second quarter, AmerisourceBergen continued executing to deliver strong financial performance while advancing our\nstrategic priorities and pursuing thoughtful capital deployment, like our recently announced agreement to invest in OneOncology.\n The fundamental strength and resilience of our business continue to allow us to capitalize on opportunities provided by our\ncapabilities, while focusing on efficiency and advancing innovation across our footprint,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n", "original_text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations. ", "page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1be8a049-344b-4ace-8a28-85686b68389d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bed465940adc0fac679efb7b5d99c81faf46694c0310df3e63aa5f31e58f21b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58388f55-3720-4b1c-800a-248f0bc82fb9", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.13 for the second quarter of fiscal 2023 compared to\n$2.59 in the prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 8.7 percent to $3.50 in the fiscal second quarter from $3.22 in the prior year second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.50 to $11.75 to a range of $11.70 to $11.90.\n \u201cIn our second quarter, AmerisourceBergen continued executing to deliver strong financial performance while advancing our\nstrategic priorities and pursuing thoughtful capital deployment, like our recently announced agreement to invest in OneOncology.\n", "original_text": "AmerisourceBergen is updating its outlook for fiscal year 2023. ", "page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ccaeef1b13473af9a257aab9f767f85b3e85adffe2e2605dd9ddab69657b0f4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df4eda42-e666-4ace-9b30-17df1f1a338d", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 8.7 percent to $3.50 in the fiscal second quarter from $3.22 in the prior year second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.50 to $11.75 to a range of $11.70 to $11.90.\n \u201cIn our second quarter, AmerisourceBergen continued executing to deliver strong financial performance while advancing our\nstrategic priorities and pursuing thoughtful capital deployment, like our recently announced agreement to invest in OneOncology.\n The fundamental strength and resilience of our business continue to allow us to capitalize on opportunities provided by our\ncapabilities, while focusing on efficiency and advancing innovation across our footprint,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cAs we move into the second half of our fiscal year, we are pleased to raise our full year financial outlook,\u201d Mr. ", "original_text": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.50 to $11.75 to a range of $11.70 to $11.90.\n"}, "hash": "d87291e6355743b1de3a8d5a151909d8c3fa18f30761545a5c520717283ed108", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations. ", "start_char_idx": 1009, "end_char_idx": 1133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df4eda42-e666-4ace-9b30-17df1f1a338d": {"__data__": {"id_": "df4eda42-e666-4ace-9b30-17df1f1a338d", "embedding": null, "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 8.7 percent to $3.50 in the fiscal second quarter from $3.22 in the prior year second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.50 to $11.75 to a range of $11.70 to $11.90.\n \u201cIn our second quarter, AmerisourceBergen continued executing to deliver strong financial performance while advancing our\nstrategic priorities and pursuing thoughtful capital deployment, like our recently announced agreement to invest in OneOncology.\n The fundamental strength and resilience of our business continue to allow us to capitalize on opportunities provided by our\ncapabilities, while focusing on efficiency and advancing innovation across our footprint,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cAs we move into the second half of our fiscal year, we are pleased to raise our full year financial outlook,\u201d Mr. ", "original_text": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.50 to $11.75 to a range of $11.70 to $11.90.\n", "page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1be8a049-344b-4ace-8a28-85686b68389d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bed465940adc0fac679efb7b5d99c81faf46694c0310df3e63aa5f31e58f21b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5cbce75-cbf0-41a8-8ccb-2bbbf0831c30", "node_type": "1", "metadata": {"window": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.13 for the second quarter of fiscal 2023 compared to\n$2.59 in the prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 8.7 percent to $3.50 in the fiscal second quarter from $3.22 in the prior year second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.50 to $11.75 to a range of $11.70 to $11.90.\n \u201cIn our second quarter, AmerisourceBergen continued executing to deliver strong financial performance while advancing our\nstrategic priorities and pursuing thoughtful capital deployment, like our recently announced agreement to invest in OneOncology.\n The fundamental strength and resilience of our business continue to allow us to capitalize on opportunities provided by our\ncapabilities, while focusing on efficiency and advancing innovation across our footprint,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n", "original_text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations. ", "page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ac9e9fcb28e2f26e01d0b6ab21e64abe0ffa25e77456927c890fc8dd1bb0a33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d741694b-cb99-4ac4-851c-763703850446", "node_type": "1", "metadata": {"window": "AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.50 to $11.75 to a range of $11.70 to $11.90.\n \u201cIn our second quarter, AmerisourceBergen continued executing to deliver strong financial performance while advancing our\nstrategic priorities and pursuing thoughtful capital deployment, like our recently announced agreement to invest in OneOncology.\n The fundamental strength and resilience of our business continue to allow us to capitalize on opportunities provided by our\ncapabilities, while focusing on efficiency and advancing innovation across our footprint,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cAs we move into the second half of our fiscal year, we are pleased to raise our full year financial outlook,\u201d Mr.  Collis continued. ", "original_text": "\u201cIn our second quarter, AmerisourceBergen continued executing to deliver strong financial performance while advancing our\nstrategic priorities and pursuing thoughtful capital deployment, like our recently announced agreement to invest in OneOncology.\n"}, "hash": "be41719e415d7e9541c77c3dc4b5ae489d0b07a3c6b4ef510973038e62e12d6b", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.50 to $11.75 to a range of $11.70 to $11.90.\n", "start_char_idx": 1133, "end_char_idx": 1255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d741694b-cb99-4ac4-851c-763703850446": {"__data__": {"id_": "d741694b-cb99-4ac4-851c-763703850446", "embedding": null, "metadata": {"window": "AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.50 to $11.75 to a range of $11.70 to $11.90.\n \u201cIn our second quarter, AmerisourceBergen continued executing to deliver strong financial performance while advancing our\nstrategic priorities and pursuing thoughtful capital deployment, like our recently announced agreement to invest in OneOncology.\n The fundamental strength and resilience of our business continue to allow us to capitalize on opportunities provided by our\ncapabilities, while focusing on efficiency and advancing innovation across our footprint,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cAs we move into the second half of our fiscal year, we are pleased to raise our full year financial outlook,\u201d Mr.  Collis continued. ", "original_text": "\u201cIn our second quarter, AmerisourceBergen continued executing to deliver strong financial performance while advancing our\nstrategic priorities and pursuing thoughtful capital deployment, like our recently announced agreement to invest in OneOncology.\n", "page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1be8a049-344b-4ace-8a28-85686b68389d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bed465940adc0fac679efb7b5d99c81faf46694c0310df3e63aa5f31e58f21b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df4eda42-e666-4ace-9b30-17df1f1a338d", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 8.7 percent to $3.50 in the fiscal second quarter from $3.22 in the prior year second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.50 to $11.75 to a range of $11.70 to $11.90.\n \u201cIn our second quarter, AmerisourceBergen continued executing to deliver strong financial performance while advancing our\nstrategic priorities and pursuing thoughtful capital deployment, like our recently announced agreement to invest in OneOncology.\n The fundamental strength and resilience of our business continue to allow us to capitalize on opportunities provided by our\ncapabilities, while focusing on efficiency and advancing innovation across our footprint,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cAs we move into the second half of our fiscal year, we are pleased to raise our full year financial outlook,\u201d Mr. ", "original_text": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.50 to $11.75 to a range of $11.70 to $11.90.\n", "page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "133d05c095f2b501ed64427193493c6f7569a477e3cf58211bf306076ed67d26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ff5b05b-d238-46ac-abee-d4af7f7f08e9", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.50 to $11.75 to a range of $11.70 to $11.90.\n \u201cIn our second quarter, AmerisourceBergen continued executing to deliver strong financial performance while advancing our\nstrategic priorities and pursuing thoughtful capital deployment, like our recently announced agreement to invest in OneOncology.\n The fundamental strength and resilience of our business continue to allow us to capitalize on opportunities provided by our\ncapabilities, while focusing on efficiency and advancing innovation across our footprint,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cAs we move into the second half of our fiscal year, we are pleased to raise our full year financial outlook,\u201d Mr.  Collis continued.  \u201cOur\nresults and the increase in our full-year outlook continue to demonstrate the value of our pharmaceutical-centric strategy, key\nstrategic partnerships, leadership in specialty and global commercialization services.\u201d\nSecond Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $63.5B $63.5B\nGross Pr ofit $2.3B $2.4B\nOperating Expenses $1.7B $1.4B\nOperating Income $561M $932M\nInterest Expense, Net $64M $64M\n1", "original_text": "The fundamental strength and resilience of our business continue to allow us to capitalize on opportunities provided by our\ncapabilities, while focusing on efficiency and advancing innovation across our footprint,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n"}, "hash": "1e40e56b91971e9a076f2e6d037654ca360ac9a4ef989add7af7fb77690233cb", "class_name": "RelatedNodeInfo"}}, "text": "\u201cIn our second quarter, AmerisourceBergen continued executing to deliver strong financial performance while advancing our\nstrategic priorities and pursuing thoughtful capital deployment, like our recently announced agreement to invest in OneOncology.\n", "start_char_idx": 1255, "end_char_idx": 1506, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ff5b05b-d238-46ac-abee-d4af7f7f08e9": {"__data__": {"id_": "9ff5b05b-d238-46ac-abee-d4af7f7f08e9", "embedding": null, "metadata": {"window": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.50 to $11.75 to a range of $11.70 to $11.90.\n \u201cIn our second quarter, AmerisourceBergen continued executing to deliver strong financial performance while advancing our\nstrategic priorities and pursuing thoughtful capital deployment, like our recently announced agreement to invest in OneOncology.\n The fundamental strength and resilience of our business continue to allow us to capitalize on opportunities provided by our\ncapabilities, while focusing on efficiency and advancing innovation across our footprint,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cAs we move into the second half of our fiscal year, we are pleased to raise our full year financial outlook,\u201d Mr.  Collis continued.  \u201cOur\nresults and the increase in our full-year outlook continue to demonstrate the value of our pharmaceutical-centric strategy, key\nstrategic partnerships, leadership in specialty and global commercialization services.\u201d\nSecond Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $63.5B $63.5B\nGross Pr ofit $2.3B $2.4B\nOperating Expenses $1.7B $1.4B\nOperating Income $561M $932M\nInterest Expense, Net $64M $64M\n1", "original_text": "The fundamental strength and resilience of our business continue to allow us to capitalize on opportunities provided by our\ncapabilities, while focusing on efficiency and advancing innovation across our footprint,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n", "page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1be8a049-344b-4ace-8a28-85686b68389d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bed465940adc0fac679efb7b5d99c81faf46694c0310df3e63aa5f31e58f21b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d741694b-cb99-4ac4-851c-763703850446", "node_type": "1", "metadata": {"window": "AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.50 to $11.75 to a range of $11.70 to $11.90.\n \u201cIn our second quarter, AmerisourceBergen continued executing to deliver strong financial performance while advancing our\nstrategic priorities and pursuing thoughtful capital deployment, like our recently announced agreement to invest in OneOncology.\n The fundamental strength and resilience of our business continue to allow us to capitalize on opportunities provided by our\ncapabilities, while focusing on efficiency and advancing innovation across our footprint,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cAs we move into the second half of our fiscal year, we are pleased to raise our full year financial outlook,\u201d Mr.  Collis continued. ", "original_text": "\u201cIn our second quarter, AmerisourceBergen continued executing to deliver strong financial performance while advancing our\nstrategic priorities and pursuing thoughtful capital deployment, like our recently announced agreement to invest in OneOncology.\n", "page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c7c110ffa11b413dff52303258b8daab2247fbd0e0f66bf6120bc5b740fbc82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b6835bb-c491-4995-8485-6fbfe7ce1c4f", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.50 to $11.75 to a range of $11.70 to $11.90.\n \u201cIn our second quarter, AmerisourceBergen continued executing to deliver strong financial performance while advancing our\nstrategic priorities and pursuing thoughtful capital deployment, like our recently announced agreement to invest in OneOncology.\n The fundamental strength and resilience of our business continue to allow us to capitalize on opportunities provided by our\ncapabilities, while focusing on efficiency and advancing innovation across our footprint,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cAs we move into the second half of our fiscal year, we are pleased to raise our full year financial outlook,\u201d Mr.  Collis continued.  \u201cOur\nresults and the increase in our full-year outlook continue to demonstrate the value of our pharmaceutical-centric strategy, key\nstrategic partnerships, leadership in specialty and global commercialization services.\u201d\nSecond Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $63.5B $63.5B\nGross Pr ofit $2.3B $2.4B\nOperating Expenses $1.7B $1.4B\nOperating Income $561M $932M\nInterest Expense, Net $64M $64M\n1", "original_text": "\u201cAs we move into the second half of our fiscal year, we are pleased to raise our full year financial outlook,\u201d Mr. "}, "hash": "ebd0c5d19166908f50c68b80f9f8bed3d47a38108a08fb3ed76ae43b156d8a42", "class_name": "RelatedNodeInfo"}}, "text": "The fundamental strength and resilience of our business continue to allow us to capitalize on opportunities provided by our\ncapabilities, while focusing on efficiency and advancing innovation across our footprint,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n", "start_char_idx": 1506, "end_char_idx": 1812, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b6835bb-c491-4995-8485-6fbfe7ce1c4f": {"__data__": {"id_": "2b6835bb-c491-4995-8485-6fbfe7ce1c4f", "embedding": null, "metadata": {"window": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.50 to $11.75 to a range of $11.70 to $11.90.\n \u201cIn our second quarter, AmerisourceBergen continued executing to deliver strong financial performance while advancing our\nstrategic priorities and pursuing thoughtful capital deployment, like our recently announced agreement to invest in OneOncology.\n The fundamental strength and resilience of our business continue to allow us to capitalize on opportunities provided by our\ncapabilities, while focusing on efficiency and advancing innovation across our footprint,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cAs we move into the second half of our fiscal year, we are pleased to raise our full year financial outlook,\u201d Mr.  Collis continued.  \u201cOur\nresults and the increase in our full-year outlook continue to demonstrate the value of our pharmaceutical-centric strategy, key\nstrategic partnerships, leadership in specialty and global commercialization services.\u201d\nSecond Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $63.5B $63.5B\nGross Pr ofit $2.3B $2.4B\nOperating Expenses $1.7B $1.4B\nOperating Income $561M $932M\nInterest Expense, Net $64M $64M\n1", "original_text": "\u201cAs we move into the second half of our fiscal year, we are pleased to raise our full year financial outlook,\u201d Mr. ", "page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1be8a049-344b-4ace-8a28-85686b68389d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bed465940adc0fac679efb7b5d99c81faf46694c0310df3e63aa5f31e58f21b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ff5b05b-d238-46ac-abee-d4af7f7f08e9", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.50 to $11.75 to a range of $11.70 to $11.90.\n \u201cIn our second quarter, AmerisourceBergen continued executing to deliver strong financial performance while advancing our\nstrategic priorities and pursuing thoughtful capital deployment, like our recently announced agreement to invest in OneOncology.\n The fundamental strength and resilience of our business continue to allow us to capitalize on opportunities provided by our\ncapabilities, while focusing on efficiency and advancing innovation across our footprint,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cAs we move into the second half of our fiscal year, we are pleased to raise our full year financial outlook,\u201d Mr.  Collis continued.  \u201cOur\nresults and the increase in our full-year outlook continue to demonstrate the value of our pharmaceutical-centric strategy, key\nstrategic partnerships, leadership in specialty and global commercialization services.\u201d\nSecond Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $63.5B $63.5B\nGross Pr ofit $2.3B $2.4B\nOperating Expenses $1.7B $1.4B\nOperating Income $561M $932M\nInterest Expense, Net $64M $64M\n1", "original_text": "The fundamental strength and resilience of our business continue to allow us to capitalize on opportunities provided by our\ncapabilities, while focusing on efficiency and advancing innovation across our footprint,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n", "page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "204b6536b338798f89e93f4cf4b9dededae6b28f3bf508556b301d3662aa597b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "644503db-33c0-4041-81b5-ecaaf4301ea4", "node_type": "1", "metadata": {"window": "\u201cIn our second quarter, AmerisourceBergen continued executing to deliver strong financial performance while advancing our\nstrategic priorities and pursuing thoughtful capital deployment, like our recently announced agreement to invest in OneOncology.\n The fundamental strength and resilience of our business continue to allow us to capitalize on opportunities provided by our\ncapabilities, while focusing on efficiency and advancing innovation across our footprint,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cAs we move into the second half of our fiscal year, we are pleased to raise our full year financial outlook,\u201d Mr.  Collis continued.  \u201cOur\nresults and the increase in our full-year outlook continue to demonstrate the value of our pharmaceutical-centric strategy, key\nstrategic partnerships, leadership in specialty and global commercialization services.\u201d\nSecond Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $63.5B $63.5B\nGross Pr ofit $2.3B $2.4B\nOperating Expenses $1.7B $1.4B\nOperating Income $561M $932M\nInterest Expense, Net $64M $64M\n1", "original_text": "Collis continued. "}, "hash": "2e4117ca7f40a07f1980e7ac1a18a49ce5246cdd87fe081a7f4dae7e277501c1", "class_name": "RelatedNodeInfo"}}, "text": "\u201cAs we move into the second half of our fiscal year, we are pleased to raise our full year financial outlook,\u201d Mr. ", "start_char_idx": 1812, "end_char_idx": 1927, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "644503db-33c0-4041-81b5-ecaaf4301ea4": {"__data__": {"id_": "644503db-33c0-4041-81b5-ecaaf4301ea4", "embedding": null, "metadata": {"window": "\u201cIn our second quarter, AmerisourceBergen continued executing to deliver strong financial performance while advancing our\nstrategic priorities and pursuing thoughtful capital deployment, like our recently announced agreement to invest in OneOncology.\n The fundamental strength and resilience of our business continue to allow us to capitalize on opportunities provided by our\ncapabilities, while focusing on efficiency and advancing innovation across our footprint,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cAs we move into the second half of our fiscal year, we are pleased to raise our full year financial outlook,\u201d Mr.  Collis continued.  \u201cOur\nresults and the increase in our full-year outlook continue to demonstrate the value of our pharmaceutical-centric strategy, key\nstrategic partnerships, leadership in specialty and global commercialization services.\u201d\nSecond Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $63.5B $63.5B\nGross Pr ofit $2.3B $2.4B\nOperating Expenses $1.7B $1.4B\nOperating Income $561M $932M\nInterest Expense, Net $64M $64M\n1", "original_text": "Collis continued. ", "page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1be8a049-344b-4ace-8a28-85686b68389d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bed465940adc0fac679efb7b5d99c81faf46694c0310df3e63aa5f31e58f21b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b6835bb-c491-4995-8485-6fbfe7ce1c4f", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.50 to $11.75 to a range of $11.70 to $11.90.\n \u201cIn our second quarter, AmerisourceBergen continued executing to deliver strong financial performance while advancing our\nstrategic priorities and pursuing thoughtful capital deployment, like our recently announced agreement to invest in OneOncology.\n The fundamental strength and resilience of our business continue to allow us to capitalize on opportunities provided by our\ncapabilities, while focusing on efficiency and advancing innovation across our footprint,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cAs we move into the second half of our fiscal year, we are pleased to raise our full year financial outlook,\u201d Mr.  Collis continued.  \u201cOur\nresults and the increase in our full-year outlook continue to demonstrate the value of our pharmaceutical-centric strategy, key\nstrategic partnerships, leadership in specialty and global commercialization services.\u201d\nSecond Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $63.5B $63.5B\nGross Pr ofit $2.3B $2.4B\nOperating Expenses $1.7B $1.4B\nOperating Income $561M $932M\nInterest Expense, Net $64M $64M\n1", "original_text": "\u201cAs we move into the second half of our fiscal year, we are pleased to raise our full year financial outlook,\u201d Mr. ", "page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f847fe29dcc5973707c3cdbf6c57d58c474af9402e0133377ee786340e9e9ff9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c17ba48c-7ab4-45f6-941e-b116774ef499", "node_type": "1", "metadata": {"window": "The fundamental strength and resilience of our business continue to allow us to capitalize on opportunities provided by our\ncapabilities, while focusing on efficiency and advancing innovation across our footprint,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cAs we move into the second half of our fiscal year, we are pleased to raise our full year financial outlook,\u201d Mr.  Collis continued.  \u201cOur\nresults and the increase in our full-year outlook continue to demonstrate the value of our pharmaceutical-centric strategy, key\nstrategic partnerships, leadership in specialty and global commercialization services.\u201d\nSecond Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $63.5B $63.5B\nGross Pr ofit $2.3B $2.4B\nOperating Expenses $1.7B $1.4B\nOperating Income $561M $932M\nInterest Expense, Net $64M $64M\n1", "original_text": "\u201cOur\nresults and the increase in our full-year outlook continue to demonstrate the value of our pharmaceutical-centric strategy, key\nstrategic partnerships, leadership in specialty and global commercialization services.\u201d\nSecond Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $63.5B $63.5B\nGross Pr ofit $2.3B $2.4B\nOperating Expenses $1.7B $1.4B\nOperating Income $561M $932M\nInterest Expense, Net $64M $64M\n1"}, "hash": "b5130ebaf26c7e0820277aeedb6e2e64a289413e7f680d9273063c04be0825ac", "class_name": "RelatedNodeInfo"}}, "text": "Collis continued. ", "start_char_idx": 1927, "end_char_idx": 1945, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c17ba48c-7ab4-45f6-941e-b116774ef499": {"__data__": {"id_": "c17ba48c-7ab4-45f6-941e-b116774ef499", "embedding": null, "metadata": {"window": "The fundamental strength and resilience of our business continue to allow us to capitalize on opportunities provided by our\ncapabilities, while focusing on efficiency and advancing innovation across our footprint,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cAs we move into the second half of our fiscal year, we are pleased to raise our full year financial outlook,\u201d Mr.  Collis continued.  \u201cOur\nresults and the increase in our full-year outlook continue to demonstrate the value of our pharmaceutical-centric strategy, key\nstrategic partnerships, leadership in specialty and global commercialization services.\u201d\nSecond Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $63.5B $63.5B\nGross Pr ofit $2.3B $2.4B\nOperating Expenses $1.7B $1.4B\nOperating Income $561M $932M\nInterest Expense, Net $64M $64M\n1", "original_text": "\u201cOur\nresults and the increase in our full-year outlook continue to demonstrate the value of our pharmaceutical-centric strategy, key\nstrategic partnerships, leadership in specialty and global commercialization services.\u201d\nSecond Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $63.5B $63.5B\nGross Pr ofit $2.3B $2.4B\nOperating Expenses $1.7B $1.4B\nOperating Income $561M $932M\nInterest Expense, Net $64M $64M\n1", "page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1be8a049-344b-4ace-8a28-85686b68389d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bed465940adc0fac679efb7b5d99c81faf46694c0310df3e63aa5f31e58f21b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "644503db-33c0-4041-81b5-ecaaf4301ea4", "node_type": "1", "metadata": {"window": "\u201cIn our second quarter, AmerisourceBergen continued executing to deliver strong financial performance while advancing our\nstrategic priorities and pursuing thoughtful capital deployment, like our recently announced agreement to invest in OneOncology.\n The fundamental strength and resilience of our business continue to allow us to capitalize on opportunities provided by our\ncapabilities, while focusing on efficiency and advancing innovation across our footprint,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cAs we move into the second half of our fiscal year, we are pleased to raise our full year financial outlook,\u201d Mr.  Collis continued.  \u201cOur\nresults and the increase in our full-year outlook continue to demonstrate the value of our pharmaceutical-centric strategy, key\nstrategic partnerships, leadership in specialty and global commercialization services.\u201d\nSecond Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $63.5B $63.5B\nGross Pr ofit $2.3B $2.4B\nOperating Expenses $1.7B $1.4B\nOperating Income $561M $932M\nInterest Expense, Net $64M $64M\n1", "original_text": "Collis continued. ", "page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ca633a9fde7ff0424d40bc1f4ef3837d215896e9471ed961ef9dc6ab6a5b595", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3bbdac0f-2d1d-480d-b4b8-e9b9a75e3c70", "node_type": "1", "metadata": {"window": "Effectiv e Tax Rat e 16.4% 19.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $435M $715M\nDilut ed Earnings P er Shar e $2.13 $3.50\nDilut ed Shar es Outstanding 204.3M 204.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2023, revenue was $63.5 billion, up 9.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 11.3 percent increase in revenue within U.S. ", "original_text": "Effectiv e Tax Rat e 16.4% 19.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $435M $715M\nDilut ed Earnings P er Shar e $2.13 $3.50\nDilut ed Shar es Outstanding 204.3M 204.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. "}, "hash": "0085a5eabc095fd46b38322372b1157289b38b9f092d93b8daadb26ce2cfceeb", "class_name": "RelatedNodeInfo"}}, "text": "\u201cOur\nresults and the increase in our full-year outlook continue to demonstrate the value of our pharmaceutical-centric strategy, key\nstrategic partnerships, leadership in specialty and global commercialization services.\u201d\nSecond Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $63.5B $63.5B\nGross Pr ofit $2.3B $2.4B\nOperating Expenses $1.7B $1.4B\nOperating Income $561M $932M\nInterest Expense, Net $64M $64M\n1", "start_char_idx": 1945, "end_char_idx": 2386, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3bbdac0f-2d1d-480d-b4b8-e9b9a75e3c70": {"__data__": {"id_": "3bbdac0f-2d1d-480d-b4b8-e9b9a75e3c70", "embedding": null, "metadata": {"window": "Effectiv e Tax Rat e 16.4% 19.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $435M $715M\nDilut ed Earnings P er Shar e $2.13 $3.50\nDilut ed Shar es Outstanding 204.3M 204.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2023, revenue was $63.5 billion, up 9.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 11.3 percent increase in revenue within U.S. ", "original_text": "Effectiv e Tax Rat e 16.4% 19.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $435M $715M\nDilut ed Earnings P er Shar e $2.13 $3.50\nDilut ed Shar es Outstanding 204.3M 204.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "810ee5449df3bbe01a568dbcaf7420159f455a328608181c691320da66b22a01", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c17ba48c-7ab4-45f6-941e-b116774ef499", "node_type": "1", "metadata": {"window": "The fundamental strength and resilience of our business continue to allow us to capitalize on opportunities provided by our\ncapabilities, while focusing on efficiency and advancing innovation across our footprint,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cAs we move into the second half of our fiscal year, we are pleased to raise our full year financial outlook,\u201d Mr.  Collis continued.  \u201cOur\nresults and the increase in our full-year outlook continue to demonstrate the value of our pharmaceutical-centric strategy, key\nstrategic partnerships, leadership in specialty and global commercialization services.\u201d\nSecond Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $63.5B $63.5B\nGross Pr ofit $2.3B $2.4B\nOperating Expenses $1.7B $1.4B\nOperating Income $561M $932M\nInterest Expense, Net $64M $64M\n1", "original_text": "\u201cOur\nresults and the increase in our full-year outlook continue to demonstrate the value of our pharmaceutical-centric strategy, key\nstrategic partnerships, leadership in specialty and global commercialization services.\u201d\nSecond Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $63.5B $63.5B\nGross Pr ofit $2.3B $2.4B\nOperating Expenses $1.7B $1.4B\nOperating Income $561M $932M\nInterest Expense, Net $64M $64M\n1", "page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "69c656810f6cc2936b6629ff1efac9226961b4e490e399ef36b00aae4dd11214", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5de0544-2670-4070-b748-6e5c09d0e2da", "node_type": "1", "metadata": {"window": "Effectiv e Tax Rat e 16.4% 19.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $435M $715M\nDilut ed Earnings P er Shar e $2.13 $3.50\nDilut ed Shar es Outstanding 204.3M 204.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2023, revenue was $63.5 billion, up 9.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 11.3 percent increase in revenue within U.S.  Healthcare Solutions. ", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. "}, "hash": "347006f1fce97b0b9baf5c775083b05e506eeb8f0f933c1ac0cd19605f1044db", "class_name": "RelatedNodeInfo"}}, "text": "Effectiv e Tax Rat e 16.4% 19.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $435M $715M\nDilut ed Earnings P er Shar e $2.13 $3.50\nDilut ed Shar es Outstanding 204.3M 204.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "start_char_idx": 0, "end_char_idx": 312, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5de0544-2670-4070-b748-6e5c09d0e2da": {"__data__": {"id_": "e5de0544-2670-4070-b748-6e5c09d0e2da", "embedding": null, "metadata": {"window": "Effectiv e Tax Rat e 16.4% 19.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $435M $715M\nDilut ed Earnings P er Shar e $2.13 $3.50\nDilut ed Shar es Outstanding 204.3M 204.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2023, revenue was $63.5 billion, up 9.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 11.3 percent increase in revenue within U.S.  Healthcare Solutions. ", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "810ee5449df3bbe01a568dbcaf7420159f455a328608181c691320da66b22a01", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3bbdac0f-2d1d-480d-b4b8-e9b9a75e3c70", "node_type": "1", "metadata": {"window": "Effectiv e Tax Rat e 16.4% 19.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $435M $715M\nDilut ed Earnings P er Shar e $2.13 $3.50\nDilut ed Shar es Outstanding 204.3M 204.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2023, revenue was $63.5 billion, up 9.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 11.3 percent increase in revenue within U.S. ", "original_text": "Effectiv e Tax Rat e 16.4% 19.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $435M $715M\nDilut ed Earnings P er Shar e $2.13 $3.50\nDilut ed Shar es Outstanding 204.3M 204.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "234835ce1f0b816c8920a6fa830d63d63061ea394ddb736c21233b351c4cc135", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f564c843-b5ae-4ccc-8766-a774aa292514", "node_type": "1", "metadata": {"window": "Effectiv e Tax Rat e 16.4% 19.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $435M $715M\nDilut ed Earnings P er Shar e $2.13 $3.50\nDilut ed Shar es Outstanding 204.3M 204.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2023, revenue was $63.5 billion, up 9.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 11.3 percent increase in revenue within U.S.  Healthcare Solutions.  International Healthcare\nSolutions revenue declined 0.2 percent primarily resulting from the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.\n", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n"}, "hash": "bc1212be268f8bd2f9d2affd84b3032252e271ce8375481045fb0704c2efbc97", "class_name": "RelatedNodeInfo"}}, "text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "start_char_idx": 312, "end_char_idx": 404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f564c843-b5ae-4ccc-8766-a774aa292514": {"__data__": {"id_": "f564c843-b5ae-4ccc-8766-a774aa292514", "embedding": null, "metadata": {"window": "Effectiv e Tax Rat e 16.4% 19.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $435M $715M\nDilut ed Earnings P er Shar e $2.13 $3.50\nDilut ed Shar es Outstanding 204.3M 204.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2023, revenue was $63.5 billion, up 9.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 11.3 percent increase in revenue within U.S.  Healthcare Solutions.  International Healthcare\nSolutions revenue declined 0.2 percent primarily resulting from the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.\n", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "810ee5449df3bbe01a568dbcaf7420159f455a328608181c691320da66b22a01", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5de0544-2670-4070-b748-6e5c09d0e2da", "node_type": "1", "metadata": {"window": "Effectiv e Tax Rat e 16.4% 19.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $435M $715M\nDilut ed Earnings P er Shar e $2.13 $3.50\nDilut ed Shar es Outstanding 204.3M 204.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2023, revenue was $63.5 billion, up 9.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 11.3 percent increase in revenue within U.S.  Healthcare Solutions. ", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "808fb0ca87d29c6072555e28d6e71fc8258eccb71f8c2f6d4e46ea165110351b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e8b6623-9569-4ae0-98eb-b7fa51c5ffb2", "node_type": "1", "metadata": {"window": "Effectiv e Tax Rat e 16.4% 19.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $435M $715M\nDilut ed Earnings P er Shar e $2.13 $3.50\nDilut ed Shar es Outstanding 204.3M 204.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2023, revenue was $63.5 billion, up 9.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 11.3 percent increase in revenue within U.S.  Healthcare Solutions.  International Healthcare\nSolutions revenue declined 0.2 percent primarily resulting from the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.\n Gross Profit:  Gross profit in the second quarter of fiscal 2023 was $2.3 billion, a 2.7 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in both reportable segments. ", "original_text": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2023, revenue was $63.5 billion, up 9.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 11.3 percent increase in revenue within U.S. "}, "hash": "96a965a9d9368ad12179928c8f5f2be18a61f18cea78c01cac327f5850cf6586", "class_name": "RelatedNodeInfo"}}, "text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n", "start_char_idx": 404, "end_char_idx": 626, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e8b6623-9569-4ae0-98eb-b7fa51c5ffb2": {"__data__": {"id_": "4e8b6623-9569-4ae0-98eb-b7fa51c5ffb2", "embedding": null, "metadata": {"window": "Effectiv e Tax Rat e 16.4% 19.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $435M $715M\nDilut ed Earnings P er Shar e $2.13 $3.50\nDilut ed Shar es Outstanding 204.3M 204.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2023, revenue was $63.5 billion, up 9.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 11.3 percent increase in revenue within U.S.  Healthcare Solutions.  International Healthcare\nSolutions revenue declined 0.2 percent primarily resulting from the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.\n Gross Profit:  Gross profit in the second quarter of fiscal 2023 was $2.3 billion, a 2.7 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in both reportable segments. ", "original_text": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2023, revenue was $63.5 billion, up 9.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 11.3 percent increase in revenue within U.S. ", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "810ee5449df3bbe01a568dbcaf7420159f455a328608181c691320da66b22a01", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f564c843-b5ae-4ccc-8766-a774aa292514", "node_type": "1", "metadata": {"window": "Effectiv e Tax Rat e 16.4% 19.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $435M $715M\nDilut ed Earnings P er Shar e $2.13 $3.50\nDilut ed Shar es Outstanding 204.3M 204.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2023, revenue was $63.5 billion, up 9.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 11.3 percent increase in revenue within U.S.  Healthcare Solutions.  International Healthcare\nSolutions revenue declined 0.2 percent primarily resulting from the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.\n", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2d289f7983568edb487387053964228be1b91a89d35df5e3ba0f60d189e000d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1fe8d39a-2f83-4084-9bd6-5a8fe30d4c55", "node_type": "1", "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2023, revenue was $63.5 billion, up 9.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 11.3 percent increase in revenue within U.S.  Healthcare Solutions.  International Healthcare\nSolutions revenue declined 0.2 percent primarily resulting from the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.\n Gross Profit:  Gross profit in the second quarter of fiscal 2023 was $2.3 billion, a 2.7 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in both reportable segments.  The increase in gross profit\nwas offset in part by a LIFO expense in the current year period versus a LIFO credit in the previous fiscal year period. ", "original_text": "Healthcare Solutions. "}, "hash": "9f027edaccbb74f4b273dbce5fee3742c9d480f744a997a6efa1fdabcc3840a0", "class_name": "RelatedNodeInfo"}}, "text": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2023, revenue was $63.5 billion, up 9.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 11.3 percent increase in revenue within U.S. ", "start_char_idx": 626, "end_char_idx": 863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1fe8d39a-2f83-4084-9bd6-5a8fe30d4c55": {"__data__": {"id_": "1fe8d39a-2f83-4084-9bd6-5a8fe30d4c55", "embedding": null, "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2023, revenue was $63.5 billion, up 9.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 11.3 percent increase in revenue within U.S.  Healthcare Solutions.  International Healthcare\nSolutions revenue declined 0.2 percent primarily resulting from the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.\n Gross Profit:  Gross profit in the second quarter of fiscal 2023 was $2.3 billion, a 2.7 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in both reportable segments.  The increase in gross profit\nwas offset in part by a LIFO expense in the current year period versus a LIFO credit in the previous fiscal year period. ", "original_text": "Healthcare Solutions. ", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "810ee5449df3bbe01a568dbcaf7420159f455a328608181c691320da66b22a01", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e8b6623-9569-4ae0-98eb-b7fa51c5ffb2", "node_type": "1", "metadata": {"window": "Effectiv e Tax Rat e 16.4% 19.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $435M $715M\nDilut ed Earnings P er Shar e $2.13 $3.50\nDilut ed Shar es Outstanding 204.3M 204.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2023, revenue was $63.5 billion, up 9.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 11.3 percent increase in revenue within U.S.  Healthcare Solutions.  International Healthcare\nSolutions revenue declined 0.2 percent primarily resulting from the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.\n Gross Profit:  Gross profit in the second quarter of fiscal 2023 was $2.3 billion, a 2.7 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in both reportable segments. ", "original_text": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2023, revenue was $63.5 billion, up 9.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 11.3 percent increase in revenue within U.S. ", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "33c25c423a569e2ee1babaa1cc6e79e5d3223a2ef4bf445230d9f7cac7b084ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9019e039-d6a4-4fd2-93c9-ac4a1b3c633c", "node_type": "1", "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2023, revenue was $63.5 billion, up 9.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 11.3 percent increase in revenue within U.S.  Healthcare Solutions.  International Healthcare\nSolutions revenue declined 0.2 percent primarily resulting from the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.\n Gross Profit:  Gross profit in the second quarter of fiscal 2023 was $2.3 billion, a 2.7 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in both reportable segments.  The increase in gross profit\nwas offset in part by a LIFO expense in the current year period versus a LIFO credit in the previous fiscal year period.  Gross\nprofit as a percentage of revenue was 3.62 percent, a decrease of 25 basis points from the prior year quarter.\n", "original_text": "International Healthcare\nSolutions revenue declined 0.2 percent primarily resulting from the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.\n"}, "hash": "4c954e6df7af63092033872fe045d251402e788969012bdc9b78c588b21bb92e", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions. ", "start_char_idx": 863, "end_char_idx": 885, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9019e039-d6a4-4fd2-93c9-ac4a1b3c633c": {"__data__": {"id_": "9019e039-d6a4-4fd2-93c9-ac4a1b3c633c", "embedding": null, "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2023, revenue was $63.5 billion, up 9.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 11.3 percent increase in revenue within U.S.  Healthcare Solutions.  International Healthcare\nSolutions revenue declined 0.2 percent primarily resulting from the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.\n Gross Profit:  Gross profit in the second quarter of fiscal 2023 was $2.3 billion, a 2.7 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in both reportable segments.  The increase in gross profit\nwas offset in part by a LIFO expense in the current year period versus a LIFO credit in the previous fiscal year period.  Gross\nprofit as a percentage of revenue was 3.62 percent, a decrease of 25 basis points from the prior year quarter.\n", "original_text": "International Healthcare\nSolutions revenue declined 0.2 percent primarily resulting from the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "810ee5449df3bbe01a568dbcaf7420159f455a328608181c691320da66b22a01", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1fe8d39a-2f83-4084-9bd6-5a8fe30d4c55", "node_type": "1", "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2023, revenue was $63.5 billion, up 9.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 11.3 percent increase in revenue within U.S.  Healthcare Solutions.  International Healthcare\nSolutions revenue declined 0.2 percent primarily resulting from the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.\n Gross Profit:  Gross profit in the second quarter of fiscal 2023 was $2.3 billion, a 2.7 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in both reportable segments.  The increase in gross profit\nwas offset in part by a LIFO expense in the current year period versus a LIFO credit in the previous fiscal year period. ", "original_text": "Healthcare Solutions. ", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e777f104bbbcf3bd726b5526af6e1914a89f145edb3c4c3627bdbecaeabe65d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "266653f0-f52f-4023-863a-7154f6ab1155", "node_type": "1", "metadata": {"window": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2023, revenue was $63.5 billion, up 9.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 11.3 percent increase in revenue within U.S.  Healthcare Solutions.  International Healthcare\nSolutions revenue declined 0.2 percent primarily resulting from the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.\n Gross Profit:  Gross profit in the second quarter of fiscal 2023 was $2.3 billion, a 2.7 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in both reportable segments.  The increase in gross profit\nwas offset in part by a LIFO expense in the current year period versus a LIFO credit in the previous fiscal year period.  Gross\nprofit as a percentage of revenue was 3.62 percent, a decrease of 25 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2023, operating expenses were $1.7 billion, a 19.2 percent increase\ncompared to the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and\nadministrative expenses, restructuring and other expenses, and depreciation and amortization expenses compared to the\nprior year quarter.\n", "original_text": "Gross Profit:  Gross profit in the second quarter of fiscal 2023 was $2.3 billion, a 2.7 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in both reportable segments. "}, "hash": "ee7f7793e21de5868ace4092fc9f5f6d38edc2cfbbf306d68bceb29c03b6212e", "class_name": "RelatedNodeInfo"}}, "text": "International Healthcare\nSolutions revenue declined 0.2 percent primarily resulting from the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.\n", "start_char_idx": 885, "end_char_idx": 1150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "266653f0-f52f-4023-863a-7154f6ab1155": {"__data__": {"id_": "266653f0-f52f-4023-863a-7154f6ab1155", "embedding": null, "metadata": {"window": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2023, revenue was $63.5 billion, up 9.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 11.3 percent increase in revenue within U.S.  Healthcare Solutions.  International Healthcare\nSolutions revenue declined 0.2 percent primarily resulting from the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.\n Gross Profit:  Gross profit in the second quarter of fiscal 2023 was $2.3 billion, a 2.7 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in both reportable segments.  The increase in gross profit\nwas offset in part by a LIFO expense in the current year period versus a LIFO credit in the previous fiscal year period.  Gross\nprofit as a percentage of revenue was 3.62 percent, a decrease of 25 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2023, operating expenses were $1.7 billion, a 19.2 percent increase\ncompared to the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and\nadministrative expenses, restructuring and other expenses, and depreciation and amortization expenses compared to the\nprior year quarter.\n", "original_text": "Gross Profit:  Gross profit in the second quarter of fiscal 2023 was $2.3 billion, a 2.7 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in both reportable segments. ", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "810ee5449df3bbe01a568dbcaf7420159f455a328608181c691320da66b22a01", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9019e039-d6a4-4fd2-93c9-ac4a1b3c633c", "node_type": "1", "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2023, revenue was $63.5 billion, up 9.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 11.3 percent increase in revenue within U.S.  Healthcare Solutions.  International Healthcare\nSolutions revenue declined 0.2 percent primarily resulting from the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.\n Gross Profit:  Gross profit in the second quarter of fiscal 2023 was $2.3 billion, a 2.7 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in both reportable segments.  The increase in gross profit\nwas offset in part by a LIFO expense in the current year period versus a LIFO credit in the previous fiscal year period.  Gross\nprofit as a percentage of revenue was 3.62 percent, a decrease of 25 basis points from the prior year quarter.\n", "original_text": "International Healthcare\nSolutions revenue declined 0.2 percent primarily resulting from the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "577c8475eafed08ede79a028c21a67ac39000308ff267ebb9c481c20a40b1b55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9238917-5bc2-4e91-b85d-af881ebba971", "node_type": "1", "metadata": {"window": "Healthcare Solutions.  International Healthcare\nSolutions revenue declined 0.2 percent primarily resulting from the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.\n Gross Profit:  Gross profit in the second quarter of fiscal 2023 was $2.3 billion, a 2.7 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in both reportable segments.  The increase in gross profit\nwas offset in part by a LIFO expense in the current year period versus a LIFO credit in the previous fiscal year period.  Gross\nprofit as a percentage of revenue was 3.62 percent, a decrease of 25 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2023, operating expenses were $1.7 billion, a 19.2 percent increase\ncompared to the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and\nadministrative expenses, restructuring and other expenses, and depreciation and amortization expenses compared to the\nprior year quarter.\n Operating Income:  In the second quarter of fiscal 2023, operating income was $560.5 million, a 28.2 percent decrease\ncompared to the same period in the previous fiscal year due to the increase in operating expenses, offset in part by the\nincrease in gross profit. ", "original_text": "The increase in gross profit\nwas offset in part by a LIFO expense in the current year period versus a LIFO credit in the previous fiscal year period. "}, "hash": "00c6066e6b752f6666b9232f2f2093ac34d2fe409cd11c2d1ceb0532b584bf7f", "class_name": "RelatedNodeInfo"}}, "text": "Gross Profit:  Gross profit in the second quarter of fiscal 2023 was $2.3 billion, a 2.7 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in both reportable segments. ", "start_char_idx": 1150, "end_char_idx": 1376, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9238917-5bc2-4e91-b85d-af881ebba971": {"__data__": {"id_": "c9238917-5bc2-4e91-b85d-af881ebba971", "embedding": null, "metadata": {"window": "Healthcare Solutions.  International Healthcare\nSolutions revenue declined 0.2 percent primarily resulting from the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.\n Gross Profit:  Gross profit in the second quarter of fiscal 2023 was $2.3 billion, a 2.7 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in both reportable segments.  The increase in gross profit\nwas offset in part by a LIFO expense in the current year period versus a LIFO credit in the previous fiscal year period.  Gross\nprofit as a percentage of revenue was 3.62 percent, a decrease of 25 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2023, operating expenses were $1.7 billion, a 19.2 percent increase\ncompared to the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and\nadministrative expenses, restructuring and other expenses, and depreciation and amortization expenses compared to the\nprior year quarter.\n Operating Income:  In the second quarter of fiscal 2023, operating income was $560.5 million, a 28.2 percent decrease\ncompared to the same period in the previous fiscal year due to the increase in operating expenses, offset in part by the\nincrease in gross profit. ", "original_text": "The increase in gross profit\nwas offset in part by a LIFO expense in the current year period versus a LIFO credit in the previous fiscal year period. ", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "810ee5449df3bbe01a568dbcaf7420159f455a328608181c691320da66b22a01", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "266653f0-f52f-4023-863a-7154f6ab1155", "node_type": "1", "metadata": {"window": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2023, revenue was $63.5 billion, up 9.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 11.3 percent increase in revenue within U.S.  Healthcare Solutions.  International Healthcare\nSolutions revenue declined 0.2 percent primarily resulting from the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.\n Gross Profit:  Gross profit in the second quarter of fiscal 2023 was $2.3 billion, a 2.7 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in both reportable segments.  The increase in gross profit\nwas offset in part by a LIFO expense in the current year period versus a LIFO credit in the previous fiscal year period.  Gross\nprofit as a percentage of revenue was 3.62 percent, a decrease of 25 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2023, operating expenses were $1.7 billion, a 19.2 percent increase\ncompared to the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and\nadministrative expenses, restructuring and other expenses, and depreciation and amortization expenses compared to the\nprior year quarter.\n", "original_text": "Gross Profit:  Gross profit in the second quarter of fiscal 2023 was $2.3 billion, a 2.7 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in both reportable segments. ", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1cd6d0b3ca0506a141b3c8d3644c4e9763f624598481f4acc1d740f35de3c4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76185ba7-db6a-49af-b34e-c4148db1778d", "node_type": "1", "metadata": {"window": "International Healthcare\nSolutions revenue declined 0.2 percent primarily resulting from the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.\n Gross Profit:  Gross profit in the second quarter of fiscal 2023 was $2.3 billion, a 2.7 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in both reportable segments.  The increase in gross profit\nwas offset in part by a LIFO expense in the current year period versus a LIFO credit in the previous fiscal year period.  Gross\nprofit as a percentage of revenue was 3.62 percent, a decrease of 25 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2023, operating expenses were $1.7 billion, a 19.2 percent increase\ncompared to the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and\nadministrative expenses, restructuring and other expenses, and depreciation and amortization expenses compared to the\nprior year quarter.\n Operating Income:  In the second quarter of fiscal 2023, operating income was $560.5 million, a 28.2 percent decrease\ncompared to the same period in the previous fiscal year due to the increase in operating expenses, offset in part by the\nincrease in gross profit.  Operating income as a percentage of revenue was 0.88 percent in the second quarter of fiscal 2023, a\ndecline of 47 basis points when compared to the prior year quarter.\n", "original_text": "Gross\nprofit as a percentage of revenue was 3.62 percent, a decrease of 25 basis points from the prior year quarter.\n"}, "hash": "50bd655e035fa59858f3ba5e1a38bdfd671d1e7a745c87c4aa0f9707ff1d5b64", "class_name": "RelatedNodeInfo"}}, "text": "The increase in gross profit\nwas offset in part by a LIFO expense in the current year period versus a LIFO credit in the previous fiscal year period. ", "start_char_idx": 1376, "end_char_idx": 1526, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76185ba7-db6a-49af-b34e-c4148db1778d": {"__data__": {"id_": "76185ba7-db6a-49af-b34e-c4148db1778d", "embedding": null, "metadata": {"window": "International Healthcare\nSolutions revenue declined 0.2 percent primarily resulting from the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.\n Gross Profit:  Gross profit in the second quarter of fiscal 2023 was $2.3 billion, a 2.7 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in both reportable segments.  The increase in gross profit\nwas offset in part by a LIFO expense in the current year period versus a LIFO credit in the previous fiscal year period.  Gross\nprofit as a percentage of revenue was 3.62 percent, a decrease of 25 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2023, operating expenses were $1.7 billion, a 19.2 percent increase\ncompared to the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and\nadministrative expenses, restructuring and other expenses, and depreciation and amortization expenses compared to the\nprior year quarter.\n Operating Income:  In the second quarter of fiscal 2023, operating income was $560.5 million, a 28.2 percent decrease\ncompared to the same period in the previous fiscal year due to the increase in operating expenses, offset in part by the\nincrease in gross profit.  Operating income as a percentage of revenue was 0.88 percent in the second quarter of fiscal 2023, a\ndecline of 47 basis points when compared to the prior year quarter.\n", "original_text": "Gross\nprofit as a percentage of revenue was 3.62 percent, a decrease of 25 basis points from the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "810ee5449df3bbe01a568dbcaf7420159f455a328608181c691320da66b22a01", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9238917-5bc2-4e91-b85d-af881ebba971", "node_type": "1", "metadata": {"window": "Healthcare Solutions.  International Healthcare\nSolutions revenue declined 0.2 percent primarily resulting from the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.\n Gross Profit:  Gross profit in the second quarter of fiscal 2023 was $2.3 billion, a 2.7 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in both reportable segments.  The increase in gross profit\nwas offset in part by a LIFO expense in the current year period versus a LIFO credit in the previous fiscal year period.  Gross\nprofit as a percentage of revenue was 3.62 percent, a decrease of 25 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2023, operating expenses were $1.7 billion, a 19.2 percent increase\ncompared to the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and\nadministrative expenses, restructuring and other expenses, and depreciation and amortization expenses compared to the\nprior year quarter.\n Operating Income:  In the second quarter of fiscal 2023, operating income was $560.5 million, a 28.2 percent decrease\ncompared to the same period in the previous fiscal year due to the increase in operating expenses, offset in part by the\nincrease in gross profit. ", "original_text": "The increase in gross profit\nwas offset in part by a LIFO expense in the current year period versus a LIFO credit in the previous fiscal year period. ", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa1c1fd43ee5acf3400d21d0f9db793aad4355805cdb24dae37c6449986e1f25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a4d5613-6a63-4969-aabb-7f163240ad47", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the second quarter of fiscal 2023 was $2.3 billion, a 2.7 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in both reportable segments.  The increase in gross profit\nwas offset in part by a LIFO expense in the current year period versus a LIFO credit in the previous fiscal year period.  Gross\nprofit as a percentage of revenue was 3.62 percent, a decrease of 25 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2023, operating expenses were $1.7 billion, a 19.2 percent increase\ncompared to the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and\nadministrative expenses, restructuring and other expenses, and depreciation and amortization expenses compared to the\nprior year quarter.\n Operating Income:  In the second quarter of fiscal 2023, operating income was $560.5 million, a 28.2 percent decrease\ncompared to the same period in the previous fiscal year due to the increase in operating expenses, offset in part by the\nincrease in gross profit.  Operating income as a percentage of revenue was 0.88 percent in the second quarter of fiscal 2023, a\ndecline of 47 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the second quarter of fiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus\nthe prior year quarter primarily due to increases in borrowings and interest rates associated with variable-rate debt, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n", "original_text": "Operating Expenses:  In the second quarter of fiscal 2023, operating expenses were $1.7 billion, a 19.2 percent increase\ncompared to the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and\nadministrative expenses, restructuring and other expenses, and depreciation and amortization expenses compared to the\nprior year quarter.\n"}, "hash": "6989a7010bd168ca8476b65aac6583a2231c30c00b5d5e2d09ca3eb7aaf4c403", "class_name": "RelatedNodeInfo"}}, "text": "Gross\nprofit as a percentage of revenue was 3.62 percent, a decrease of 25 basis points from the prior year quarter.\n", "start_char_idx": 1526, "end_char_idx": 1643, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a4d5613-6a63-4969-aabb-7f163240ad47": {"__data__": {"id_": "5a4d5613-6a63-4969-aabb-7f163240ad47", "embedding": null, "metadata": {"window": "Gross Profit:  Gross profit in the second quarter of fiscal 2023 was $2.3 billion, a 2.7 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in both reportable segments.  The increase in gross profit\nwas offset in part by a LIFO expense in the current year period versus a LIFO credit in the previous fiscal year period.  Gross\nprofit as a percentage of revenue was 3.62 percent, a decrease of 25 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2023, operating expenses were $1.7 billion, a 19.2 percent increase\ncompared to the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and\nadministrative expenses, restructuring and other expenses, and depreciation and amortization expenses compared to the\nprior year quarter.\n Operating Income:  In the second quarter of fiscal 2023, operating income was $560.5 million, a 28.2 percent decrease\ncompared to the same period in the previous fiscal year due to the increase in operating expenses, offset in part by the\nincrease in gross profit.  Operating income as a percentage of revenue was 0.88 percent in the second quarter of fiscal 2023, a\ndecline of 47 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the second quarter of fiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus\nthe prior year quarter primarily due to increases in borrowings and interest rates associated with variable-rate debt, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n", "original_text": "Operating Expenses:  In the second quarter of fiscal 2023, operating expenses were $1.7 billion, a 19.2 percent increase\ncompared to the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and\nadministrative expenses, restructuring and other expenses, and depreciation and amortization expenses compared to the\nprior year quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "810ee5449df3bbe01a568dbcaf7420159f455a328608181c691320da66b22a01", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76185ba7-db6a-49af-b34e-c4148db1778d", "node_type": "1", "metadata": {"window": "International Healthcare\nSolutions revenue declined 0.2 percent primarily resulting from the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.\n Gross Profit:  Gross profit in the second quarter of fiscal 2023 was $2.3 billion, a 2.7 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in both reportable segments.  The increase in gross profit\nwas offset in part by a LIFO expense in the current year period versus a LIFO credit in the previous fiscal year period.  Gross\nprofit as a percentage of revenue was 3.62 percent, a decrease of 25 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2023, operating expenses were $1.7 billion, a 19.2 percent increase\ncompared to the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and\nadministrative expenses, restructuring and other expenses, and depreciation and amortization expenses compared to the\nprior year quarter.\n Operating Income:  In the second quarter of fiscal 2023, operating income was $560.5 million, a 28.2 percent decrease\ncompared to the same period in the previous fiscal year due to the increase in operating expenses, offset in part by the\nincrease in gross profit.  Operating income as a percentage of revenue was 0.88 percent in the second quarter of fiscal 2023, a\ndecline of 47 basis points when compared to the prior year quarter.\n", "original_text": "Gross\nprofit as a percentage of revenue was 3.62 percent, a decrease of 25 basis points from the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4a3d76f44e8dfef9bdb4d3dfa3e93dafa7ab70381642f0586f4594ef640e9509", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19f5dc5d-443a-4f1e-927c-2675277b362a", "node_type": "1", "metadata": {"window": "The increase in gross profit\nwas offset in part by a LIFO expense in the current year period versus a LIFO credit in the previous fiscal year period.  Gross\nprofit as a percentage of revenue was 3.62 percent, a decrease of 25 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2023, operating expenses were $1.7 billion, a 19.2 percent increase\ncompared to the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and\nadministrative expenses, restructuring and other expenses, and depreciation and amortization expenses compared to the\nprior year quarter.\n Operating Income:  In the second quarter of fiscal 2023, operating income was $560.5 million, a 28.2 percent decrease\ncompared to the same period in the previous fiscal year due to the increase in operating expenses, offset in part by the\nincrease in gross profit.  Operating income as a percentage of revenue was 0.88 percent in the second quarter of fiscal 2023, a\ndecline of 47 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the second quarter of fiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus\nthe prior year quarter primarily due to increases in borrowings and interest rates associated with variable-rate debt, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 16.4 percent for the second quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income and discrete tax benefits. ", "original_text": "Operating Income:  In the second quarter of fiscal 2023, operating income was $560.5 million, a 28.2 percent decrease\ncompared to the same period in the previous fiscal year due to the increase in operating expenses, offset in part by the\nincrease in gross profit. "}, "hash": "de4e987261ea0635e393f75e48e63f769f60553d44221c5bd5198915641fa999", "class_name": "RelatedNodeInfo"}}, "text": "Operating Expenses:  In the second quarter of fiscal 2023, operating expenses were $1.7 billion, a 19.2 percent increase\ncompared to the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and\nadministrative expenses, restructuring and other expenses, and depreciation and amortization expenses compared to the\nprior year quarter.\n", "start_char_idx": 1643, "end_char_idx": 2019, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19f5dc5d-443a-4f1e-927c-2675277b362a": {"__data__": {"id_": "19f5dc5d-443a-4f1e-927c-2675277b362a", "embedding": null, "metadata": {"window": "The increase in gross profit\nwas offset in part by a LIFO expense in the current year period versus a LIFO credit in the previous fiscal year period.  Gross\nprofit as a percentage of revenue was 3.62 percent, a decrease of 25 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2023, operating expenses were $1.7 billion, a 19.2 percent increase\ncompared to the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and\nadministrative expenses, restructuring and other expenses, and depreciation and amortization expenses compared to the\nprior year quarter.\n Operating Income:  In the second quarter of fiscal 2023, operating income was $560.5 million, a 28.2 percent decrease\ncompared to the same period in the previous fiscal year due to the increase in operating expenses, offset in part by the\nincrease in gross profit.  Operating income as a percentage of revenue was 0.88 percent in the second quarter of fiscal 2023, a\ndecline of 47 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the second quarter of fiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus\nthe prior year quarter primarily due to increases in borrowings and interest rates associated with variable-rate debt, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 16.4 percent for the second quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income and discrete tax benefits. ", "original_text": "Operating Income:  In the second quarter of fiscal 2023, operating income was $560.5 million, a 28.2 percent decrease\ncompared to the same period in the previous fiscal year due to the increase in operating expenses, offset in part by the\nincrease in gross profit. ", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "810ee5449df3bbe01a568dbcaf7420159f455a328608181c691320da66b22a01", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a4d5613-6a63-4969-aabb-7f163240ad47", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the second quarter of fiscal 2023 was $2.3 billion, a 2.7 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in both reportable segments.  The increase in gross profit\nwas offset in part by a LIFO expense in the current year period versus a LIFO credit in the previous fiscal year period.  Gross\nprofit as a percentage of revenue was 3.62 percent, a decrease of 25 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2023, operating expenses were $1.7 billion, a 19.2 percent increase\ncompared to the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and\nadministrative expenses, restructuring and other expenses, and depreciation and amortization expenses compared to the\nprior year quarter.\n Operating Income:  In the second quarter of fiscal 2023, operating income was $560.5 million, a 28.2 percent decrease\ncompared to the same period in the previous fiscal year due to the increase in operating expenses, offset in part by the\nincrease in gross profit.  Operating income as a percentage of revenue was 0.88 percent in the second quarter of fiscal 2023, a\ndecline of 47 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the second quarter of fiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus\nthe prior year quarter primarily due to increases in borrowings and interest rates associated with variable-rate debt, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n", "original_text": "Operating Expenses:  In the second quarter of fiscal 2023, operating expenses were $1.7 billion, a 19.2 percent increase\ncompared to the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and\nadministrative expenses, restructuring and other expenses, and depreciation and amortization expenses compared to the\nprior year quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42dd228549e25fbc34d74ed1bf9d71bb3d1e4423ccbea81b187f5e6df91c66a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03da905a-591c-4ce7-95e2-bcd5ae8c191a", "node_type": "1", "metadata": {"window": "Gross\nprofit as a percentage of revenue was 3.62 percent, a decrease of 25 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2023, operating expenses were $1.7 billion, a 19.2 percent increase\ncompared to the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and\nadministrative expenses, restructuring and other expenses, and depreciation and amortization expenses compared to the\nprior year quarter.\n Operating Income:  In the second quarter of fiscal 2023, operating income was $560.5 million, a 28.2 percent decrease\ncompared to the same period in the previous fiscal year due to the increase in operating expenses, offset in part by the\nincrease in gross profit.  Operating income as a percentage of revenue was 0.88 percent in the second quarter of fiscal 2023, a\ndecline of 47 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the second quarter of fiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus\nthe prior year quarter primarily due to increases in borrowings and interest rates associated with variable-rate debt, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 16.4 percent for the second quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income and discrete tax benefits.  This compares to 23.7 percent in the prior year\nquarter, which reflected discrete tax expenses.\n", "original_text": "Operating income as a percentage of revenue was 0.88 percent in the second quarter of fiscal 2023, a\ndecline of 47 basis points when compared to the prior year quarter.\n"}, "hash": "f8cfb181a150850bbcd1780714c7353c37840a83c5e6e91f396d310f188e2dcb", "class_name": "RelatedNodeInfo"}}, "text": "Operating Income:  In the second quarter of fiscal 2023, operating income was $560.5 million, a 28.2 percent decrease\ncompared to the same period in the previous fiscal year due to the increase in operating expenses, offset in part by the\nincrease in gross profit. ", "start_char_idx": 2019, "end_char_idx": 2284, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03da905a-591c-4ce7-95e2-bcd5ae8c191a": {"__data__": {"id_": "03da905a-591c-4ce7-95e2-bcd5ae8c191a", "embedding": null, "metadata": {"window": "Gross\nprofit as a percentage of revenue was 3.62 percent, a decrease of 25 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2023, operating expenses were $1.7 billion, a 19.2 percent increase\ncompared to the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and\nadministrative expenses, restructuring and other expenses, and depreciation and amortization expenses compared to the\nprior year quarter.\n Operating Income:  In the second quarter of fiscal 2023, operating income was $560.5 million, a 28.2 percent decrease\ncompared to the same period in the previous fiscal year due to the increase in operating expenses, offset in part by the\nincrease in gross profit.  Operating income as a percentage of revenue was 0.88 percent in the second quarter of fiscal 2023, a\ndecline of 47 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the second quarter of fiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus\nthe prior year quarter primarily due to increases in borrowings and interest rates associated with variable-rate debt, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 16.4 percent for the second quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income and discrete tax benefits.  This compares to 23.7 percent in the prior year\nquarter, which reflected discrete tax expenses.\n", "original_text": "Operating income as a percentage of revenue was 0.88 percent in the second quarter of fiscal 2023, a\ndecline of 47 basis points when compared to the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "810ee5449df3bbe01a568dbcaf7420159f455a328608181c691320da66b22a01", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19f5dc5d-443a-4f1e-927c-2675277b362a", "node_type": "1", "metadata": {"window": "The increase in gross profit\nwas offset in part by a LIFO expense in the current year period versus a LIFO credit in the previous fiscal year period.  Gross\nprofit as a percentage of revenue was 3.62 percent, a decrease of 25 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2023, operating expenses were $1.7 billion, a 19.2 percent increase\ncompared to the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and\nadministrative expenses, restructuring and other expenses, and depreciation and amortization expenses compared to the\nprior year quarter.\n Operating Income:  In the second quarter of fiscal 2023, operating income was $560.5 million, a 28.2 percent decrease\ncompared to the same period in the previous fiscal year due to the increase in operating expenses, offset in part by the\nincrease in gross profit.  Operating income as a percentage of revenue was 0.88 percent in the second quarter of fiscal 2023, a\ndecline of 47 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the second quarter of fiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus\nthe prior year quarter primarily due to increases in borrowings and interest rates associated with variable-rate debt, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 16.4 percent for the second quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income and discrete tax benefits. ", "original_text": "Operating Income:  In the second quarter of fiscal 2023, operating income was $560.5 million, a 28.2 percent decrease\ncompared to the same period in the previous fiscal year due to the increase in operating expenses, offset in part by the\nincrease in gross profit. ", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c28baa1a09106cc30f2e09caa0f7e6c523e14f9c93f12355e2861481c23acad8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ed60717-183c-4bf7-aeeb-0e6ecd24553a", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the second quarter of fiscal 2023, operating expenses were $1.7 billion, a 19.2 percent increase\ncompared to the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and\nadministrative expenses, restructuring and other expenses, and depreciation and amortization expenses compared to the\nprior year quarter.\n Operating Income:  In the second quarter of fiscal 2023, operating income was $560.5 million, a 28.2 percent decrease\ncompared to the same period in the previous fiscal year due to the increase in operating expenses, offset in part by the\nincrease in gross profit.  Operating income as a percentage of revenue was 0.88 percent in the second quarter of fiscal 2023, a\ndecline of 47 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the second quarter of fiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus\nthe prior year quarter primarily due to increases in borrowings and interest rates associated with variable-rate debt, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 16.4 percent for the second quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income and discrete tax benefits.  This compares to 23.7 percent in the prior year\nquarter, which reflected discrete tax expenses.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.13 in the second quarter of fiscal 2023, a 17.8 percent decrease\ncompared to $2.59 in the previous fiscal year\u2019s second quarter.\n", "original_text": "Interest Expense, Net:  In the second quarter of fiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus\nthe prior year quarter primarily due to increases in borrowings and interest rates associated with variable-rate debt, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n"}, "hash": "143b056ef6fbc19a2362ce970a19c5794dbad2984a438f05c3cdaf014cf82c87", "class_name": "RelatedNodeInfo"}}, "text": "Operating income as a percentage of revenue was 0.88 percent in the second quarter of fiscal 2023, a\ndecline of 47 basis points when compared to the prior year quarter.\n", "start_char_idx": 2284, "end_char_idx": 2453, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ed60717-183c-4bf7-aeeb-0e6ecd24553a": {"__data__": {"id_": "7ed60717-183c-4bf7-aeeb-0e6ecd24553a", "embedding": null, "metadata": {"window": "Operating Expenses:  In the second quarter of fiscal 2023, operating expenses were $1.7 billion, a 19.2 percent increase\ncompared to the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and\nadministrative expenses, restructuring and other expenses, and depreciation and amortization expenses compared to the\nprior year quarter.\n Operating Income:  In the second quarter of fiscal 2023, operating income was $560.5 million, a 28.2 percent decrease\ncompared to the same period in the previous fiscal year due to the increase in operating expenses, offset in part by the\nincrease in gross profit.  Operating income as a percentage of revenue was 0.88 percent in the second quarter of fiscal 2023, a\ndecline of 47 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the second quarter of fiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus\nthe prior year quarter primarily due to increases in borrowings and interest rates associated with variable-rate debt, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 16.4 percent for the second quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income and discrete tax benefits.  This compares to 23.7 percent in the prior year\nquarter, which reflected discrete tax expenses.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.13 in the second quarter of fiscal 2023, a 17.8 percent decrease\ncompared to $2.59 in the previous fiscal year\u2019s second quarter.\n", "original_text": "Interest Expense, Net:  In the second quarter of fiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus\nthe prior year quarter primarily due to increases in borrowings and interest rates associated with variable-rate debt, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "810ee5449df3bbe01a568dbcaf7420159f455a328608181c691320da66b22a01", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03da905a-591c-4ce7-95e2-bcd5ae8c191a", "node_type": "1", "metadata": {"window": "Gross\nprofit as a percentage of revenue was 3.62 percent, a decrease of 25 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2023, operating expenses were $1.7 billion, a 19.2 percent increase\ncompared to the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and\nadministrative expenses, restructuring and other expenses, and depreciation and amortization expenses compared to the\nprior year quarter.\n Operating Income:  In the second quarter of fiscal 2023, operating income was $560.5 million, a 28.2 percent decrease\ncompared to the same period in the previous fiscal year due to the increase in operating expenses, offset in part by the\nincrease in gross profit.  Operating income as a percentage of revenue was 0.88 percent in the second quarter of fiscal 2023, a\ndecline of 47 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the second quarter of fiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus\nthe prior year quarter primarily due to increases in borrowings and interest rates associated with variable-rate debt, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 16.4 percent for the second quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income and discrete tax benefits.  This compares to 23.7 percent in the prior year\nquarter, which reflected discrete tax expenses.\n", "original_text": "Operating income as a percentage of revenue was 0.88 percent in the second quarter of fiscal 2023, a\ndecline of 47 basis points when compared to the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e6275468b0e23e308f0803453e4daa1c6853adae1653ddf25e64f5bad56dbbd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd18b0a6-d283-4ccc-8ba2-72083c4bb391", "node_type": "1", "metadata": {"window": "Operating Income:  In the second quarter of fiscal 2023, operating income was $560.5 million, a 28.2 percent decrease\ncompared to the same period in the previous fiscal year due to the increase in operating expenses, offset in part by the\nincrease in gross profit.  Operating income as a percentage of revenue was 0.88 percent in the second quarter of fiscal 2023, a\ndecline of 47 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the second quarter of fiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus\nthe prior year quarter primarily due to increases in borrowings and interest rates associated with variable-rate debt, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 16.4 percent for the second quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income and discrete tax benefits.  This compares to 23.7 percent in the prior year\nquarter, which reflected discrete tax expenses.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.13 in the second quarter of fiscal 2023, a 17.8 percent decrease\ncompared to $2.59 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2023 were 204.3\nmillion, a decrease of 7.7 million shares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share\nrepurchases.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 16.4 percent for the second quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income and discrete tax benefits. "}, "hash": "5f6201d20772429be3d7b3d6a7050c142602c79a8e57cfd7c68040dff47b4b1c", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  In the second quarter of fiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus\nthe prior year quarter primarily due to increases in borrowings and interest rates associated with variable-rate debt, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n", "start_char_idx": 2453, "end_char_idx": 2800, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd18b0a6-d283-4ccc-8ba2-72083c4bb391": {"__data__": {"id_": "dd18b0a6-d283-4ccc-8ba2-72083c4bb391", "embedding": null, "metadata": {"window": "Operating Income:  In the second quarter of fiscal 2023, operating income was $560.5 million, a 28.2 percent decrease\ncompared to the same period in the previous fiscal year due to the increase in operating expenses, offset in part by the\nincrease in gross profit.  Operating income as a percentage of revenue was 0.88 percent in the second quarter of fiscal 2023, a\ndecline of 47 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the second quarter of fiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus\nthe prior year quarter primarily due to increases in borrowings and interest rates associated with variable-rate debt, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 16.4 percent for the second quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income and discrete tax benefits.  This compares to 23.7 percent in the prior year\nquarter, which reflected discrete tax expenses.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.13 in the second quarter of fiscal 2023, a 17.8 percent decrease\ncompared to $2.59 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2023 were 204.3\nmillion, a decrease of 7.7 million shares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share\nrepurchases.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 16.4 percent for the second quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income and discrete tax benefits. ", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "810ee5449df3bbe01a568dbcaf7420159f455a328608181c691320da66b22a01", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ed60717-183c-4bf7-aeeb-0e6ecd24553a", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the second quarter of fiscal 2023, operating expenses were $1.7 billion, a 19.2 percent increase\ncompared to the same period in the previous fiscal year, primarily driven by increases in distribution, selling, and\nadministrative expenses, restructuring and other expenses, and depreciation and amortization expenses compared to the\nprior year quarter.\n Operating Income:  In the second quarter of fiscal 2023, operating income was $560.5 million, a 28.2 percent decrease\ncompared to the same period in the previous fiscal year due to the increase in operating expenses, offset in part by the\nincrease in gross profit.  Operating income as a percentage of revenue was 0.88 percent in the second quarter of fiscal 2023, a\ndecline of 47 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the second quarter of fiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus\nthe prior year quarter primarily due to increases in borrowings and interest rates associated with variable-rate debt, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 16.4 percent for the second quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income and discrete tax benefits.  This compares to 23.7 percent in the prior year\nquarter, which reflected discrete tax expenses.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.13 in the second quarter of fiscal 2023, a 17.8 percent decrease\ncompared to $2.59 in the previous fiscal year\u2019s second quarter.\n", "original_text": "Interest Expense, Net:  In the second quarter of fiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus\nthe prior year quarter primarily due to increases in borrowings and interest rates associated with variable-rate debt, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "427288b2bbe6cbc59c5ff47961fdac5427415895990cf1befd934300dfb9bb5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5fdfe2b-02d7-4c13-b559-8207a94295c1", "node_type": "1", "metadata": {"window": "Operating income as a percentage of revenue was 0.88 percent in the second quarter of fiscal 2023, a\ndecline of 47 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the second quarter of fiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus\nthe prior year quarter primarily due to increases in borrowings and interest rates associated with variable-rate debt, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 16.4 percent for the second quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income and discrete tax benefits.  This compares to 23.7 percent in the prior year\nquarter, which reflected discrete tax expenses.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.13 in the second quarter of fiscal 2023, a 17.8 percent decrease\ncompared to $2.59 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2023 were 204.3\nmillion, a decrease of 7.7 million shares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share\nrepurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "This compares to 23.7 percent in the prior year\nquarter, which reflected discrete tax expenses.\n"}, "hash": "c2c9036048f4284c9dfb9ae66ddfa1ab23372f3bc7ddba1782960f572d08cf6e", "class_name": "RelatedNodeInfo"}}, "text": "Effective Tax Rate:  The effective tax rate was 16.4 percent for the second quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income and discrete tax benefits. ", "start_char_idx": 2800, "end_char_idx": 2997, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5fdfe2b-02d7-4c13-b559-8207a94295c1": {"__data__": {"id_": "d5fdfe2b-02d7-4c13-b559-8207a94295c1", "embedding": null, "metadata": {"window": "Operating income as a percentage of revenue was 0.88 percent in the second quarter of fiscal 2023, a\ndecline of 47 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the second quarter of fiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus\nthe prior year quarter primarily due to increases in borrowings and interest rates associated with variable-rate debt, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 16.4 percent for the second quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income and discrete tax benefits.  This compares to 23.7 percent in the prior year\nquarter, which reflected discrete tax expenses.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.13 in the second quarter of fiscal 2023, a 17.8 percent decrease\ncompared to $2.59 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2023 were 204.3\nmillion, a decrease of 7.7 million shares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share\nrepurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "This compares to 23.7 percent in the prior year\nquarter, which reflected discrete tax expenses.\n", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "810ee5449df3bbe01a568dbcaf7420159f455a328608181c691320da66b22a01", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd18b0a6-d283-4ccc-8ba2-72083c4bb391", "node_type": "1", "metadata": {"window": "Operating Income:  In the second quarter of fiscal 2023, operating income was $560.5 million, a 28.2 percent decrease\ncompared to the same period in the previous fiscal year due to the increase in operating expenses, offset in part by the\nincrease in gross profit.  Operating income as a percentage of revenue was 0.88 percent in the second quarter of fiscal 2023, a\ndecline of 47 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the second quarter of fiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus\nthe prior year quarter primarily due to increases in borrowings and interest rates associated with variable-rate debt, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 16.4 percent for the second quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income and discrete tax benefits.  This compares to 23.7 percent in the prior year\nquarter, which reflected discrete tax expenses.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.13 in the second quarter of fiscal 2023, a 17.8 percent decrease\ncompared to $2.59 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2023 were 204.3\nmillion, a decrease of 7.7 million shares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share\nrepurchases.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 16.4 percent for the second quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income and discrete tax benefits. ", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f886c1b4d51c25ef2e737341d1cf35a152ad08cc2be6b316f0a72e00c6ceca10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af33271f-e531-46b6-beec-b14e6055e3e1", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the second quarter of fiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus\nthe prior year quarter primarily due to increases in borrowings and interest rates associated with variable-rate debt, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 16.4 percent for the second quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income and discrete tax benefits.  This compares to 23.7 percent in the prior year\nquarter, which reflected discrete tax expenses.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.13 in the second quarter of fiscal 2023, a 17.8 percent decrease\ncompared to $2.59 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2023 were 204.3\nmillion, a decrease of 7.7 million shares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share\nrepurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2023, revenue was\n$63.5 billion, up 9.9 percent compared to the same quarter in the previous fiscal year, reflecting an 11.3 percent increase in\nrevenue within U.S. ", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $2.13 in the second quarter of fiscal 2023, a 17.8 percent decrease\ncompared to $2.59 in the previous fiscal year\u2019s second quarter.\n"}, "hash": "03f14bdd26572408572370ba62b004e29dc0ddb7128822827fb5e779cd5f153e", "class_name": "RelatedNodeInfo"}}, "text": "This compares to 23.7 percent in the prior year\nquarter, which reflected discrete tax expenses.\n", "start_char_idx": 2997, "end_char_idx": 3093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af33271f-e531-46b6-beec-b14e6055e3e1": {"__data__": {"id_": "af33271f-e531-46b6-beec-b14e6055e3e1", "embedding": null, "metadata": {"window": "Interest Expense, Net:  In the second quarter of fiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus\nthe prior year quarter primarily due to increases in borrowings and interest rates associated with variable-rate debt, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 16.4 percent for the second quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income and discrete tax benefits.  This compares to 23.7 percent in the prior year\nquarter, which reflected discrete tax expenses.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.13 in the second quarter of fiscal 2023, a 17.8 percent decrease\ncompared to $2.59 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2023 were 204.3\nmillion, a decrease of 7.7 million shares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share\nrepurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2023, revenue was\n$63.5 billion, up 9.9 percent compared to the same quarter in the previous fiscal year, reflecting an 11.3 percent increase in\nrevenue within U.S. ", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $2.13 in the second quarter of fiscal 2023, a 17.8 percent decrease\ncompared to $2.59 in the previous fiscal year\u2019s second quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "810ee5449df3bbe01a568dbcaf7420159f455a328608181c691320da66b22a01", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5fdfe2b-02d7-4c13-b559-8207a94295c1", "node_type": "1", "metadata": {"window": "Operating income as a percentage of revenue was 0.88 percent in the second quarter of fiscal 2023, a\ndecline of 47 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the second quarter of fiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus\nthe prior year quarter primarily due to increases in borrowings and interest rates associated with variable-rate debt, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 16.4 percent for the second quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income and discrete tax benefits.  This compares to 23.7 percent in the prior year\nquarter, which reflected discrete tax expenses.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.13 in the second quarter of fiscal 2023, a 17.8 percent decrease\ncompared to $2.59 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2023 were 204.3\nmillion, a decrease of 7.7 million shares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share\nrepurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "This compares to 23.7 percent in the prior year\nquarter, which reflected discrete tax expenses.\n", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8ec34a84150822edbe8d8096157920eea835750cbe28f46f5198685d6311d21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e266e7e7-2523-4dce-b735-798efce6cc5b", "node_type": "1", "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 16.4 percent for the second quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income and discrete tax benefits.  This compares to 23.7 percent in the prior year\nquarter, which reflected discrete tax expenses.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.13 in the second quarter of fiscal 2023, a 17.8 percent decrease\ncompared to $2.59 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2023 were 204.3\nmillion, a decrease of 7.7 million shares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share\nrepurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2023, revenue was\n$63.5 billion, up 9.9 percent compared to the same quarter in the previous fiscal year, reflecting an 11.3 percent increase in\nrevenue within U.S.  Healthcare Solutions. ", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2023 were 204.3\nmillion, a decrease of 7.7 million shares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share\nrepurchases.\n"}, "hash": "80a330d0ac5ef1533aeb7e5fe770c3588872943ec5a5e46e4328226f11e4be40", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Earnings Per Share:  Diluted earnings per share was $2.13 in the second quarter of fiscal 2023, a 17.8 percent decrease\ncompared to $2.59 in the previous fiscal year\u2019s second quarter.\n", "start_char_idx": 3093, "end_char_idx": 3285, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e266e7e7-2523-4dce-b735-798efce6cc5b": {"__data__": {"id_": "e266e7e7-2523-4dce-b735-798efce6cc5b", "embedding": null, "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 16.4 percent for the second quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income and discrete tax benefits.  This compares to 23.7 percent in the prior year\nquarter, which reflected discrete tax expenses.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.13 in the second quarter of fiscal 2023, a 17.8 percent decrease\ncompared to $2.59 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2023 were 204.3\nmillion, a decrease of 7.7 million shares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share\nrepurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2023, revenue was\n$63.5 billion, up 9.9 percent compared to the same quarter in the previous fiscal year, reflecting an 11.3 percent increase in\nrevenue within U.S.  Healthcare Solutions. ", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2023 were 204.3\nmillion, a decrease of 7.7 million shares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share\nrepurchases.\n", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "810ee5449df3bbe01a568dbcaf7420159f455a328608181c691320da66b22a01", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af33271f-e531-46b6-beec-b14e6055e3e1", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the second quarter of fiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus\nthe prior year quarter primarily due to increases in borrowings and interest rates associated with variable-rate debt, offset in\npart by an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 16.4 percent for the second quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income and discrete tax benefits.  This compares to 23.7 percent in the prior year\nquarter, which reflected discrete tax expenses.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.13 in the second quarter of fiscal 2023, a 17.8 percent decrease\ncompared to $2.59 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2023 were 204.3\nmillion, a decrease of 7.7 million shares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share\nrepurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2023, revenue was\n$63.5 billion, up 9.9 percent compared to the same quarter in the previous fiscal year, reflecting an 11.3 percent increase in\nrevenue within U.S. ", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $2.13 in the second quarter of fiscal 2023, a 17.8 percent decrease\ncompared to $2.59 in the previous fiscal year\u2019s second quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "48bcb208076ca6ce39bdbc8a2b8a1fbd45d717cf4143e7e54122f8a657a41895", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "815a9878-af3c-482c-a607-65aa2ce0ddac", "node_type": "1", "metadata": {"window": "This compares to 23.7 percent in the prior year\nquarter, which reflected discrete tax expenses.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.13 in the second quarter of fiscal 2023, a 17.8 percent decrease\ncompared to $2.59 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2023 were 204.3\nmillion, a decrease of 7.7 million shares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share\nrepurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2023, revenue was\n$63.5 billion, up 9.9 percent compared to the same quarter in the previous fiscal year, reflecting an 11.3 percent increase in\nrevenue within U.S.  Healthcare Solutions.  International Healthcare Solutions revenue declined 0.2 percent primarily resulting\nfrom the June 2022 divestiture of our Brazil specialty business and unfavorable foreign currency exchange rates in the current\n2", "original_text": "Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. "}, "hash": "144fc8dcee869df46f1f5d2d960597b6f2ffebb2592ba3734b930eb6f019f7b7", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2023 were 204.3\nmillion, a decrease of 7.7 million shares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share\nrepurchases.\n", "start_char_idx": 3285, "end_char_idx": 3553, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "815a9878-af3c-482c-a607-65aa2ce0ddac": {"__data__": {"id_": "815a9878-af3c-482c-a607-65aa2ce0ddac", "embedding": null, "metadata": {"window": "This compares to 23.7 percent in the prior year\nquarter, which reflected discrete tax expenses.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.13 in the second quarter of fiscal 2023, a 17.8 percent decrease\ncompared to $2.59 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2023 were 204.3\nmillion, a decrease of 7.7 million shares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share\nrepurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2023, revenue was\n$63.5 billion, up 9.9 percent compared to the same quarter in the previous fiscal year, reflecting an 11.3 percent increase in\nrevenue within U.S.  Healthcare Solutions.  International Healthcare Solutions revenue declined 0.2 percent primarily resulting\nfrom the June 2022 divestiture of our Brazil specialty business and unfavorable foreign currency exchange rates in the current\n2", "original_text": "Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "810ee5449df3bbe01a568dbcaf7420159f455a328608181c691320da66b22a01", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e266e7e7-2523-4dce-b735-798efce6cc5b", "node_type": "1", "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 16.4 percent for the second quarter of fiscal 2023, reflecting the mix of the\nCompany\u2019s domestic and international income and discrete tax benefits.  This compares to 23.7 percent in the prior year\nquarter, which reflected discrete tax expenses.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.13 in the second quarter of fiscal 2023, a 17.8 percent decrease\ncompared to $2.59 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2023 were 204.3\nmillion, a decrease of 7.7 million shares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share\nrepurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2023, revenue was\n$63.5 billion, up 9.9 percent compared to the same quarter in the previous fiscal year, reflecting an 11.3 percent increase in\nrevenue within U.S.  Healthcare Solutions. ", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2023 were 204.3\nmillion, a decrease of 7.7 million shares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share\nrepurchases.\n", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ddedecec10b98df9f18c02064c440a8af8a64cbfa48db932d711894c3961d7ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67466426-f58b-425e-a50c-8da4769e59dd", "node_type": "1", "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $2.13 in the second quarter of fiscal 2023, a 17.8 percent decrease\ncompared to $2.59 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2023 were 204.3\nmillion, a decrease of 7.7 million shares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share\nrepurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2023, revenue was\n$63.5 billion, up 9.9 percent compared to the same quarter in the previous fiscal year, reflecting an 11.3 percent increase in\nrevenue within U.S.  Healthcare Solutions.  International Healthcare Solutions revenue declined 0.2 percent primarily resulting\nfrom the June 2022 divestiture of our Brazil specialty business and unfavorable foreign currency exchange rates in the current\n2", "original_text": "In the second quarter of fiscal 2023, revenue was\n$63.5 billion, up 9.9 percent compared to the same quarter in the previous fiscal year, reflecting an 11.3 percent increase in\nrevenue within U.S. "}, "hash": "c8cbf6d13718a22610178235521cd4c038ecc00e010b02164b7e999c52e26ac5", "class_name": "RelatedNodeInfo"}}, "text": "Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "start_char_idx": 3553, "end_char_idx": 3671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67466426-f58b-425e-a50c-8da4769e59dd": {"__data__": {"id_": "67466426-f58b-425e-a50c-8da4769e59dd", "embedding": null, "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $2.13 in the second quarter of fiscal 2023, a 17.8 percent decrease\ncompared to $2.59 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2023 were 204.3\nmillion, a decrease of 7.7 million shares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share\nrepurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2023, revenue was\n$63.5 billion, up 9.9 percent compared to the same quarter in the previous fiscal year, reflecting an 11.3 percent increase in\nrevenue within U.S.  Healthcare Solutions.  International Healthcare Solutions revenue declined 0.2 percent primarily resulting\nfrom the June 2022 divestiture of our Brazil specialty business and unfavorable foreign currency exchange rates in the current\n2", "original_text": "In the second quarter of fiscal 2023, revenue was\n$63.5 billion, up 9.9 percent compared to the same quarter in the previous fiscal year, reflecting an 11.3 percent increase in\nrevenue within U.S. ", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "810ee5449df3bbe01a568dbcaf7420159f455a328608181c691320da66b22a01", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "815a9878-af3c-482c-a607-65aa2ce0ddac", "node_type": "1", "metadata": {"window": "This compares to 23.7 percent in the prior year\nquarter, which reflected discrete tax expenses.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.13 in the second quarter of fiscal 2023, a 17.8 percent decrease\ncompared to $2.59 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2023 were 204.3\nmillion, a decrease of 7.7 million shares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share\nrepurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2023, revenue was\n$63.5 billion, up 9.9 percent compared to the same quarter in the previous fiscal year, reflecting an 11.3 percent increase in\nrevenue within U.S.  Healthcare Solutions.  International Healthcare Solutions revenue declined 0.2 percent primarily resulting\nfrom the June 2022 divestiture of our Brazil specialty business and unfavorable foreign currency exchange rates in the current\n2", "original_text": "Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0a2f5d4ff1477e6f5794c4e49370661c24e3641edb6e3cbf583c994d8d0b1e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01f0683a-7c0d-4a69-9cce-19f0cc927188", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2023 were 204.3\nmillion, a decrease of 7.7 million shares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share\nrepurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2023, revenue was\n$63.5 billion, up 9.9 percent compared to the same quarter in the previous fiscal year, reflecting an 11.3 percent increase in\nrevenue within U.S.  Healthcare Solutions.  International Healthcare Solutions revenue declined 0.2 percent primarily resulting\nfrom the June 2022 divestiture of our Brazil specialty business and unfavorable foreign currency exchange rates in the current\n2", "original_text": "Healthcare Solutions. "}, "hash": "fc53e9905c0d39386e0ac0e5ef164f41c73fc2d757aae4422f05ae18679020c3", "class_name": "RelatedNodeInfo"}}, "text": "In the second quarter of fiscal 2023, revenue was\n$63.5 billion, up 9.9 percent compared to the same quarter in the previous fiscal year, reflecting an 11.3 percent increase in\nrevenue within U.S. ", "start_char_idx": 3671, "end_char_idx": 3868, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01f0683a-7c0d-4a69-9cce-19f0cc927188": {"__data__": {"id_": "01f0683a-7c0d-4a69-9cce-19f0cc927188", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2023 were 204.3\nmillion, a decrease of 7.7 million shares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share\nrepurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2023, revenue was\n$63.5 billion, up 9.9 percent compared to the same quarter in the previous fiscal year, reflecting an 11.3 percent increase in\nrevenue within U.S.  Healthcare Solutions.  International Healthcare Solutions revenue declined 0.2 percent primarily resulting\nfrom the June 2022 divestiture of our Brazil specialty business and unfavorable foreign currency exchange rates in the current\n2", "original_text": "Healthcare Solutions. ", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "810ee5449df3bbe01a568dbcaf7420159f455a328608181c691320da66b22a01", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67466426-f58b-425e-a50c-8da4769e59dd", "node_type": "1", "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $2.13 in the second quarter of fiscal 2023, a 17.8 percent decrease\ncompared to $2.59 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2023 were 204.3\nmillion, a decrease of 7.7 million shares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share\nrepurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2023, revenue was\n$63.5 billion, up 9.9 percent compared to the same quarter in the previous fiscal year, reflecting an 11.3 percent increase in\nrevenue within U.S.  Healthcare Solutions.  International Healthcare Solutions revenue declined 0.2 percent primarily resulting\nfrom the June 2022 divestiture of our Brazil specialty business and unfavorable foreign currency exchange rates in the current\n2", "original_text": "In the second quarter of fiscal 2023, revenue was\n$63.5 billion, up 9.9 percent compared to the same quarter in the previous fiscal year, reflecting an 11.3 percent increase in\nrevenue within U.S. ", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "27f6bc8a63a9dec90e641d81fc139b657a27d3f6f7aadfb5e32b634662400b89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c3aa4c2-9213-4f15-8cec-637ab6bcc139", "node_type": "1", "metadata": {"window": "Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2023, revenue was\n$63.5 billion, up 9.9 percent compared to the same quarter in the previous fiscal year, reflecting an 11.3 percent increase in\nrevenue within U.S.  Healthcare Solutions.  International Healthcare Solutions revenue declined 0.2 percent primarily resulting\nfrom the June 2022 divestiture of our Brazil specialty business and unfavorable foreign currency exchange rates in the current\n2", "original_text": "International Healthcare Solutions revenue declined 0.2 percent primarily resulting\nfrom the June 2022 divestiture of our Brazil specialty business and unfavorable foreign currency exchange rates in the current\n2"}, "hash": "99c644eb167cb21e2a86ae712f9f1ff1bb92d3b9ed1f94899db1f9fa2f32192f", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions. ", "start_char_idx": 863, "end_char_idx": 885, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c3aa4c2-9213-4f15-8cec-637ab6bcc139": {"__data__": {"id_": "8c3aa4c2-9213-4f15-8cec-637ab6bcc139", "embedding": null, "metadata": {"window": "Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2023, revenue was\n$63.5 billion, up 9.9 percent compared to the same quarter in the previous fiscal year, reflecting an 11.3 percent increase in\nrevenue within U.S.  Healthcare Solutions.  International Healthcare Solutions revenue declined 0.2 percent primarily resulting\nfrom the June 2022 divestiture of our Brazil specialty business and unfavorable foreign currency exchange rates in the current\n2", "original_text": "International Healthcare Solutions revenue declined 0.2 percent primarily resulting\nfrom the June 2022 divestiture of our Brazil specialty business and unfavorable foreign currency exchange rates in the current\n2", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "810ee5449df3bbe01a568dbcaf7420159f455a328608181c691320da66b22a01", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01f0683a-7c0d-4a69-9cce-19f0cc927188", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2023 were 204.3\nmillion, a decrease of 7.7 million shares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share\nrepurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2023, revenue was\n$63.5 billion, up 9.9 percent compared to the same quarter in the previous fiscal year, reflecting an 11.3 percent increase in\nrevenue within U.S.  Healthcare Solutions.  International Healthcare Solutions revenue declined 0.2 percent primarily resulting\nfrom the June 2022 divestiture of our Brazil specialty business and unfavorable foreign currency exchange rates in the current\n2", "original_text": "Healthcare Solutions. ", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18855b512d8d9b0b6a124ea1a64db173103b9604ff9265c9787ed335d34fc9a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7a09a98-ec97-467f-be34-8d252768727c", "node_type": "1", "metadata": {"window": "year quarter in comparison to the prior year quarter.  On a constant currency basis, revenue was up 11.4 percent, reflecting\n11.9 percent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2023 was $2.4 billion, a 6.2 percent increase\ncompared to the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.71 percent in the fiscal 2023 second quarter, a decrease of 13 basis\npoints from the prior year quarter.\n", "original_text": "year quarter in comparison to the prior year quarter. "}, "hash": "75300a0d1f7dcdc4df192cfa48e51d34c2e763730109d142a370dcac96720e04", "class_name": "RelatedNodeInfo"}}, "text": "International Healthcare Solutions revenue declined 0.2 percent primarily resulting\nfrom the June 2022 divestiture of our Brazil specialty business and unfavorable foreign currency exchange rates in the current\n2", "start_char_idx": 3890, "end_char_idx": 4102, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7a09a98-ec97-467f-be34-8d252768727c": {"__data__": {"id_": "a7a09a98-ec97-467f-be34-8d252768727c", "embedding": null, "metadata": {"window": "year quarter in comparison to the prior year quarter.  On a constant currency basis, revenue was up 11.4 percent, reflecting\n11.9 percent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2023 was $2.4 billion, a 6.2 percent increase\ncompared to the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.71 percent in the fiscal 2023 second quarter, a decrease of 13 basis\npoints from the prior year quarter.\n", "original_text": "year quarter in comparison to the prior year quarter. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e2e724-303c-4a3c-a394-4f851829c7bc", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db72d27a283ad0e0c84697fa67a2a9812d01a4838ab15567742056a8f6f30c42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c3aa4c2-9213-4f15-8cec-637ab6bcc139", "node_type": "1", "metadata": {"window": "Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2023, revenue was\n$63.5 billion, up 9.9 percent compared to the same quarter in the previous fiscal year, reflecting an 11.3 percent increase in\nrevenue within U.S.  Healthcare Solutions.  International Healthcare Solutions revenue declined 0.2 percent primarily resulting\nfrom the June 2022 divestiture of our Brazil specialty business and unfavorable foreign currency exchange rates in the current\n2", "original_text": "International Healthcare Solutions revenue declined 0.2 percent primarily resulting\nfrom the June 2022 divestiture of our Brazil specialty business and unfavorable foreign currency exchange rates in the current\n2", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3fb30b34572aa949fd1b869dd18ea2ba43c1def0087beb5543a2122fb5fd881b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a29eb57a-664e-42e2-b183-38d25402e53c", "node_type": "1", "metadata": {"window": "year quarter in comparison to the prior year quarter.  On a constant currency basis, revenue was up 11.4 percent, reflecting\n11.9 percent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2023 was $2.4 billion, a 6.2 percent increase\ncompared to the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.71 percent in the fiscal 2023 second quarter, a decrease of 13 basis\npoints from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.4\npercent increase, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S. ", "original_text": "On a constant currency basis, revenue was up 11.4 percent, reflecting\n11.9 percent constant currency growth in International Healthcare Solutions revenue.\n"}, "hash": "3389c04320353580af3a66987078d3e569483efc4074eace1c749b4c7bf13d9f", "class_name": "RelatedNodeInfo"}}, "text": "year quarter in comparison to the prior year quarter. ", "start_char_idx": 0, "end_char_idx": 54, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a29eb57a-664e-42e2-b183-38d25402e53c": {"__data__": {"id_": "a29eb57a-664e-42e2-b183-38d25402e53c", "embedding": null, "metadata": {"window": "year quarter in comparison to the prior year quarter.  On a constant currency basis, revenue was up 11.4 percent, reflecting\n11.9 percent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2023 was $2.4 billion, a 6.2 percent increase\ncompared to the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.71 percent in the fiscal 2023 second quarter, a decrease of 13 basis\npoints from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.4\npercent increase, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S. ", "original_text": "On a constant currency basis, revenue was up 11.4 percent, reflecting\n11.9 percent constant currency growth in International Healthcare Solutions revenue.\n", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e2e724-303c-4a3c-a394-4f851829c7bc", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db72d27a283ad0e0c84697fa67a2a9812d01a4838ab15567742056a8f6f30c42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7a09a98-ec97-467f-be34-8d252768727c", "node_type": "1", "metadata": {"window": "year quarter in comparison to the prior year quarter.  On a constant currency basis, revenue was up 11.4 percent, reflecting\n11.9 percent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2023 was $2.4 billion, a 6.2 percent increase\ncompared to the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.71 percent in the fiscal 2023 second quarter, a decrease of 13 basis\npoints from the prior year quarter.\n", "original_text": "year quarter in comparison to the prior year quarter. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a64b030d80e45366c15321a31cd7204f66950a9e91e6dd536f342e39b335944", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7fc5adb-f448-4377-a1f7-42d0e2b121af", "node_type": "1", "metadata": {"window": "year quarter in comparison to the prior year quarter.  On a constant currency basis, revenue was up 11.4 percent, reflecting\n11.9 percent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2023 was $2.4 billion, a 6.2 percent increase\ncompared to the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.71 percent in the fiscal 2023 second quarter, a decrease of 13 basis\npoints from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.4\npercent increase, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and reflecting inflationary impacts on certain operating\nexpenses.\n", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2023 was $2.4 billion, a 6.2 percent increase\ncompared to the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.\n"}, "hash": "3a444da4c90ea9f3aa4a9cc41d9dec73ff9dc3bde23197b816b7bddfddecbbd0", "class_name": "RelatedNodeInfo"}}, "text": "On a constant currency basis, revenue was up 11.4 percent, reflecting\n11.9 percent constant currency growth in International Healthcare Solutions revenue.\n", "start_char_idx": 54, "end_char_idx": 209, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7fc5adb-f448-4377-a1f7-42d0e2b121af": {"__data__": {"id_": "f7fc5adb-f448-4377-a1f7-42d0e2b121af", "embedding": null, "metadata": {"window": "year quarter in comparison to the prior year quarter.  On a constant currency basis, revenue was up 11.4 percent, reflecting\n11.9 percent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2023 was $2.4 billion, a 6.2 percent increase\ncompared to the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.71 percent in the fiscal 2023 second quarter, a decrease of 13 basis\npoints from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.4\npercent increase, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and reflecting inflationary impacts on certain operating\nexpenses.\n", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2023 was $2.4 billion, a 6.2 percent increase\ncompared to the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.\n", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e2e724-303c-4a3c-a394-4f851829c7bc", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db72d27a283ad0e0c84697fa67a2a9812d01a4838ab15567742056a8f6f30c42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a29eb57a-664e-42e2-b183-38d25402e53c", "node_type": "1", "metadata": {"window": "year quarter in comparison to the prior year quarter.  On a constant currency basis, revenue was up 11.4 percent, reflecting\n11.9 percent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2023 was $2.4 billion, a 6.2 percent increase\ncompared to the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.71 percent in the fiscal 2023 second quarter, a decrease of 13 basis\npoints from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.4\npercent increase, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S. ", "original_text": "On a constant currency basis, revenue was up 11.4 percent, reflecting\n11.9 percent constant currency growth in International Healthcare Solutions revenue.\n", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b08d83fecb9e7135cc48dd96b35730da509c05e2d347d48aa2ded0ab8c2907bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3da5c0e-b712-4d8f-a1ef-1a27f827be65", "node_type": "1", "metadata": {"window": "year quarter in comparison to the prior year quarter.  On a constant currency basis, revenue was up 11.4 percent, reflecting\n11.9 percent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2023 was $2.4 billion, a 6.2 percent increase\ncompared to the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.71 percent in the fiscal 2023 second quarter, a decrease of 13 basis\npoints from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.4\npercent increase, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and reflecting inflationary impacts on certain operating\nexpenses.\n Adjusted Operating Income:  In the second quarter of fiscal 2023, adjusted operating income was $932.1 million, a 1.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 3.6 percent increase in U.S. ", "original_text": "Adjusted gross profit as a percentage of revenue was 3.71 percent in the fiscal 2023 second quarter, a decrease of 13 basis\npoints from the prior year quarter.\n"}, "hash": "353685b6fbb841d4e4f9747e0d9112f110970e2a2a5bdfeefabfc98d28d41aa1", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2023 was $2.4 billion, a 6.2 percent increase\ncompared to the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.\n", "start_char_idx": 209, "end_char_idx": 453, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3da5c0e-b712-4d8f-a1ef-1a27f827be65": {"__data__": {"id_": "c3da5c0e-b712-4d8f-a1ef-1a27f827be65", "embedding": null, "metadata": {"window": "year quarter in comparison to the prior year quarter.  On a constant currency basis, revenue was up 11.4 percent, reflecting\n11.9 percent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2023 was $2.4 billion, a 6.2 percent increase\ncompared to the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.71 percent in the fiscal 2023 second quarter, a decrease of 13 basis\npoints from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.4\npercent increase, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and reflecting inflationary impacts on certain operating\nexpenses.\n Adjusted Operating Income:  In the second quarter of fiscal 2023, adjusted operating income was $932.1 million, a 1.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 3.6 percent increase in U.S. ", "original_text": "Adjusted gross profit as a percentage of revenue was 3.71 percent in the fiscal 2023 second quarter, a decrease of 13 basis\npoints from the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e2e724-303c-4a3c-a394-4f851829c7bc", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db72d27a283ad0e0c84697fa67a2a9812d01a4838ab15567742056a8f6f30c42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7fc5adb-f448-4377-a1f7-42d0e2b121af", "node_type": "1", "metadata": {"window": "year quarter in comparison to the prior year quarter.  On a constant currency basis, revenue was up 11.4 percent, reflecting\n11.9 percent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2023 was $2.4 billion, a 6.2 percent increase\ncompared to the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.71 percent in the fiscal 2023 second quarter, a decrease of 13 basis\npoints from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.4\npercent increase, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and reflecting inflationary impacts on certain operating\nexpenses.\n", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2023 was $2.4 billion, a 6.2 percent increase\ncompared to the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.\n", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed5bf9cc2c1b17477357009b3850c95d839f793302b97b816c12ee7dc573b477", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31ddcb6a-e3f3-44af-9f51-d9f7fec4636e", "node_type": "1", "metadata": {"window": "On a constant currency basis, revenue was up 11.4 percent, reflecting\n11.9 percent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2023 was $2.4 billion, a 6.2 percent increase\ncompared to the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.71 percent in the fiscal 2023 second quarter, a decrease of 13 basis\npoints from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.4\npercent increase, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and reflecting inflationary impacts on certain operating\nexpenses.\n Adjusted Operating Income:  In the second quarter of fiscal 2023, adjusted operating income was $932.1 million, a 1.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 3.6 percent increase in U.S.  Healthcare Solutions,\noffset in part by a 5.9 percent decline in International Healthcare Solutions due to unfavorable foreign currency exchange\nrates in the current year quarter in comparison to the prior year quarter. ", "original_text": "Adjusted Operating Expenses:  In the second quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.4\npercent increase, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S. "}, "hash": "42c6807a872313cfc354e7d3f4a811f80435fc07ceb9d56c6e234f4297fad69e", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit as a percentage of revenue was 3.71 percent in the fiscal 2023 second quarter, a decrease of 13 basis\npoints from the prior year quarter.\n", "start_char_idx": 453, "end_char_idx": 613, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31ddcb6a-e3f3-44af-9f51-d9f7fec4636e": {"__data__": {"id_": "31ddcb6a-e3f3-44af-9f51-d9f7fec4636e", "embedding": null, "metadata": {"window": "On a constant currency basis, revenue was up 11.4 percent, reflecting\n11.9 percent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2023 was $2.4 billion, a 6.2 percent increase\ncompared to the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.71 percent in the fiscal 2023 second quarter, a decrease of 13 basis\npoints from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.4\npercent increase, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and reflecting inflationary impacts on certain operating\nexpenses.\n Adjusted Operating Income:  In the second quarter of fiscal 2023, adjusted operating income was $932.1 million, a 1.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 3.6 percent increase in U.S.  Healthcare Solutions,\noffset in part by a 5.9 percent decline in International Healthcare Solutions due to unfavorable foreign currency exchange\nrates in the current year quarter in comparison to the prior year quarter. ", "original_text": "Adjusted Operating Expenses:  In the second quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.4\npercent increase, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e2e724-303c-4a3c-a394-4f851829c7bc", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db72d27a283ad0e0c84697fa67a2a9812d01a4838ab15567742056a8f6f30c42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3da5c0e-b712-4d8f-a1ef-1a27f827be65", "node_type": "1", "metadata": {"window": "year quarter in comparison to the prior year quarter.  On a constant currency basis, revenue was up 11.4 percent, reflecting\n11.9 percent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2023 was $2.4 billion, a 6.2 percent increase\ncompared to the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.71 percent in the fiscal 2023 second quarter, a decrease of 13 basis\npoints from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.4\npercent increase, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and reflecting inflationary impacts on certain operating\nexpenses.\n Adjusted Operating Income:  In the second quarter of fiscal 2023, adjusted operating income was $932.1 million, a 1.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 3.6 percent increase in U.S. ", "original_text": "Adjusted gross profit as a percentage of revenue was 3.71 percent in the fiscal 2023 second quarter, a decrease of 13 basis\npoints from the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c8da99aed5ffe79fa32f57bd46d3ec2d52208b2e36f9abbf46d8c6745e8896b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e2f8188-3449-4588-9b15-45a6b1253ab0", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2023 was $2.4 billion, a 6.2 percent increase\ncompared to the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.71 percent in the fiscal 2023 second quarter, a decrease of 13 basis\npoints from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.4\npercent increase, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and reflecting inflationary impacts on certain operating\nexpenses.\n Adjusted Operating Income:  In the second quarter of fiscal 2023, adjusted operating income was $932.1 million, a 1.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 3.6 percent increase in U.S.  Healthcare Solutions,\noffset in part by a 5.9 percent decline in International Healthcare Solutions due to unfavorable foreign currency exchange\nrates in the current year quarter in comparison to the prior year quarter.  On a constant currency basis, adjusted operating\nincome increased 4.4 percent compared to the prior year quarter. ", "original_text": "Healthcare Solutions and reflecting inflationary impacts on certain operating\nexpenses.\n"}, "hash": "cd3f4c348ac8d18e906fddb45e26c686a35bd16d3abeb2c6b488404d57f6ded5", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Expenses:  In the second quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.4\npercent increase, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S. ", "start_char_idx": 613, "end_char_idx": 907, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e2f8188-3449-4588-9b15-45a6b1253ab0": {"__data__": {"id_": "7e2f8188-3449-4588-9b15-45a6b1253ab0", "embedding": null, "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2023 was $2.4 billion, a 6.2 percent increase\ncompared to the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.71 percent in the fiscal 2023 second quarter, a decrease of 13 basis\npoints from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.4\npercent increase, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and reflecting inflationary impacts on certain operating\nexpenses.\n Adjusted Operating Income:  In the second quarter of fiscal 2023, adjusted operating income was $932.1 million, a 1.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 3.6 percent increase in U.S.  Healthcare Solutions,\noffset in part by a 5.9 percent decline in International Healthcare Solutions due to unfavorable foreign currency exchange\nrates in the current year quarter in comparison to the prior year quarter.  On a constant currency basis, adjusted operating\nincome increased 4.4 percent compared to the prior year quarter. ", "original_text": "Healthcare Solutions and reflecting inflationary impacts on certain operating\nexpenses.\n", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e2e724-303c-4a3c-a394-4f851829c7bc", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db72d27a283ad0e0c84697fa67a2a9812d01a4838ab15567742056a8f6f30c42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31ddcb6a-e3f3-44af-9f51-d9f7fec4636e", "node_type": "1", "metadata": {"window": "On a constant currency basis, revenue was up 11.4 percent, reflecting\n11.9 percent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2023 was $2.4 billion, a 6.2 percent increase\ncompared to the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.71 percent in the fiscal 2023 second quarter, a decrease of 13 basis\npoints from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.4\npercent increase, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and reflecting inflationary impacts on certain operating\nexpenses.\n Adjusted Operating Income:  In the second quarter of fiscal 2023, adjusted operating income was $932.1 million, a 1.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 3.6 percent increase in U.S.  Healthcare Solutions,\noffset in part by a 5.9 percent decline in International Healthcare Solutions due to unfavorable foreign currency exchange\nrates in the current year quarter in comparison to the prior year quarter. ", "original_text": "Adjusted Operating Expenses:  In the second quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.4\npercent increase, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "993af1ad076785ad4c61e12d58f02c0769a555ec3188d84a13be4b8ef0ffa61a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "219bd29e-7f9b-4af9-8e30-b290926fb587", "node_type": "1", "metadata": {"window": "Adjusted gross profit as a percentage of revenue was 3.71 percent in the fiscal 2023 second quarter, a decrease of 13 basis\npoints from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.4\npercent increase, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and reflecting inflationary impacts on certain operating\nexpenses.\n Adjusted Operating Income:  In the second quarter of fiscal 2023, adjusted operating income was $932.1 million, a 1.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 3.6 percent increase in U.S.  Healthcare Solutions,\noffset in part by a 5.9 percent decline in International Healthcare Solutions due to unfavorable foreign currency exchange\nrates in the current year quarter in comparison to the prior year quarter.  On a constant currency basis, adjusted operating\nincome increased 4.4 percent compared to the prior year quarter.  On a constant currency basis, International Healthcare\nSolutions segment operating income increased 7.3 percent. ", "original_text": "Adjusted Operating Income:  In the second quarter of fiscal 2023, adjusted operating income was $932.1 million, a 1.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 3.6 percent increase in U.S. "}, "hash": "b8bd957355536d07e600239f666051925710fe0163cbd2c638c9d5b1b8a3d1f5", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions and reflecting inflationary impacts on certain operating\nexpenses.\n", "start_char_idx": 907, "end_char_idx": 995, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "219bd29e-7f9b-4af9-8e30-b290926fb587": {"__data__": {"id_": "219bd29e-7f9b-4af9-8e30-b290926fb587", "embedding": null, "metadata": {"window": "Adjusted gross profit as a percentage of revenue was 3.71 percent in the fiscal 2023 second quarter, a decrease of 13 basis\npoints from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.4\npercent increase, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and reflecting inflationary impacts on certain operating\nexpenses.\n Adjusted Operating Income:  In the second quarter of fiscal 2023, adjusted operating income was $932.1 million, a 1.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 3.6 percent increase in U.S.  Healthcare Solutions,\noffset in part by a 5.9 percent decline in International Healthcare Solutions due to unfavorable foreign currency exchange\nrates in the current year quarter in comparison to the prior year quarter.  On a constant currency basis, adjusted operating\nincome increased 4.4 percent compared to the prior year quarter.  On a constant currency basis, International Healthcare\nSolutions segment operating income increased 7.3 percent. ", "original_text": "Adjusted Operating Income:  In the second quarter of fiscal 2023, adjusted operating income was $932.1 million, a 1.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 3.6 percent increase in U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e2e724-303c-4a3c-a394-4f851829c7bc", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db72d27a283ad0e0c84697fa67a2a9812d01a4838ab15567742056a8f6f30c42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e2f8188-3449-4588-9b15-45a6b1253ab0", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2023 was $2.4 billion, a 6.2 percent increase\ncompared to the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.71 percent in the fiscal 2023 second quarter, a decrease of 13 basis\npoints from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.4\npercent increase, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and reflecting inflationary impacts on certain operating\nexpenses.\n Adjusted Operating Income:  In the second quarter of fiscal 2023, adjusted operating income was $932.1 million, a 1.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 3.6 percent increase in U.S.  Healthcare Solutions,\noffset in part by a 5.9 percent decline in International Healthcare Solutions due to unfavorable foreign currency exchange\nrates in the current year quarter in comparison to the prior year quarter.  On a constant currency basis, adjusted operating\nincome increased 4.4 percent compared to the prior year quarter. ", "original_text": "Healthcare Solutions and reflecting inflationary impacts on certain operating\nexpenses.\n", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d722f56db9a2e51e0d41e1adf24b6d552430822d5c88b2506dc21cfdbaaae2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "168f6baf-a5b4-47c1-8f45-4a7464ba0f09", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the second quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.4\npercent increase, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and reflecting inflationary impacts on certain operating\nexpenses.\n Adjusted Operating Income:  In the second quarter of fiscal 2023, adjusted operating income was $932.1 million, a 1.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 3.6 percent increase in U.S.  Healthcare Solutions,\noffset in part by a 5.9 percent decline in International Healthcare Solutions due to unfavorable foreign currency exchange\nrates in the current year quarter in comparison to the prior year quarter.  On a constant currency basis, adjusted operating\nincome increased 4.4 percent compared to the prior year quarter.  On a constant currency basis, International Healthcare\nSolutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of revenue was 1.47\npercent in the fiscal 2023 second quarter, a decrease of 12 basis points when compared to the prior year quarter.\n", "original_text": "Healthcare Solutions,\noffset in part by a 5.9 percent decline in International Healthcare Solutions due to unfavorable foreign currency exchange\nrates in the current year quarter in comparison to the prior year quarter. "}, "hash": "694ba58374a8713315eecf93bca08b268b883194677a6cd211408ad58c8b83c6", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Income:  In the second quarter of fiscal 2023, adjusted operating income was $932.1 million, a 1.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 3.6 percent increase in U.S. ", "start_char_idx": 995, "end_char_idx": 1225, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "168f6baf-a5b4-47c1-8f45-4a7464ba0f09": {"__data__": {"id_": "168f6baf-a5b4-47c1-8f45-4a7464ba0f09", "embedding": null, "metadata": {"window": "Adjusted Operating Expenses:  In the second quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.4\npercent increase, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and reflecting inflationary impacts on certain operating\nexpenses.\n Adjusted Operating Income:  In the second quarter of fiscal 2023, adjusted operating income was $932.1 million, a 1.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 3.6 percent increase in U.S.  Healthcare Solutions,\noffset in part by a 5.9 percent decline in International Healthcare Solutions due to unfavorable foreign currency exchange\nrates in the current year quarter in comparison to the prior year quarter.  On a constant currency basis, adjusted operating\nincome increased 4.4 percent compared to the prior year quarter.  On a constant currency basis, International Healthcare\nSolutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of revenue was 1.47\npercent in the fiscal 2023 second quarter, a decrease of 12 basis points when compared to the prior year quarter.\n", "original_text": "Healthcare Solutions,\noffset in part by a 5.9 percent decline in International Healthcare Solutions due to unfavorable foreign currency exchange\nrates in the current year quarter in comparison to the prior year quarter. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e2e724-303c-4a3c-a394-4f851829c7bc", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db72d27a283ad0e0c84697fa67a2a9812d01a4838ab15567742056a8f6f30c42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "219bd29e-7f9b-4af9-8e30-b290926fb587", "node_type": "1", "metadata": {"window": "Adjusted gross profit as a percentage of revenue was 3.71 percent in the fiscal 2023 second quarter, a decrease of 13 basis\npoints from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.4\npercent increase, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and reflecting inflationary impacts on certain operating\nexpenses.\n Adjusted Operating Income:  In the second quarter of fiscal 2023, adjusted operating income was $932.1 million, a 1.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 3.6 percent increase in U.S.  Healthcare Solutions,\noffset in part by a 5.9 percent decline in International Healthcare Solutions due to unfavorable foreign currency exchange\nrates in the current year quarter in comparison to the prior year quarter.  On a constant currency basis, adjusted operating\nincome increased 4.4 percent compared to the prior year quarter.  On a constant currency basis, International Healthcare\nSolutions segment operating income increased 7.3 percent. ", "original_text": "Adjusted Operating Income:  In the second quarter of fiscal 2023, adjusted operating income was $932.1 million, a 1.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 3.6 percent increase in U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a295d23de15ca3ca2be3e54946951de329153be5f592e286f20164993e150ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94dacbd4-6937-4c5e-b48d-538cbbae7d33", "node_type": "1", "metadata": {"window": "Healthcare Solutions and reflecting inflationary impacts on certain operating\nexpenses.\n Adjusted Operating Income:  In the second quarter of fiscal 2023, adjusted operating income was $932.1 million, a 1.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 3.6 percent increase in U.S.  Healthcare Solutions,\noffset in part by a 5.9 percent decline in International Healthcare Solutions due to unfavorable foreign currency exchange\nrates in the current year quarter in comparison to the prior year quarter.  On a constant currency basis, adjusted operating\nincome increased 4.4 percent compared to the prior year quarter.  On a constant currency basis, International Healthcare\nSolutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of revenue was 1.47\npercent in the fiscal 2023 second quarter, a decrease of 12 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "On a constant currency basis, adjusted operating\nincome increased 4.4 percent compared to the prior year quarter. "}, "hash": "54b2581001d62e3f9952cb6e010139bf7322ef12a8a87b34e5e30146ba3d27f9", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions,\noffset in part by a 5.9 percent decline in International Healthcare Solutions due to unfavorable foreign currency exchange\nrates in the current year quarter in comparison to the prior year quarter. ", "start_char_idx": 1225, "end_char_idx": 1445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94dacbd4-6937-4c5e-b48d-538cbbae7d33": {"__data__": {"id_": "94dacbd4-6937-4c5e-b48d-538cbbae7d33", "embedding": null, "metadata": {"window": "Healthcare Solutions and reflecting inflationary impacts on certain operating\nexpenses.\n Adjusted Operating Income:  In the second quarter of fiscal 2023, adjusted operating income was $932.1 million, a 1.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 3.6 percent increase in U.S.  Healthcare Solutions,\noffset in part by a 5.9 percent decline in International Healthcare Solutions due to unfavorable foreign currency exchange\nrates in the current year quarter in comparison to the prior year quarter.  On a constant currency basis, adjusted operating\nincome increased 4.4 percent compared to the prior year quarter.  On a constant currency basis, International Healthcare\nSolutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of revenue was 1.47\npercent in the fiscal 2023 second quarter, a decrease of 12 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "On a constant currency basis, adjusted operating\nincome increased 4.4 percent compared to the prior year quarter. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e2e724-303c-4a3c-a394-4f851829c7bc", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db72d27a283ad0e0c84697fa67a2a9812d01a4838ab15567742056a8f6f30c42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "168f6baf-a5b4-47c1-8f45-4a7464ba0f09", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the second quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.4\npercent increase, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and reflecting inflationary impacts on certain operating\nexpenses.\n Adjusted Operating Income:  In the second quarter of fiscal 2023, adjusted operating income was $932.1 million, a 1.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 3.6 percent increase in U.S.  Healthcare Solutions,\noffset in part by a 5.9 percent decline in International Healthcare Solutions due to unfavorable foreign currency exchange\nrates in the current year quarter in comparison to the prior year quarter.  On a constant currency basis, adjusted operating\nincome increased 4.4 percent compared to the prior year quarter.  On a constant currency basis, International Healthcare\nSolutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of revenue was 1.47\npercent in the fiscal 2023 second quarter, a decrease of 12 basis points when compared to the prior year quarter.\n", "original_text": "Healthcare Solutions,\noffset in part by a 5.9 percent decline in International Healthcare Solutions due to unfavorable foreign currency exchange\nrates in the current year quarter in comparison to the prior year quarter. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f3502253a771f14c69307707cf26eee47548f9b0ba296e8f879945fc32683bfe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "199e38b8-d6f7-4052-a216-5080c7979d69", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the second quarter of fiscal 2023, adjusted operating income was $932.1 million, a 1.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 3.6 percent increase in U.S.  Healthcare Solutions,\noffset in part by a 5.9 percent decline in International Healthcare Solutions due to unfavorable foreign currency exchange\nrates in the current year quarter in comparison to the prior year quarter.  On a constant currency basis, adjusted operating\nincome increased 4.4 percent compared to the prior year quarter.  On a constant currency basis, International Healthcare\nSolutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of revenue was 1.47\npercent in the fiscal 2023 second quarter, a decrease of 12 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus the prior year quarter primarily due to\nincreases in borrowings and interest rates associated with variable-rate debt, offset in part by an increase in interest income\nas a result of higher investment interest rates.\n", "original_text": "On a constant currency basis, International Healthcare\nSolutions segment operating income increased 7.3 percent. "}, "hash": "650ef83910d6efea0c2bc14e98ad5c3d60cbd8e6fa5941c17417375ed8dcb8a3", "class_name": "RelatedNodeInfo"}}, "text": "On a constant currency basis, adjusted operating\nincome increased 4.4 percent compared to the prior year quarter. ", "start_char_idx": 1445, "end_char_idx": 1559, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "199e38b8-d6f7-4052-a216-5080c7979d69": {"__data__": {"id_": "199e38b8-d6f7-4052-a216-5080c7979d69", "embedding": null, "metadata": {"window": "Adjusted Operating Income:  In the second quarter of fiscal 2023, adjusted operating income was $932.1 million, a 1.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 3.6 percent increase in U.S.  Healthcare Solutions,\noffset in part by a 5.9 percent decline in International Healthcare Solutions due to unfavorable foreign currency exchange\nrates in the current year quarter in comparison to the prior year quarter.  On a constant currency basis, adjusted operating\nincome increased 4.4 percent compared to the prior year quarter.  On a constant currency basis, International Healthcare\nSolutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of revenue was 1.47\npercent in the fiscal 2023 second quarter, a decrease of 12 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus the prior year quarter primarily due to\nincreases in borrowings and interest rates associated with variable-rate debt, offset in part by an increase in interest income\nas a result of higher investment interest rates.\n", "original_text": "On a constant currency basis, International Healthcare\nSolutions segment operating income increased 7.3 percent. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e2e724-303c-4a3c-a394-4f851829c7bc", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db72d27a283ad0e0c84697fa67a2a9812d01a4838ab15567742056a8f6f30c42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94dacbd4-6937-4c5e-b48d-538cbbae7d33", "node_type": "1", "metadata": {"window": "Healthcare Solutions and reflecting inflationary impacts on certain operating\nexpenses.\n Adjusted Operating Income:  In the second quarter of fiscal 2023, adjusted operating income was $932.1 million, a 1.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 3.6 percent increase in U.S.  Healthcare Solutions,\noffset in part by a 5.9 percent decline in International Healthcare Solutions due to unfavorable foreign currency exchange\nrates in the current year quarter in comparison to the prior year quarter.  On a constant currency basis, adjusted operating\nincome increased 4.4 percent compared to the prior year quarter.  On a constant currency basis, International Healthcare\nSolutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of revenue was 1.47\npercent in the fiscal 2023 second quarter, a decrease of 12 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "On a constant currency basis, adjusted operating\nincome increased 4.4 percent compared to the prior year quarter. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a934ca2a50430549fe5f0464fadde199da87baafa865ad3e5e67af2400599cbe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62660e88-ea6b-484f-89fa-ff84f0a620f1", "node_type": "1", "metadata": {"window": "Healthcare Solutions,\noffset in part by a 5.9 percent decline in International Healthcare Solutions due to unfavorable foreign currency exchange\nrates in the current year quarter in comparison to the prior year quarter.  On a constant currency basis, adjusted operating\nincome increased 4.4 percent compared to the prior year quarter.  On a constant currency basis, International Healthcare\nSolutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of revenue was 1.47\npercent in the fiscal 2023 second quarter, a decrease of 12 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus the prior year quarter primarily due to\nincreases in borrowings and interest rates associated with variable-rate debt, offset in part by an increase in interest income\nas a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.0 percent for the second quarter of fiscal 2023 compared\nto 21.0 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a percentage of revenue was 1.47\npercent in the fiscal 2023 second quarter, a decrease of 12 basis points when compared to the prior year quarter.\n"}, "hash": "43158a0ab386246fa49de0120472e9673526a065e467ad2a5ca4a7432f29bd9f", "class_name": "RelatedNodeInfo"}}, "text": "On a constant currency basis, International Healthcare\nSolutions segment operating income increased 7.3 percent. ", "start_char_idx": 1559, "end_char_idx": 1672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62660e88-ea6b-484f-89fa-ff84f0a620f1": {"__data__": {"id_": "62660e88-ea6b-484f-89fa-ff84f0a620f1", "embedding": null, "metadata": {"window": "Healthcare Solutions,\noffset in part by a 5.9 percent decline in International Healthcare Solutions due to unfavorable foreign currency exchange\nrates in the current year quarter in comparison to the prior year quarter.  On a constant currency basis, adjusted operating\nincome increased 4.4 percent compared to the prior year quarter.  On a constant currency basis, International Healthcare\nSolutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of revenue was 1.47\npercent in the fiscal 2023 second quarter, a decrease of 12 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus the prior year quarter primarily due to\nincreases in borrowings and interest rates associated with variable-rate debt, offset in part by an increase in interest income\nas a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.0 percent for the second quarter of fiscal 2023 compared\nto 21.0 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a percentage of revenue was 1.47\npercent in the fiscal 2023 second quarter, a decrease of 12 basis points when compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e2e724-303c-4a3c-a394-4f851829c7bc", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db72d27a283ad0e0c84697fa67a2a9812d01a4838ab15567742056a8f6f30c42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "199e38b8-d6f7-4052-a216-5080c7979d69", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the second quarter of fiscal 2023, adjusted operating income was $932.1 million, a 1.7 percent\nincrease compared to the same period in the prior fiscal year, driven by a 3.6 percent increase in U.S.  Healthcare Solutions,\noffset in part by a 5.9 percent decline in International Healthcare Solutions due to unfavorable foreign currency exchange\nrates in the current year quarter in comparison to the prior year quarter.  On a constant currency basis, adjusted operating\nincome increased 4.4 percent compared to the prior year quarter.  On a constant currency basis, International Healthcare\nSolutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of revenue was 1.47\npercent in the fiscal 2023 second quarter, a decrease of 12 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus the prior year quarter primarily due to\nincreases in borrowings and interest rates associated with variable-rate debt, offset in part by an increase in interest income\nas a result of higher investment interest rates.\n", "original_text": "On a constant currency basis, International Healthcare\nSolutions segment operating income increased 7.3 percent. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a934526b3b072a601dab3f64720c52398191e2c8cdd4ec3b05cbaec9bc1c37b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae4d5271-9f17-4cad-82e5-9690991fd840", "node_type": "1", "metadata": {"window": "On a constant currency basis, adjusted operating\nincome increased 4.4 percent compared to the prior year quarter.  On a constant currency basis, International Healthcare\nSolutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of revenue was 1.47\npercent in the fiscal 2023 second quarter, a decrease of 12 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus the prior year quarter primarily due to\nincreases in borrowings and interest rates associated with variable-rate debt, offset in part by an increase in interest income\nas a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.0 percent for the second quarter of fiscal 2023 compared\nto 21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.50 in the second quarter of fiscal 2023, an\n8.7 percent increase compared to $3.22 in the previous fiscal year\u2019s second quarter. ", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. "}, "hash": "8332b1a8527fdf43395b14c9a57cb9c56ea0b9b6924357efc367e89a2787b224", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income as a percentage of revenue was 1.47\npercent in the fiscal 2023 second quarter, a decrease of 12 basis points when compared to the prior year quarter.\n", "start_char_idx": 1672, "end_char_idx": 1848, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae4d5271-9f17-4cad-82e5-9690991fd840": {"__data__": {"id_": "ae4d5271-9f17-4cad-82e5-9690991fd840", "embedding": null, "metadata": {"window": "On a constant currency basis, adjusted operating\nincome increased 4.4 percent compared to the prior year quarter.  On a constant currency basis, International Healthcare\nSolutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of revenue was 1.47\npercent in the fiscal 2023 second quarter, a decrease of 12 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus the prior year quarter primarily due to\nincreases in borrowings and interest rates associated with variable-rate debt, offset in part by an increase in interest income\nas a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.0 percent for the second quarter of fiscal 2023 compared\nto 21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.50 in the second quarter of fiscal 2023, an\n8.7 percent increase compared to $3.22 in the previous fiscal year\u2019s second quarter. ", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e2e724-303c-4a3c-a394-4f851829c7bc", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db72d27a283ad0e0c84697fa67a2a9812d01a4838ab15567742056a8f6f30c42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62660e88-ea6b-484f-89fa-ff84f0a620f1", "node_type": "1", "metadata": {"window": "Healthcare Solutions,\noffset in part by a 5.9 percent decline in International Healthcare Solutions due to unfavorable foreign currency exchange\nrates in the current year quarter in comparison to the prior year quarter.  On a constant currency basis, adjusted operating\nincome increased 4.4 percent compared to the prior year quarter.  On a constant currency basis, International Healthcare\nSolutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of revenue was 1.47\npercent in the fiscal 2023 second quarter, a decrease of 12 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus the prior year quarter primarily due to\nincreases in borrowings and interest rates associated with variable-rate debt, offset in part by an increase in interest income\nas a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.0 percent for the second quarter of fiscal 2023 compared\nto 21.0 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a percentage of revenue was 1.47\npercent in the fiscal 2023 second quarter, a decrease of 12 basis points when compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ce4579e08a9edb631069637163f193c296cf7b6648ef1a5b20efe47f188eccd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74c302f1-4d44-4f3b-9f94-e32decd05c95", "node_type": "1", "metadata": {"window": "On a constant currency basis, International Healthcare\nSolutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of revenue was 1.47\npercent in the fiscal 2023 second quarter, a decrease of 12 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus the prior year quarter primarily due to\nincreases in borrowings and interest rates associated with variable-rate debt, offset in part by an increase in interest income\nas a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.0 percent for the second quarter of fiscal 2023 compared\nto 21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.50 in the second quarter of fiscal 2023, an\n8.7 percent increase compared to $3.22 in the previous fiscal year\u2019s second quarter.  On a constant currency basis, adjusted\ndiluted earnings per share increased 11.2 percent compared to the prior year quarter.\n", "original_text": "In the second quarter of\nfiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus the prior year quarter primarily due to\nincreases in borrowings and interest rates associated with variable-rate debt, offset in part by an increase in interest income\nas a result of higher investment interest rates.\n"}, "hash": "a9e5a9b4ff5d54c73d10feeaf335be7a382dc5943cf48927b11f4beba3241656", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "start_char_idx": 1848, "end_char_idx": 1947, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74c302f1-4d44-4f3b-9f94-e32decd05c95": {"__data__": {"id_": "74c302f1-4d44-4f3b-9f94-e32decd05c95", "embedding": null, "metadata": {"window": "On a constant currency basis, International Healthcare\nSolutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of revenue was 1.47\npercent in the fiscal 2023 second quarter, a decrease of 12 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus the prior year quarter primarily due to\nincreases in borrowings and interest rates associated with variable-rate debt, offset in part by an increase in interest income\nas a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.0 percent for the second quarter of fiscal 2023 compared\nto 21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.50 in the second quarter of fiscal 2023, an\n8.7 percent increase compared to $3.22 in the previous fiscal year\u2019s second quarter.  On a constant currency basis, adjusted\ndiluted earnings per share increased 11.2 percent compared to the prior year quarter.\n", "original_text": "In the second quarter of\nfiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus the prior year quarter primarily due to\nincreases in borrowings and interest rates associated with variable-rate debt, offset in part by an increase in interest income\nas a result of higher investment interest rates.\n", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e2e724-303c-4a3c-a394-4f851829c7bc", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db72d27a283ad0e0c84697fa67a2a9812d01a4838ab15567742056a8f6f30c42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae4d5271-9f17-4cad-82e5-9690991fd840", "node_type": "1", "metadata": {"window": "On a constant currency basis, adjusted operating\nincome increased 4.4 percent compared to the prior year quarter.  On a constant currency basis, International Healthcare\nSolutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of revenue was 1.47\npercent in the fiscal 2023 second quarter, a decrease of 12 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus the prior year quarter primarily due to\nincreases in borrowings and interest rates associated with variable-rate debt, offset in part by an increase in interest income\nas a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.0 percent for the second quarter of fiscal 2023 compared\nto 21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.50 in the second quarter of fiscal 2023, an\n8.7 percent increase compared to $3.22 in the previous fiscal year\u2019s second quarter. ", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51fc755457df36f21163b98f269737e90f3a99a410311987324136ce850bc204", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77348027-7b24-4989-8a4f-0a3866fac559", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of revenue was 1.47\npercent in the fiscal 2023 second quarter, a decrease of 12 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus the prior year quarter primarily due to\nincreases in borrowings and interest rates associated with variable-rate debt, offset in part by an increase in interest income\nas a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.0 percent for the second quarter of fiscal 2023 compared\nto 21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.50 in the second quarter of fiscal 2023, an\n8.7 percent increase compared to $3.22 in the previous fiscal year\u2019s second quarter.  On a constant currency basis, adjusted\ndiluted earnings per share increased 11.2 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.0 percent for the second quarter of fiscal 2023 compared\nto 21.0 percent in the prior year quarter.\n"}, "hash": "7daaf1e7a6b3130b1263449cb253fa766b4ad09993ae099bc6a821b66eb70e98", "class_name": "RelatedNodeInfo"}}, "text": "In the second quarter of\nfiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus the prior year quarter primarily due to\nincreases in borrowings and interest rates associated with variable-rate debt, offset in part by an increase in interest income\nas a result of higher investment interest rates.\n", "start_char_idx": 1947, "end_char_idx": 2270, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77348027-7b24-4989-8a4f-0a3866fac559": {"__data__": {"id_": "77348027-7b24-4989-8a4f-0a3866fac559", "embedding": null, "metadata": {"window": "Adjusted operating income as a percentage of revenue was 1.47\npercent in the fiscal 2023 second quarter, a decrease of 12 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus the prior year quarter primarily due to\nincreases in borrowings and interest rates associated with variable-rate debt, offset in part by an increase in interest income\nas a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.0 percent for the second quarter of fiscal 2023 compared\nto 21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.50 in the second quarter of fiscal 2023, an\n8.7 percent increase compared to $3.22 in the previous fiscal year\u2019s second quarter.  On a constant currency basis, adjusted\ndiluted earnings per share increased 11.2 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.0 percent for the second quarter of fiscal 2023 compared\nto 21.0 percent in the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e2e724-303c-4a3c-a394-4f851829c7bc", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db72d27a283ad0e0c84697fa67a2a9812d01a4838ab15567742056a8f6f30c42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74c302f1-4d44-4f3b-9f94-e32decd05c95", "node_type": "1", "metadata": {"window": "On a constant currency basis, International Healthcare\nSolutions segment operating income increased 7.3 percent.  Adjusted operating income as a percentage of revenue was 1.47\npercent in the fiscal 2023 second quarter, a decrease of 12 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus the prior year quarter primarily due to\nincreases in borrowings and interest rates associated with variable-rate debt, offset in part by an increase in interest income\nas a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.0 percent for the second quarter of fiscal 2023 compared\nto 21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.50 in the second quarter of fiscal 2023, an\n8.7 percent increase compared to $3.22 in the previous fiscal year\u2019s second quarter.  On a constant currency basis, adjusted\ndiluted earnings per share increased 11.2 percent compared to the prior year quarter.\n", "original_text": "In the second quarter of\nfiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus the prior year quarter primarily due to\nincreases in borrowings and interest rates associated with variable-rate debt, offset in part by an increase in interest income\nas a result of higher investment interest rates.\n", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d3ac229e4d1602722635a0722f4a9c54e5310bc87c41c4e1b15447eff883c9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "833c4bf9-f693-4659-bf04-0734d22d4b88", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus the prior year quarter primarily due to\nincreases in borrowings and interest rates associated with variable-rate debt, offset in part by an increase in interest income\nas a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.0 percent for the second quarter of fiscal 2023 compared\nto 21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.50 in the second quarter of fiscal 2023, an\n8.7 percent increase compared to $3.22 in the previous fiscal year\u2019s second quarter.  On a constant currency basis, adjusted\ndiluted earnings per share increased 11.2 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2023 were 204.3 million, a decrease of 7.7 million\nshares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.50 in the second quarter of fiscal 2023, an\n8.7 percent increase compared to $3.22 in the previous fiscal year\u2019s second quarter. "}, "hash": "1a97eca608a9795b4848c9321fedb580b4bf4986db3c086ac9de07f621b887af", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.0 percent for the second quarter of fiscal 2023 compared\nto 21.0 percent in the prior year quarter.\n", "start_char_idx": 2270, "end_char_idx": 2439, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "833c4bf9-f693-4659-bf04-0734d22d4b88": {"__data__": {"id_": "833c4bf9-f693-4659-bf04-0734d22d4b88", "embedding": null, "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus the prior year quarter primarily due to\nincreases in borrowings and interest rates associated with variable-rate debt, offset in part by an increase in interest income\nas a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.0 percent for the second quarter of fiscal 2023 compared\nto 21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.50 in the second quarter of fiscal 2023, an\n8.7 percent increase compared to $3.22 in the previous fiscal year\u2019s second quarter.  On a constant currency basis, adjusted\ndiluted earnings per share increased 11.2 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2023 were 204.3 million, a decrease of 7.7 million\nshares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.50 in the second quarter of fiscal 2023, an\n8.7 percent increase compared to $3.22 in the previous fiscal year\u2019s second quarter. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e2e724-303c-4a3c-a394-4f851829c7bc", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db72d27a283ad0e0c84697fa67a2a9812d01a4838ab15567742056a8f6f30c42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77348027-7b24-4989-8a4f-0a3866fac559", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of revenue was 1.47\npercent in the fiscal 2023 second quarter, a decrease of 12 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus the prior year quarter primarily due to\nincreases in borrowings and interest rates associated with variable-rate debt, offset in part by an increase in interest income\nas a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.0 percent for the second quarter of fiscal 2023 compared\nto 21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.50 in the second quarter of fiscal 2023, an\n8.7 percent increase compared to $3.22 in the previous fiscal year\u2019s second quarter.  On a constant currency basis, adjusted\ndiluted earnings per share increased 11.2 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.0 percent for the second quarter of fiscal 2023 compared\nto 21.0 percent in the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "264587c4ecd3c3933b856a31e7b8b1b411704201f7bd8d6f1b8f8e24976b6a36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05400520-791d-41f8-9c1c-e74b7473a104", "node_type": "1", "metadata": {"window": "In the second quarter of\nfiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus the prior year quarter primarily due to\nincreases in borrowings and interest rates associated with variable-rate debt, offset in part by an increase in interest income\nas a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.0 percent for the second quarter of fiscal 2023 compared\nto 21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.50 in the second quarter of fiscal 2023, an\n8.7 percent increase compared to $3.22 in the previous fiscal year\u2019s second quarter.  On a constant currency basis, adjusted\ndiluted earnings per share increased 11.2 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2023 were 204.3 million, a decrease of 7.7 million\nshares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "original_text": "On a constant currency basis, adjusted\ndiluted earnings per share increased 11.2 percent compared to the prior year quarter.\n"}, "hash": "7946355f542c7142bc25b720836dcd526daa92e6843294e7db7db243412f400e", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.50 in the second quarter of fiscal 2023, an\n8.7 percent increase compared to $3.22 in the previous fiscal year\u2019s second quarter. ", "start_char_idx": 2439, "end_char_idx": 2649, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05400520-791d-41f8-9c1c-e74b7473a104": {"__data__": {"id_": "05400520-791d-41f8-9c1c-e74b7473a104", "embedding": null, "metadata": {"window": "In the second quarter of\nfiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus the prior year quarter primarily due to\nincreases in borrowings and interest rates associated with variable-rate debt, offset in part by an increase in interest income\nas a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.0 percent for the second quarter of fiscal 2023 compared\nto 21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.50 in the second quarter of fiscal 2023, an\n8.7 percent increase compared to $3.22 in the previous fiscal year\u2019s second quarter.  On a constant currency basis, adjusted\ndiluted earnings per share increased 11.2 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2023 were 204.3 million, a decrease of 7.7 million\nshares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "original_text": "On a constant currency basis, adjusted\ndiluted earnings per share increased 11.2 percent compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e2e724-303c-4a3c-a394-4f851829c7bc", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db72d27a283ad0e0c84697fa67a2a9812d01a4838ab15567742056a8f6f30c42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "833c4bf9-f693-4659-bf04-0734d22d4b88", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus the prior year quarter primarily due to\nincreases in borrowings and interest rates associated with variable-rate debt, offset in part by an increase in interest income\nas a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.0 percent for the second quarter of fiscal 2023 compared\nto 21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.50 in the second quarter of fiscal 2023, an\n8.7 percent increase compared to $3.22 in the previous fiscal year\u2019s second quarter.  On a constant currency basis, adjusted\ndiluted earnings per share increased 11.2 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2023 were 204.3 million, a decrease of 7.7 million\nshares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.50 in the second quarter of fiscal 2023, an\n8.7 percent increase compared to $3.22 in the previous fiscal year\u2019s second quarter. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "93a0f42176ce25b09093c6299f05269a1a2e1c701ceab99eda864a656bafbb50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "490f2417-a24b-4cee-9261-afdcf7ecff5b", "node_type": "1", "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.0 percent for the second quarter of fiscal 2023 compared\nto 21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.50 in the second quarter of fiscal 2023, an\n8.7 percent increase compared to $3.22 in the previous fiscal year\u2019s second quarter.  On a constant currency basis, adjusted\ndiluted earnings per share increased 11.2 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2023 were 204.3 million, a decrease of 7.7 million\nshares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. "}, "hash": "a0b8a25743a8fa0c59a8122bbcb8a1004486925ca8884a8970d4417c6dc07b15", "class_name": "RelatedNodeInfo"}}, "text": "On a constant currency basis, adjusted\ndiluted earnings per share increased 11.2 percent compared to the prior year quarter.\n", "start_char_idx": 2649, "end_char_idx": 2774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "490f2417-a24b-4cee-9261-afdcf7ecff5b": {"__data__": {"id_": "490f2417-a24b-4cee-9261-afdcf7ecff5b", "embedding": null, "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.0 percent for the second quarter of fiscal 2023 compared\nto 21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.50 in the second quarter of fiscal 2023, an\n8.7 percent increase compared to $3.22 in the previous fiscal year\u2019s second quarter.  On a constant currency basis, adjusted\ndiluted earnings per share increased 11.2 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2023 were 204.3 million, a decrease of 7.7 million\nshares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e2e724-303c-4a3c-a394-4f851829c7bc", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db72d27a283ad0e0c84697fa67a2a9812d01a4838ab15567742056a8f6f30c42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05400520-791d-41f8-9c1c-e74b7473a104", "node_type": "1", "metadata": {"window": "In the second quarter of\nfiscal 2023, net interest expense of $64.1 million increased 21.2 percent versus the prior year quarter primarily due to\nincreases in borrowings and interest rates associated with variable-rate debt, offset in part by an increase in interest income\nas a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.0 percent for the second quarter of fiscal 2023 compared\nto 21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.50 in the second quarter of fiscal 2023, an\n8.7 percent increase compared to $3.22 in the previous fiscal year\u2019s second quarter.  On a constant currency basis, adjusted\ndiluted earnings per share increased 11.2 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2023 were 204.3 million, a decrease of 7.7 million\nshares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "original_text": "On a constant currency basis, adjusted\ndiluted earnings per share increased 11.2 percent compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d9066844aebd42a96bdda492896d41e96097d87b85b1f24c60f21414bf8cf68d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1fa9961b-0205-4640-885a-032ea5cb9f86", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.50 in the second quarter of fiscal 2023, an\n8.7 percent increase compared to $3.22 in the previous fiscal year\u2019s second quarter.  On a constant currency basis, adjusted\ndiluted earnings per share increased 11.2 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2023 were 204.3 million, a decrease of 7.7 million\nshares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S. ", "original_text": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2023 were 204.3 million, a decrease of 7.7 million\nshares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n"}, "hash": "bb6f6ac3ce6abf8b8a21e4225978cac08d7b13e698f857299be756ef92712226", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "start_char_idx": 2774, "end_char_idx": 2884, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1fa9961b-0205-4640-885a-032ea5cb9f86": {"__data__": {"id_": "1fa9961b-0205-4640-885a-032ea5cb9f86", "embedding": null, "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.50 in the second quarter of fiscal 2023, an\n8.7 percent increase compared to $3.22 in the previous fiscal year\u2019s second quarter.  On a constant currency basis, adjusted\ndiluted earnings per share increased 11.2 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2023 were 204.3 million, a decrease of 7.7 million\nshares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S. ", "original_text": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2023 were 204.3 million, a decrease of 7.7 million\nshares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e2e724-303c-4a3c-a394-4f851829c7bc", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db72d27a283ad0e0c84697fa67a2a9812d01a4838ab15567742056a8f6f30c42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "490f2417-a24b-4cee-9261-afdcf7ecff5b", "node_type": "1", "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.0 percent for the second quarter of fiscal 2023 compared\nto 21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.50 in the second quarter of fiscal 2023, an\n8.7 percent increase compared to $3.22 in the previous fiscal year\u2019s second quarter.  On a constant currency basis, adjusted\ndiluted earnings per share increased 11.2 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2023 were 204.3 million, a decrease of 7.7 million\nshares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "745f5bc1c5ee0f5084d1a621b2a25eeb24041f835a94797ee1f0a7cf0e5b379c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1248b045-1dad-4160-b9f0-5b9ebfa7c9f6", "node_type": "1", "metadata": {"window": "On a constant currency basis, adjusted\ndiluted earnings per share increased 11.2 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2023 were 204.3 million, a decrease of 7.7 million\nshares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S. ", "original_text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. "}, "hash": "f6c6d0946c5f31cac160f07ef64fc85645b92a733e4f283227d38acd016abc6b", "class_name": "RelatedNodeInfo"}}, "text": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2023 were 204.3 million, a decrease of 7.7 million\nshares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n", "start_char_idx": 2884, "end_char_idx": 3123, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1248b045-1dad-4160-b9f0-5b9ebfa7c9f6": {"__data__": {"id_": "1248b045-1dad-4160-b9f0-5b9ebfa7c9f6", "embedding": null, "metadata": {"window": "On a constant currency basis, adjusted\ndiluted earnings per share increased 11.2 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2023 were 204.3 million, a decrease of 7.7 million\nshares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S. ", "original_text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e2e724-303c-4a3c-a394-4f851829c7bc", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db72d27a283ad0e0c84697fa67a2a9812d01a4838ab15567742056a8f6f30c42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1fa9961b-0205-4640-885a-032ea5cb9f86", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.50 in the second quarter of fiscal 2023, an\n8.7 percent increase compared to $3.22 in the previous fiscal year\u2019s second quarter.  On a constant currency basis, adjusted\ndiluted earnings per share increased 11.2 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2023 were 204.3 million, a decrease of 7.7 million\nshares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S. ", "original_text": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2023 were 204.3 million, a decrease of 7.7 million\nshares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be26aaf5f6157154726fc7943d834540acdf364afbe73ec3144f0aa207da072b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cfad33d0-737c-460d-9571-2ba295447fe5", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2023 were 204.3 million, a decrease of 7.7 million\nshares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.7 billion in the second quarter of fiscal 2023, an increase of 11.3 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nto our two largest customers and increased sales of specialty products to physician practices and health systems, offset in part by a\ndecline in sales of commercial COVID-19 treatments. ", "original_text": "Healthcare Solutions and International Healthcare Solutions.\n"}, "hash": "44be737b4163a42a44f41d033e5f3236b195626cdbf98dd79261fb8b0f3bcb53", "class_name": "RelatedNodeInfo"}}, "text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "start_char_idx": 3123, "end_char_idx": 3284, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cfad33d0-737c-460d-9571-2ba295447fe5": {"__data__": {"id_": "cfad33d0-737c-460d-9571-2ba295447fe5", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2023 were 204.3 million, a decrease of 7.7 million\nshares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.7 billion in the second quarter of fiscal 2023, an increase of 11.3 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nto our two largest customers and increased sales of specialty products to physician practices and health systems, offset in part by a\ndecline in sales of commercial COVID-19 treatments. ", "original_text": "Healthcare Solutions and International Healthcare Solutions.\n", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e2e724-303c-4a3c-a394-4f851829c7bc", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db72d27a283ad0e0c84697fa67a2a9812d01a4838ab15567742056a8f6f30c42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1248b045-1dad-4160-b9f0-5b9ebfa7c9f6", "node_type": "1", "metadata": {"window": "On a constant currency basis, adjusted\ndiluted earnings per share increased 11.2 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2023 were 204.3 million, a decrease of 7.7 million\nshares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S. ", "original_text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31beefeb05218d363dffa09201fb523e4343ef1af78e5fa1f07c97514fc18dd0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e5978b1-1906-48c4-92b4-a0110942b184", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2023 were 204.3 million, a decrease of 7.7 million\nshares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.7 billion in the second quarter of fiscal 2023, an increase of 11.3 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nto our two largest customers and increased sales of specialty products to physician practices and health systems, offset in part by a\ndecline in sales of commercial COVID-19 treatments.  Segment operating income of $756.1 million in the second quarter of fiscal\n2023 was up 3.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross profit, offset in\npart by the increase in operating expenses, which included inflationary impacts on certain operating expenses.\n", "original_text": "U.S. "}, "hash": "2cdfb42a2bcb35952c2972a95be2a65fb86d6057f9ba939677e52663a4f10b47", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions and International Healthcare Solutions.\n", "start_char_idx": 3284, "end_char_idx": 3345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e5978b1-1906-48c4-92b4-a0110942b184": {"__data__": {"id_": "5e5978b1-1906-48c4-92b4-a0110942b184", "embedding": null, "metadata": {"window": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2023 were 204.3 million, a decrease of 7.7 million\nshares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.7 billion in the second quarter of fiscal 2023, an increase of 11.3 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nto our two largest customers and increased sales of specialty products to physician practices and health systems, offset in part by a\ndecline in sales of commercial COVID-19 treatments.  Segment operating income of $756.1 million in the second quarter of fiscal\n2023 was up 3.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross profit, offset in\npart by the increase in operating expenses, which included inflationary impacts on certain operating expenses.\n", "original_text": "U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e2e724-303c-4a3c-a394-4f851829c7bc", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db72d27a283ad0e0c84697fa67a2a9812d01a4838ab15567742056a8f6f30c42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cfad33d0-737c-460d-9571-2ba295447fe5", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2023 were 204.3 million, a decrease of 7.7 million\nshares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.7 billion in the second quarter of fiscal 2023, an increase of 11.3 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nto our two largest customers and increased sales of specialty products to physician practices and health systems, offset in part by a\ndecline in sales of commercial COVID-19 treatments. ", "original_text": "Healthcare Solutions and International Healthcare Solutions.\n", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65ec9f888c92d08bb6a2d68054a2b5f2749a5c57c432f08b9162bc7c05947c2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d79cba85-a093-4acb-9328-a1898f2fdc06", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.7 billion in the second quarter of fiscal 2023, an increase of 11.3 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nto our two largest customers and increased sales of specialty products to physician practices and health systems, offset in part by a\ndecline in sales of commercial COVID-19 treatments.  Segment operating income of $756.1 million in the second quarter of fiscal\n2023 was up 3.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross profit, offset in\npart by the increase in operating expenses, which included inflationary impacts on certain operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2023, a decrease of 0.2 percent from\nthe previous fiscal year\u2019s second quarter. ", "original_text": "Healthcare Solutions\nU.S. "}, "hash": "63144b10d72e1ef79d1498280014b7e6a70a323f50675a51136428c174f2e047", "class_name": "RelatedNodeInfo"}}, "text": "U.S. ", "start_char_idx": 902, "end_char_idx": 907, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d79cba85-a093-4acb-9328-a1898f2fdc06": {"__data__": {"id_": "d79cba85-a093-4acb-9328-a1898f2fdc06", "embedding": null, "metadata": {"window": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.7 billion in the second quarter of fiscal 2023, an increase of 11.3 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nto our two largest customers and increased sales of specialty products to physician practices and health systems, offset in part by a\ndecline in sales of commercial COVID-19 treatments.  Segment operating income of $756.1 million in the second quarter of fiscal\n2023 was up 3.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross profit, offset in\npart by the increase in operating expenses, which included inflationary impacts on certain operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2023, a decrease of 0.2 percent from\nthe previous fiscal year\u2019s second quarter. ", "original_text": "Healthcare Solutions\nU.S. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e2e724-303c-4a3c-a394-4f851829c7bc", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db72d27a283ad0e0c84697fa67a2a9812d01a4838ab15567742056a8f6f30c42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e5978b1-1906-48c4-92b4-a0110942b184", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2023 were 204.3 million, a decrease of 7.7 million\nshares, or 3.6 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.7 billion in the second quarter of fiscal 2023, an increase of 11.3 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nto our two largest customers and increased sales of specialty products to physician practices and health systems, offset in part by a\ndecline in sales of commercial COVID-19 treatments.  Segment operating income of $756.1 million in the second quarter of fiscal\n2023 was up 3.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross profit, offset in\npart by the increase in operating expenses, which included inflationary impacts on certain operating expenses.\n", "original_text": "U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb2021901d699353a5e90ca219a20d551a30e14c88f08f3fdcf45f193cd982d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb8837da-caef-495e-a0f9-499ac0bc5b92", "node_type": "1", "metadata": {"window": "Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.7 billion in the second quarter of fiscal 2023, an increase of 11.3 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nto our two largest customers and increased sales of specialty products to physician practices and health systems, offset in part by a\ndecline in sales of commercial COVID-19 treatments.  Segment operating income of $756.1 million in the second quarter of fiscal\n2023 was up 3.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross profit, offset in\npart by the increase in operating expenses, which included inflationary impacts on certain operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2023, a decrease of 0.2 percent from\nthe previous fiscal year\u2019s second quarter.  Segment operating income in the second quarter of fiscal 2023 was $176.0 million, a\n3", "original_text": "Healthcare Solutions revenue was $56.7 billion in the second quarter of fiscal 2023, an increase of 11.3 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nto our two largest customers and increased sales of specialty products to physician practices and health systems, offset in part by a\ndecline in sales of commercial COVID-19 treatments. "}, "hash": "301d5d746bc7c975677212f65e916304c9a5beaa99388440fee759b49f1d8f12", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions\nU.S. ", "start_char_idx": 3350, "end_char_idx": 3376, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb8837da-caef-495e-a0f9-499ac0bc5b92": {"__data__": {"id_": "bb8837da-caef-495e-a0f9-499ac0bc5b92", "embedding": null, "metadata": {"window": "Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.7 billion in the second quarter of fiscal 2023, an increase of 11.3 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nto our two largest customers and increased sales of specialty products to physician practices and health systems, offset in part by a\ndecline in sales of commercial COVID-19 treatments.  Segment operating income of $756.1 million in the second quarter of fiscal\n2023 was up 3.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross profit, offset in\npart by the increase in operating expenses, which included inflationary impacts on certain operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2023, a decrease of 0.2 percent from\nthe previous fiscal year\u2019s second quarter.  Segment operating income in the second quarter of fiscal 2023 was $176.0 million, a\n3", "original_text": "Healthcare Solutions revenue was $56.7 billion in the second quarter of fiscal 2023, an increase of 11.3 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nto our two largest customers and increased sales of specialty products to physician practices and health systems, offset in part by a\ndecline in sales of commercial COVID-19 treatments. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e2e724-303c-4a3c-a394-4f851829c7bc", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db72d27a283ad0e0c84697fa67a2a9812d01a4838ab15567742056a8f6f30c42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d79cba85-a093-4acb-9328-a1898f2fdc06", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.7 billion in the second quarter of fiscal 2023, an increase of 11.3 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nto our two largest customers and increased sales of specialty products to physician practices and health systems, offset in part by a\ndecline in sales of commercial COVID-19 treatments.  Segment operating income of $756.1 million in the second quarter of fiscal\n2023 was up 3.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross profit, offset in\npart by the increase in operating expenses, which included inflationary impacts on certain operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2023, a decrease of 0.2 percent from\nthe previous fiscal year\u2019s second quarter. ", "original_text": "Healthcare Solutions\nU.S. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bc2e1b4164a4a0639ef355e2ca3b3eba21e2133d23991b21359d24eb69f207", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1210e7b-b36a-482e-9312-59fb895a4cb1", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.7 billion in the second quarter of fiscal 2023, an increase of 11.3 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nto our two largest customers and increased sales of specialty products to physician practices and health systems, offset in part by a\ndecline in sales of commercial COVID-19 treatments.  Segment operating income of $756.1 million in the second quarter of fiscal\n2023 was up 3.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross profit, offset in\npart by the increase in operating expenses, which included inflationary impacts on certain operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2023, a decrease of 0.2 percent from\nthe previous fiscal year\u2019s second quarter.  Segment operating income in the second quarter of fiscal 2023 was $176.0 million, a\n3", "original_text": "Segment operating income of $756.1 million in the second quarter of fiscal\n2023 was up 3.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross profit, offset in\npart by the increase in operating expenses, which included inflationary impacts on certain operating expenses.\n"}, "hash": "e14c3af1e519a6bcacd649ea9e7738a9d94b888a8202d3fa814b0ecd79f56aec", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions revenue was $56.7 billion in the second quarter of fiscal 2023, an increase of 11.3 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nto our two largest customers and increased sales of specialty products to physician practices and health systems, offset in part by a\ndecline in sales of commercial COVID-19 treatments. ", "start_char_idx": 3376, "end_char_idx": 3824, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1210e7b-b36a-482e-9312-59fb895a4cb1": {"__data__": {"id_": "d1210e7b-b36a-482e-9312-59fb895a4cb1", "embedding": null, "metadata": {"window": "U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.7 billion in the second quarter of fiscal 2023, an increase of 11.3 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nto our two largest customers and increased sales of specialty products to physician practices and health systems, offset in part by a\ndecline in sales of commercial COVID-19 treatments.  Segment operating income of $756.1 million in the second quarter of fiscal\n2023 was up 3.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross profit, offset in\npart by the increase in operating expenses, which included inflationary impacts on certain operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2023, a decrease of 0.2 percent from\nthe previous fiscal year\u2019s second quarter.  Segment operating income in the second quarter of fiscal 2023 was $176.0 million, a\n3", "original_text": "Segment operating income of $756.1 million in the second quarter of fiscal\n2023 was up 3.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross profit, offset in\npart by the increase in operating expenses, which included inflationary impacts on certain operating expenses.\n", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e2e724-303c-4a3c-a394-4f851829c7bc", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db72d27a283ad0e0c84697fa67a2a9812d01a4838ab15567742056a8f6f30c42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb8837da-caef-495e-a0f9-499ac0bc5b92", "node_type": "1", "metadata": {"window": "Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.7 billion in the second quarter of fiscal 2023, an increase of 11.3 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nto our two largest customers and increased sales of specialty products to physician practices and health systems, offset in part by a\ndecline in sales of commercial COVID-19 treatments.  Segment operating income of $756.1 million in the second quarter of fiscal\n2023 was up 3.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross profit, offset in\npart by the increase in operating expenses, which included inflationary impacts on certain operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2023, a decrease of 0.2 percent from\nthe previous fiscal year\u2019s second quarter.  Segment operating income in the second quarter of fiscal 2023 was $176.0 million, a\n3", "original_text": "Healthcare Solutions revenue was $56.7 billion in the second quarter of fiscal 2023, an increase of 11.3 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nto our two largest customers and increased sales of specialty products to physician practices and health systems, offset in part by a\ndecline in sales of commercial COVID-19 treatments. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44d7e89a515744833d70f9083293353133232172768996ccefd094376895141f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74663052-5d3a-4131-8de6-e6d8e007744e", "node_type": "1", "metadata": {"window": "Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.7 billion in the second quarter of fiscal 2023, an increase of 11.3 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nto our two largest customers and increased sales of specialty products to physician practices and health systems, offset in part by a\ndecline in sales of commercial COVID-19 treatments.  Segment operating income of $756.1 million in the second quarter of fiscal\n2023 was up 3.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross profit, offset in\npart by the increase in operating expenses, which included inflationary impacts on certain operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2023, a decrease of 0.2 percent from\nthe previous fiscal year\u2019s second quarter.  Segment operating income in the second quarter of fiscal 2023 was $176.0 million, a\n3", "original_text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2023, a decrease of 0.2 percent from\nthe previous fiscal year\u2019s second quarter. "}, "hash": "5950d157e5695af9c96264bc35053830f885d0a7fa3edce16a3d497aee8ab7fc", "class_name": "RelatedNodeInfo"}}, "text": "Segment operating income of $756.1 million in the second quarter of fiscal\n2023 was up 3.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross profit, offset in\npart by the increase in operating expenses, which included inflationary impacts on certain operating expenses.\n", "start_char_idx": 3824, "end_char_idx": 4144, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74663052-5d3a-4131-8de6-e6d8e007744e": {"__data__": {"id_": "74663052-5d3a-4131-8de6-e6d8e007744e", "embedding": null, "metadata": {"window": "Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.7 billion in the second quarter of fiscal 2023, an increase of 11.3 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nto our two largest customers and increased sales of specialty products to physician practices and health systems, offset in part by a\ndecline in sales of commercial COVID-19 treatments.  Segment operating income of $756.1 million in the second quarter of fiscal\n2023 was up 3.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross profit, offset in\npart by the increase in operating expenses, which included inflationary impacts on certain operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2023, a decrease of 0.2 percent from\nthe previous fiscal year\u2019s second quarter.  Segment operating income in the second quarter of fiscal 2023 was $176.0 million, a\n3", "original_text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2023, a decrease of 0.2 percent from\nthe previous fiscal year\u2019s second quarter. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e2e724-303c-4a3c-a394-4f851829c7bc", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db72d27a283ad0e0c84697fa67a2a9812d01a4838ab15567742056a8f6f30c42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1210e7b-b36a-482e-9312-59fb895a4cb1", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.7 billion in the second quarter of fiscal 2023, an increase of 11.3 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nto our two largest customers and increased sales of specialty products to physician practices and health systems, offset in part by a\ndecline in sales of commercial COVID-19 treatments.  Segment operating income of $756.1 million in the second quarter of fiscal\n2023 was up 3.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross profit, offset in\npart by the increase in operating expenses, which included inflationary impacts on certain operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2023, a decrease of 0.2 percent from\nthe previous fiscal year\u2019s second quarter.  Segment operating income in the second quarter of fiscal 2023 was $176.0 million, a\n3", "original_text": "Segment operating income of $756.1 million in the second quarter of fiscal\n2023 was up 3.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross profit, offset in\npart by the increase in operating expenses, which included inflationary impacts on certain operating expenses.\n", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "666c8e99f374a9b4f9b429233500e097ef1808d5491f88ae015a97298305ab60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a438fcd9-2945-4e36-8de5-d7fc9f354d68", "node_type": "1", "metadata": {"window": "Healthcare Solutions revenue was $56.7 billion in the second quarter of fiscal 2023, an increase of 11.3 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nto our two largest customers and increased sales of specialty products to physician practices and health systems, offset in part by a\ndecline in sales of commercial COVID-19 treatments.  Segment operating income of $756.1 million in the second quarter of fiscal\n2023 was up 3.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross profit, offset in\npart by the increase in operating expenses, which included inflationary impacts on certain operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2023, a decrease of 0.2 percent from\nthe previous fiscal year\u2019s second quarter.  Segment operating income in the second quarter of fiscal 2023 was $176.0 million, a\n3", "original_text": "Segment operating income in the second quarter of fiscal 2023 was $176.0 million, a\n3"}, "hash": "b0a500b56b72c17160aea99c4fee0a1cf915f477b61f1f8d1ab24fbf69a7ce9f", "class_name": "RelatedNodeInfo"}}, "text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2023, a decrease of 0.2 percent from\nthe previous fiscal year\u2019s second quarter. ", "start_char_idx": 4144, "end_char_idx": 4354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a438fcd9-2945-4e36-8de5-d7fc9f354d68": {"__data__": {"id_": "a438fcd9-2945-4e36-8de5-d7fc9f354d68", "embedding": null, "metadata": {"window": "Healthcare Solutions revenue was $56.7 billion in the second quarter of fiscal 2023, an increase of 11.3 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nto our two largest customers and increased sales of specialty products to physician practices and health systems, offset in part by a\ndecline in sales of commercial COVID-19 treatments.  Segment operating income of $756.1 million in the second quarter of fiscal\n2023 was up 3.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross profit, offset in\npart by the increase in operating expenses, which included inflationary impacts on certain operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2023, a decrease of 0.2 percent from\nthe previous fiscal year\u2019s second quarter.  Segment operating income in the second quarter of fiscal 2023 was $176.0 million, a\n3", "original_text": "Segment operating income in the second quarter of fiscal 2023 was $176.0 million, a\n3", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "27e2e724-303c-4a3c-a394-4f851829c7bc", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db72d27a283ad0e0c84697fa67a2a9812d01a4838ab15567742056a8f6f30c42", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74663052-5d3a-4131-8de6-e6d8e007744e", "node_type": "1", "metadata": {"window": "Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.7 billion in the second quarter of fiscal 2023, an increase of 11.3 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nto our two largest customers and increased sales of specialty products to physician practices and health systems, offset in part by a\ndecline in sales of commercial COVID-19 treatments.  Segment operating income of $756.1 million in the second quarter of fiscal\n2023 was up 3.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross profit, offset in\npart by the increase in operating expenses, which included inflationary impacts on certain operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2023, a decrease of 0.2 percent from\nthe previous fiscal year\u2019s second quarter.  Segment operating income in the second quarter of fiscal 2023 was $176.0 million, a\n3", "original_text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2023, a decrease of 0.2 percent from\nthe previous fiscal year\u2019s second quarter. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f8208fbff315ac85b89284f8dfbcf17705cbf61dfd7dd0430abf1bb254b3021", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1717eba-3a66-4c74-a0c3-df019208e2db", "node_type": "1", "metadata": {"window": "decrease of 5.9 percent.  The period over period declines were due to the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.  On a constant\ncurrency basis, International Healthcare Solutions revenue and operating income increased by 11.9 percent and 7.3 percent,\nrespectively.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and TPG announced an agreement to acquire OneOncology, a network of leading oncology practices.\n", "original_text": "decrease of 5.9 percent. "}, "hash": "2d815c47c3ba16ca880c34ef9aa517cb6c3633332e005ca037f6161f341b7051", "class_name": "RelatedNodeInfo"}}, "text": "Segment operating income in the second quarter of fiscal 2023 was $176.0 million, a\n3", "start_char_idx": 4354, "end_char_idx": 4439, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1717eba-3a66-4c74-a0c3-df019208e2db": {"__data__": {"id_": "b1717eba-3a66-4c74-a0c3-df019208e2db", "embedding": null, "metadata": {"window": "decrease of 5.9 percent.  The period over period declines were due to the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.  On a constant\ncurrency basis, International Healthcare Solutions revenue and operating income increased by 11.9 percent and 7.3 percent,\nrespectively.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and TPG announced an agreement to acquire OneOncology, a network of leading oncology practices.\n", "original_text": "decrease of 5.9 percent. ", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7129ecf3-7586-4969-be47-487cdb63cac3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f36fb7167c27bf3ab1b38d53c613bcb8d4edcabfe5a6ab15ff66ed9f2370eb1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a438fcd9-2945-4e36-8de5-d7fc9f354d68", "node_type": "1", "metadata": {"window": "Healthcare Solutions revenue was $56.7 billion in the second quarter of fiscal 2023, an increase of 11.3 percent compared to the\nsame quarter in the prior fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales\nto our two largest customers and increased sales of specialty products to physician practices and health systems, offset in part by a\ndecline in sales of commercial COVID-19 treatments.  Segment operating income of $756.1 million in the second quarter of fiscal\n2023 was up 3.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross profit, offset in\npart by the increase in operating expenses, which included inflationary impacts on certain operating expenses.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2023, a decrease of 0.2 percent from\nthe previous fiscal year\u2019s second quarter.  Segment operating income in the second quarter of fiscal 2023 was $176.0 million, a\n3", "original_text": "Segment operating income in the second quarter of fiscal 2023 was $176.0 million, a\n3", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e27466b28df66b2dc11ad9b21cbc0149b79bde53a7bf5260540fe8092b95a32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a403200a-bc9c-4f8b-856f-a692a7d6b174", "node_type": "1", "metadata": {"window": "decrease of 5.9 percent.  The period over period declines were due to the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.  On a constant\ncurrency basis, International Healthcare Solutions revenue and operating income increased by 11.9 percent and 7.3 percent,\nrespectively.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and TPG announced an agreement to acquire OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n", "original_text": "The period over period declines were due to the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter. "}, "hash": "aac9ca223e5e084c949bc19196ce4c6c4dc4395d02ba4af0527d3b86195a3cbc", "class_name": "RelatedNodeInfo"}}, "text": "decrease of 5.9 percent. ", "start_char_idx": 0, "end_char_idx": 25, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a403200a-bc9c-4f8b-856f-a692a7d6b174": {"__data__": {"id_": "a403200a-bc9c-4f8b-856f-a692a7d6b174", "embedding": null, "metadata": {"window": "decrease of 5.9 percent.  The period over period declines were due to the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.  On a constant\ncurrency basis, International Healthcare Solutions revenue and operating income increased by 11.9 percent and 7.3 percent,\nrespectively.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and TPG announced an agreement to acquire OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n", "original_text": "The period over period declines were due to the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter. ", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7129ecf3-7586-4969-be47-487cdb63cac3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f36fb7167c27bf3ab1b38d53c613bcb8d4edcabfe5a6ab15ff66ed9f2370eb1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1717eba-3a66-4c74-a0c3-df019208e2db", "node_type": "1", "metadata": {"window": "decrease of 5.9 percent.  The period over period declines were due to the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.  On a constant\ncurrency basis, International Healthcare Solutions revenue and operating income increased by 11.9 percent and 7.3 percent,\nrespectively.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and TPG announced an agreement to acquire OneOncology, a network of leading oncology practices.\n", "original_text": "decrease of 5.9 percent. ", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "237cc7dcd4cda63dde123adc153494000a66069ec750e6542fdfb6fcc06914f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae6acd26-380f-44b0-b49d-43bf6f716bbe", "node_type": "1", "metadata": {"window": "decrease of 5.9 percent.  The period over period declines were due to the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.  On a constant\ncurrency basis, International Healthcare Solutions revenue and operating income increased by 11.9 percent and 7.3 percent,\nrespectively.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and TPG announced an agreement to acquire OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen launched its Cell and Gene Therapy Integration Hub, a platform-agnostic system that can be integrated\nwith biopharma and provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the\ntreatment development and patient journey.\n", "original_text": "On a constant\ncurrency basis, International Healthcare Solutions revenue and operating income increased by 11.9 percent and 7.3 percent,\nrespectively.\n"}, "hash": "f82a6e78dd0e002097becb5baf23440a4596739ebb09df6056cd4f7a1a9ece94", "class_name": "RelatedNodeInfo"}}, "text": "The period over period declines were due to the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter. ", "start_char_idx": 25, "end_char_idx": 245, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae6acd26-380f-44b0-b49d-43bf6f716bbe": {"__data__": {"id_": "ae6acd26-380f-44b0-b49d-43bf6f716bbe", "embedding": null, "metadata": {"window": "decrease of 5.9 percent.  The period over period declines were due to the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.  On a constant\ncurrency basis, International Healthcare Solutions revenue and operating income increased by 11.9 percent and 7.3 percent,\nrespectively.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and TPG announced an agreement to acquire OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen launched its Cell and Gene Therapy Integration Hub, a platform-agnostic system that can be integrated\nwith biopharma and provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the\ntreatment development and patient journey.\n", "original_text": "On a constant\ncurrency basis, International Healthcare Solutions revenue and operating income increased by 11.9 percent and 7.3 percent,\nrespectively.\n", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7129ecf3-7586-4969-be47-487cdb63cac3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f36fb7167c27bf3ab1b38d53c613bcb8d4edcabfe5a6ab15ff66ed9f2370eb1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a403200a-bc9c-4f8b-856f-a692a7d6b174", "node_type": "1", "metadata": {"window": "decrease of 5.9 percent.  The period over period declines were due to the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.  On a constant\ncurrency basis, International Healthcare Solutions revenue and operating income increased by 11.9 percent and 7.3 percent,\nrespectively.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and TPG announced an agreement to acquire OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n", "original_text": "The period over period declines were due to the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter. ", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e01877e8246beeb8ae81b98b34a08eff607a47c497c35bb63b9341fd22638d84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0c84da1-8f08-4a1a-92c3-8b95725609a7", "node_type": "1", "metadata": {"window": "decrease of 5.9 percent.  The period over period declines were due to the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.  On a constant\ncurrency basis, International Healthcare Solutions revenue and operating income increased by 11.9 percent and 7.3 percent,\nrespectively.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and TPG announced an agreement to acquire OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen launched its Cell and Gene Therapy Integration Hub, a platform-agnostic system that can be integrated\nwith biopharma and provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the\ntreatment development and patient journey.\n World Courier is deploying real-time location monitoring on all of its multi-use packages, enabling increased visibility into the\nprecise location of shipments in transit globally. ", "original_text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen and TPG announced an agreement to acquire OneOncology, a network of leading oncology practices.\n"}, "hash": "edba43418b4e1151a313baa623660d75ab7d7331d8aed3f799f58481fbf1ce23", "class_name": "RelatedNodeInfo"}}, "text": "On a constant\ncurrency basis, International Healthcare Solutions revenue and operating income increased by 11.9 percent and 7.3 percent,\nrespectively.\n", "start_char_idx": 245, "end_char_idx": 396, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0c84da1-8f08-4a1a-92c3-8b95725609a7": {"__data__": {"id_": "e0c84da1-8f08-4a1a-92c3-8b95725609a7", "embedding": null, "metadata": {"window": "decrease of 5.9 percent.  The period over period declines were due to the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.  On a constant\ncurrency basis, International Healthcare Solutions revenue and operating income increased by 11.9 percent and 7.3 percent,\nrespectively.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and TPG announced an agreement to acquire OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen launched its Cell and Gene Therapy Integration Hub, a platform-agnostic system that can be integrated\nwith biopharma and provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the\ntreatment development and patient journey.\n World Courier is deploying real-time location monitoring on all of its multi-use packages, enabling increased visibility into the\nprecise location of shipments in transit globally. ", "original_text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen and TPG announced an agreement to acquire OneOncology, a network of leading oncology practices.\n", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7129ecf3-7586-4969-be47-487cdb63cac3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f36fb7167c27bf3ab1b38d53c613bcb8d4edcabfe5a6ab15ff66ed9f2370eb1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae6acd26-380f-44b0-b49d-43bf6f716bbe", "node_type": "1", "metadata": {"window": "decrease of 5.9 percent.  The period over period declines were due to the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.  On a constant\ncurrency basis, International Healthcare Solutions revenue and operating income increased by 11.9 percent and 7.3 percent,\nrespectively.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and TPG announced an agreement to acquire OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen launched its Cell and Gene Therapy Integration Hub, a platform-agnostic system that can be integrated\nwith biopharma and provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the\ntreatment development and patient journey.\n", "original_text": "On a constant\ncurrency basis, International Healthcare Solutions revenue and operating income increased by 11.9 percent and 7.3 percent,\nrespectively.\n", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0b633b4652f1e34379dd91d0e5b682b6c297f7757716d50411a02e242d6b103", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83086610-76a7-49de-b3ce-6bf31086cd53", "node_type": "1", "metadata": {"window": "The period over period declines were due to the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.  On a constant\ncurrency basis, International Healthcare Solutions revenue and operating income increased by 11.9 percent and 7.3 percent,\nrespectively.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and TPG announced an agreement to acquire OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen launched its Cell and Gene Therapy Integration Hub, a platform-agnostic system that can be integrated\nwith biopharma and provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the\ntreatment development and patient journey.\n World Courier is deploying real-time location monitoring on all of its multi-use packages, enabling increased visibility into the\nprecise location of shipments in transit globally.  The technology will enhance the ability to proactively monitor shipments,\nanticipate potential risks and intervene, if needed, to ensure the secure and timely distribution of products.\n", "original_text": "AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n"}, "hash": "e636d11114d9aecbfd0c791bb04ea8c448904460ee620e29bb78d717a42b69f9", "class_name": "RelatedNodeInfo"}}, "text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen and TPG announced an agreement to acquire OneOncology, a network of leading oncology practices.\n", "start_char_idx": 396, "end_char_idx": 551, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83086610-76a7-49de-b3ce-6bf31086cd53": {"__data__": {"id_": "83086610-76a7-49de-b3ce-6bf31086cd53", "embedding": null, "metadata": {"window": "The period over period declines were due to the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.  On a constant\ncurrency basis, International Healthcare Solutions revenue and operating income increased by 11.9 percent and 7.3 percent,\nrespectively.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and TPG announced an agreement to acquire OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen launched its Cell and Gene Therapy Integration Hub, a platform-agnostic system that can be integrated\nwith biopharma and provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the\ntreatment development and patient journey.\n World Courier is deploying real-time location monitoring on all of its multi-use packages, enabling increased visibility into the\nprecise location of shipments in transit globally.  The technology will enhance the ability to proactively monitor shipments,\nanticipate potential risks and intervene, if needed, to ensure the secure and timely distribution of products.\n", "original_text": "AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7129ecf3-7586-4969-be47-487cdb63cac3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f36fb7167c27bf3ab1b38d53c613bcb8d4edcabfe5a6ab15ff66ed9f2370eb1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0c84da1-8f08-4a1a-92c3-8b95725609a7", "node_type": "1", "metadata": {"window": "decrease of 5.9 percent.  The period over period declines were due to the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.  On a constant\ncurrency basis, International Healthcare Solutions revenue and operating income increased by 11.9 percent and 7.3 percent,\nrespectively.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and TPG announced an agreement to acquire OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen launched its Cell and Gene Therapy Integration Hub, a platform-agnostic system that can be integrated\nwith biopharma and provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the\ntreatment development and patient journey.\n World Courier is deploying real-time location monitoring on all of its multi-use packages, enabling increased visibility into the\nprecise location of shipments in transit globally. ", "original_text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen and TPG announced an agreement to acquire OneOncology, a network of leading oncology practices.\n", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d7f520a0c251c94f4944b0c26527e15ec84451c583e7d6be7f449ae8cc3c6ae4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e4f9bac-e48f-4480-9f64-4e990a1b8890", "node_type": "1", "metadata": {"window": "On a constant\ncurrency basis, International Healthcare Solutions revenue and operating income increased by 11.9 percent and 7.3 percent,\nrespectively.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and TPG announced an agreement to acquire OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen launched its Cell and Gene Therapy Integration Hub, a platform-agnostic system that can be integrated\nwith biopharma and provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the\ntreatment development and patient journey.\n World Courier is deploying real-time location monitoring on all of its multi-use packages, enabling increased visibility into the\nprecise location of shipments in transit globally.  The technology will enhance the ability to proactively monitor shipments,\nanticipate potential risks and intervene, if needed, to ensure the secure and timely distribution of products.\n The AmerisourceBergen Foundation contributed to non-profit partners to support disaster response efforts in T\u00fcrkiye\nfollowing earthquakes in February.\n", "original_text": "AmerisourceBergen launched its Cell and Gene Therapy Integration Hub, a platform-agnostic system that can be integrated\nwith biopharma and provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the\ntreatment development and patient journey.\n"}, "hash": "fcd2a96895bae2f1e2e6180d234ad50c1d13a3978e4a6cbb9f48601f6f116de8", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n", "start_char_idx": 551, "end_char_idx": 709, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e4f9bac-e48f-4480-9f64-4e990a1b8890": {"__data__": {"id_": "8e4f9bac-e48f-4480-9f64-4e990a1b8890", "embedding": null, "metadata": {"window": "On a constant\ncurrency basis, International Healthcare Solutions revenue and operating income increased by 11.9 percent and 7.3 percent,\nrespectively.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and TPG announced an agreement to acquire OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen launched its Cell and Gene Therapy Integration Hub, a platform-agnostic system that can be integrated\nwith biopharma and provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the\ntreatment development and patient journey.\n World Courier is deploying real-time location monitoring on all of its multi-use packages, enabling increased visibility into the\nprecise location of shipments in transit globally.  The technology will enhance the ability to proactively monitor shipments,\nanticipate potential risks and intervene, if needed, to ensure the secure and timely distribution of products.\n The AmerisourceBergen Foundation contributed to non-profit partners to support disaster response efforts in T\u00fcrkiye\nfollowing earthquakes in February.\n", "original_text": "AmerisourceBergen launched its Cell and Gene Therapy Integration Hub, a platform-agnostic system that can be integrated\nwith biopharma and provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the\ntreatment development and patient journey.\n", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7129ecf3-7586-4969-be47-487cdb63cac3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f36fb7167c27bf3ab1b38d53c613bcb8d4edcabfe5a6ab15ff66ed9f2370eb1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83086610-76a7-49de-b3ce-6bf31086cd53", "node_type": "1", "metadata": {"window": "The period over period declines were due to the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.  On a constant\ncurrency basis, International Healthcare Solutions revenue and operating income increased by 11.9 percent and 7.3 percent,\nrespectively.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and TPG announced an agreement to acquire OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen launched its Cell and Gene Therapy Integration Hub, a platform-agnostic system that can be integrated\nwith biopharma and provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the\ntreatment development and patient journey.\n World Courier is deploying real-time location monitoring on all of its multi-use packages, enabling increased visibility into the\nprecise location of shipments in transit globally.  The technology will enhance the ability to proactively monitor shipments,\nanticipate potential risks and intervene, if needed, to ensure the secure and timely distribution of products.\n", "original_text": "AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7b6aa14ad195f13d74b71d7f328eefddb8b9f4d53f8cc54892c1a1921c249609", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5da72bf4-ef5f-4463-a5bd-3bc7f9abb205", "node_type": "1", "metadata": {"window": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen and TPG announced an agreement to acquire OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen launched its Cell and Gene Therapy Integration Hub, a platform-agnostic system that can be integrated\nwith biopharma and provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the\ntreatment development and patient journey.\n World Courier is deploying real-time location monitoring on all of its multi-use packages, enabling increased visibility into the\nprecise location of shipments in transit globally.  The technology will enhance the ability to proactively monitor shipments,\nanticipate potential risks and intervene, if needed, to ensure the secure and timely distribution of products.\n The AmerisourceBergen Foundation contributed to non-profit partners to support disaster response efforts in T\u00fcrkiye\nfollowing earthquakes in February.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "World Courier is deploying real-time location monitoring on all of its multi-use packages, enabling increased visibility into the\nprecise location of shipments in transit globally. "}, "hash": "6efd6f6dfe8a5164d21995e65361f1970348abf1aaa9eff21f3d9defbbece589", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen launched its Cell and Gene Therapy Integration Hub, a platform-agnostic system that can be integrated\nwith biopharma and provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the\ntreatment development and patient journey.\n", "start_char_idx": 709, "end_char_idx": 996, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5da72bf4-ef5f-4463-a5bd-3bc7f9abb205": {"__data__": {"id_": "5da72bf4-ef5f-4463-a5bd-3bc7f9abb205", "embedding": null, "metadata": {"window": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen and TPG announced an agreement to acquire OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen launched its Cell and Gene Therapy Integration Hub, a platform-agnostic system that can be integrated\nwith biopharma and provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the\ntreatment development and patient journey.\n World Courier is deploying real-time location monitoring on all of its multi-use packages, enabling increased visibility into the\nprecise location of shipments in transit globally.  The technology will enhance the ability to proactively monitor shipments,\nanticipate potential risks and intervene, if needed, to ensure the secure and timely distribution of products.\n The AmerisourceBergen Foundation contributed to non-profit partners to support disaster response efforts in T\u00fcrkiye\nfollowing earthquakes in February.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "World Courier is deploying real-time location monitoring on all of its multi-use packages, enabling increased visibility into the\nprecise location of shipments in transit globally. ", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7129ecf3-7586-4969-be47-487cdb63cac3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f36fb7167c27bf3ab1b38d53c613bcb8d4edcabfe5a6ab15ff66ed9f2370eb1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e4f9bac-e48f-4480-9f64-4e990a1b8890", "node_type": "1", "metadata": {"window": "On a constant\ncurrency basis, International Healthcare Solutions revenue and operating income increased by 11.9 percent and 7.3 percent,\nrespectively.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and TPG announced an agreement to acquire OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen launched its Cell and Gene Therapy Integration Hub, a platform-agnostic system that can be integrated\nwith biopharma and provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the\ntreatment development and patient journey.\n World Courier is deploying real-time location monitoring on all of its multi-use packages, enabling increased visibility into the\nprecise location of shipments in transit globally.  The technology will enhance the ability to proactively monitor shipments,\nanticipate potential risks and intervene, if needed, to ensure the secure and timely distribution of products.\n The AmerisourceBergen Foundation contributed to non-profit partners to support disaster response efforts in T\u00fcrkiye\nfollowing earthquakes in February.\n", "original_text": "AmerisourceBergen launched its Cell and Gene Therapy Integration Hub, a platform-agnostic system that can be integrated\nwith biopharma and provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the\ntreatment development and patient journey.\n", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a303c4a6ccfeaa6fad74fb6057cc10becf6a03db39269139b21368112021f285", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44450600-dfa3-437a-af3a-a8c4c238d2ae", "node_type": "1", "metadata": {"window": "AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen launched its Cell and Gene Therapy Integration Hub, a platform-agnostic system that can be integrated\nwith biopharma and provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the\ntreatment development and patient journey.\n World Courier is deploying real-time location monitoring on all of its multi-use packages, enabling increased visibility into the\nprecise location of shipments in transit globally.  The technology will enhance the ability to proactively monitor shipments,\nanticipate potential risks and intervene, if needed, to ensure the secure and timely distribution of products.\n The AmerisourceBergen Foundation contributed to non-profit partners to support disaster response efforts in T\u00fcrkiye\nfollowing earthquakes in February.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "The technology will enhance the ability to proactively monitor shipments,\nanticipate potential risks and intervene, if needed, to ensure the secure and timely distribution of products.\n"}, "hash": "ef2082a810d58c6303194fb25557e340735252256169f411f08c0cda60bf4e9a", "class_name": "RelatedNodeInfo"}}, "text": "World Courier is deploying real-time location monitoring on all of its multi-use packages, enabling increased visibility into the\nprecise location of shipments in transit globally. ", "start_char_idx": 996, "end_char_idx": 1177, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44450600-dfa3-437a-af3a-a8c4c238d2ae": {"__data__": {"id_": "44450600-dfa3-437a-af3a-a8c4c238d2ae", "embedding": null, "metadata": {"window": "AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen launched its Cell and Gene Therapy Integration Hub, a platform-agnostic system that can be integrated\nwith biopharma and provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the\ntreatment development and patient journey.\n World Courier is deploying real-time location monitoring on all of its multi-use packages, enabling increased visibility into the\nprecise location of shipments in transit globally.  The technology will enhance the ability to proactively monitor shipments,\nanticipate potential risks and intervene, if needed, to ensure the secure and timely distribution of products.\n The AmerisourceBergen Foundation contributed to non-profit partners to support disaster response efforts in T\u00fcrkiye\nfollowing earthquakes in February.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "The technology will enhance the ability to proactively monitor shipments,\nanticipate potential risks and intervene, if needed, to ensure the secure and timely distribution of products.\n", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7129ecf3-7586-4969-be47-487cdb63cac3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f36fb7167c27bf3ab1b38d53c613bcb8d4edcabfe5a6ab15ff66ed9f2370eb1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5da72bf4-ef5f-4463-a5bd-3bc7f9abb205", "node_type": "1", "metadata": {"window": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen and TPG announced an agreement to acquire OneOncology, a network of leading oncology practices.\n AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen launched its Cell and Gene Therapy Integration Hub, a platform-agnostic system that can be integrated\nwith biopharma and provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the\ntreatment development and patient journey.\n World Courier is deploying real-time location monitoring on all of its multi-use packages, enabling increased visibility into the\nprecise location of shipments in transit globally.  The technology will enhance the ability to proactively monitor shipments,\nanticipate potential risks and intervene, if needed, to ensure the secure and timely distribution of products.\n The AmerisourceBergen Foundation contributed to non-profit partners to support disaster response efforts in T\u00fcrkiye\nfollowing earthquakes in February.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "World Courier is deploying real-time location monitoring on all of its multi-use packages, enabling increased visibility into the\nprecise location of shipments in transit globally. ", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3fa94b78de583b2d18fe81326dfd5bc7dbb15795ff3f291c21a6456a381d294c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1340242b-90ab-4594-855f-a593a5f48bac", "node_type": "1", "metadata": {"window": "AmerisourceBergen launched its Cell and Gene Therapy Integration Hub, a platform-agnostic system that can be integrated\nwith biopharma and provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the\ntreatment development and patient journey.\n World Courier is deploying real-time location monitoring on all of its multi-use packages, enabling increased visibility into the\nprecise location of shipments in transit globally.  The technology will enhance the ability to proactively monitor shipments,\nanticipate potential risks and intervene, if needed, to ensure the secure and timely distribution of products.\n The AmerisourceBergen Foundation contributed to non-profit partners to support disaster response efforts in T\u00fcrkiye\nfollowing earthquakes in February.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect stronger core growth in the U.S.\n", "original_text": "The AmerisourceBergen Foundation contributed to non-profit partners to support disaster response efforts in T\u00fcrkiye\nfollowing earthquakes in February.\n"}, "hash": "d5ed48ae7234f5a62ad681fd1634f57ec34f9c6153068b3b0f2a67493a9af69c", "class_name": "RelatedNodeInfo"}}, "text": "The technology will enhance the ability to proactively monitor shipments,\nanticipate potential risks and intervene, if needed, to ensure the secure and timely distribution of products.\n", "start_char_idx": 1177, "end_char_idx": 1362, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1340242b-90ab-4594-855f-a593a5f48bac": {"__data__": {"id_": "1340242b-90ab-4594-855f-a593a5f48bac", "embedding": null, "metadata": {"window": "AmerisourceBergen launched its Cell and Gene Therapy Integration Hub, a platform-agnostic system that can be integrated\nwith biopharma and provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the\ntreatment development and patient journey.\n World Courier is deploying real-time location monitoring on all of its multi-use packages, enabling increased visibility into the\nprecise location of shipments in transit globally.  The technology will enhance the ability to proactively monitor shipments,\nanticipate potential risks and intervene, if needed, to ensure the secure and timely distribution of products.\n The AmerisourceBergen Foundation contributed to non-profit partners to support disaster response efforts in T\u00fcrkiye\nfollowing earthquakes in February.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect stronger core growth in the U.S.\n", "original_text": "The AmerisourceBergen Foundation contributed to non-profit partners to support disaster response efforts in T\u00fcrkiye\nfollowing earthquakes in February.\n", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7129ecf3-7586-4969-be47-487cdb63cac3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f36fb7167c27bf3ab1b38d53c613bcb8d4edcabfe5a6ab15ff66ed9f2370eb1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44450600-dfa3-437a-af3a-a8c4c238d2ae", "node_type": "1", "metadata": {"window": "AmerisourceBergen\u2019s minority investment will allow it to further deepen its relationship with community oncologists and\nexpand on its solutions in specialty.\n AmerisourceBergen launched its Cell and Gene Therapy Integration Hub, a platform-agnostic system that can be integrated\nwith biopharma and provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the\ntreatment development and patient journey.\n World Courier is deploying real-time location monitoring on all of its multi-use packages, enabling increased visibility into the\nprecise location of shipments in transit globally.  The technology will enhance the ability to proactively monitor shipments,\nanticipate potential risks and intervene, if needed, to ensure the secure and timely distribution of products.\n The AmerisourceBergen Foundation contributed to non-profit partners to support disaster response efforts in T\u00fcrkiye\nfollowing earthquakes in February.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "The technology will enhance the ability to proactively monitor shipments,\nanticipate potential risks and intervene, if needed, to ensure the secure and timely distribution of products.\n", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa2647e8c7e6826b22a6571b1d7dd09c6fcc2af1666bdfe74e189254ab53881d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a52f9b2c-6c02-4cb9-9022-a04bb200f913", "node_type": "1", "metadata": {"window": "World Courier is deploying real-time location monitoring on all of its multi-use packages, enabling increased visibility into the\nprecise location of shipments in transit globally.  The technology will enhance the ability to proactively monitor shipments,\nanticipate potential risks and intervene, if needed, to ensure the secure and timely distribution of products.\n The AmerisourceBergen Foundation contributed to non-profit partners to support disaster response efforts in T\u00fcrkiye\nfollowing earthquakes in February.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect stronger core growth in the U.S.\n Healthcare Solutions segment. ", "original_text": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. "}, "hash": "3b1a9c500e91375bb29e5d8fc8302d58f2e9bd044ee5b15e386eaa09d8e37d8f", "class_name": "RelatedNodeInfo"}}, "text": "The AmerisourceBergen Foundation contributed to non-profit partners to support disaster response efforts in T\u00fcrkiye\nfollowing earthquakes in February.\n", "start_char_idx": 1362, "end_char_idx": 1513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a52f9b2c-6c02-4cb9-9022-a04bb200f913": {"__data__": {"id_": "a52f9b2c-6c02-4cb9-9022-a04bb200f913", "embedding": null, "metadata": {"window": "World Courier is deploying real-time location monitoring on all of its multi-use packages, enabling increased visibility into the\nprecise location of shipments in transit globally.  The technology will enhance the ability to proactively monitor shipments,\nanticipate potential risks and intervene, if needed, to ensure the secure and timely distribution of products.\n The AmerisourceBergen Foundation contributed to non-profit partners to support disaster response efforts in T\u00fcrkiye\nfollowing earthquakes in February.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect stronger core growth in the U.S.\n Healthcare Solutions segment. ", "original_text": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7129ecf3-7586-4969-be47-487cdb63cac3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f36fb7167c27bf3ab1b38d53c613bcb8d4edcabfe5a6ab15ff66ed9f2370eb1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1340242b-90ab-4594-855f-a593a5f48bac", "node_type": "1", "metadata": {"window": "AmerisourceBergen launched its Cell and Gene Therapy Integration Hub, a platform-agnostic system that can be integrated\nwith biopharma and provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the\ntreatment development and patient journey.\n World Courier is deploying real-time location monitoring on all of its multi-use packages, enabling increased visibility into the\nprecise location of shipments in transit globally.  The technology will enhance the ability to proactively monitor shipments,\nanticipate potential risks and intervene, if needed, to ensure the secure and timely distribution of products.\n The AmerisourceBergen Foundation contributed to non-profit partners to support disaster response efforts in T\u00fcrkiye\nfollowing earthquakes in February.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect stronger core growth in the U.S.\n", "original_text": "The AmerisourceBergen Foundation contributed to non-profit partners to support disaster response efforts in T\u00fcrkiye\nfollowing earthquakes in February.\n", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "929fba019c33001d072e2f72d1d22cab6487bdb6e14ab679d54909c53459cf56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "366d93fc-c2bc-488a-91ed-8026ed62f635", "node_type": "1", "metadata": {"window": "The technology will enhance the ability to proactively monitor shipments,\nanticipate potential risks and intervene, if needed, to ensure the secure and timely distribution of products.\n The AmerisourceBergen Foundation contributed to non-profit partners to support disaster response efforts in T\u00fcrkiye\nfollowing earthquakes in February.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect stronger core growth in the U.S.\n Healthcare Solutions segment.  The Company now expects:\nRevenue growth to be in the range of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nU.S. ", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n"}, "hash": "476aaa22e17f6c38b4be568aaf6975b7cefce6e44fa4aa95d51026aa575fbaa8", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "start_char_idx": 1513, "end_char_idx": 1757, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "366d93fc-c2bc-488a-91ed-8026ed62f635": {"__data__": {"id_": "366d93fc-c2bc-488a-91ed-8026ed62f635", "embedding": null, "metadata": {"window": "The technology will enhance the ability to proactively monitor shipments,\nanticipate potential risks and intervene, if needed, to ensure the secure and timely distribution of products.\n The AmerisourceBergen Foundation contributed to non-profit partners to support disaster response efforts in T\u00fcrkiye\nfollowing earthquakes in February.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect stronger core growth in the U.S.\n Healthcare Solutions segment.  The Company now expects:\nRevenue growth to be in the range of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nU.S. ", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7129ecf3-7586-4969-be47-487cdb63cac3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f36fb7167c27bf3ab1b38d53c613bcb8d4edcabfe5a6ab15ff66ed9f2370eb1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a52f9b2c-6c02-4cb9-9022-a04bb200f913", "node_type": "1", "metadata": {"window": "World Courier is deploying real-time location monitoring on all of its multi-use packages, enabling increased visibility into the\nprecise location of shipments in transit globally.  The technology will enhance the ability to proactively monitor shipments,\nanticipate potential risks and intervene, if needed, to ensure the secure and timely distribution of products.\n The AmerisourceBergen Foundation contributed to non-profit partners to support disaster response efforts in T\u00fcrkiye\nfollowing earthquakes in February.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect stronger core growth in the U.S.\n Healthcare Solutions segment. ", "original_text": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1821b2b744f7e7e558ee64fbaeec7d215ced22da919475c522256ee99316293", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b4db343-bdcf-4042-bcdc-a637411b9b12", "node_type": "1", "metadata": {"window": "The AmerisourceBergen Foundation contributed to non-profit partners to support disaster response efforts in T\u00fcrkiye\nfollowing earthquakes in February.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect stronger core growth in the U.S.\n Healthcare Solutions segment.  The Company now expects:\nRevenue growth to be in the range of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 8 percent, narrowed from the previous range of 6 to\n8 percent;\nInternational Healthcare Solutions revenue to be in the range of a 3 percent decline to flat, up from the previous range\nof a 1 to 5 percent decline;\nAdjusted Diluted Earnings Per Share to be in the range of $11.70 to $11.90, representing growth of 6 to 8 percent, raised from\nthe previous range of $11.50 to $11.75;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 8 to 10 percent, raised\nfrom the previous range of 6 to 9 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 11 to 13\npercent, raised from the previous range of 9 to 11 percent; and\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 15 percent, raised from the previous range of 11 to 13 percent.\n", "original_text": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect stronger core growth in the U.S.\n"}, "hash": "c5b86f5f5e80f17d3862fd5076bd98940e0e024528be304f2eecf21c5ed321a5", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "start_char_idx": 1757, "end_char_idx": 1889, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b4db343-bdcf-4042-bcdc-a637411b9b12": {"__data__": {"id_": "3b4db343-bdcf-4042-bcdc-a637411b9b12", "embedding": null, "metadata": {"window": "The AmerisourceBergen Foundation contributed to non-profit partners to support disaster response efforts in T\u00fcrkiye\nfollowing earthquakes in February.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect stronger core growth in the U.S.\n Healthcare Solutions segment.  The Company now expects:\nRevenue growth to be in the range of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 8 percent, narrowed from the previous range of 6 to\n8 percent;\nInternational Healthcare Solutions revenue to be in the range of a 3 percent decline to flat, up from the previous range\nof a 1 to 5 percent decline;\nAdjusted Diluted Earnings Per Share to be in the range of $11.70 to $11.90, representing growth of 6 to 8 percent, raised from\nthe previous range of $11.50 to $11.75;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 8 to 10 percent, raised\nfrom the previous range of 6 to 9 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 11 to 13\npercent, raised from the previous range of 9 to 11 percent; and\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 15 percent, raised from the previous range of 11 to 13 percent.\n", "original_text": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect stronger core growth in the U.S.\n", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7129ecf3-7586-4969-be47-487cdb63cac3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f36fb7167c27bf3ab1b38d53c613bcb8d4edcabfe5a6ab15ff66ed9f2370eb1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "366d93fc-c2bc-488a-91ed-8026ed62f635", "node_type": "1", "metadata": {"window": "The technology will enhance the ability to proactively monitor shipments,\nanticipate potential risks and intervene, if needed, to ensure the secure and timely distribution of products.\n The AmerisourceBergen Foundation contributed to non-profit partners to support disaster response efforts in T\u00fcrkiye\nfollowing earthquakes in February.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect stronger core growth in the U.S.\n Healthcare Solutions segment.  The Company now expects:\nRevenue growth to be in the range of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nU.S. ", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e39910ca68fdb70c43b14d41957bc5b399628e17ca96308adacd2a6630fc8e78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ff9fc40-f568-44e0-8470-b64b743373e5", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect stronger core growth in the U.S.\n Healthcare Solutions segment.  The Company now expects:\nRevenue growth to be in the range of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 8 percent, narrowed from the previous range of 6 to\n8 percent;\nInternational Healthcare Solutions revenue to be in the range of a 3 percent decline to flat, up from the previous range\nof a 1 to 5 percent decline;\nAdjusted Diluted Earnings Per Share to be in the range of $11.70 to $11.90, representing growth of 6 to 8 percent, raised from\nthe previous range of $11.50 to $11.75;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 8 to 10 percent, raised\nfrom the previous range of 6 to 9 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 11 to 13\npercent, raised from the previous range of 9 to 11 percent; and\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 15 percent, raised from the previous range of 11 to 13 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 2 to 4 percent, up from the previous range of 0 to 3\n4", "original_text": "Healthcare Solutions segment. "}, "hash": "9c96f72f84276fe57af5226e5a1f49c875ad7fdc889e2a5a710db69344c2ab7e", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect stronger core growth in the U.S.\n", "start_char_idx": 1889, "end_char_idx": 2081, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ff9fc40-f568-44e0-8470-b64b743373e5": {"__data__": {"id_": "1ff9fc40-f568-44e0-8470-b64b743373e5", "embedding": null, "metadata": {"window": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect stronger core growth in the U.S.\n Healthcare Solutions segment.  The Company now expects:\nRevenue growth to be in the range of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 8 percent, narrowed from the previous range of 6 to\n8 percent;\nInternational Healthcare Solutions revenue to be in the range of a 3 percent decline to flat, up from the previous range\nof a 1 to 5 percent decline;\nAdjusted Diluted Earnings Per Share to be in the range of $11.70 to $11.90, representing growth of 6 to 8 percent, raised from\nthe previous range of $11.50 to $11.75;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 8 to 10 percent, raised\nfrom the previous range of 6 to 9 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 11 to 13\npercent, raised from the previous range of 9 to 11 percent; and\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 15 percent, raised from the previous range of 11 to 13 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 2 to 4 percent, up from the previous range of 0 to 3\n4", "original_text": "Healthcare Solutions segment. ", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7129ecf3-7586-4969-be47-487cdb63cac3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f36fb7167c27bf3ab1b38d53c613bcb8d4edcabfe5a6ab15ff66ed9f2370eb1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b4db343-bdcf-4042-bcdc-a637411b9b12", "node_type": "1", "metadata": {"window": "The AmerisourceBergen Foundation contributed to non-profit partners to support disaster response efforts in T\u00fcrkiye\nfollowing earthquakes in February.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect stronger core growth in the U.S.\n Healthcare Solutions segment.  The Company now expects:\nRevenue growth to be in the range of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 8 percent, narrowed from the previous range of 6 to\n8 percent;\nInternational Healthcare Solutions revenue to be in the range of a 3 percent decline to flat, up from the previous range\nof a 1 to 5 percent decline;\nAdjusted Diluted Earnings Per Share to be in the range of $11.70 to $11.90, representing growth of 6 to 8 percent, raised from\nthe previous range of $11.50 to $11.75;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 8 to 10 percent, raised\nfrom the previous range of 6 to 9 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 11 to 13\npercent, raised from the previous range of 9 to 11 percent; and\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 15 percent, raised from the previous range of 11 to 13 percent.\n", "original_text": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect stronger core growth in the U.S.\n", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "69123a20bfa3fe7e2886231e33dcc3a890d7292305e22ae38105ae73e19628d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e653783-8ebf-4ddf-8125-27a1fb37edd8", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect stronger core growth in the U.S.\n Healthcare Solutions segment.  The Company now expects:\nRevenue growth to be in the range of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 8 percent, narrowed from the previous range of 6 to\n8 percent;\nInternational Healthcare Solutions revenue to be in the range of a 3 percent decline to flat, up from the previous range\nof a 1 to 5 percent decline;\nAdjusted Diluted Earnings Per Share to be in the range of $11.70 to $11.90, representing growth of 6 to 8 percent, raised from\nthe previous range of $11.50 to $11.75;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 8 to 10 percent, raised\nfrom the previous range of 6 to 9 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 11 to 13\npercent, raised from the previous range of 9 to 11 percent; and\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 15 percent, raised from the previous range of 11 to 13 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 2 to 4 percent, up from the previous range of 0 to 3\n4", "original_text": "The Company now expects:\nRevenue growth to be in the range of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nU.S. "}, "hash": "cf74e182f3d5f945e6534d7f2b6be9cff52c50233a6f4312899fdf40bab7d432", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions segment. ", "start_char_idx": 2081, "end_char_idx": 2111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e653783-8ebf-4ddf-8125-27a1fb37edd8": {"__data__": {"id_": "2e653783-8ebf-4ddf-8125-27a1fb37edd8", "embedding": null, "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect stronger core growth in the U.S.\n Healthcare Solutions segment.  The Company now expects:\nRevenue growth to be in the range of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 8 percent, narrowed from the previous range of 6 to\n8 percent;\nInternational Healthcare Solutions revenue to be in the range of a 3 percent decline to flat, up from the previous range\nof a 1 to 5 percent decline;\nAdjusted Diluted Earnings Per Share to be in the range of $11.70 to $11.90, representing growth of 6 to 8 percent, raised from\nthe previous range of $11.50 to $11.75;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 8 to 10 percent, raised\nfrom the previous range of 6 to 9 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 11 to 13\npercent, raised from the previous range of 9 to 11 percent; and\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 15 percent, raised from the previous range of 11 to 13 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 2 to 4 percent, up from the previous range of 0 to 3\n4", "original_text": "The Company now expects:\nRevenue growth to be in the range of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nU.S. ", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7129ecf3-7586-4969-be47-487cdb63cac3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f36fb7167c27bf3ab1b38d53c613bcb8d4edcabfe5a6ab15ff66ed9f2370eb1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ff9fc40-f568-44e0-8470-b64b743373e5", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect stronger core growth in the U.S.\n Healthcare Solutions segment.  The Company now expects:\nRevenue growth to be in the range of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 8 percent, narrowed from the previous range of 6 to\n8 percent;\nInternational Healthcare Solutions revenue to be in the range of a 3 percent decline to flat, up from the previous range\nof a 1 to 5 percent decline;\nAdjusted Diluted Earnings Per Share to be in the range of $11.70 to $11.90, representing growth of 6 to 8 percent, raised from\nthe previous range of $11.50 to $11.75;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 8 to 10 percent, raised\nfrom the previous range of 6 to 9 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 11 to 13\npercent, raised from the previous range of 9 to 11 percent; and\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 15 percent, raised from the previous range of 11 to 13 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 2 to 4 percent, up from the previous range of 0 to 3\n4", "original_text": "Healthcare Solutions segment. ", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "905652f2c662fb3567fa1bf18453d7dc32762defc1fc64a9599dfad4b1182025", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b584290-4f8b-47b9-b0f4-14be7baa3e2c", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect stronger core growth in the U.S.\n Healthcare Solutions segment.  The Company now expects:\nRevenue growth to be in the range of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 8 percent, narrowed from the previous range of 6 to\n8 percent;\nInternational Healthcare Solutions revenue to be in the range of a 3 percent decline to flat, up from the previous range\nof a 1 to 5 percent decline;\nAdjusted Diluted Earnings Per Share to be in the range of $11.70 to $11.90, representing growth of 6 to 8 percent, raised from\nthe previous range of $11.50 to $11.75;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 8 to 10 percent, raised\nfrom the previous range of 6 to 9 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 11 to 13\npercent, raised from the previous range of 9 to 11 percent; and\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 15 percent, raised from the previous range of 11 to 13 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 2 to 4 percent, up from the previous range of 0 to 3\n4", "original_text": "Healthcare Solutions revenue growth to be in the range of 7 to 8 percent, narrowed from the previous range of 6 to\n8 percent;\nInternational Healthcare Solutions revenue to be in the range of a 3 percent decline to flat, up from the previous range\nof a 1 to 5 percent decline;\nAdjusted Diluted Earnings Per Share to be in the range of $11.70 to $11.90, representing growth of 6 to 8 percent, raised from\nthe previous range of $11.50 to $11.75;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 8 to 10 percent, raised\nfrom the previous range of 6 to 9 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 11 to 13\npercent, raised from the previous range of 9 to 11 percent; and\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 15 percent, raised from the previous range of 11 to 13 percent.\n"}, "hash": "35af62abd283671f0fd0e1c7ea2a67166fc21d95766408eea2f12a4a95238413", "class_name": "RelatedNodeInfo"}}, "text": "The Company now expects:\nRevenue growth to be in the range of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nU.S. ", "start_char_idx": 2111, "end_char_idx": 2240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b584290-4f8b-47b9-b0f4-14be7baa3e2c": {"__data__": {"id_": "7b584290-4f8b-47b9-b0f4-14be7baa3e2c", "embedding": null, "metadata": {"window": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect stronger core growth in the U.S.\n Healthcare Solutions segment.  The Company now expects:\nRevenue growth to be in the range of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 8 percent, narrowed from the previous range of 6 to\n8 percent;\nInternational Healthcare Solutions revenue to be in the range of a 3 percent decline to flat, up from the previous range\nof a 1 to 5 percent decline;\nAdjusted Diluted Earnings Per Share to be in the range of $11.70 to $11.90, representing growth of 6 to 8 percent, raised from\nthe previous range of $11.50 to $11.75;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 8 to 10 percent, raised\nfrom the previous range of 6 to 9 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 11 to 13\npercent, raised from the previous range of 9 to 11 percent; and\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 15 percent, raised from the previous range of 11 to 13 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 2 to 4 percent, up from the previous range of 0 to 3\n4", "original_text": "Healthcare Solutions revenue growth to be in the range of 7 to 8 percent, narrowed from the previous range of 6 to\n8 percent;\nInternational Healthcare Solutions revenue to be in the range of a 3 percent decline to flat, up from the previous range\nof a 1 to 5 percent decline;\nAdjusted Diluted Earnings Per Share to be in the range of $11.70 to $11.90, representing growth of 6 to 8 percent, raised from\nthe previous range of $11.50 to $11.75;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 8 to 10 percent, raised\nfrom the previous range of 6 to 9 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 11 to 13\npercent, raised from the previous range of 9 to 11 percent; and\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 15 percent, raised from the previous range of 11 to 13 percent.\n", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7129ecf3-7586-4969-be47-487cdb63cac3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f36fb7167c27bf3ab1b38d53c613bcb8d4edcabfe5a6ab15ff66ed9f2370eb1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e653783-8ebf-4ddf-8125-27a1fb37edd8", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect stronger core growth in the U.S.\n Healthcare Solutions segment.  The Company now expects:\nRevenue growth to be in the range of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 8 percent, narrowed from the previous range of 6 to\n8 percent;\nInternational Healthcare Solutions revenue to be in the range of a 3 percent decline to flat, up from the previous range\nof a 1 to 5 percent decline;\nAdjusted Diluted Earnings Per Share to be in the range of $11.70 to $11.90, representing growth of 6 to 8 percent, raised from\nthe previous range of $11.50 to $11.75;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 8 to 10 percent, raised\nfrom the previous range of 6 to 9 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 11 to 13\npercent, raised from the previous range of 9 to 11 percent; and\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 15 percent, raised from the previous range of 11 to 13 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 2 to 4 percent, up from the previous range of 0 to 3\n4", "original_text": "The Company now expects:\nRevenue growth to be in the range of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nU.S. ", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f387ef9a3891fe38bb90eec49eeab7be1ad3bde63540c9ae6f54e8c2b424abd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "207dc282-f542-497a-a357-153f1347b913", "node_type": "1", "metadata": {"window": "Healthcare Solutions segment.  The Company now expects:\nRevenue growth to be in the range of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 8 percent, narrowed from the previous range of 6 to\n8 percent;\nInternational Healthcare Solutions revenue to be in the range of a 3 percent decline to flat, up from the previous range\nof a 1 to 5 percent decline;\nAdjusted Diluted Earnings Per Share to be in the range of $11.70 to $11.90, representing growth of 6 to 8 percent, raised from\nthe previous range of $11.50 to $11.75;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 8 to 10 percent, raised\nfrom the previous range of 6 to 9 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 11 to 13\npercent, raised from the previous range of 9 to 11 percent; and\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 15 percent, raised from the previous range of 11 to 13 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 2 to 4 percent, up from the previous range of 0 to 3\n4", "original_text": "Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 2 to 4 percent, up from the previous range of 0 to 3\n4"}, "hash": "f1f1b1d510917bffc448e13982d57965e3b232901382c8bf26392038ed584161", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions revenue growth to be in the range of 7 to 8 percent, narrowed from the previous range of 6 to\n8 percent;\nInternational Healthcare Solutions revenue to be in the range of a 3 percent decline to flat, up from the previous range\nof a 1 to 5 percent decline;\nAdjusted Diluted Earnings Per Share to be in the range of $11.70 to $11.90, representing growth of 6 to 8 percent, raised from\nthe previous range of $11.50 to $11.75;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 8 to 10 percent, raised\nfrom the previous range of 6 to 9 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 11 to 13\npercent, raised from the previous range of 9 to 11 percent; and\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 15 percent, raised from the previous range of 11 to 13 percent.\n", "start_char_idx": 2240, "end_char_idx": 3237, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "207dc282-f542-497a-a357-153f1347b913": {"__data__": {"id_": "207dc282-f542-497a-a357-153f1347b913", "embedding": null, "metadata": {"window": "Healthcare Solutions segment.  The Company now expects:\nRevenue growth to be in the range of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 8 percent, narrowed from the previous range of 6 to\n8 percent;\nInternational Healthcare Solutions revenue to be in the range of a 3 percent decline to flat, up from the previous range\nof a 1 to 5 percent decline;\nAdjusted Diluted Earnings Per Share to be in the range of $11.70 to $11.90, representing growth of 6 to 8 percent, raised from\nthe previous range of $11.50 to $11.75;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 8 to 10 percent, raised\nfrom the previous range of 6 to 9 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 11 to 13\npercent, raised from the previous range of 9 to 11 percent; and\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 15 percent, raised from the previous range of 11 to 13 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 2 to 4 percent, up from the previous range of 0 to 3\n4", "original_text": "Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 2 to 4 percent, up from the previous range of 0 to 3\n4", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7129ecf3-7586-4969-be47-487cdb63cac3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f36fb7167c27bf3ab1b38d53c613bcb8d4edcabfe5a6ab15ff66ed9f2370eb1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b584290-4f8b-47b9-b0f4-14be7baa3e2c", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to primarily reflect stronger core growth in the U.S.\n Healthcare Solutions segment.  The Company now expects:\nRevenue growth to be in the range of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 8 percent, narrowed from the previous range of 6 to\n8 percent;\nInternational Healthcare Solutions revenue to be in the range of a 3 percent decline to flat, up from the previous range\nof a 1 to 5 percent decline;\nAdjusted Diluted Earnings Per Share to be in the range of $11.70 to $11.90, representing growth of 6 to 8 percent, raised from\nthe previous range of $11.50 to $11.75;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 8 to 10 percent, raised\nfrom the previous range of 6 to 9 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 11 to 13\npercent, raised from the previous range of 9 to 11 percent; and\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 15 percent, raised from the previous range of 11 to 13 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 2 to 4 percent, up from the previous range of 0 to 3\n4", "original_text": "Healthcare Solutions revenue growth to be in the range of 7 to 8 percent, narrowed from the previous range of 6 to\n8 percent;\nInternational Healthcare Solutions revenue to be in the range of a 3 percent decline to flat, up from the previous range\nof a 1 to 5 percent decline;\nAdjusted Diluted Earnings Per Share to be in the range of $11.70 to $11.90, representing growth of 6 to 8 percent, raised from\nthe previous range of $11.50 to $11.75;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 8 to 10 percent, raised\nfrom the previous range of 6 to 9 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 11 to 13\npercent, raised from the previous range of 9 to 11 percent; and\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 15 percent, raised from the previous range of 11 to 13 percent.\n", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65d0b2bcd626b3d0abd9ef95096fd978300f1e6d3980eb43afce82bcc19f8063", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d548d5d-1f59-4671-9b15-213eac1001f2", "node_type": "1", "metadata": {"window": "percent.  Excluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 5 to 7\npercent, up from the previous range of 4 to 6 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 3 percent to 5 percent, up from the\nprevious range of 1 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions have been raised to growth of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nWeighted average diluted shares to be approximately 205 million shares for the fiscal year, lowered from the previous range\nof approximately 206 million shares; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis, please refer to our slide presentation for investors.\n", "original_text": "percent. "}, "hash": "a1c71e67241731dd942736df56e2dff2eda15780dea1b4e8ba9536926e991660", "class_name": "RelatedNodeInfo"}}, "text": "Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 2 to 4 percent, up from the previous range of 0 to 3\n4", "start_char_idx": 3237, "end_char_idx": 3396, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d548d5d-1f59-4671-9b15-213eac1001f2": {"__data__": {"id_": "8d548d5d-1f59-4671-9b15-213eac1001f2", "embedding": null, "metadata": {"window": "percent.  Excluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 5 to 7\npercent, up from the previous range of 4 to 6 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 3 percent to 5 percent, up from the\nprevious range of 1 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions have been raised to growth of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nWeighted average diluted shares to be approximately 205 million shares for the fiscal year, lowered from the previous range\nof approximately 206 million shares; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis, please refer to our slide presentation for investors.\n", "original_text": "percent. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09858b6e-6f03-4927-8378-7b281265574e", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac667de9b12f1f3414ae1b31cd0b880fb1f2486cdd63f2be739aafcd36de1c22", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "207dc282-f542-497a-a357-153f1347b913", "node_type": "1", "metadata": {"window": "Healthcare Solutions segment.  The Company now expects:\nRevenue growth to be in the range of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 7 to 8 percent, narrowed from the previous range of 6 to\n8 percent;\nInternational Healthcare Solutions revenue to be in the range of a 3 percent decline to flat, up from the previous range\nof a 1 to 5 percent decline;\nAdjusted Diluted Earnings Per Share to be in the range of $11.70 to $11.90, representing growth of 6 to 8 percent, raised from\nthe previous range of $11.50 to $11.75;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 8 to 10 percent, raised\nfrom the previous range of 6 to 9 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 11 to 13\npercent, raised from the previous range of 9 to 11 percent; and\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 13 to 15 percent, raised from the previous range of 11 to 13 percent.\n Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 2 to 4 percent, up from the previous range of 0 to 3\n4", "original_text": "Additional expectations now include:\nAdjusted consolidated operating income growth to be in the range of 2 to 4 percent, up from the previous range of 0 to 3\n4", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "382808bd6ae9f02bd6faeb88f3e71c5feeab627a3ff154ba350e85b440d87397", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03d779dc-9735-49b4-a529-708437b390de", "node_type": "1", "metadata": {"window": "percent.  Excluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 5 to 7\npercent, up from the previous range of 4 to 6 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 3 percent to 5 percent, up from the\nprevious range of 1 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions have been raised to growth of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nWeighted average diluted shares to be approximately 205 million shares for the fiscal year, lowered from the previous range\nof approximately 206 million shares; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n", "original_text": "Excluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 5 to 7\npercent, up from the previous range of 4 to 6 percent;\nU.S. "}, "hash": "a33b6e6923bcf623eba9b02e8b67916bc9eed5581efdb03cf700c461070c3c3c", "class_name": "RelatedNodeInfo"}}, "text": "percent. ", "start_char_idx": 0, "end_char_idx": 9, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03d779dc-9735-49b4-a529-708437b390de": {"__data__": {"id_": "03d779dc-9735-49b4-a529-708437b390de", "embedding": null, "metadata": {"window": "percent.  Excluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 5 to 7\npercent, up from the previous range of 4 to 6 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 3 percent to 5 percent, up from the\nprevious range of 1 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions have been raised to growth of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nWeighted average diluted shares to be approximately 205 million shares for the fiscal year, lowered from the previous range\nof approximately 206 million shares; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n", "original_text": "Excluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 5 to 7\npercent, up from the previous range of 4 to 6 percent;\nU.S. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09858b6e-6f03-4927-8378-7b281265574e", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac667de9b12f1f3414ae1b31cd0b880fb1f2486cdd63f2be739aafcd36de1c22", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d548d5d-1f59-4671-9b15-213eac1001f2", "node_type": "1", "metadata": {"window": "percent.  Excluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 5 to 7\npercent, up from the previous range of 4 to 6 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 3 percent to 5 percent, up from the\nprevious range of 1 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions have been raised to growth of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nWeighted average diluted shares to be approximately 205 million shares for the fiscal year, lowered from the previous range\nof approximately 206 million shares; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis, please refer to our slide presentation for investors.\n", "original_text": "percent. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7262fc04f741dd04bba1b1f75661ba6941b4ff5176bf26cf33838bbdd7c6f9c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77d1c990-cdc9-4509-b103-8c080d9960cd", "node_type": "1", "metadata": {"window": "percent.  Excluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 5 to 7\npercent, up from the previous range of 4 to 6 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 3 percent to 5 percent, up from the\nprevious range of 1 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions have been raised to growth of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nWeighted average diluted shares to be approximately 205 million shares for the fiscal year, lowered from the previous range\nof approximately 206 million shares; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable May 30, 2023, to\nstockholders of record at the close of business on May 12, 2023.\n", "original_text": "Healthcare Solutions segment operating income growth to be in the range of 3 percent to 5 percent, up from the\nprevious range of 1 percent to 4 percent. "}, "hash": "7b48fa0e2d6994ef4e58b6cfb7114f6ef7292351cb9e7f19f949cfa461819964", "class_name": "RelatedNodeInfo"}}, "text": "Excluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 5 to 7\npercent, up from the previous range of 4 to 6 percent;\nU.S. ", "start_char_idx": 9, "end_char_idx": 183, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77d1c990-cdc9-4509-b103-8c080d9960cd": {"__data__": {"id_": "77d1c990-cdc9-4509-b103-8c080d9960cd", "embedding": null, "metadata": {"window": "percent.  Excluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 5 to 7\npercent, up from the previous range of 4 to 6 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 3 percent to 5 percent, up from the\nprevious range of 1 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions have been raised to growth of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nWeighted average diluted shares to be approximately 205 million shares for the fiscal year, lowered from the previous range\nof approximately 206 million shares; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable May 30, 2023, to\nstockholders of record at the close of business on May 12, 2023.\n", "original_text": "Healthcare Solutions segment operating income growth to be in the range of 3 percent to 5 percent, up from the\nprevious range of 1 percent to 4 percent. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09858b6e-6f03-4927-8378-7b281265574e", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac667de9b12f1f3414ae1b31cd0b880fb1f2486cdd63f2be739aafcd36de1c22", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03d779dc-9735-49b4-a529-708437b390de", "node_type": "1", "metadata": {"window": "percent.  Excluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 5 to 7\npercent, up from the previous range of 4 to 6 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 3 percent to 5 percent, up from the\nprevious range of 1 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions have been raised to growth of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nWeighted average diluted shares to be approximately 205 million shares for the fiscal year, lowered from the previous range\nof approximately 206 million shares; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n", "original_text": "Excluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 5 to 7\npercent, up from the previous range of 4 to 6 percent;\nU.S. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bea62003b38d608b9b95b2fa43d7c1e6081540071f4ec1af6bef89267b959e03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25fc97ed-1cad-459a-ab4d-fea617d55e1a", "node_type": "1", "metadata": {"window": "percent.  Excluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 5 to 7\npercent, up from the previous range of 4 to 6 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 3 percent to 5 percent, up from the\nprevious range of 1 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions have been raised to growth of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nWeighted average diluted shares to be approximately 205 million shares for the fiscal year, lowered from the previous range\nof approximately 206 million shares; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable May 30, 2023, to\nstockholders of record at the close of business on May 12, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "Expectations for segment operating income growth excluding COVID-19\ncontributions have been raised to growth of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nWeighted average diluted shares to be approximately 205 million shares for the fiscal year, lowered from the previous range\nof approximately 206 million shares; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis, please refer to our slide presentation for investors.\n"}, "hash": "bb3d9fbec60184905efef5ae17e81fdc4b6f59f59ff522e41646a4683327aafd", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions segment operating income growth to be in the range of 3 percent to 5 percent, up from the\nprevious range of 1 percent to 4 percent. ", "start_char_idx": 183, "end_char_idx": 336, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25fc97ed-1cad-459a-ab4d-fea617d55e1a": {"__data__": {"id_": "25fc97ed-1cad-459a-ab4d-fea617d55e1a", "embedding": null, "metadata": {"window": "percent.  Excluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 5 to 7\npercent, up from the previous range of 4 to 6 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 3 percent to 5 percent, up from the\nprevious range of 1 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions have been raised to growth of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nWeighted average diluted shares to be approximately 205 million shares for the fiscal year, lowered from the previous range\nof approximately 206 million shares; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable May 30, 2023, to\nstockholders of record at the close of business on May 12, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "Expectations for segment operating income growth excluding COVID-19\ncontributions have been raised to growth of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nWeighted average diluted shares to be approximately 205 million shares for the fiscal year, lowered from the previous range\nof approximately 206 million shares; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis, please refer to our slide presentation for investors.\n", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09858b6e-6f03-4927-8378-7b281265574e", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac667de9b12f1f3414ae1b31cd0b880fb1f2486cdd63f2be739aafcd36de1c22", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77d1c990-cdc9-4509-b103-8c080d9960cd", "node_type": "1", "metadata": {"window": "percent.  Excluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 5 to 7\npercent, up from the previous range of 4 to 6 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 3 percent to 5 percent, up from the\nprevious range of 1 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions have been raised to growth of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nWeighted average diluted shares to be approximately 205 million shares for the fiscal year, lowered from the previous range\nof approximately 206 million shares; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable May 30, 2023, to\nstockholders of record at the close of business on May 12, 2023.\n", "original_text": "Healthcare Solutions segment operating income growth to be in the range of 3 percent to 5 percent, up from the\nprevious range of 1 percent to 4 percent. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3847cf502cea77cb247e3d20af3b2e2b9fe3dd871b6f6474e36bf73fe1df508b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "184afaea-e1cb-4a62-9278-67bd4d9bbdf2", "node_type": "1", "metadata": {"window": "Excluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 5 to 7\npercent, up from the previous range of 4 to 6 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 3 percent to 5 percent, up from the\nprevious range of 1 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions have been raised to growth of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nWeighted average diluted shares to be approximately 205 million shares for the fiscal year, lowered from the previous range\nof approximately 206 million shares; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable May 30, 2023, to\nstockholders of record at the close of business on May 12, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 2, 2023. ", "original_text": "All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n"}, "hash": "320e9cee0d572a05db7037f74ca397bf23006b11a3a3e02bc20fe21db2d67cd6", "class_name": "RelatedNodeInfo"}}, "text": "Expectations for segment operating income growth excluding COVID-19\ncontributions have been raised to growth of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nWeighted average diluted shares to be approximately 205 million shares for the fiscal year, lowered from the previous range\nof approximately 206 million shares; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis, please refer to our slide presentation for investors.\n", "start_char_idx": 336, "end_char_idx": 862, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "184afaea-e1cb-4a62-9278-67bd4d9bbdf2": {"__data__": {"id_": "184afaea-e1cb-4a62-9278-67bd4d9bbdf2", "embedding": null, "metadata": {"window": "Excluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 5 to 7\npercent, up from the previous range of 4 to 6 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 3 percent to 5 percent, up from the\nprevious range of 1 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions have been raised to growth of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nWeighted average diluted shares to be approximately 205 million shares for the fiscal year, lowered from the previous range\nof approximately 206 million shares; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable May 30, 2023, to\nstockholders of record at the close of business on May 12, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 2, 2023. ", "original_text": "All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09858b6e-6f03-4927-8378-7b281265574e", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac667de9b12f1f3414ae1b31cd0b880fb1f2486cdd63f2be739aafcd36de1c22", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25fc97ed-1cad-459a-ab4d-fea617d55e1a", "node_type": "1", "metadata": {"window": "percent.  Excluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 5 to 7\npercent, up from the previous range of 4 to 6 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 3 percent to 5 percent, up from the\nprevious range of 1 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions have been raised to growth of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nWeighted average diluted shares to be approximately 205 million shares for the fiscal year, lowered from the previous range\nof approximately 206 million shares; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable May 30, 2023, to\nstockholders of record at the close of business on May 12, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "Expectations for segment operating income growth excluding COVID-19\ncontributions have been raised to growth of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nWeighted average diluted shares to be approximately 205 million shares for the fiscal year, lowered from the previous range\nof approximately 206 million shares; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis, please refer to our slide presentation for investors.\n", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d00a18c4415fa5e1794eefbaa70e7abd2ce41e5f9315085eda394144b5331ec4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "127ce416-9c4a-4a5e-8c07-082d70636218", "node_type": "1", "metadata": {"window": "Healthcare Solutions segment operating income growth to be in the range of 3 percent to 5 percent, up from the\nprevious range of 1 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions have been raised to growth of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nWeighted average diluted shares to be approximately 205 million shares for the fiscal year, lowered from the previous range\nof approximately 206 million shares; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable May 30, 2023, to\nstockholders of record at the close of business on May 12, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 2, 2023.  A slide presentation for investors has\nalso been posted on the Company\u2019s website at investor.amerisourcebergen.com. ", "original_text": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable May 30, 2023, to\nstockholders of record at the close of business on May 12, 2023.\n"}, "hash": "6ac7f1dde6ac5d5be422941e378f6468f4a83ff3980cb6005259726fee4d1c92", "class_name": "RelatedNodeInfo"}}, "text": "All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n", "start_char_idx": 862, "end_char_idx": 1003, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "127ce416-9c4a-4a5e-8c07-082d70636218": {"__data__": {"id_": "127ce416-9c4a-4a5e-8c07-082d70636218", "embedding": null, "metadata": {"window": "Healthcare Solutions segment operating income growth to be in the range of 3 percent to 5 percent, up from the\nprevious range of 1 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions have been raised to growth of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nWeighted average diluted shares to be approximately 205 million shares for the fiscal year, lowered from the previous range\nof approximately 206 million shares; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable May 30, 2023, to\nstockholders of record at the close of business on May 12, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 2, 2023.  A slide presentation for investors has\nalso been posted on the Company\u2019s website at investor.amerisourcebergen.com. ", "original_text": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable May 30, 2023, to\nstockholders of record at the close of business on May 12, 2023.\n", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09858b6e-6f03-4927-8378-7b281265574e", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac667de9b12f1f3414ae1b31cd0b880fb1f2486cdd63f2be739aafcd36de1c22", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "184afaea-e1cb-4a62-9278-67bd4d9bbdf2", "node_type": "1", "metadata": {"window": "Excluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 5 to 7\npercent, up from the previous range of 4 to 6 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 3 percent to 5 percent, up from the\nprevious range of 1 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions have been raised to growth of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nWeighted average diluted shares to be approximately 205 million shares for the fiscal year, lowered from the previous range\nof approximately 206 million shares; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable May 30, 2023, to\nstockholders of record at the close of business on May 12, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 2, 2023. ", "original_text": "All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f0c7ddd84077a77806b5b87a7089dfe1f186a30b0143c936ca71abf4f1585412", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57b5047f-2b89-4baa-9edb-abc87239fcf4", "node_type": "1", "metadata": {"window": "Expectations for segment operating income growth excluding COVID-19\ncontributions have been raised to growth of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nWeighted average diluted shares to be approximately 205 million shares for the fiscal year, lowered from the previous range\nof approximately 206 million shares; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable May 30, 2023, to\nstockholders of record at the close of business on May 12, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 2, 2023.  A slide presentation for investors has\nalso been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. "}, "hash": "f1fdc1df6b3a514e561edd600d0c8b154371f01e50bb444b26a64866ba5a817c", "class_name": "RelatedNodeInfo"}}, "text": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable May 30, 2023, to\nstockholders of record at the close of business on May 12, 2023.\n", "start_char_idx": 1003, "end_char_idx": 1210, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57b5047f-2b89-4baa-9edb-abc87239fcf4": {"__data__": {"id_": "57b5047f-2b89-4baa-9edb-abc87239fcf4", "embedding": null, "metadata": {"window": "Expectations for segment operating income growth excluding COVID-19\ncontributions have been raised to growth of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nWeighted average diluted shares to be approximately 205 million shares for the fiscal year, lowered from the previous range\nof approximately 206 million shares; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable May 30, 2023, to\nstockholders of record at the close of business on May 12, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 2, 2023.  A slide presentation for investors has\nalso been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09858b6e-6f03-4927-8378-7b281265574e", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac667de9b12f1f3414ae1b31cd0b880fb1f2486cdd63f2be739aafcd36de1c22", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "127ce416-9c4a-4a5e-8c07-082d70636218", "node_type": "1", "metadata": {"window": "Healthcare Solutions segment operating income growth to be in the range of 3 percent to 5 percent, up from the\nprevious range of 1 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions have been raised to growth of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nWeighted average diluted shares to be approximately 205 million shares for the fiscal year, lowered from the previous range\nof approximately 206 million shares; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable May 30, 2023, to\nstockholders of record at the close of business on May 12, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 2, 2023.  A slide presentation for investors has\nalso been posted on the Company\u2019s website at investor.amerisourcebergen.com. ", "original_text": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable May 30, 2023, to\nstockholders of record at the close of business on May 12, 2023.\n", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9811d6af5872431bacc96f898d23c886f4c0618f897a2778e6791455292de537", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ac65456-4a5f-4a40-89c0-d24e15e07a03", "node_type": "1", "metadata": {"window": "All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable May 30, 2023, to\nstockholders of record at the close of business on May 12, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 2, 2023.  A slide presentation for investors has\nalso been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United States and Canada, dial +1 (404) 975-4839. ", "original_text": "ET on May 2, 2023. "}, "hash": "43ac71f459e998cf84889bd5eaa7e07741ffbeb5834169ba071f381fca211516", "class_name": "RelatedNodeInfo"}}, "text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "start_char_idx": 1210, "end_char_idx": 1325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ac65456-4a5f-4a40-89c0-d24e15e07a03": {"__data__": {"id_": "8ac65456-4a5f-4a40-89c0-d24e15e07a03", "embedding": null, "metadata": {"window": "All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable May 30, 2023, to\nstockholders of record at the close of business on May 12, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 2, 2023.  A slide presentation for investors has\nalso been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United States and Canada, dial +1 (404) 975-4839. ", "original_text": "ET on May 2, 2023. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09858b6e-6f03-4927-8378-7b281265574e", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac667de9b12f1f3414ae1b31cd0b880fb1f2486cdd63f2be739aafcd36de1c22", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57b5047f-2b89-4baa-9edb-abc87239fcf4", "node_type": "1", "metadata": {"window": "Expectations for segment operating income growth excluding COVID-19\ncontributions have been raised to growth of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nWeighted average diluted shares to be approximately 205 million shares for the fiscal year, lowered from the previous range\nof approximately 206 million shares; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis, please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable May 30, 2023, to\nstockholders of record at the close of business on May 12, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 2, 2023.  A slide presentation for investors has\nalso been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c0c982b45f75c75fbf2de4558f1e72f01c3e32e9be3627b28020dd5fed3f503", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31ae8181-b0fa-4e7e-80eb-4ca666ede20d", "node_type": "1", "metadata": {"window": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable May 30, 2023, to\nstockholders of record at the close of business on May 12, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 2, 2023.  A slide presentation for investors has\nalso been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United States and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 439143. ", "original_text": "A slide presentation for investors has\nalso been posted on the Company\u2019s website at investor.amerisourcebergen.com. "}, "hash": "c120cbc492e3f5936da5f3236f5fba6c3bcc35392f49cdf68266dbae16549608", "class_name": "RelatedNodeInfo"}}, "text": "ET on May 2, 2023. ", "start_char_idx": 1325, "end_char_idx": 1344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31ae8181-b0fa-4e7e-80eb-4ca666ede20d": {"__data__": {"id_": "31ae8181-b0fa-4e7e-80eb-4ca666ede20d", "embedding": null, "metadata": {"window": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable May 30, 2023, to\nstockholders of record at the close of business on May 12, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 2, 2023.  A slide presentation for investors has\nalso been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United States and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 439143. ", "original_text": "A slide presentation for investors has\nalso been posted on the Company\u2019s website at investor.amerisourcebergen.com. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09858b6e-6f03-4927-8378-7b281265574e", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac667de9b12f1f3414ae1b31cd0b880fb1f2486cdd63f2be739aafcd36de1c22", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ac65456-4a5f-4a40-89c0-d24e15e07a03", "node_type": "1", "metadata": {"window": "All other previously communicated aspects of the Company\u2019s fiscal year 2023 consolidated financial guidance and assumptions\nremain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable May 30, 2023, to\nstockholders of record at the close of business on May 12, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 2, 2023.  A slide presentation for investors has\nalso been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United States and Canada, dial +1 (404) 975-4839. ", "original_text": "ET on May 2, 2023. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f1a1c11ae4acc83b1b885ba38b7b6de3810123e1cb8b3eb5b95216a56087207", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9cc3448-51c9-43b5-b448-3f1d765cac8b", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 2, 2023.  A slide presentation for investors has\nalso been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United States and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 439143.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com. ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. "}, "hash": "a4ceadc953662097626cc1f096ba15c7f190d6a85b65a82a6a25f8e3b7d635a0", "class_name": "RelatedNodeInfo"}}, "text": "A slide presentation for investors has\nalso been posted on the Company\u2019s website at investor.amerisourcebergen.com. ", "start_char_idx": 1344, "end_char_idx": 1460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9cc3448-51c9-43b5-b448-3f1d765cac8b": {"__data__": {"id_": "c9cc3448-51c9-43b5-b448-3f1d765cac8b", "embedding": null, "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 2, 2023.  A slide presentation for investors has\nalso been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United States and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 439143.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com. ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09858b6e-6f03-4927-8378-7b281265574e", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac667de9b12f1f3414ae1b31cd0b880fb1f2486cdd63f2be739aafcd36de1c22", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31ae8181-b0fa-4e7e-80eb-4ca666ede20d", "node_type": "1", "metadata": {"window": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable May 30, 2023, to\nstockholders of record at the close of business on May 12, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 2, 2023.  A slide presentation for investors has\nalso been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United States and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 439143. ", "original_text": "A slide presentation for investors has\nalso been posted on the Company\u2019s website at investor.amerisourcebergen.com. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7b2541fb8b56f89066464f82712a367332226523709d7a5462ca34eab6816de2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2282575-55dc-4217-b030-84f5ee3dd149", "node_type": "1", "metadata": {"window": "ET on May 2, 2023.  A slide presentation for investors has\nalso been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United States and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 439143.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "original_text": "From outside the United States and Canada, dial +1 (404) 975-4839. "}, "hash": "418946691a2b3e3e76571cd3c22c3dd8f29e69c66e117d13a6e97a199ec8ee0e", "class_name": "RelatedNodeInfo"}}, "text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. ", "start_char_idx": 1460, "end_char_idx": 1699, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2282575-55dc-4217-b030-84f5ee3dd149": {"__data__": {"id_": "b2282575-55dc-4217-b030-84f5ee3dd149", "embedding": null, "metadata": {"window": "ET on May 2, 2023.  A slide presentation for investors has\nalso been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United States and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 439143.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "original_text": "From outside the United States and Canada, dial +1 (404) 975-4839. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09858b6e-6f03-4927-8378-7b281265574e", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac667de9b12f1f3414ae1b31cd0b880fb1f2486cdd63f2be739aafcd36de1c22", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9cc3448-51c9-43b5-b448-3f1d765cac8b", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 2, 2023.  A slide presentation for investors has\nalso been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United States and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 439143.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com. ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f04fb3e2527745d21cc03576dbca0d78ea681b0bce9c7acf4c7d2c4478371fc5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eecdaadd-ddaf-42de-902b-2b1c14076857", "node_type": "1", "metadata": {"window": "A slide presentation for investors has\nalso been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United States and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 439143.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "The\naccess code for the call will be 439143. "}, "hash": "73e10913e967a70d8663c7b55bf8f66ab489de1f0108ea1426976bf00eba56a8", "class_name": "RelatedNodeInfo"}}, "text": "From outside the United States and Canada, dial +1 (404) 975-4839. ", "start_char_idx": 1699, "end_char_idx": 1766, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eecdaadd-ddaf-42de-902b-2b1c14076857": {"__data__": {"id_": "eecdaadd-ddaf-42de-902b-2b1c14076857", "embedding": null, "metadata": {"window": "A slide presentation for investors has\nalso been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United States and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 439143.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "The\naccess code for the call will be 439143. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09858b6e-6f03-4927-8378-7b281265574e", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac667de9b12f1f3414ae1b31cd0b880fb1f2486cdd63f2be739aafcd36de1c22", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2282575-55dc-4217-b030-84f5ee3dd149", "node_type": "1", "metadata": {"window": "ET on May 2, 2023.  A slide presentation for investors has\nalso been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United States and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 439143.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "original_text": "From outside the United States and Canada, dial +1 (404) 975-4839. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e8394bb5003e3af371496a7f2257756e4f0f0ec44f236a390802ee1815cfb89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0162d3e6-5409-4c77-a92a-a4638189705a", "node_type": "1", "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United States and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 439143.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com. "}, "hash": "6d26ef91cb166c2794060b6aed18f925addaeb87527bdfcf0a7b4e68c8098b59", "class_name": "RelatedNodeInfo"}}, "text": "The\naccess code for the call will be 439143. ", "start_char_idx": 1766, "end_char_idx": 1811, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0162d3e6-5409-4c77-a92a-a4638189705a": {"__data__": {"id_": "0162d3e6-5409-4c77-a92a-a4638189705a", "embedding": null, "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United States and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 439143.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09858b6e-6f03-4927-8378-7b281265574e", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac667de9b12f1f3414ae1b31cd0b880fb1f2486cdd63f2be739aafcd36de1c22", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eecdaadd-ddaf-42de-902b-2b1c14076857", "node_type": "1", "metadata": {"window": "A slide presentation for investors has\nalso been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United States and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 439143.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "The\naccess code for the call will be 439143. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cdff5bc77086d4f02930edbc7d470ef4f3a62baada88e117a6112abdd9965ab4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43e9388d-392c-4fed-8c7a-4f7854225096", "node_type": "1", "metadata": {"window": "From outside the United States and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 439143.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n"}, "hash": "f9b88ed8dc6f0a32fa610e87c4cd9613f2ec098fa8b3b2a4f566a3c84c8c7b4d", "class_name": "RelatedNodeInfo"}}, "text": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com. ", "start_char_idx": 1811, "end_char_idx": 1907, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43e9388d-392c-4fed-8c7a-4f7854225096": {"__data__": {"id_": "43e9388d-392c-4fed-8c7a-4f7854225096", "embedding": null, "metadata": {"window": "From outside the United States and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 439143.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09858b6e-6f03-4927-8378-7b281265574e", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac667de9b12f1f3414ae1b31cd0b880fb1f2486cdd63f2be739aafcd36de1c22", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0162d3e6-5409-4c77-a92a-a4638189705a", "node_type": "1", "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (833) 470-1428.  From outside the United States and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 439143.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "439f84c3c9f8e318726ffa48544af00ab9e01028efa304adf3b2e05227322d31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "412b50b1-6c5b-456e-ae65-eb3702e99dee", "node_type": "1", "metadata": {"window": "The\naccess code for the call will be 439143.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S. ", "original_text": "Replays of the call will be made available via telephone and webcast. "}, "hash": "1661710ac2c97d6680d70f39c27e7c4b6dbb8e146c24020854db616f95761548", "class_name": "RelatedNodeInfo"}}, "text": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "start_char_idx": 1907, "end_char_idx": 2030, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "412b50b1-6c5b-456e-ae65-eb3702e99dee": {"__data__": {"id_": "412b50b1-6c5b-456e-ae65-eb3702e99dee", "embedding": null, "metadata": {"window": "The\naccess code for the call will be 439143.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09858b6e-6f03-4927-8378-7b281265574e", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac667de9b12f1f3414ae1b31cd0b880fb1f2486cdd63f2be739aafcd36de1c22", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43e9388d-392c-4fed-8c7a-4f7854225096", "node_type": "1", "metadata": {"window": "From outside the United States and Canada, dial +1 (404) 975-4839.  The\naccess code for the call will be 439143.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a19b5b0d19bcdab5f66429ae2ae49368b6721d499c77a6ffe0352b84974eb7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea311a20-290e-48f3-ae76-5928e5710ab7", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year. "}, "hash": "665794127c353235633041e4a3f30ac45e41a283d2800ddeb38913fc47fd8407", "class_name": "RelatedNodeInfo"}}, "text": "Replays of the call will be made available via telephone and webcast. ", "start_char_idx": 2030, "end_char_idx": 2100, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea311a20-290e-48f3-ae76-5928e5710ab7": {"__data__": {"id_": "ea311a20-290e-48f3-ae76-5928e5710ab7", "embedding": null, "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09858b6e-6f03-4927-8378-7b281265574e", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac667de9b12f1f3414ae1b31cd0b880fb1f2486cdd63f2be739aafcd36de1c22", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "412b50b1-6c5b-456e-ae65-eb3702e99dee", "node_type": "1", "metadata": {"window": "The\naccess code for the call will be 439143.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9f30b5c4552156b59da6dae5102beaa029c00be1b3d8e61ca3720058488e2348", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45fb4dec-22e5-4e7f-8576-3f35259ef2fe", "node_type": "1", "metadata": {"window": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. "}, "hash": "f5efe44ee59ce347c36a8ae16d09be386f3b1cf41ace247186490b1846a45192", "class_name": "RelatedNodeInfo"}}, "text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year. ", "start_char_idx": 2100, "end_char_idx": 2269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45fb4dec-22e5-4e7f-8576-3f35259ef2fe": {"__data__": {"id_": "45fb4dec-22e5-4e7f-8576-3f35259ef2fe", "embedding": null, "metadata": {"window": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09858b6e-6f03-4927-8378-7b281265574e", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac667de9b12f1f3414ae1b31cd0b880fb1f2486cdd63f2be739aafcd36de1c22", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea311a20-290e-48f3-ae76-5928e5710ab7", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7cca61015659b37ceb7590127ae2b0db73d78f00beddf988f9504b51de0fca96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7f6cb07-3e73-4dbc-a245-28cddd411def", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 519030.\n", "original_text": "To access the telephone replay from within the U.S. "}, "hash": "c5dd9865e5067140bb0a288889e8ffbd0b6cee1c4f1799c030e444a766b55453", "class_name": "RelatedNodeInfo"}}, "text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "start_char_idx": 2269, "end_char_idx": 2411, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7f6cb07-3e73-4dbc-a245-28cddd411def": {"__data__": {"id_": "e7f6cb07-3e73-4dbc-a245-28cddd411def", "embedding": null, "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 519030.\n", "original_text": "To access the telephone replay from within the U.S. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09858b6e-6f03-4927-8378-7b281265574e", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac667de9b12f1f3414ae1b31cd0b880fb1f2486cdd63f2be739aafcd36de1c22", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45fb4dec-22e5-4e7f-8576-3f35259ef2fe", "node_type": "1", "metadata": {"window": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b01bb6b8aff08981170b4c0aa5d25f14447b47a78fdcf8770a0f7e5007340525", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29b82857-1aff-481a-87f0-2818aeb39fa1", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 519030.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 10, 2023;\nUBS Healthcare Services Summit, June 26 to 28, 2023.\n", "original_text": "and Canada, dial (866) 813-9403. "}, "hash": "bb45100fe56b77756d49813ba7d12d1c621409ab67c35e6f918c960fecc918d7", "class_name": "RelatedNodeInfo"}}, "text": "To access the telephone replay from within the U.S. ", "start_char_idx": 2411, "end_char_idx": 2463, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29b82857-1aff-481a-87f0-2818aeb39fa1": {"__data__": {"id_": "29b82857-1aff-481a-87f0-2818aeb39fa1", "embedding": null, "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 519030.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 10, 2023;\nUBS Healthcare Services Summit, June 26 to 28, 2023.\n", "original_text": "and Canada, dial (866) 813-9403. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09858b6e-6f03-4927-8378-7b281265574e", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac667de9b12f1f3414ae1b31cd0b880fb1f2486cdd63f2be739aafcd36de1c22", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7f6cb07-3e73-4dbc-a245-28cddd411def", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 519030.\n", "original_text": "To access the telephone replay from within the U.S. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be05fcc5aa584ae6bc4e468882c4480645820b2d205dbc3658cfebb12f13ed60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93618fd6-3ddf-46ab-9d7c-90dcefec4a45", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 519030.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 10, 2023;\nUBS Healthcare Services Summit, June 26 to 28, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "From outside the United States and\nCanada, dial +44 (204) 525-0658. "}, "hash": "4bfbfe1ad257cc5356dc818b8af3559abcbe60f55b193b6c2503b1768ee583e4", "class_name": "RelatedNodeInfo"}}, "text": "and Canada, dial (866) 813-9403. ", "start_char_idx": 2463, "end_char_idx": 2496, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93618fd6-3ddf-46ab-9d7c-90dcefec4a45": {"__data__": {"id_": "93618fd6-3ddf-46ab-9d7c-90dcefec4a45", "embedding": null, "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 519030.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 10, 2023;\nUBS Healthcare Services Summit, June 26 to 28, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "From outside the United States and\nCanada, dial +44 (204) 525-0658. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09858b6e-6f03-4927-8378-7b281265574e", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac667de9b12f1f3414ae1b31cd0b880fb1f2486cdd63f2be739aafcd36de1c22", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29b82857-1aff-481a-87f0-2818aeb39fa1", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 519030.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 10, 2023;\nUBS Healthcare Services Summit, June 26 to 28, 2023.\n", "original_text": "and Canada, dial (866) 813-9403. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "510c83286cf8d046fe1dbf708703cceeb002faccfdbd1a52254ef18adb7d5bbd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6a60497-f25d-46fc-8e91-500598cb5346", "node_type": "1", "metadata": {"window": "To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 519030.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 10, 2023;\nUBS Healthcare Services Summit, June 26 to 28, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\n5", "original_text": "The access code for the replay is 519030.\n"}, "hash": "4c608049ec1c5c8658e26cae294fdd4d397e35067b1d4fbd2345036329d0b1ee", "class_name": "RelatedNodeInfo"}}, "text": "From outside the United States and\nCanada, dial +44 (204) 525-0658. ", "start_char_idx": 2496, "end_char_idx": 2564, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6a60497-f25d-46fc-8e91-500598cb5346": {"__data__": {"id_": "b6a60497-f25d-46fc-8e91-500598cb5346", "embedding": null, "metadata": {"window": "To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 519030.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 10, 2023;\nUBS Healthcare Services Summit, June 26 to 28, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\n5", "original_text": "The access code for the replay is 519030.\n", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09858b6e-6f03-4927-8378-7b281265574e", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac667de9b12f1f3414ae1b31cd0b880fb1f2486cdd63f2be739aafcd36de1c22", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93618fd6-3ddf-46ab-9d7c-90dcefec4a45", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 519030.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 10, 2023;\nUBS Healthcare Services Summit, June 26 to 28, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "From outside the United States and\nCanada, dial +44 (204) 525-0658. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5403b54e4df3cb1218155c70038f8a1ebdc79435dc2e7310290259b5523dc600", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11920c85-0ba8-4427-b5e4-5cd0317eac2d", "node_type": "1", "metadata": {"window": "and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 519030.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 10, 2023;\nUBS Healthcare Services Summit, June 26 to 28, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\n5", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 10, 2023;\nUBS Healthcare Services Summit, June 26 to 28, 2023.\n"}, "hash": "3fa86fac35cebaadc94212298aa1f4a1a215867be4ee0a307d59135a0fcedc4d", "class_name": "RelatedNodeInfo"}}, "text": "The access code for the replay is 519030.\n", "start_char_idx": 2564, "end_char_idx": 2606, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11920c85-0ba8-4427-b5e4-5cd0317eac2d": {"__data__": {"id_": "11920c85-0ba8-4427-b5e4-5cd0317eac2d", "embedding": null, "metadata": {"window": "and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 519030.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 10, 2023;\nUBS Healthcare Services Summit, June 26 to 28, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\n5", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 10, 2023;\nUBS Healthcare Services Summit, June 26 to 28, 2023.\n", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09858b6e-6f03-4927-8378-7b281265574e", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac667de9b12f1f3414ae1b31cd0b880fb1f2486cdd63f2be739aafcd36de1c22", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6a60497-f25d-46fc-8e91-500598cb5346", "node_type": "1", "metadata": {"window": "To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 519030.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 10, 2023;\nUBS Healthcare Services Summit, June 26 to 28, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\n5", "original_text": "The access code for the replay is 519030.\n", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61d2baf24e6cfa8396011a7712d21e3dce6a5d53c733a352f42cde98e1a4f0e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71ceb11f-a3cb-4817-8f1f-a0d8574117c0", "node_type": "1", "metadata": {"window": "From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 519030.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 10, 2023;\nUBS Healthcare Services Summit, June 26 to 28, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\n5", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n"}, "hash": "5a20d2f4e3cea8408d0b852abd068006bf7af15b13b155ab78835e4140cfc310", "class_name": "RelatedNodeInfo"}}, "text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 10, 2023;\nUBS Healthcare Services Summit, June 26 to 28, 2023.\n", "start_char_idx": 2606, "end_char_idx": 2838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71ceb11f-a3cb-4817-8f1f-a0d8574117c0": {"__data__": {"id_": "71ceb11f-a3cb-4817-8f1f-a0d8574117c0", "embedding": null, "metadata": {"window": "From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 519030.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 10, 2023;\nUBS Healthcare Services Summit, June 26 to 28, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\n5", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09858b6e-6f03-4927-8378-7b281265574e", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac667de9b12f1f3414ae1b31cd0b880fb1f2486cdd63f2be739aafcd36de1c22", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11920c85-0ba8-4427-b5e4-5cd0317eac2d", "node_type": "1", "metadata": {"window": "and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 519030.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 10, 2023;\nUBS Healthcare Services Summit, June 26 to 28, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\n5", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 10, 2023;\nUBS Healthcare Services Summit, June 26 to 28, 2023.\n", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1601e12e584ede02c3f41495b83fc36715ebb17a0e65cd2d5e15a63bbe808b34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0aa52601-bcc4-447f-bd6f-cd0853f2566a", "node_type": "1", "metadata": {"window": "The access code for the replay is 519030.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 10, 2023;\nUBS Healthcare Services Summit, June 26 to 28, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\n5", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\n5"}, "hash": "22f37b3dfebe622c3d96a1e046ab1aa740e79beb51a85fca42a68dacbe1c5de1", "class_name": "RelatedNodeInfo"}}, "text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "start_char_idx": 2838, "end_char_idx": 2967, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0aa52601-bcc4-447f-bd6f-cd0853f2566a": {"__data__": {"id_": "0aa52601-bcc4-447f-bd6f-cd0853f2566a", "embedding": null, "metadata": {"window": "The access code for the replay is 519030.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 10, 2023;\nUBS Healthcare Services Summit, June 26 to 28, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\n5", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\n5", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09858b6e-6f03-4927-8378-7b281265574e", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac667de9b12f1f3414ae1b31cd0b880fb1f2486cdd63f2be739aafcd36de1c22", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71ceb11f-a3cb-4817-8f1f-a0d8574117c0", "node_type": "1", "metadata": {"window": "From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 519030.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 10, 2023;\nUBS Healthcare Services Summit, June 26 to 28, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\n5", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5fa87583a663a4acac7cb1c29955c7cb8283c257d4f6efa56685f8d9e9c7b00f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4e2e62c-1fd0-4c23-9d81-dcd10d18506c", "node_type": "1", "metadata": {"window": "around the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures. ", "original_text": "around the world. "}, "hash": "9a2dd4956f2285e7d91c77e895a069529c350d59c45081b434ba10dd5248cf68", "class_name": "RelatedNodeInfo"}}, "text": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\n5", "start_char_idx": 2967, "end_char_idx": 3124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4e2e62c-1fd0-4c23-9d81-dcd10d18506c": {"__data__": {"id_": "c4e2e62c-1fd0-4c23-9d81-dcd10d18506c", "embedding": null, "metadata": {"window": "around the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures. ", "original_text": "around the world. ", "page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cfd904d4-27a2-44eb-86a3-80c14449c264", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a20d5be02a60c9f2e91fc153fd16d1e0f0b62972c18c6f65d4dea48fdb0bbae8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0aa52601-bcc4-447f-bd6f-cd0853f2566a", "node_type": "1", "metadata": {"window": "The access code for the replay is 519030.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 10, 2023;\nUBS Healthcare Services Summit, June 26 to 28, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\n5", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\n5", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bac122434942a3275e22db87e9ebae6c55895f4880be737d44262e170a65c3d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c30088e4-f8dd-41ca-8643-66646218c12a", "node_type": "1", "metadata": {"window": "around the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue. ", "original_text": "We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies. "}, "hash": "d5f948509f88d17ad2d048b7a7e6ffcd1b4108d665436a06f9c6b89d77e175ef", "class_name": "RelatedNodeInfo"}}, "text": "around the world. ", "start_char_idx": 0, "end_char_idx": 18, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c30088e4-f8dd-41ca-8643-66646218c12a": {"__data__": {"id_": "c30088e4-f8dd-41ca-8643-66646218c12a", "embedding": null, "metadata": {"window": "around the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue. ", "original_text": "We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies. ", "page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cfd904d4-27a2-44eb-86a3-80c14449c264", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a20d5be02a60c9f2e91fc153fd16d1e0f0b62972c18c6f65d4dea48fdb0bbae8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4e2e62c-1fd0-4c23-9d81-dcd10d18506c", "node_type": "1", "metadata": {"window": "around the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures. ", "original_text": "around the world. ", "page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b6bcf4b1f5b231afa65d2854eeb58d5de81cb9fa08723ec0a94a98d0aa2e8b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0bcae8c-544c-4937-8357-0740606a094f", "node_type": "1", "metadata": {"window": "around the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n", "original_text": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. "}, "hash": "a7a50c7417f3c6ed4e81519cc1f229ac88db4bb562ecb32a6100931377dbee21", "class_name": "RelatedNodeInfo"}}, "text": "We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies. ", "start_char_idx": 18, "end_char_idx": 138, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0bcae8c-544c-4937-8357-0740606a094f": {"__data__": {"id_": "d0bcae8c-544c-4937-8357-0740606a094f", "embedding": null, "metadata": {"window": "around the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n", "original_text": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cfd904d4-27a2-44eb-86a3-80c14449c264", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a20d5be02a60c9f2e91fc153fd16d1e0f0b62972c18c6f65d4dea48fdb0bbae8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c30088e4-f8dd-41ca-8643-66646218c12a", "node_type": "1", "metadata": {"window": "around the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue. ", "original_text": "We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies. ", "page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "262f1072e09be76c269756352b2354a5e1bd1b4fccaed8a7d1c15c84d53be206", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cacde9be-25a7-4e9e-ae0d-43b911eef2e0", "node_type": "1", "metadata": {"window": "around the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements \n Certain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "original_text": "Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures. "}, "hash": "2b2119dfc196e0567d3f6b5498d4e1a4bf40794fb84fbe8c6197f3bfd7aa2c60", "class_name": "RelatedNodeInfo"}}, "text": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "start_char_idx": 138, "end_char_idx": 256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cacde9be-25a7-4e9e-ae0d-43b911eef2e0": {"__data__": {"id_": "cacde9be-25a7-4e9e-ae0d-43b911eef2e0", "embedding": null, "metadata": {"window": "around the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements \n Certain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "original_text": "Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures. ", "page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cfd904d4-27a2-44eb-86a3-80c14449c264", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a20d5be02a60c9f2e91fc153fd16d1e0f0b62972c18c6f65d4dea48fdb0bbae8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0bcae8c-544c-4937-8357-0740606a094f", "node_type": "1", "metadata": {"window": "around the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n", "original_text": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9c499f6952d0c94e5d43e591efd41c8fab73c1f61d7e15c84e9187ceaff9f26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85b8b537-01b2-439c-939e-d86f81aeec20", "node_type": "1", "metadata": {"window": "We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements \n Certain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. ", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue. "}, "hash": "7330e69f274c006b0430328033939fb696dd3ee7586580924671d04babfd776e", "class_name": "RelatedNodeInfo"}}, "text": "Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures. ", "start_char_idx": 256, "end_char_idx": 429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85b8b537-01b2-439c-939e-d86f81aeec20": {"__data__": {"id_": "85b8b537-01b2-439c-939e-d86f81aeec20", "embedding": null, "metadata": {"window": "We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements \n Certain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. ", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue. ", "page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cfd904d4-27a2-44eb-86a3-80c14449c264", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a20d5be02a60c9f2e91fc153fd16d1e0f0b62972c18c6f65d4dea48fdb0bbae8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cacde9be-25a7-4e9e-ae0d-43b911eef2e0", "node_type": "1", "metadata": {"window": "around the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements \n Certain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "original_text": "Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures. ", "page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8163d66e5bf23564726c330005f7a4efba687d68077f7d9aaa80b1180e50f543", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "164ef264-1039-4f33-a735-2ad587f4ffaa", "node_type": "1", "metadata": {"window": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements \n Certain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com.\n"}, "hash": "a77c7d635c06f1bab1766c76bd80dc778bf120d9cee8b4c5f69bb3d1dea9e235", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue. ", "start_char_idx": 429, "end_char_idx": 561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "164ef264-1039-4f33-a735-2ad587f4ffaa": {"__data__": {"id_": "164ef264-1039-4f33-a735-2ad587f4ffaa", "embedding": null, "metadata": {"window": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements \n Certain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com.\n", "page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cfd904d4-27a2-44eb-86a3-80c14449c264", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a20d5be02a60c9f2e91fc153fd16d1e0f0b62972c18c6f65d4dea48fdb0bbae8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85b8b537-01b2-439c-939e-d86f81aeec20", "node_type": "1", "metadata": {"window": "We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements \n Certain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. ", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue. ", "page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c99b16afe059f1735469861d4a91ef5f2818ef369243f390b40a70ca725627ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f007cac8-fbfd-4e5e-a72a-75113e1568cd", "node_type": "1", "metadata": {"window": "Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements \n Certain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. ", "original_text": "Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements \n Certain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). "}, "hash": "27d164ceb420951eecf0fd6f5c6105282ccd4b57fdfa828ce2e21f4a97d9dda4", "class_name": "RelatedNodeInfo"}}, "text": "Learn more at investor.amerisourcebergen.com.\n", "start_char_idx": 561, "end_char_idx": 607, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f007cac8-fbfd-4e5e-a72a-75113e1568cd": {"__data__": {"id_": "f007cac8-fbfd-4e5e-a72a-75113e1568cd", "embedding": null, "metadata": {"window": "Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements \n Certain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. ", "original_text": "Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements \n Certain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cfd904d4-27a2-44eb-86a3-80c14449c264", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a20d5be02a60c9f2e91fc153fd16d1e0f0b62972c18c6f65d4dea48fdb0bbae8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "164ef264-1039-4f33-a735-2ad587f4ffaa", "node_type": "1", "metadata": {"window": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements \n Certain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com.\n", "page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2211526b95eb69f8430ddeb6d535c6bb670efe6e58e9450236b62dec01c0b5d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0201e0ea-6163-4ed3-a3d1-a3091e36af0d", "node_type": "1", "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements \n Certain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing COVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the COVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\n6", "original_text": "Words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. "}, "hash": "b592408003bff6c883ce62be6fe59d1979b10b3ddd99a28864bed759df4881be", "class_name": "RelatedNodeInfo"}}, "text": "Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements \n Certain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "start_char_idx": 607, "end_char_idx": 956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0201e0ea-6163-4ed3-a3d1-a3091e36af0d": {"__data__": {"id_": "0201e0ea-6163-4ed3-a3d1-a3091e36af0d", "embedding": null, "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements \n Certain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing COVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the COVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\n6", "original_text": "Words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. ", "page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cfd904d4-27a2-44eb-86a3-80c14449c264", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a20d5be02a60c9f2e91fc153fd16d1e0f0b62972c18c6f65d4dea48fdb0bbae8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f007cac8-fbfd-4e5e-a72a-75113e1568cd", "node_type": "1", "metadata": {"window": "Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements \n Certain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. ", "original_text": "Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements \n Certain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "149edd48e5869835fb233e0d53af9a51242bf44ad60ef52f85d632850983ad8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0632d3bd-3e2b-4802-ad61-79891039b026", "node_type": "1", "metadata": {"window": "Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements \n Certain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing COVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the COVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\n6", "original_text": "These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. "}, "hash": "873ed9a899aaea2bad1aa9a3a5d6ef07e39f07d6bbd8142ca4caab863207e47a", "class_name": "RelatedNodeInfo"}}, "text": "Words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. ", "start_char_idx": 956, "end_char_idx": 1400, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0632d3bd-3e2b-4802-ad61-79891039b026": {"__data__": {"id_": "0632d3bd-3e2b-4802-ad61-79891039b026", "embedding": null, "metadata": {"window": "Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements \n Certain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing COVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the COVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\n6", "original_text": "These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. ", "page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cfd904d4-27a2-44eb-86a3-80c14449c264", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a20d5be02a60c9f2e91fc153fd16d1e0f0b62972c18c6f65d4dea48fdb0bbae8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0201e0ea-6163-4ed3-a3d1-a3091e36af0d", "node_type": "1", "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements \n Certain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing COVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the COVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\n6", "original_text": "Words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking. ", "page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "677625a79457ba0c965b22da51b91853934064c2e1bd5909639f67beb8933d9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c45d857-cfeb-4cd1-9345-36ca2789755b", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements \n Certain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing COVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the COVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\n6", "original_text": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. "}, "hash": "7205d2257b10acaf80119153c6d894c2b068e6659d9228923ff3dc7600b9c5b4", "class_name": "RelatedNodeInfo"}}, "text": "These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. ", "start_char_idx": 1400, "end_char_idx": 1562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c45d857-cfeb-4cd1-9345-36ca2789755b": {"__data__": {"id_": "5c45d857-cfeb-4cd1-9345-36ca2789755b", "embedding": null, "metadata": {"window": "Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements \n Certain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing COVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the COVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\n6", "original_text": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. ", "page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cfd904d4-27a2-44eb-86a3-80c14449c264", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a20d5be02a60c9f2e91fc153fd16d1e0f0b62972c18c6f65d4dea48fdb0bbae8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0632d3bd-3e2b-4802-ad61-79891039b026", "node_type": "1", "metadata": {"window": "Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements \n Certain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing COVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the COVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\n6", "original_text": "These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof. ", "page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9ccb46b787008d889daba9cb8e599ca4ceb0f57ce3fd7c38d7dc5230aa9ab36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f06b64b7-fdad-4662-bf21-70652b94f9db", "node_type": "1", "metadata": {"window": "Words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing COVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the COVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\n6", "original_text": "Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing COVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the COVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\n6"}, "hash": "f385897fee413c9a0c028020168e73bdddd4e82215d4684738064c927aaec1fb", "class_name": "RelatedNodeInfo"}}, "text": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. ", "start_char_idx": 1562, "end_char_idx": 1761, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f06b64b7-fdad-4662-bf21-70652b94f9db": {"__data__": {"id_": "f06b64b7-fdad-4662-bf21-70652b94f9db", "embedding": null, "metadata": {"window": "Words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing COVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the COVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\n6", "original_text": "Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing COVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the COVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\n6", "page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cfd904d4-27a2-44eb-86a3-80c14449c264", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a20d5be02a60c9f2e91fc153fd16d1e0f0b62972c18c6f65d4dea48fdb0bbae8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c45d857-cfeb-4cd1-9345-36ca2789755b", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements \n Certain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing COVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the COVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\n6", "original_text": "These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated. ", "page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d454fcd6bc61fb0a7877fe4c91974b3f0389ae55845e8b0246931b4ed4cdb831", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5baeb4d0-6160-470b-97f6-8bbbe851923a", "node_type": "1", "metadata": {"window": "the possibility that various conditions to the consummation of the acquisition of OneOncology may not be satisfied or that\ntheir satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of OneOncology;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\nAlliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19;\nfinancial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the unfolding situation in Russia\nand Ukraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United States and abroad; and\n7", "original_text": "the possibility that various conditions to the consummation of the acquisition of OneOncology may not be satisfied or that\ntheir satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of OneOncology;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\nAlliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. "}, "hash": "f9cc32f850c3a591f79c87f1c919c23a9e69cc460625e3c15dade37c2408f4a2", "class_name": "RelatedNodeInfo"}}, "text": "Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing COVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the COVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\n6", "start_char_idx": 1761, "end_char_idx": 4282, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5baeb4d0-6160-470b-97f6-8bbbe851923a": {"__data__": {"id_": "5baeb4d0-6160-470b-97f6-8bbbe851923a", "embedding": null, "metadata": {"window": "the possibility that various conditions to the consummation of the acquisition of OneOncology may not be satisfied or that\ntheir satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of OneOncology;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\nAlliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19;\nfinancial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the unfolding situation in Russia\nand Ukraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United States and abroad; and\n7", "original_text": "the possibility that various conditions to the consummation of the acquisition of OneOncology may not be satisfied or that\ntheir satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of OneOncology;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\nAlliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. ", "page_label": "7", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d137db6-3360-4408-8451-4f38761e2b23", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "521506cec9e352c6819a2297ab37a17a9279d8a9b92489714b2cbcd4d420039b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f06b64b7-fdad-4662-bf21-70652b94f9db", "node_type": "1", "metadata": {"window": "Words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d, \u201cestimate,\u201d \"expect,\" \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201con\ntrack,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201csustain,\u201d \u201csynergy,\u201d \u201ctarget,\u201d \u201cwill,\u201d\n\u201cwould\u201d and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean\nthat a statement is not forward-looking.  These statements are based on management\u2019s current expectations and are subject to\nuncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees of future\nperformance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially\nfrom those indicated.  Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing COVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the COVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\n6", "original_text": "Among the factors that could cause actual results to differ materially from those projected, anticipated, or\nimplied are the following:\nthe effect of and uncertainties related to the ongoing COVID-19 pandemic (including any government responses thereto) and\nany continued recovery from the impact of the COVID-19 pandemic;\nour ability to achieve and maintain profitability in the future;\nour ability to respond to general economic conditions, including elevated levels of inflation;\nour ability to manage our growth effectively and our expectations regarding the development and expansion of our business;\nthe impact on our business of the regulatory environment and complexities with compliance;\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for\nour products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;\nincreasing governmental regulations regarding the pharmaceutical supply channel;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled\nsubstances and the diversion of controlled substances;\ncontinued prosecution or suit by federal and state governmental entities and other parties (including third-party payors,\nhospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and\nany related disputes, including shareholder derivative lawsuits;\nincreased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing\nthe marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;\nfailure to comply with the Corporate Integrity Agreement;\nthe outcome of any legal or governmental proceedings that may be instituted against us, including material adverse\nresolution of pending legal proceedings;\nthe retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any\ncontract or other dispute with customers or suppliers;\nchanges to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\n6", "page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0aeb19511699f4db99c42bc1751c2349adad060bb6943bd2218d44d4aac44f11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52ef53ef-53a8-4fef-9e8d-572392013414", "node_type": "1", "metadata": {"window": "the possibility that various conditions to the consummation of the acquisition of OneOncology may not be satisfied or that\ntheir satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of OneOncology;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\nAlliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19;\nfinancial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the unfolding situation in Russia\nand Ukraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United States and abroad; and\n7", "original_text": "and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S. "}, "hash": "288b7b1899758e88c56f6deb9f41e2bff441761351554f5fb33bab4014f1a638", "class_name": "RelatedNodeInfo"}}, "text": "the possibility that various conditions to the consummation of the acquisition of OneOncology may not be satisfied or that\ntheir satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of OneOncology;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\nAlliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. ", "start_char_idx": 0, "end_char_idx": 1501, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52ef53ef-53a8-4fef-9e8d-572392013414": {"__data__": {"id_": "52ef53ef-53a8-4fef-9e8d-572392013414", "embedding": null, "metadata": {"window": "the possibility that various conditions to the consummation of the acquisition of OneOncology may not be satisfied or that\ntheir satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of OneOncology;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\nAlliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19;\nfinancial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the unfolding situation in Russia\nand Ukraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United States and abroad; and\n7", "original_text": "and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S. ", "page_label": "7", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d137db6-3360-4408-8451-4f38761e2b23", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "521506cec9e352c6819a2297ab37a17a9279d8a9b92489714b2cbcd4d420039b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5baeb4d0-6160-470b-97f6-8bbbe851923a", "node_type": "1", "metadata": {"window": "the possibility that various conditions to the consummation of the acquisition of OneOncology may not be satisfied or that\ntheir satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of OneOncology;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\nAlliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19;\nfinancial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the unfolding situation in Russia\nand Ukraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United States and abroad; and\n7", "original_text": "the possibility that various conditions to the consummation of the acquisition of OneOncology may not be satisfied or that\ntheir satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of OneOncology;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\nAlliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. ", "page_label": "7", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0af19aa03c9f404525ebbb91b0dd26bde559b27bc91b24dd7aef278f8767bc9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12d4fc00-9c7c-468a-b5b2-92cdf9888d55", "node_type": "1", "metadata": {"window": "the possibility that various conditions to the consummation of the acquisition of OneOncology may not be satisfied or that\ntheir satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of OneOncology;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\nAlliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19;\nfinancial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the unfolding situation in Russia\nand Ukraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United States and abroad; and\n7", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19;\nfinancial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the unfolding situation in Russia\nand Ukraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United States and abroad; and\n7"}, "hash": "b98363336f3f1f78f67d76f361aad9b317a6a677b3885cfb9057d74c478a5491", "class_name": "RelatedNodeInfo"}}, "text": "and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S. ", "start_char_idx": 1501, "end_char_idx": 1712, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "12d4fc00-9c7c-468a-b5b2-92cdf9888d55": {"__data__": {"id_": "12d4fc00-9c7c-468a-b5b2-92cdf9888d55", "embedding": null, "metadata": {"window": "the possibility that various conditions to the consummation of the acquisition of OneOncology may not be satisfied or that\ntheir satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of OneOncology;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\nAlliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19;\nfinancial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the unfolding situation in Russia\nand Ukraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United States and abroad; and\n7", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19;\nfinancial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the unfolding situation in Russia\nand Ukraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United States and abroad; and\n7", "page_label": "7", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d137db6-3360-4408-8451-4f38761e2b23", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "521506cec9e352c6819a2297ab37a17a9279d8a9b92489714b2cbcd4d420039b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52ef53ef-53a8-4fef-9e8d-572392013414", "node_type": "1", "metadata": {"window": "the possibility that various conditions to the consummation of the acquisition of OneOncology may not be satisfied or that\ntheir satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of OneOncology;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\nAlliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19;\nfinancial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the unfolding situation in Russia\nand Ukraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United States and abroad; and\n7", "original_text": "and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S. ", "page_label": "7", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b195b284538b3ba453a600fafffb1681dac1d1b0031ff5a31f5790294fa72795", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5c51f15-21f4-46db-980f-62fdb0c975e4", "node_type": "1", "metadata": {"window": "other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded \nMarch 31,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded \nMarch 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$63,457,205 \u00a0\u00a0 \u00a0$57,719,446 \u00a0\u00a0 \u00a09.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a061,161,763 \u00a0\u00a0 \u00a0\u00a055,484,366 \u00a0\u00a0 \u00a010.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,295,442 \u00a03.62% \u00a0\u00a02,235,080 \u00a03.87% \u00a02.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,321,087 \u00a02.08% \u00a0\u00a01,203,238 \u00a02.08% \u00a09.8%\nDepreciation and amortization \u00a0\u00a0241,466 \u00a00.38% \u00a0\u00a0175,290 \u00a00.30% \u00a037.8%\nLitigation and opioid-related expenses \u00a0\u00a015,813 \u00a0\u00a0 \u00a0\u00a052,090 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a059,113 \u00a0\u00a0 \u00a0\u00a011,790 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a097,444 \u00a0\u00a0 \u00a0\u00a012,515 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,734,923 \u00a02.73% \u00a0\u00a01,454,923 \u00a02.52% \u00a019.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0560,519 \u00a00.88% \u00a0\u00a0780,157 \u00a01.35% \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n"}, "hash": "5fab521a6f4e49db0baee255d6da302bf972e92fa9ce44228c87bea253c3af49", "class_name": "RelatedNodeInfo"}}, "text": "Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19;\nfinancial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the unfolding situation in Russia\nand Ukraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United States and abroad; and\n7", "start_char_idx": 1712, "end_char_idx": 3657, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5c51f15-21f4-46db-980f-62fdb0c975e4": {"__data__": {"id_": "a5c51f15-21f4-46db-980f-62fdb0c975e4", "embedding": null, "metadata": {"window": "other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded \nMarch 31,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded \nMarch 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$63,457,205 \u00a0\u00a0 \u00a0$57,719,446 \u00a0\u00a0 \u00a09.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a061,161,763 \u00a0\u00a0 \u00a0\u00a055,484,366 \u00a0\u00a0 \u00a010.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,295,442 \u00a03.62% \u00a0\u00a02,235,080 \u00a03.87% \u00a02.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,321,087 \u00a02.08% \u00a0\u00a01,203,238 \u00a02.08% \u00a09.8%\nDepreciation and amortization \u00a0\u00a0241,466 \u00a00.38% \u00a0\u00a0175,290 \u00a00.30% \u00a037.8%\nLitigation and opioid-related expenses \u00a0\u00a015,813 \u00a0\u00a0 \u00a0\u00a052,090 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a059,113 \u00a0\u00a0 \u00a0\u00a011,790 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a097,444 \u00a0\u00a0 \u00a0\u00a012,515 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,734,923 \u00a02.73% \u00a0\u00a01,454,923 \u00a02.52% \u00a019.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0560,519 \u00a00.88% \u00a0\u00a0780,157 \u00a01.35% \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n", "page_label": "8", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d629b4d-da68-46db-9b09-ded3bdf928c2", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6df01a59136b5f21efab15b0046ba743a1194569b1de46a7908015087d73627a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12d4fc00-9c7c-468a-b5b2-92cdf9888d55", "node_type": "1", "metadata": {"window": "the possibility that various conditions to the consummation of the acquisition of OneOncology may not be satisfied or that\ntheir satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of OneOncology;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\nAlliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19;\nfinancial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the unfolding situation in Russia\nand Ukraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United States and abroad; and\n7", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19;\nfinancial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the unfolding situation in Russia\nand Ukraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United States and abroad; and\n7", "page_label": "7", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1937a4710fd5511694a50c1ab7d9f387467d0e6a7cbcce2fe06cb2266aeb334a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c37f560a-fe7b-4ebf-9a78-676ad4932aa0", "node_type": "1", "metadata": {"window": "other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded \nMarch 31,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded \nMarch 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$63,457,205 \u00a0\u00a0 \u00a0$57,719,446 \u00a0\u00a0 \u00a09.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a061,161,763 \u00a0\u00a0 \u00a0\u00a055,484,366 \u00a0\u00a0 \u00a010.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,295,442 \u00a03.62% \u00a0\u00a02,235,080 \u00a03.87% \u00a02.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,321,087 \u00a02.08% \u00a0\u00a01,203,238 \u00a02.08% \u00a09.8%\nDepreciation and amortization \u00a0\u00a0241,466 \u00a00.38% \u00a0\u00a0175,290 \u00a00.30% \u00a037.8%\nLitigation and opioid-related expenses \u00a0\u00a015,813 \u00a0\u00a0 \u00a0\u00a052,090 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a059,113 \u00a0\u00a0 \u00a0\u00a011,790 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a097,444 \u00a0\u00a0 \u00a0\u00a012,515 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,734,923 \u00a02.73% \u00a0\u00a01,454,923 \u00a02.52% \u00a019.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0560,519 \u00a00.88% \u00a0\u00a0780,157 \u00a01.35% \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act. "}, "hash": "b12513d17b56eaa5541fcdb63efdcc2ac7bbbb4b039ba2a4489c2c3dfd89fc4b", "class_name": "RelatedNodeInfo"}}, "text": "other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n", "start_char_idx": 0, "end_char_idx": 133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c37f560a-fe7b-4ebf-9a78-676ad4932aa0": {"__data__": {"id_": "c37f560a-fe7b-4ebf-9a78-676ad4932aa0", "embedding": null, "metadata": {"window": "other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded \nMarch 31,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded \nMarch 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$63,457,205 \u00a0\u00a0 \u00a0$57,719,446 \u00a0\u00a0 \u00a09.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a061,161,763 \u00a0\u00a0 \u00a0\u00a055,484,366 \u00a0\u00a0 \u00a010.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,295,442 \u00a03.62% \u00a0\u00a02,235,080 \u00a03.87% \u00a02.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,321,087 \u00a02.08% \u00a0\u00a01,203,238 \u00a02.08% \u00a09.8%\nDepreciation and amortization \u00a0\u00a0241,466 \u00a00.38% \u00a0\u00a0175,290 \u00a00.30% \u00a037.8%\nLitigation and opioid-related expenses \u00a0\u00a015,813 \u00a0\u00a0 \u00a0\u00a052,090 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a059,113 \u00a0\u00a0 \u00a0\u00a011,790 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a097,444 \u00a0\u00a0 \u00a0\u00a012,515 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,734,923 \u00a02.73% \u00a0\u00a01,454,923 \u00a02.52% \u00a019.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0560,519 \u00a00.88% \u00a0\u00a0780,157 \u00a01.35% \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act. ", "page_label": "8", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d629b4d-da68-46db-9b09-ded3bdf928c2", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6df01a59136b5f21efab15b0046ba743a1194569b1de46a7908015087d73627a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5c51f15-21f4-46db-980f-62fdb0c975e4", "node_type": "1", "metadata": {"window": "other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded \nMarch 31,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded \nMarch 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$63,457,205 \u00a0\u00a0 \u00a0$57,719,446 \u00a0\u00a0 \u00a09.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a061,161,763 \u00a0\u00a0 \u00a0\u00a055,484,366 \u00a0\u00a0 \u00a010.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,295,442 \u00a03.62% \u00a0\u00a02,235,080 \u00a03.87% \u00a02.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,321,087 \u00a02.08% \u00a0\u00a01,203,238 \u00a02.08% \u00a09.8%\nDepreciation and amortization \u00a0\u00a0241,466 \u00a00.38% \u00a0\u00a0175,290 \u00a00.30% \u00a037.8%\nLitigation and opioid-related expenses \u00a0\u00a015,813 \u00a0\u00a0 \u00a0\u00a052,090 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a059,113 \u00a0\u00a0 \u00a0\u00a011,790 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a097,444 \u00a0\u00a0 \u00a0\u00a012,515 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,734,923 \u00a02.73% \u00a0\u00a01,454,923 \u00a02.52% \u00a019.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0560,519 \u00a00.88% \u00a0\u00a0780,157 \u00a01.35% \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n", "page_label": "8", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "25f0d9d300aa2ce148865af443ffdce7a646a22158b5d050119bedf1de654157", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9e70527-4a16-4b3f-9a4e-5d580ce50b8b", "node_type": "1", "metadata": {"window": "other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded \nMarch 31,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded \nMarch 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$63,457,205 \u00a0\u00a0 \u00a0$57,719,446 \u00a0\u00a0 \u00a09.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a061,161,763 \u00a0\u00a0 \u00a0\u00a055,484,366 \u00a0\u00a0 \u00a010.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,295,442 \u00a03.62% \u00a0\u00a02,235,080 \u00a03.87% \u00a02.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,321,087 \u00a02.08% \u00a0\u00a01,203,238 \u00a02.08% \u00a09.8%\nDepreciation and amortization \u00a0\u00a0241,466 \u00a00.38% \u00a0\u00a0175,290 \u00a00.30% \u00a037.8%\nLitigation and opioid-related expenses \u00a0\u00a015,813 \u00a0\u00a0 \u00a0\u00a052,090 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a059,113 \u00a0\u00a0 \u00a0\u00a011,790 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a097,444 \u00a0\u00a0 \u00a0\u00a012,515 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,734,923 \u00a02.73% \u00a0\u00a01,454,923 \u00a02.52% \u00a019.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0560,519 \u00a00.88% \u00a0\u00a0780,157 \u00a01.35% \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n"}, "hash": "415557d6e384fe24f0f9001f4e388c275b8b643fadefd275f04e993985018cbe", "class_name": "RelatedNodeInfo"}}, "text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act. ", "start_char_idx": 133, "end_char_idx": 548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9e70527-4a16-4b3f-9a4e-5d580ce50b8b": {"__data__": {"id_": "d9e70527-4a16-4b3f-9a4e-5d580ce50b8b", "embedding": null, "metadata": {"window": "other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded \nMarch 31,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded \nMarch 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$63,457,205 \u00a0\u00a0 \u00a0$57,719,446 \u00a0\u00a0 \u00a09.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a061,161,763 \u00a0\u00a0 \u00a0\u00a055,484,366 \u00a0\u00a0 \u00a010.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,295,442 \u00a03.62% \u00a0\u00a02,235,080 \u00a03.87% \u00a02.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,321,087 \u00a02.08% \u00a0\u00a01,203,238 \u00a02.08% \u00a09.8%\nDepreciation and amortization \u00a0\u00a0241,466 \u00a00.38% \u00a0\u00a0175,290 \u00a00.30% \u00a037.8%\nLitigation and opioid-related expenses \u00a0\u00a015,813 \u00a0\u00a0 \u00a0\u00a052,090 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a059,113 \u00a0\u00a0 \u00a0\u00a011,790 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a097,444 \u00a0\u00a0 \u00a0\u00a012,515 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,734,923 \u00a02.73% \u00a0\u00a01,454,923 \u00a02.52% \u00a019.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0560,519 \u00a00.88% \u00a0\u00a0780,157 \u00a01.35% \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n", "page_label": "8", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d629b4d-da68-46db-9b09-ded3bdf928c2", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6df01a59136b5f21efab15b0046ba743a1194569b1de46a7908015087d73627a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c37f560a-fe7b-4ebf-9a78-676ad4932aa0", "node_type": "1", "metadata": {"window": "other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded \nMarch 31,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded \nMarch 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$63,457,205 \u00a0\u00a0 \u00a0$57,719,446 \u00a0\u00a0 \u00a09.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a061,161,763 \u00a0\u00a0 \u00a0\u00a055,484,366 \u00a0\u00a0 \u00a010.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,295,442 \u00a03.62% \u00a0\u00a02,235,080 \u00a03.87% \u00a02.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,321,087 \u00a02.08% \u00a0\u00a01,203,238 \u00a02.08% \u00a09.8%\nDepreciation and amortization \u00a0\u00a0241,466 \u00a00.38% \u00a0\u00a0175,290 \u00a00.30% \u00a037.8%\nLitigation and opioid-related expenses \u00a0\u00a015,813 \u00a0\u00a0 \u00a0\u00a052,090 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a059,113 \u00a0\u00a0 \u00a0\u00a011,790 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a097,444 \u00a0\u00a0 \u00a0\u00a012,515 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,734,923 \u00a02.73% \u00a0\u00a01,454,923 \u00a02.52% \u00a019.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0560,519 \u00a00.88% \u00a0\u00a0780,157 \u00a01.35% \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act. ", "page_label": "8", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfd8367f5b1863f72e6ebb12f86bc1276628c88a731e0ce3ec7cf99416e9fb4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a91697a3-fd02-418f-a1e1-0b5b1a5e7d33", "node_type": "1", "metadata": {"window": "other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded \nMarch 31,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded \nMarch 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$63,457,205 \u00a0\u00a0 \u00a0$57,719,446 \u00a0\u00a0 \u00a09.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a061,161,763 \u00a0\u00a0 \u00a0\u00a055,484,366 \u00a0\u00a0 \u00a010.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,295,442 \u00a03.62% \u00a0\u00a02,235,080 \u00a03.87% \u00a02.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,321,087 \u00a02.08% \u00a0\u00a01,203,238 \u00a02.08% \u00a09.8%\nDepreciation and amortization \u00a0\u00a0241,466 \u00a00.38% \u00a0\u00a0175,290 \u00a00.30% \u00a037.8%\nLitigation and opioid-related expenses \u00a0\u00a015,813 \u00a0\u00a0 \u00a0\u00a052,090 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a059,113 \u00a0\u00a0 \u00a0\u00a011,790 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a097,444 \u00a0\u00a0 \u00a0\u00a012,515 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,734,923 \u00a02.73% \u00a0\u00a01,454,923 \u00a02.52% \u00a019.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0560,519 \u00a00.88% \u00a0\u00a0780,157 \u00a01.35% \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded \nMarch 31,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded \nMarch 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$63,457,205 \u00a0\u00a0 \u00a0$57,719,446 \u00a0\u00a0 \u00a09.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a061,161,763 \u00a0\u00a0 \u00a0\u00a055,484,366 \u00a0\u00a0 \u00a010.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,295,442 \u00a03.62% \u00a0\u00a02,235,080 \u00a03.87% \u00a02.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,321,087 \u00a02.08% \u00a0\u00a01,203,238 \u00a02.08% \u00a09.8%\nDepreciation and amortization \u00a0\u00a0241,466 \u00a00.38% \u00a0\u00a0175,290 \u00a00.30% \u00a037.8%\nLitigation and opioid-related expenses \u00a0\u00a015,813 \u00a0\u00a0 \u00a0\u00a052,090 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a059,113 \u00a0\u00a0 \u00a0\u00a011,790 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a097,444 \u00a0\u00a0 \u00a0\u00a012,515 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,734,923 \u00a02.73% \u00a0\u00a01,454,923 \u00a02.52% \u00a019.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0560,519 \u00a00.88% \u00a0\u00a0780,157 \u00a01.35% \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8"}, "hash": "25a51dd7198c01e0348911eea67888ed004a8a302650c2e9acacdba215618f51", "class_name": "RelatedNodeInfo"}}, "text": "The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n", "start_char_idx": 548, "end_char_idx": 697, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a91697a3-fd02-418f-a1e1-0b5b1a5e7d33": {"__data__": {"id_": "a91697a3-fd02-418f-a1e1-0b5b1a5e7d33", "embedding": null, "metadata": {"window": "other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded \nMarch 31,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded \nMarch 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$63,457,205 \u00a0\u00a0 \u00a0$57,719,446 \u00a0\u00a0 \u00a09.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a061,161,763 \u00a0\u00a0 \u00a0\u00a055,484,366 \u00a0\u00a0 \u00a010.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,295,442 \u00a03.62% \u00a0\u00a02,235,080 \u00a03.87% \u00a02.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,321,087 \u00a02.08% \u00a0\u00a01,203,238 \u00a02.08% \u00a09.8%\nDepreciation and amortization \u00a0\u00a0241,466 \u00a00.38% \u00a0\u00a0175,290 \u00a00.30% \u00a037.8%\nLitigation and opioid-related expenses \u00a0\u00a015,813 \u00a0\u00a0 \u00a0\u00a052,090 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a059,113 \u00a0\u00a0 \u00a0\u00a011,790 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a097,444 \u00a0\u00a0 \u00a0\u00a012,515 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,734,923 \u00a02.73% \u00a0\u00a01,454,923 \u00a02.52% \u00a019.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0560,519 \u00a00.88% \u00a0\u00a0780,157 \u00a01.35% \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded \nMarch 31,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded \nMarch 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$63,457,205 \u00a0\u00a0 \u00a0$57,719,446 \u00a0\u00a0 \u00a09.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a061,161,763 \u00a0\u00a0 \u00a0\u00a055,484,366 \u00a0\u00a0 \u00a010.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,295,442 \u00a03.62% \u00a0\u00a02,235,080 \u00a03.87% \u00a02.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,321,087 \u00a02.08% \u00a0\u00a01,203,238 \u00a02.08% \u00a09.8%\nDepreciation and amortization \u00a0\u00a0241,466 \u00a00.38% \u00a0\u00a0175,290 \u00a00.30% \u00a037.8%\nLitigation and opioid-related expenses \u00a0\u00a015,813 \u00a0\u00a0 \u00a0\u00a052,090 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a059,113 \u00a0\u00a0 \u00a0\u00a011,790 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a097,444 \u00a0\u00a0 \u00a0\u00a012,515 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,734,923 \u00a02.73% \u00a0\u00a01,454,923 \u00a02.52% \u00a019.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0560,519 \u00a00.88% \u00a0\u00a0780,157 \u00a01.35% \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "page_label": "8", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d629b4d-da68-46db-9b09-ded3bdf928c2", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6df01a59136b5f21efab15b0046ba743a1194569b1de46a7908015087d73627a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9e70527-4a16-4b3f-9a4e-5d580ce50b8b", "node_type": "1", "metadata": {"window": "other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded \nMarch 31,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded \nMarch 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$63,457,205 \u00a0\u00a0 \u00a0$57,719,446 \u00a0\u00a0 \u00a09.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a061,161,763 \u00a0\u00a0 \u00a0\u00a055,484,366 \u00a0\u00a0 \u00a010.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,295,442 \u00a03.62% \u00a0\u00a02,235,080 \u00a03.87% \u00a02.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,321,087 \u00a02.08% \u00a0\u00a01,203,238 \u00a02.08% \u00a09.8%\nDepreciation and amortization \u00a0\u00a0241,466 \u00a00.38% \u00a0\u00a0175,290 \u00a00.30% \u00a037.8%\nLitigation and opioid-related expenses \u00a0\u00a015,813 \u00a0\u00a0 \u00a0\u00a052,090 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a059,113 \u00a0\u00a0 \u00a0\u00a011,790 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a097,444 \u00a0\u00a0 \u00a0\u00a012,515 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,734,923 \u00a02.73% \u00a0\u00a01,454,923 \u00a02.52% \u00a019.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0560,519 \u00a00.88% \u00a0\u00a0780,157 \u00a01.35% \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n", "page_label": "8", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a894ab2614409a30395a34fdc97134558a10589576b9fe8eaf25e7bb39b87fba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c34477e8-da40-4366-87ec-f83824234c05", "node_type": "1", "metadata": {"window": "Other income, net \u00a0\u00a0(15,720) \u00a0\u00a0 \u00a0\u00a0(948) \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a064,109 \u00a0\u00a0 \u00a0\u00a052,916 \u00a0\u00a0 \u00a021.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0512,130 \u00a00.81% \u00a0\u00a0728,189 \u00a01.26% \u00a0(29.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,917 \u00a0\u00a0 \u00a0\u00a0172,944 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0428,213 \u00a00.67% \u00a0\u00a0555,245 \u00a00.96% \u00a0(22.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a07,189 \u00a0\u00a0 \u00a0\u00a0(7,231) \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$435,402 \u00a00.69% \u00a0$548,014 \u00a00.95% \u00a0(20.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.15 \u00a0\u00a0 \u00a0$2.62 \u00a0\u00a0 \u00a0(17.9)%\nDiluted \u00a0$2.13 \u00a0\u00a0 \u00a0$2.59 \u00a0\u00a0 \u00a0(17.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,316 \u00a0\u00a0 \u00a0\u00a0209,244 \u00a0\u00a0 \u00a0(3.3)%\nDiluted \u00a0\u00a0204,256 \u00a0\u00a0 \u00a0\u00a0211,991 \u00a0\u00a0 \u00a0(3.6)%\n________________________________________ \n 1 Includes a $54.3 million LIFO expense in the three months ended March 31, 2023 and a $16.1 million LIFO credit in the three\nmonths ended March 31, 2022.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n9", "original_text": "Other income, net \u00a0\u00a0(15,720) \u00a0\u00a0 \u00a0\u00a0(948) \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a064,109 \u00a0\u00a0 \u00a0\u00a052,916 \u00a0\u00a0 \u00a021.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0512,130 \u00a00.81% \u00a0\u00a0728,189 \u00a01.26% \u00a0(29.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,917 \u00a0\u00a0 \u00a0\u00a0172,944 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0428,213 \u00a00.67% \u00a0\u00a0555,245 \u00a00.96% \u00a0(22.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a07,189 \u00a0\u00a0 \u00a0\u00a0(7,231) \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$435,402 \u00a00.69% \u00a0$548,014 \u00a00.95% \u00a0(20.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.15 \u00a0\u00a0 \u00a0$2.62 \u00a0\u00a0 \u00a0(17.9)%\nDiluted \u00a0$2.13 \u00a0\u00a0 \u00a0$2.59 \u00a0\u00a0 \u00a0(17.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,316 \u00a0\u00a0 \u00a0\u00a0209,244 \u00a0\u00a0 \u00a0(3.3)%\nDiluted \u00a0\u00a0204,256 \u00a0\u00a0 \u00a0\u00a0211,991 \u00a0\u00a0 \u00a0(3.6)%\n________________________________________ \n 1 Includes a $54.3 million LIFO expense in the three months ended March 31, 2023 and a $16.1 million LIFO credit in the three\nmonths ended March 31, 2022.\n"}, "hash": "0b41194b1244aa0717a84933f5cae7c1a4787265d5df4a11b92bbeb35e9d2296", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded \nMarch 31,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded \nMarch 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$63,457,205 \u00a0\u00a0 \u00a0$57,719,446 \u00a0\u00a0 \u00a09.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a061,161,763 \u00a0\u00a0 \u00a0\u00a055,484,366 \u00a0\u00a0 \u00a010.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,295,442 \u00a03.62% \u00a0\u00a02,235,080 \u00a03.87% \u00a02.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,321,087 \u00a02.08% \u00a0\u00a01,203,238 \u00a02.08% \u00a09.8%\nDepreciation and amortization \u00a0\u00a0241,466 \u00a00.38% \u00a0\u00a0175,290 \u00a00.30% \u00a037.8%\nLitigation and opioid-related expenses \u00a0\u00a015,813 \u00a0\u00a0 \u00a0\u00a052,090 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a059,113 \u00a0\u00a0 \u00a0\u00a011,790 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a097,444 \u00a0\u00a0 \u00a0\u00a012,515 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,734,923 \u00a02.73% \u00a0\u00a01,454,923 \u00a02.52% \u00a019.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0560,519 \u00a00.88% \u00a0\u00a0780,157 \u00a01.35% \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "start_char_idx": 697, "end_char_idx": 1687, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c34477e8-da40-4366-87ec-f83824234c05": {"__data__": {"id_": "c34477e8-da40-4366-87ec-f83824234c05", "embedding": null, "metadata": {"window": "Other income, net \u00a0\u00a0(15,720) \u00a0\u00a0 \u00a0\u00a0(948) \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a064,109 \u00a0\u00a0 \u00a0\u00a052,916 \u00a0\u00a0 \u00a021.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0512,130 \u00a00.81% \u00a0\u00a0728,189 \u00a01.26% \u00a0(29.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,917 \u00a0\u00a0 \u00a0\u00a0172,944 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0428,213 \u00a00.67% \u00a0\u00a0555,245 \u00a00.96% \u00a0(22.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a07,189 \u00a0\u00a0 \u00a0\u00a0(7,231) \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$435,402 \u00a00.69% \u00a0$548,014 \u00a00.95% \u00a0(20.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.15 \u00a0\u00a0 \u00a0$2.62 \u00a0\u00a0 \u00a0(17.9)%\nDiluted \u00a0$2.13 \u00a0\u00a0 \u00a0$2.59 \u00a0\u00a0 \u00a0(17.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,316 \u00a0\u00a0 \u00a0\u00a0209,244 \u00a0\u00a0 \u00a0(3.3)%\nDiluted \u00a0\u00a0204,256 \u00a0\u00a0 \u00a0\u00a0211,991 \u00a0\u00a0 \u00a0(3.6)%\n________________________________________ \n 1 Includes a $54.3 million LIFO expense in the three months ended March 31, 2023 and a $16.1 million LIFO credit in the three\nmonths ended March 31, 2022.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n9", "original_text": "Other income, net \u00a0\u00a0(15,720) \u00a0\u00a0 \u00a0\u00a0(948) \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a064,109 \u00a0\u00a0 \u00a0\u00a052,916 \u00a0\u00a0 \u00a021.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0512,130 \u00a00.81% \u00a0\u00a0728,189 \u00a01.26% \u00a0(29.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,917 \u00a0\u00a0 \u00a0\u00a0172,944 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0428,213 \u00a00.67% \u00a0\u00a0555,245 \u00a00.96% \u00a0(22.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a07,189 \u00a0\u00a0 \u00a0\u00a0(7,231) \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$435,402 \u00a00.69% \u00a0$548,014 \u00a00.95% \u00a0(20.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.15 \u00a0\u00a0 \u00a0$2.62 \u00a0\u00a0 \u00a0(17.9)%\nDiluted \u00a0$2.13 \u00a0\u00a0 \u00a0$2.59 \u00a0\u00a0 \u00a0(17.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,316 \u00a0\u00a0 \u00a0\u00a0209,244 \u00a0\u00a0 \u00a0(3.3)%\nDiluted \u00a0\u00a0204,256 \u00a0\u00a0 \u00a0\u00a0211,991 \u00a0\u00a0 \u00a0(3.6)%\n________________________________________ \n 1 Includes a $54.3 million LIFO expense in the three months ended March 31, 2023 and a $16.1 million LIFO credit in the three\nmonths ended March 31, 2022.\n", "page_label": "9", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "37177a96-950b-40f8-b0fd-e9f26ad4974a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8705f8882b72ecdec38fd599e9eaeca001afa95699d9e0a59013eefbc5b8ebdb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a91697a3-fd02-418f-a1e1-0b5b1a5e7d33", "node_type": "1", "metadata": {"window": "other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded \nMarch 31,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded \nMarch 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$63,457,205 \u00a0\u00a0 \u00a0$57,719,446 \u00a0\u00a0 \u00a09.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a061,161,763 \u00a0\u00a0 \u00a0\u00a055,484,366 \u00a0\u00a0 \u00a010.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,295,442 \u00a03.62% \u00a0\u00a02,235,080 \u00a03.87% \u00a02.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,321,087 \u00a02.08% \u00a0\u00a01,203,238 \u00a02.08% \u00a09.8%\nDepreciation and amortization \u00a0\u00a0241,466 \u00a00.38% \u00a0\u00a0175,290 \u00a00.30% \u00a037.8%\nLitigation and opioid-related expenses \u00a0\u00a015,813 \u00a0\u00a0 \u00a0\u00a052,090 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a059,113 \u00a0\u00a0 \u00a0\u00a011,790 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a097,444 \u00a0\u00a0 \u00a0\u00a012,515 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,734,923 \u00a02.73% \u00a0\u00a01,454,923 \u00a02.52% \u00a019.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0560,519 \u00a00.88% \u00a0\u00a0780,157 \u00a01.35% \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded \nMarch 31,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded \nMarch 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$63,457,205 \u00a0\u00a0 \u00a0$57,719,446 \u00a0\u00a0 \u00a09.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a061,161,763 \u00a0\u00a0 \u00a0\u00a055,484,366 \u00a0\u00a0 \u00a010.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,295,442 \u00a03.62% \u00a0\u00a02,235,080 \u00a03.87% \u00a02.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,321,087 \u00a02.08% \u00a0\u00a01,203,238 \u00a02.08% \u00a09.8%\nDepreciation and amortization \u00a0\u00a0241,466 \u00a00.38% \u00a0\u00a0175,290 \u00a00.30% \u00a037.8%\nLitigation and opioid-related expenses \u00a0\u00a015,813 \u00a0\u00a0 \u00a0\u00a052,090 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a059,113 \u00a0\u00a0 \u00a0\u00a011,790 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a097,444 \u00a0\u00a0 \u00a0\u00a012,515 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,734,923 \u00a02.73% \u00a0\u00a01,454,923 \u00a02.52% \u00a019.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0560,519 \u00a00.88% \u00a0\u00a0780,157 \u00a01.35% \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "page_label": "8", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cde385a76d238b915235ec223bc8f4dd31c039a3faec2481487e35994973bae1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d909fccf-e2d1-412d-92bd-98153fa872c9", "node_type": "1", "metadata": {"window": "Other income, net \u00a0\u00a0(15,720) \u00a0\u00a0 \u00a0\u00a0(948) \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a064,109 \u00a0\u00a0 \u00a0\u00a052,916 \u00a0\u00a0 \u00a021.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0512,130 \u00a00.81% \u00a0\u00a0728,189 \u00a01.26% \u00a0(29.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,917 \u00a0\u00a0 \u00a0\u00a0172,944 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0428,213 \u00a00.67% \u00a0\u00a0555,245 \u00a00.96% \u00a0(22.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a07,189 \u00a0\u00a0 \u00a0\u00a0(7,231) \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$435,402 \u00a00.69% \u00a0$548,014 \u00a00.95% \u00a0(20.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.15 \u00a0\u00a0 \u00a0$2.62 \u00a0\u00a0 \u00a0(17.9)%\nDiluted \u00a0$2.13 \u00a0\u00a0 \u00a0$2.59 \u00a0\u00a0 \u00a0(17.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,316 \u00a0\u00a0 \u00a0\u00a0209,244 \u00a0\u00a0 \u00a0(3.3)%\nDiluted \u00a0\u00a0204,256 \u00a0\u00a0 \u00a0\u00a0211,991 \u00a0\u00a0 \u00a0(3.6)%\n________________________________________ \n 1 Includes a $54.3 million LIFO expense in the three months ended March 31, 2023 and a $16.1 million LIFO credit in the three\nmonths ended March 31, 2022.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n9", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n9"}, "hash": "bd0b20cd47d2be48041b8be4d64813d06d9537b2178bce7f414eacb64a9df938", "class_name": "RelatedNodeInfo"}}, "text": "Other income, net \u00a0\u00a0(15,720) \u00a0\u00a0 \u00a0\u00a0(948) \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a064,109 \u00a0\u00a0 \u00a0\u00a052,916 \u00a0\u00a0 \u00a021.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0512,130 \u00a00.81% \u00a0\u00a0728,189 \u00a01.26% \u00a0(29.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,917 \u00a0\u00a0 \u00a0\u00a0172,944 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0428,213 \u00a00.67% \u00a0\u00a0555,245 \u00a00.96% \u00a0(22.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a07,189 \u00a0\u00a0 \u00a0\u00a0(7,231) \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$435,402 \u00a00.69% \u00a0$548,014 \u00a00.95% \u00a0(20.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.15 \u00a0\u00a0 \u00a0$2.62 \u00a0\u00a0 \u00a0(17.9)%\nDiluted \u00a0$2.13 \u00a0\u00a0 \u00a0$2.59 \u00a0\u00a0 \u00a0(17.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,316 \u00a0\u00a0 \u00a0\u00a0209,244 \u00a0\u00a0 \u00a0(3.3)%\nDiluted \u00a0\u00a0204,256 \u00a0\u00a0 \u00a0\u00a0211,991 \u00a0\u00a0 \u00a0(3.6)%\n________________________________________ \n 1 Includes a $54.3 million LIFO expense in the three months ended March 31, 2023 and a $16.1 million LIFO credit in the three\nmonths ended March 31, 2022.\n", "start_char_idx": 0, "end_char_idx": 1021, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d909fccf-e2d1-412d-92bd-98153fa872c9": {"__data__": {"id_": "d909fccf-e2d1-412d-92bd-98153fa872c9", "embedding": null, "metadata": {"window": "Other income, net \u00a0\u00a0(15,720) \u00a0\u00a0 \u00a0\u00a0(948) \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a064,109 \u00a0\u00a0 \u00a0\u00a052,916 \u00a0\u00a0 \u00a021.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0512,130 \u00a00.81% \u00a0\u00a0728,189 \u00a01.26% \u00a0(29.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,917 \u00a0\u00a0 \u00a0\u00a0172,944 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0428,213 \u00a00.67% \u00a0\u00a0555,245 \u00a00.96% \u00a0(22.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a07,189 \u00a0\u00a0 \u00a0\u00a0(7,231) \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$435,402 \u00a00.69% \u00a0$548,014 \u00a00.95% \u00a0(20.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.15 \u00a0\u00a0 \u00a0$2.62 \u00a0\u00a0 \u00a0(17.9)%\nDiluted \u00a0$2.13 \u00a0\u00a0 \u00a0$2.59 \u00a0\u00a0 \u00a0(17.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,316 \u00a0\u00a0 \u00a0\u00a0209,244 \u00a0\u00a0 \u00a0(3.3)%\nDiluted \u00a0\u00a0204,256 \u00a0\u00a0 \u00a0\u00a0211,991 \u00a0\u00a0 \u00a0(3.6)%\n________________________________________ \n 1 Includes a $54.3 million LIFO expense in the three months ended March 31, 2023 and a $16.1 million LIFO credit in the three\nmonths ended March 31, 2022.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n9", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n9", "page_label": "9", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "37177a96-950b-40f8-b0fd-e9f26ad4974a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8705f8882b72ecdec38fd599e9eaeca001afa95699d9e0a59013eefbc5b8ebdb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c34477e8-da40-4366-87ec-f83824234c05", "node_type": "1", "metadata": {"window": "Other income, net \u00a0\u00a0(15,720) \u00a0\u00a0 \u00a0\u00a0(948) \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a064,109 \u00a0\u00a0 \u00a0\u00a052,916 \u00a0\u00a0 \u00a021.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0512,130 \u00a00.81% \u00a0\u00a0728,189 \u00a01.26% \u00a0(29.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,917 \u00a0\u00a0 \u00a0\u00a0172,944 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0428,213 \u00a00.67% \u00a0\u00a0555,245 \u00a00.96% \u00a0(22.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a07,189 \u00a0\u00a0 \u00a0\u00a0(7,231) \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$435,402 \u00a00.69% \u00a0$548,014 \u00a00.95% \u00a0(20.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.15 \u00a0\u00a0 \u00a0$2.62 \u00a0\u00a0 \u00a0(17.9)%\nDiluted \u00a0$2.13 \u00a0\u00a0 \u00a0$2.59 \u00a0\u00a0 \u00a0(17.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,316 \u00a0\u00a0 \u00a0\u00a0209,244 \u00a0\u00a0 \u00a0(3.3)%\nDiluted \u00a0\u00a0204,256 \u00a0\u00a0 \u00a0\u00a0211,991 \u00a0\u00a0 \u00a0(3.6)%\n________________________________________ \n 1 Includes a $54.3 million LIFO expense in the three months ended March 31, 2023 and a $16.1 million LIFO credit in the three\nmonths ended March 31, 2022.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n9", "original_text": "Other income, net \u00a0\u00a0(15,720) \u00a0\u00a0 \u00a0\u00a0(948) \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a064,109 \u00a0\u00a0 \u00a0\u00a052,916 \u00a0\u00a0 \u00a021.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0512,130 \u00a00.81% \u00a0\u00a0728,189 \u00a01.26% \u00a0(29.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,917 \u00a0\u00a0 \u00a0\u00a0172,944 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0428,213 \u00a00.67% \u00a0\u00a0555,245 \u00a00.96% \u00a0(22.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a07,189 \u00a0\u00a0 \u00a0\u00a0(7,231) \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$435,402 \u00a00.69% \u00a0$548,014 \u00a00.95% \u00a0(20.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.15 \u00a0\u00a0 \u00a0$2.62 \u00a0\u00a0 \u00a0(17.9)%\nDiluted \u00a0$2.13 \u00a0\u00a0 \u00a0$2.59 \u00a0\u00a0 \u00a0(17.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,316 \u00a0\u00a0 \u00a0\u00a0209,244 \u00a0\u00a0 \u00a0(3.3)%\nDiluted \u00a0\u00a0204,256 \u00a0\u00a0 \u00a0\u00a0211,991 \u00a0\u00a0 \u00a0(3.6)%\n________________________________________ \n 1 Includes a $54.3 million LIFO expense in the three months ended March 31, 2023 and a $16.1 million LIFO credit in the three\nmonths ended March 31, 2022.\n", "page_label": "9", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67918300fac90869418403dcf0075a359f3e2b84f10648ac475434fb71c49cb1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d2ab4c7-6354-4c88-929b-a4355e9b70d2", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Six Months\nEnded \nMarch 31,\n2023 \u00a0% of\nRevenue \u00a0Six Months\nEnded \nMarch 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$126,304,037 \u00a0\u00a0 \u00a0$117,348,256 \u00a0\u00a0 \u00a07.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0121,862,642 \u00a0\u00a0 \u00a0\u00a0113,052,817 \u00a0\u00a0 \u00a07.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a04,441,395 \u00a03.52% \u00a0\u00a04,295,439 \u00a03.66% \u00a03.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a02,612,015 \u00a02.07% \u00a0\u00a02,373,348 \u00a02.02% \u00a010.1%\nDepreciation and amortization \u00a0\u00a0413,406 \u00a00.33% \u00a0\u00a0351,219 \u00a00.30% \u00a017.7%\nLitigation and opioid-related expenses \u00a0\u00a028,519 \u00a0\u00a0 \u00a0\u00a084,725 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a080,109 \u00a0\u00a0 \u00a0\u00a033,140 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0113,684 \u00a0\u00a0 \u00a0\u00a023,499 \u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a03,247,733 \u00a02.57% \u00a0\u00a02,870,877 \u00a02.45% \u00a013.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,193,662 \u00a00.95% \u00a0\u00a01,424,562 \u00a01.21% \u00a0(16.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(22,048) \u00a0\u00a0 \u00a0\u00a0(6,120) \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0110,125 \u00a0\u00a0 \u00a0\u00a0106,288 \u00a0\u00a0 \u00a03.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,105,585 \u00a00.88% \u00a0\u00a01,324,394 \u00a01.13% \u00a0(16.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0201,202 \u00a0\u00a0 \u00a0\u00a0319,733 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "original_text": "\u00a0 \u00a0Six Months\nEnded \nMarch 31,\n2023 \u00a0% of\nRevenue \u00a0Six Months\nEnded \nMarch 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$126,304,037 \u00a0\u00a0 \u00a0$117,348,256 \u00a0\u00a0 \u00a07.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0121,862,642 \u00a0\u00a0 \u00a0\u00a0113,052,817 \u00a0\u00a0 \u00a07.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a04,441,395 \u00a03.52% \u00a0\u00a04,295,439 \u00a03.66% \u00a03.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a02,612,015 \u00a02.07% \u00a0\u00a02,373,348 \u00a02.02% \u00a010.1%\nDepreciation and amortization \u00a0\u00a0413,406 \u00a00.33% \u00a0\u00a0351,219 \u00a00.30% \u00a017.7%\nLitigation and opioid-related expenses \u00a0\u00a028,519 \u00a0\u00a0 \u00a0\u00a084,725 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a080,109 \u00a0\u00a0 \u00a0\u00a033,140 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0113,684 \u00a0\u00a0 \u00a0\u00a023,499 \u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a03,247,733 \u00a02.57% \u00a0\u00a02,870,877 \u00a02.45% \u00a013.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,193,662 \u00a00.95% \u00a0\u00a01,424,562 \u00a01.21% \u00a0(16.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(22,048) \u00a0\u00a0 \u00a0\u00a0(6,120) \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0110,125 \u00a0\u00a0 \u00a0\u00a0106,288 \u00a0\u00a0 \u00a03.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,105,585 \u00a00.88% \u00a0\u00a01,324,394 \u00a01.13% \u00a0(16.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0201,202 \u00a0\u00a0 \u00a0\u00a0319,733 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10"}, "hash": "1fc0736b875d3767aa12954ead53dc773f152aad970c1b50ae40bca3c202a4df", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n9", "start_char_idx": 1021, "end_char_idx": 1124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d2ab4c7-6354-4c88-929b-a4355e9b70d2": {"__data__": {"id_": "0d2ab4c7-6354-4c88-929b-a4355e9b70d2", "embedding": null, "metadata": {"window": "\u00a0 \u00a0Six Months\nEnded \nMarch 31,\n2023 \u00a0% of\nRevenue \u00a0Six Months\nEnded \nMarch 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$126,304,037 \u00a0\u00a0 \u00a0$117,348,256 \u00a0\u00a0 \u00a07.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0121,862,642 \u00a0\u00a0 \u00a0\u00a0113,052,817 \u00a0\u00a0 \u00a07.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a04,441,395 \u00a03.52% \u00a0\u00a04,295,439 \u00a03.66% \u00a03.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a02,612,015 \u00a02.07% \u00a0\u00a02,373,348 \u00a02.02% \u00a010.1%\nDepreciation and amortization \u00a0\u00a0413,406 \u00a00.33% \u00a0\u00a0351,219 \u00a00.30% \u00a017.7%\nLitigation and opioid-related expenses \u00a0\u00a028,519 \u00a0\u00a0 \u00a0\u00a084,725 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a080,109 \u00a0\u00a0 \u00a0\u00a033,140 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0113,684 \u00a0\u00a0 \u00a0\u00a023,499 \u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a03,247,733 \u00a02.57% \u00a0\u00a02,870,877 \u00a02.45% \u00a013.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,193,662 \u00a00.95% \u00a0\u00a01,424,562 \u00a01.21% \u00a0(16.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(22,048) \u00a0\u00a0 \u00a0\u00a0(6,120) \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0110,125 \u00a0\u00a0 \u00a0\u00a0106,288 \u00a0\u00a0 \u00a03.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,105,585 \u00a00.88% \u00a0\u00a01,324,394 \u00a01.13% \u00a0(16.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0201,202 \u00a0\u00a0 \u00a0\u00a0319,733 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "original_text": "\u00a0 \u00a0Six Months\nEnded \nMarch 31,\n2023 \u00a0% of\nRevenue \u00a0Six Months\nEnded \nMarch 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$126,304,037 \u00a0\u00a0 \u00a0$117,348,256 \u00a0\u00a0 \u00a07.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0121,862,642 \u00a0\u00a0 \u00a0\u00a0113,052,817 \u00a0\u00a0 \u00a07.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a04,441,395 \u00a03.52% \u00a0\u00a04,295,439 \u00a03.66% \u00a03.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a02,612,015 \u00a02.07% \u00a0\u00a02,373,348 \u00a02.02% \u00a010.1%\nDepreciation and amortization \u00a0\u00a0413,406 \u00a00.33% \u00a0\u00a0351,219 \u00a00.30% \u00a017.7%\nLitigation and opioid-related expenses \u00a0\u00a028,519 \u00a0\u00a0 \u00a0\u00a084,725 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a080,109 \u00a0\u00a0 \u00a0\u00a033,140 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0113,684 \u00a0\u00a0 \u00a0\u00a023,499 \u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a03,247,733 \u00a02.57% \u00a0\u00a02,870,877 \u00a02.45% \u00a013.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,193,662 \u00a00.95% \u00a0\u00a01,424,562 \u00a01.21% \u00a0(16.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(22,048) \u00a0\u00a0 \u00a0\u00a0(6,120) \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0110,125 \u00a0\u00a0 \u00a0\u00a0106,288 \u00a0\u00a0 \u00a03.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,105,585 \u00a00.88% \u00a0\u00a01,324,394 \u00a01.13% \u00a0(16.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0201,202 \u00a0\u00a0 \u00a0\u00a0319,733 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "page_label": "10", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f1c344d-531d-4d97-8f84-76bd8391b766", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "edea4126c1f462ead4be13e55721b44e393962f3a72201180114b56dbd60df72", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d909fccf-e2d1-412d-92bd-98153fa872c9", "node_type": "1", "metadata": {"window": "Other income, net \u00a0\u00a0(15,720) \u00a0\u00a0 \u00a0\u00a0(948) \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a064,109 \u00a0\u00a0 \u00a0\u00a052,916 \u00a0\u00a0 \u00a021.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0512,130 \u00a00.81% \u00a0\u00a0728,189 \u00a01.26% \u00a0(29.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,917 \u00a0\u00a0 \u00a0\u00a0172,944 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0428,213 \u00a00.67% \u00a0\u00a0555,245 \u00a00.96% \u00a0(22.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a07,189 \u00a0\u00a0 \u00a0\u00a0(7,231) \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$435,402 \u00a00.69% \u00a0$548,014 \u00a00.95% \u00a0(20.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.15 \u00a0\u00a0 \u00a0$2.62 \u00a0\u00a0 \u00a0(17.9)%\nDiluted \u00a0$2.13 \u00a0\u00a0 \u00a0$2.59 \u00a0\u00a0 \u00a0(17.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,316 \u00a0\u00a0 \u00a0\u00a0209,244 \u00a0\u00a0 \u00a0(3.3)%\nDiluted \u00a0\u00a0204,256 \u00a0\u00a0 \u00a0\u00a0211,991 \u00a0\u00a0 \u00a0(3.6)%\n________________________________________ \n 1 Includes a $54.3 million LIFO expense in the three months ended March 31, 2023 and a $16.1 million LIFO credit in the three\nmonths ended March 31, 2022.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n9", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n9", "page_label": "9", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f75ba50de518ea2011b7189b6a541a2ba7cc48a12e0029faa1f7af026fc50097", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2960218-5cc7-4893-a326-eb062e7d6b5c", "node_type": "1", "metadata": {"window": "Net income \u00a0\u00a0904,383 \u00a00.72% \u00a0\u00a01,004,661 \u00a00.86% \u00a0(10.0)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a010,764 \u00a0\u00a0 \u00a0\u00a0(7,542) \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$915,147 \u00a00.72% \u00a0$997,119 \u00a00.85% \u00a0(8.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.50 \u00a0\u00a0 \u00a0$4.77 \u00a0\u00a0 \u00a0(5.7)%\nDiluted \u00a0$4.46 \u00a0\u00a0 \u00a0$4.71 \u00a0\u00a0 \u00a0(5.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0203,188 \u00a0\u00a0 \u00a0\u00a0208,900 \u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0\u00a0205,306 \u00a0\u00a0 \u00a0\u00a0211,580 \u00a0\u00a0 \u00a0(3.0)%\n________________________________________ \n 1 Includes a $79.3 million LIFO expense and a $49.9 million gain from antitrust litigation settlements in the six months ended March\n31, 2023.  Includes a $60.7 million LIFO credit in the six months ended March 31, 2022.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0$560,519 \u00a0$512,130 \u00a0$83,917 \u00a0$7,189 \u00a0$435,402 \u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02 \u00a0\u00a0\u2014 \u00a0\u00a0(2) \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "original_text": "Net income \u00a0\u00a0904,383 \u00a00.72% \u00a0\u00a01,004,661 \u00a00.86% \u00a0(10.0)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a010,764 \u00a0\u00a0 \u00a0\u00a0(7,542) \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$915,147 \u00a00.72% \u00a0$997,119 \u00a00.85% \u00a0(8.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.50 \u00a0\u00a0 \u00a0$4.77 \u00a0\u00a0 \u00a0(5.7)%\nDiluted \u00a0$4.46 \u00a0\u00a0 \u00a0$4.71 \u00a0\u00a0 \u00a0(5.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0203,188 \u00a0\u00a0 \u00a0\u00a0208,900 \u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0\u00a0205,306 \u00a0\u00a0 \u00a0\u00a0211,580 \u00a0\u00a0 \u00a0(3.0)%\n________________________________________ \n 1 Includes a $79.3 million LIFO expense and a $49.9 million gain from antitrust litigation settlements in the six months ended March\n31, 2023. "}, "hash": "21f02533cd8b944e4c34775ee2afac6e24705782c3806ac0c7ae128c9cd98372", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0Six Months\nEnded \nMarch 31,\n2023 \u00a0% of\nRevenue \u00a0Six Months\nEnded \nMarch 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$126,304,037 \u00a0\u00a0 \u00a0$117,348,256 \u00a0\u00a0 \u00a07.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0121,862,642 \u00a0\u00a0 \u00a0\u00a0113,052,817 \u00a0\u00a0 \u00a07.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a04,441,395 \u00a03.52% \u00a0\u00a04,295,439 \u00a03.66% \u00a03.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a02,612,015 \u00a02.07% \u00a0\u00a02,373,348 \u00a02.02% \u00a010.1%\nDepreciation and amortization \u00a0\u00a0413,406 \u00a00.33% \u00a0\u00a0351,219 \u00a00.30% \u00a017.7%\nLitigation and opioid-related expenses \u00a0\u00a028,519 \u00a0\u00a0 \u00a0\u00a084,725 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a080,109 \u00a0\u00a0 \u00a0\u00a033,140 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0113,684 \u00a0\u00a0 \u00a0\u00a023,499 \u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a03,247,733 \u00a02.57% \u00a0\u00a02,870,877 \u00a02.45% \u00a013.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,193,662 \u00a00.95% \u00a0\u00a01,424,562 \u00a01.21% \u00a0(16.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(22,048) \u00a0\u00a0 \u00a0\u00a0(6,120) \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0110,125 \u00a0\u00a0 \u00a0\u00a0106,288 \u00a0\u00a0 \u00a03.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,105,585 \u00a00.88% \u00a0\u00a01,324,394 \u00a01.13% \u00a0(16.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0201,202 \u00a0\u00a0 \u00a0\u00a0319,733 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "start_char_idx": 0, "end_char_idx": 1209, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2960218-5cc7-4893-a326-eb062e7d6b5c": {"__data__": {"id_": "b2960218-5cc7-4893-a326-eb062e7d6b5c", "embedding": null, "metadata": {"window": "Net income \u00a0\u00a0904,383 \u00a00.72% \u00a0\u00a01,004,661 \u00a00.86% \u00a0(10.0)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a010,764 \u00a0\u00a0 \u00a0\u00a0(7,542) \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$915,147 \u00a00.72% \u00a0$997,119 \u00a00.85% \u00a0(8.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.50 \u00a0\u00a0 \u00a0$4.77 \u00a0\u00a0 \u00a0(5.7)%\nDiluted \u00a0$4.46 \u00a0\u00a0 \u00a0$4.71 \u00a0\u00a0 \u00a0(5.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0203,188 \u00a0\u00a0 \u00a0\u00a0208,900 \u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0\u00a0205,306 \u00a0\u00a0 \u00a0\u00a0211,580 \u00a0\u00a0 \u00a0(3.0)%\n________________________________________ \n 1 Includes a $79.3 million LIFO expense and a $49.9 million gain from antitrust litigation settlements in the six months ended March\n31, 2023.  Includes a $60.7 million LIFO credit in the six months ended March 31, 2022.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0$560,519 \u00a0$512,130 \u00a0$83,917 \u00a0$7,189 \u00a0$435,402 \u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02 \u00a0\u00a0\u2014 \u00a0\u00a0(2) \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "original_text": "Net income \u00a0\u00a0904,383 \u00a00.72% \u00a0\u00a01,004,661 \u00a00.86% \u00a0(10.0)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a010,764 \u00a0\u00a0 \u00a0\u00a0(7,542) \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$915,147 \u00a00.72% \u00a0$997,119 \u00a00.85% \u00a0(8.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.50 \u00a0\u00a0 \u00a0$4.77 \u00a0\u00a0 \u00a0(5.7)%\nDiluted \u00a0$4.46 \u00a0\u00a0 \u00a0$4.71 \u00a0\u00a0 \u00a0(5.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0203,188 \u00a0\u00a0 \u00a0\u00a0208,900 \u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0\u00a0205,306 \u00a0\u00a0 \u00a0\u00a0211,580 \u00a0\u00a0 \u00a0(3.0)%\n________________________________________ \n 1 Includes a $79.3 million LIFO expense and a $49.9 million gain from antitrust litigation settlements in the six months ended March\n31, 2023. ", "page_label": "11", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1bb47096-a02d-4d23-85cc-7b9438626f38", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a435d031a314d1f1e95870e862771d5bb192488d0c156c2e058eba05b8bf7566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d2ab4c7-6354-4c88-929b-a4355e9b70d2", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Six Months\nEnded \nMarch 31,\n2023 \u00a0% of\nRevenue \u00a0Six Months\nEnded \nMarch 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$126,304,037 \u00a0\u00a0 \u00a0$117,348,256 \u00a0\u00a0 \u00a07.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0121,862,642 \u00a0\u00a0 \u00a0\u00a0113,052,817 \u00a0\u00a0 \u00a07.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a04,441,395 \u00a03.52% \u00a0\u00a04,295,439 \u00a03.66% \u00a03.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a02,612,015 \u00a02.07% \u00a0\u00a02,373,348 \u00a02.02% \u00a010.1%\nDepreciation and amortization \u00a0\u00a0413,406 \u00a00.33% \u00a0\u00a0351,219 \u00a00.30% \u00a017.7%\nLitigation and opioid-related expenses \u00a0\u00a028,519 \u00a0\u00a0 \u00a0\u00a084,725 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a080,109 \u00a0\u00a0 \u00a0\u00a033,140 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0113,684 \u00a0\u00a0 \u00a0\u00a023,499 \u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a03,247,733 \u00a02.57% \u00a0\u00a02,870,877 \u00a02.45% \u00a013.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,193,662 \u00a00.95% \u00a0\u00a01,424,562 \u00a01.21% \u00a0(16.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(22,048) \u00a0\u00a0 \u00a0\u00a0(6,120) \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0110,125 \u00a0\u00a0 \u00a0\u00a0106,288 \u00a0\u00a0 \u00a03.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,105,585 \u00a00.88% \u00a0\u00a01,324,394 \u00a01.13% \u00a0(16.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0201,202 \u00a0\u00a0 \u00a0\u00a0319,733 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "original_text": "\u00a0 \u00a0Six Months\nEnded \nMarch 31,\n2023 \u00a0% of\nRevenue \u00a0Six Months\nEnded \nMarch 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$126,304,037 \u00a0\u00a0 \u00a0$117,348,256 \u00a0\u00a0 \u00a07.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0121,862,642 \u00a0\u00a0 \u00a0\u00a0113,052,817 \u00a0\u00a0 \u00a07.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a04,441,395 \u00a03.52% \u00a0\u00a04,295,439 \u00a03.66% \u00a03.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a02,612,015 \u00a02.07% \u00a0\u00a02,373,348 \u00a02.02% \u00a010.1%\nDepreciation and amortization \u00a0\u00a0413,406 \u00a00.33% \u00a0\u00a0351,219 \u00a00.30% \u00a017.7%\nLitigation and opioid-related expenses \u00a0\u00a028,519 \u00a0\u00a0 \u00a0\u00a084,725 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a080,109 \u00a0\u00a0 \u00a0\u00a033,140 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0113,684 \u00a0\u00a0 \u00a0\u00a023,499 \u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a03,247,733 \u00a02.57% \u00a0\u00a02,870,877 \u00a02.45% \u00a013.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,193,662 \u00a00.95% \u00a0\u00a01,424,562 \u00a01.21% \u00a0(16.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(22,048) \u00a0\u00a0 \u00a0\u00a0(6,120) \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0110,125 \u00a0\u00a0 \u00a0\u00a0106,288 \u00a0\u00a0 \u00a03.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,105,585 \u00a00.88% \u00a0\u00a01,324,394 \u00a01.13% \u00a0(16.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0201,202 \u00a0\u00a0 \u00a0\u00a0319,733 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "page_label": "10", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8755d7e8b2858a122743656f3ed851f065616c67e07c23ea2663fb8bd5b6c62b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "283efd3c-6c39-43e4-aa17-28f15cb63d7e", "node_type": "1", "metadata": {"window": "Net income \u00a0\u00a0904,383 \u00a00.72% \u00a0\u00a01,004,661 \u00a00.86% \u00a0(10.0)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a010,764 \u00a0\u00a0 \u00a0\u00a0(7,542) \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$915,147 \u00a00.72% \u00a0$997,119 \u00a00.85% \u00a0(8.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.50 \u00a0\u00a0 \u00a0$4.77 \u00a0\u00a0 \u00a0(5.7)%\nDiluted \u00a0$4.46 \u00a0\u00a0 \u00a0$4.71 \u00a0\u00a0 \u00a0(5.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0203,188 \u00a0\u00a0 \u00a0\u00a0208,900 \u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0\u00a0205,306 \u00a0\u00a0 \u00a0\u00a0211,580 \u00a0\u00a0 \u00a0(3.0)%\n________________________________________ \n 1 Includes a $79.3 million LIFO expense and a $49.9 million gain from antitrust litigation settlements in the six months ended March\n31, 2023.  Includes a $60.7 million LIFO credit in the six months ended March 31, 2022.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0$560,519 \u00a0$512,130 \u00a0$83,917 \u00a0$7,189 \u00a0$435,402 \u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02 \u00a0\u00a0\u2014 \u00a0\u00a0(2) \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "original_text": "Includes a $60.7 million LIFO credit in the six months ended March 31, 2022.\n"}, "hash": "e8a0c59ad5c9b9404fca26e195517ed21353da72294912be5eb2539415152500", "class_name": "RelatedNodeInfo"}}, "text": "Net income \u00a0\u00a0904,383 \u00a00.72% \u00a0\u00a01,004,661 \u00a00.86% \u00a0(10.0)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a010,764 \u00a0\u00a0 \u00a0\u00a0(7,542) \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$915,147 \u00a00.72% \u00a0$997,119 \u00a00.85% \u00a0(8.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.50 \u00a0\u00a0 \u00a0$4.77 \u00a0\u00a0 \u00a0(5.7)%\nDiluted \u00a0$4.46 \u00a0\u00a0 \u00a0$4.71 \u00a0\u00a0 \u00a0(5.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0203,188 \u00a0\u00a0 \u00a0\u00a0208,900 \u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0\u00a0205,306 \u00a0\u00a0 \u00a0\u00a0211,580 \u00a0\u00a0 \u00a0(3.0)%\n________________________________________ \n 1 Includes a $79.3 million LIFO expense and a $49.9 million gain from antitrust litigation settlements in the six months ended March\n31, 2023. ", "start_char_idx": 0, "end_char_idx": 742, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "283efd3c-6c39-43e4-aa17-28f15cb63d7e": {"__data__": {"id_": "283efd3c-6c39-43e4-aa17-28f15cb63d7e", "embedding": null, "metadata": {"window": "Net income \u00a0\u00a0904,383 \u00a00.72% \u00a0\u00a01,004,661 \u00a00.86% \u00a0(10.0)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a010,764 \u00a0\u00a0 \u00a0\u00a0(7,542) \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$915,147 \u00a00.72% \u00a0$997,119 \u00a00.85% \u00a0(8.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.50 \u00a0\u00a0 \u00a0$4.77 \u00a0\u00a0 \u00a0(5.7)%\nDiluted \u00a0$4.46 \u00a0\u00a0 \u00a0$4.71 \u00a0\u00a0 \u00a0(5.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0203,188 \u00a0\u00a0 \u00a0\u00a0208,900 \u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0\u00a0205,306 \u00a0\u00a0 \u00a0\u00a0211,580 \u00a0\u00a0 \u00a0(3.0)%\n________________________________________ \n 1 Includes a $79.3 million LIFO expense and a $49.9 million gain from antitrust litigation settlements in the six months ended March\n31, 2023.  Includes a $60.7 million LIFO credit in the six months ended March 31, 2022.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0$560,519 \u00a0$512,130 \u00a0$83,917 \u00a0$7,189 \u00a0$435,402 \u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02 \u00a0\u00a0\u2014 \u00a0\u00a0(2) \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "original_text": "Includes a $60.7 million LIFO credit in the six months ended March 31, 2022.\n", "page_label": "11", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1bb47096-a02d-4d23-85cc-7b9438626f38", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a435d031a314d1f1e95870e862771d5bb192488d0c156c2e058eba05b8bf7566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2960218-5cc7-4893-a326-eb062e7d6b5c", "node_type": "1", "metadata": {"window": "Net income \u00a0\u00a0904,383 \u00a00.72% \u00a0\u00a01,004,661 \u00a00.86% \u00a0(10.0)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a010,764 \u00a0\u00a0 \u00a0\u00a0(7,542) \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$915,147 \u00a00.72% \u00a0$997,119 \u00a00.85% \u00a0(8.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.50 \u00a0\u00a0 \u00a0$4.77 \u00a0\u00a0 \u00a0(5.7)%\nDiluted \u00a0$4.46 \u00a0\u00a0 \u00a0$4.71 \u00a0\u00a0 \u00a0(5.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0203,188 \u00a0\u00a0 \u00a0\u00a0208,900 \u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0\u00a0205,306 \u00a0\u00a0 \u00a0\u00a0211,580 \u00a0\u00a0 \u00a0(3.0)%\n________________________________________ \n 1 Includes a $79.3 million LIFO expense and a $49.9 million gain from antitrust litigation settlements in the six months ended March\n31, 2023.  Includes a $60.7 million LIFO credit in the six months ended March 31, 2022.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0$560,519 \u00a0$512,130 \u00a0$83,917 \u00a0$7,189 \u00a0$435,402 \u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02 \u00a0\u00a0\u2014 \u00a0\u00a0(2) \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "original_text": "Net income \u00a0\u00a0904,383 \u00a00.72% \u00a0\u00a01,004,661 \u00a00.86% \u00a0(10.0)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a010,764 \u00a0\u00a0 \u00a0\u00a0(7,542) \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$915,147 \u00a00.72% \u00a0$997,119 \u00a00.85% \u00a0(8.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.50 \u00a0\u00a0 \u00a0$4.77 \u00a0\u00a0 \u00a0(5.7)%\nDiluted \u00a0$4.46 \u00a0\u00a0 \u00a0$4.71 \u00a0\u00a0 \u00a0(5.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0203,188 \u00a0\u00a0 \u00a0\u00a0208,900 \u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0\u00a0205,306 \u00a0\u00a0 \u00a0\u00a0211,580 \u00a0\u00a0 \u00a0(3.0)%\n________________________________________ \n 1 Includes a $79.3 million LIFO expense and a $49.9 million gain from antitrust litigation settlements in the six months ended March\n31, 2023. ", "page_label": "11", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc24d3dd166948264f504a2905da2b007ce43fce781cfed0470642db7f956756", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01c3d115-1cd7-41df-a191-cd67779d1837", "node_type": "1", "metadata": {"window": "Net income \u00a0\u00a0904,383 \u00a00.72% \u00a0\u00a01,004,661 \u00a00.86% \u00a0(10.0)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a010,764 \u00a0\u00a0 \u00a0\u00a0(7,542) \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$915,147 \u00a00.72% \u00a0$997,119 \u00a00.85% \u00a0(8.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.50 \u00a0\u00a0 \u00a0$4.77 \u00a0\u00a0 \u00a0(5.7)%\nDiluted \u00a0$4.46 \u00a0\u00a0 \u00a0$4.71 \u00a0\u00a0 \u00a0(5.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0203,188 \u00a0\u00a0 \u00a0\u00a0208,900 \u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0\u00a0205,306 \u00a0\u00a0 \u00a0\u00a0211,580 \u00a0\u00a0 \u00a0(3.0)%\n________________________________________ \n 1 Includes a $79.3 million LIFO expense and a $49.9 million gain from antitrust litigation settlements in the six months ended March\n31, 2023.  Includes a $60.7 million LIFO credit in the six months ended March 31, 2022.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0$560,519 \u00a0$512,130 \u00a0$83,917 \u00a0$7,189 \u00a0$435,402 \u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02 \u00a0\u00a0\u2014 \u00a0\u00a0(2) \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0$560,519 \u00a0$512,130 \u00a0$83,917 \u00a0$7,189 \u00a0$435,402 \u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02 \u00a0\u00a0\u2014 \u00a0\u00a0(2) \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11"}, "hash": "f4e78fbceab75c0a0caa44f0bd0d8c16d2fe2400379fced846eebf4cf101acd8", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $60.7 million LIFO credit in the six months ended March 31, 2022.\n", "start_char_idx": 742, "end_char_idx": 819, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01c3d115-1cd7-41df-a191-cd67779d1837": {"__data__": {"id_": "01c3d115-1cd7-41df-a191-cd67779d1837", "embedding": null, "metadata": {"window": "Net income \u00a0\u00a0904,383 \u00a00.72% \u00a0\u00a01,004,661 \u00a00.86% \u00a0(10.0)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a010,764 \u00a0\u00a0 \u00a0\u00a0(7,542) \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$915,147 \u00a00.72% \u00a0$997,119 \u00a00.85% \u00a0(8.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.50 \u00a0\u00a0 \u00a0$4.77 \u00a0\u00a0 \u00a0(5.7)%\nDiluted \u00a0$4.46 \u00a0\u00a0 \u00a0$4.71 \u00a0\u00a0 \u00a0(5.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0203,188 \u00a0\u00a0 \u00a0\u00a0208,900 \u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0\u00a0205,306 \u00a0\u00a0 \u00a0\u00a0211,580 \u00a0\u00a0 \u00a0(3.0)%\n________________________________________ \n 1 Includes a $79.3 million LIFO expense and a $49.9 million gain from antitrust litigation settlements in the six months ended March\n31, 2023.  Includes a $60.7 million LIFO credit in the six months ended March 31, 2022.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0$560,519 \u00a0$512,130 \u00a0$83,917 \u00a0$7,189 \u00a0$435,402 \u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02 \u00a0\u00a0\u2014 \u00a0\u00a0(2) \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0$560,519 \u00a0$512,130 \u00a0$83,917 \u00a0$7,189 \u00a0$435,402 \u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02 \u00a0\u00a0\u2014 \u00a0\u00a0(2) \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "page_label": "11", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1bb47096-a02d-4d23-85cc-7b9438626f38", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a435d031a314d1f1e95870e862771d5bb192488d0c156c2e058eba05b8bf7566", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "283efd3c-6c39-43e4-aa17-28f15cb63d7e", "node_type": "1", "metadata": {"window": "Net income \u00a0\u00a0904,383 \u00a00.72% \u00a0\u00a01,004,661 \u00a00.86% \u00a0(10.0)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a010,764 \u00a0\u00a0 \u00a0\u00a0(7,542) \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$915,147 \u00a00.72% \u00a0$997,119 \u00a00.85% \u00a0(8.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.50 \u00a0\u00a0 \u00a0$4.77 \u00a0\u00a0 \u00a0(5.7)%\nDiluted \u00a0$4.46 \u00a0\u00a0 \u00a0$4.71 \u00a0\u00a0 \u00a0(5.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0203,188 \u00a0\u00a0 \u00a0\u00a0208,900 \u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0\u00a0205,306 \u00a0\u00a0 \u00a0\u00a0211,580 \u00a0\u00a0 \u00a0(3.0)%\n________________________________________ \n 1 Includes a $79.3 million LIFO expense and a $49.9 million gain from antitrust litigation settlements in the six months ended March\n31, 2023.  Includes a $60.7 million LIFO credit in the six months ended March 31, 2022.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0$560,519 \u00a0$512,130 \u00a0$83,917 \u00a0$7,189 \u00a0$435,402 \u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02 \u00a0\u00a0\u2014 \u00a0\u00a0(2) \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "original_text": "Includes a $60.7 million LIFO credit in the six months ended March 31, 2022.\n", "page_label": "11", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d51e2a0ecd4c589d3bdafedae6a5bb3f9a007a9571c2a07fd4e65888a01258d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d33315da-1936-4a5b-8462-3ddd7374d822", "node_type": "1", "metadata": {"window": "Turkey highly\ninflationary impact \u00a0\u00a04,855 \u00a0\u00a0\u2014 \u00a0\u00a04,855 \u00a0\u00a04,455 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a04,455 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a054,270 \u00a0\u00a0\u2014 \u00a0\u00a054,270 \u00a0\u00a054,270 \u00a0\u00a012,676 \u00a0\u00a0\u2014 \u00a0\u00a041,594 \u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(140,114) \u00a0\u00a0140,114 \u00a0\u00a0140,114 \u00a0\u00a032,727 \u00a0\u00a0(984) \u00a0\u00a0106,403 \u00a0\u00a00.52 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,813) \u00a0\u00a015,813 \u00a0\u00a015,813 \u00a0\u00a03,693 \u00a0\u00a0\u2014 \u00a0\u00a012,120 \u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(59,113) \u00a0\u00a059,113 \u00a0\u00a059,113 \u00a0\u00a013,808 \u00a0\u00a0\u2014 \u00a0\u00a045,305 \u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(97,444) \u00a0\u00a097,444 \u00a0\u00a097,444 \u00a0\u00a022,763 \u00a0\u00a0\u2014 \u00a0\u00a074,681 \u00a0\u00a00.37 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0(0.03) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(2,182) \u00a0\u00a0(3,244) \u00a0\u00a0\u2014 \u00a0\u00a01,062 \u00a0\u00a00.01 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,354,567 \u00a0$1,422,439 \u00a0$932,128 \u00a0$875,494 \u00a0$166,342 \u00a0$6,205 \u00a0$715,357 \u00a0$3.50 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP\n% change vs.  prior\nyear \u00a0\u00a06.2 % \u00a0\u00a09.4 % \u00a0\u00a01.7 % \u00a0\u00a00.9 % \u00a0\u00a0(8.5) % \u00a0\u00a0 \u00a0\u00a04.7 % \u00a0\u00a08.7 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.62% \u00a03.71%\nOperating expenses \u00a02.73% \u00a02.24%\n12", "original_text": "Turkey highly\ninflationary impact \u00a0\u00a04,855 \u00a0\u00a0\u2014 \u00a0\u00a04,855 \u00a0\u00a04,455 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a04,455 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a054,270 \u00a0\u00a0\u2014 \u00a0\u00a054,270 \u00a0\u00a054,270 \u00a0\u00a012,676 \u00a0\u00a0\u2014 \u00a0\u00a041,594 \u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(140,114) \u00a0\u00a0140,114 \u00a0\u00a0140,114 \u00a0\u00a032,727 \u00a0\u00a0(984) \u00a0\u00a0106,403 \u00a0\u00a00.52 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,813) \u00a0\u00a015,813 \u00a0\u00a015,813 \u00a0\u00a03,693 \u00a0\u00a0\u2014 \u00a0\u00a012,120 \u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(59,113) \u00a0\u00a059,113 \u00a0\u00a059,113 \u00a0\u00a013,808 \u00a0\u00a0\u2014 \u00a0\u00a045,305 \u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(97,444) \u00a0\u00a097,444 \u00a0\u00a097,444 \u00a0\u00a022,763 \u00a0\u00a0\u2014 \u00a0\u00a074,681 \u00a0\u00a00.37 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0(0.03) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(2,182) \u00a0\u00a0(3,244) \u00a0\u00a0\u2014 \u00a0\u00a01,062 \u00a0\u00a00.01 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,354,567 \u00a0$1,422,439 \u00a0$932,128 \u00a0$875,494 \u00a0$166,342 \u00a0$6,205 \u00a0$715,357 \u00a0$3.50 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP\n% change vs. "}, "hash": "4728bb002d8f0ed5ff0afae571d85cc4b9e372107b5324c2db971d9e2f79af29", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0$560,519 \u00a0$512,130 \u00a0$83,917 \u00a0$7,189 \u00a0$435,402 \u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02 \u00a0\u00a0\u2014 \u00a0\u00a0(2) \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "start_char_idx": 819, "end_char_idx": 1428, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d33315da-1936-4a5b-8462-3ddd7374d822": {"__data__": {"id_": "d33315da-1936-4a5b-8462-3ddd7374d822", "embedding": null, "metadata": {"window": "Turkey highly\ninflationary impact \u00a0\u00a04,855 \u00a0\u00a0\u2014 \u00a0\u00a04,855 \u00a0\u00a04,455 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a04,455 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a054,270 \u00a0\u00a0\u2014 \u00a0\u00a054,270 \u00a0\u00a054,270 \u00a0\u00a012,676 \u00a0\u00a0\u2014 \u00a0\u00a041,594 \u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(140,114) \u00a0\u00a0140,114 \u00a0\u00a0140,114 \u00a0\u00a032,727 \u00a0\u00a0(984) \u00a0\u00a0106,403 \u00a0\u00a00.52 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,813) \u00a0\u00a015,813 \u00a0\u00a015,813 \u00a0\u00a03,693 \u00a0\u00a0\u2014 \u00a0\u00a012,120 \u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(59,113) \u00a0\u00a059,113 \u00a0\u00a059,113 \u00a0\u00a013,808 \u00a0\u00a0\u2014 \u00a0\u00a045,305 \u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(97,444) \u00a0\u00a097,444 \u00a0\u00a097,444 \u00a0\u00a022,763 \u00a0\u00a0\u2014 \u00a0\u00a074,681 \u00a0\u00a00.37 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0(0.03) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(2,182) \u00a0\u00a0(3,244) \u00a0\u00a0\u2014 \u00a0\u00a01,062 \u00a0\u00a00.01 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,354,567 \u00a0$1,422,439 \u00a0$932,128 \u00a0$875,494 \u00a0$166,342 \u00a0$6,205 \u00a0$715,357 \u00a0$3.50 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP\n% change vs.  prior\nyear \u00a0\u00a06.2 % \u00a0\u00a09.4 % \u00a0\u00a01.7 % \u00a0\u00a00.9 % \u00a0\u00a0(8.5) % \u00a0\u00a0 \u00a0\u00a04.7 % \u00a0\u00a08.7 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.62% \u00a03.71%\nOperating expenses \u00a02.73% \u00a02.24%\n12", "original_text": "Turkey highly\ninflationary impact \u00a0\u00a04,855 \u00a0\u00a0\u2014 \u00a0\u00a04,855 \u00a0\u00a04,455 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a04,455 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a054,270 \u00a0\u00a0\u2014 \u00a0\u00a054,270 \u00a0\u00a054,270 \u00a0\u00a012,676 \u00a0\u00a0\u2014 \u00a0\u00a041,594 \u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(140,114) \u00a0\u00a0140,114 \u00a0\u00a0140,114 \u00a0\u00a032,727 \u00a0\u00a0(984) \u00a0\u00a0106,403 \u00a0\u00a00.52 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,813) \u00a0\u00a015,813 \u00a0\u00a015,813 \u00a0\u00a03,693 \u00a0\u00a0\u2014 \u00a0\u00a012,120 \u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(59,113) \u00a0\u00a059,113 \u00a0\u00a059,113 \u00a0\u00a013,808 \u00a0\u00a0\u2014 \u00a0\u00a045,305 \u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(97,444) \u00a0\u00a097,444 \u00a0\u00a097,444 \u00a0\u00a022,763 \u00a0\u00a0\u2014 \u00a0\u00a074,681 \u00a0\u00a00.37 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0(0.03) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(2,182) \u00a0\u00a0(3,244) \u00a0\u00a0\u2014 \u00a0\u00a01,062 \u00a0\u00a00.01 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,354,567 \u00a0$1,422,439 \u00a0$932,128 \u00a0$875,494 \u00a0$166,342 \u00a0$6,205 \u00a0$715,357 \u00a0$3.50 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP\n% change vs. ", "page_label": "12", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cf471dd7-da88-4f99-af33-033da7024c63", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af84c62ccb0768ba0394a325d7dd25b57984c40f156c66a1199f309e0ebfe5ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01c3d115-1cd7-41df-a191-cd67779d1837", "node_type": "1", "metadata": {"window": "Net income \u00a0\u00a0904,383 \u00a00.72% \u00a0\u00a01,004,661 \u00a00.86% \u00a0(10.0)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a010,764 \u00a0\u00a0 \u00a0\u00a0(7,542) \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$915,147 \u00a00.72% \u00a0$997,119 \u00a00.85% \u00a0(8.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.50 \u00a0\u00a0 \u00a0$4.77 \u00a0\u00a0 \u00a0(5.7)%\nDiluted \u00a0$4.46 \u00a0\u00a0 \u00a0$4.71 \u00a0\u00a0 \u00a0(5.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0203,188 \u00a0\u00a0 \u00a0\u00a0208,900 \u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0\u00a0205,306 \u00a0\u00a0 \u00a0\u00a0211,580 \u00a0\u00a0 \u00a0(3.0)%\n________________________________________ \n 1 Includes a $79.3 million LIFO expense and a $49.9 million gain from antitrust litigation settlements in the six months ended March\n31, 2023.  Includes a $60.7 million LIFO credit in the six months ended March 31, 2022.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0$560,519 \u00a0$512,130 \u00a0$83,917 \u00a0$7,189 \u00a0$435,402 \u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02 \u00a0\u00a0\u2014 \u00a0\u00a0(2) \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0$560,519 \u00a0$512,130 \u00a0$83,917 \u00a0$7,189 \u00a0$435,402 \u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02 \u00a0\u00a0\u2014 \u00a0\u00a0(2) \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "page_label": "11", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "924de0197119b4f523c089b466ae152acb2cb232c2f782bdf5431a446ee75225", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c81751d0-3240-4f8c-ad5c-1e9d3a917823", "node_type": "1", "metadata": {"window": "Turkey highly\ninflationary impact \u00a0\u00a04,855 \u00a0\u00a0\u2014 \u00a0\u00a04,855 \u00a0\u00a04,455 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a04,455 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a054,270 \u00a0\u00a0\u2014 \u00a0\u00a054,270 \u00a0\u00a054,270 \u00a0\u00a012,676 \u00a0\u00a0\u2014 \u00a0\u00a041,594 \u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(140,114) \u00a0\u00a0140,114 \u00a0\u00a0140,114 \u00a0\u00a032,727 \u00a0\u00a0(984) \u00a0\u00a0106,403 \u00a0\u00a00.52 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,813) \u00a0\u00a015,813 \u00a0\u00a015,813 \u00a0\u00a03,693 \u00a0\u00a0\u2014 \u00a0\u00a012,120 \u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(59,113) \u00a0\u00a059,113 \u00a0\u00a059,113 \u00a0\u00a013,808 \u00a0\u00a0\u2014 \u00a0\u00a045,305 \u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(97,444) \u00a0\u00a097,444 \u00a0\u00a097,444 \u00a0\u00a022,763 \u00a0\u00a0\u2014 \u00a0\u00a074,681 \u00a0\u00a00.37 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0(0.03) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(2,182) \u00a0\u00a0(3,244) \u00a0\u00a0\u2014 \u00a0\u00a01,062 \u00a0\u00a00.01 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,354,567 \u00a0$1,422,439 \u00a0$932,128 \u00a0$875,494 \u00a0$166,342 \u00a0$6,205 \u00a0$715,357 \u00a0$3.50 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP\n% change vs.  prior\nyear \u00a0\u00a06.2 % \u00a0\u00a09.4 % \u00a0\u00a01.7 % \u00a0\u00a00.9 % \u00a0\u00a0(8.5) % \u00a0\u00a0 \u00a0\u00a04.7 % \u00a0\u00a08.7 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.62% \u00a03.71%\nOperating expenses \u00a02.73% \u00a02.24%\n12", "original_text": "prior\nyear \u00a0\u00a06.2 % \u00a0\u00a09.4 % \u00a0\u00a01.7 % \u00a0\u00a00.9 % \u00a0\u00a0(8.5) % \u00a0\u00a0 \u00a0\u00a04.7 % \u00a0\u00a08.7 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.62% \u00a03.71%\nOperating expenses \u00a02.73% \u00a02.24%\n12"}, "hash": "fe0d1e000542181e81f31642025bd4788b3fdf6f0ead4f0439df3210591578b6", "class_name": "RelatedNodeInfo"}}, "text": "Turkey highly\ninflationary impact \u00a0\u00a04,855 \u00a0\u00a0\u2014 \u00a0\u00a04,855 \u00a0\u00a04,455 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a04,455 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a054,270 \u00a0\u00a0\u2014 \u00a0\u00a054,270 \u00a0\u00a054,270 \u00a0\u00a012,676 \u00a0\u00a0\u2014 \u00a0\u00a041,594 \u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(140,114) \u00a0\u00a0140,114 \u00a0\u00a0140,114 \u00a0\u00a032,727 \u00a0\u00a0(984) \u00a0\u00a0106,403 \u00a0\u00a00.52 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,813) \u00a0\u00a015,813 \u00a0\u00a015,813 \u00a0\u00a03,693 \u00a0\u00a0\u2014 \u00a0\u00a012,120 \u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(59,113) \u00a0\u00a059,113 \u00a0\u00a059,113 \u00a0\u00a013,808 \u00a0\u00a0\u2014 \u00a0\u00a045,305 \u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(97,444) \u00a0\u00a097,444 \u00a0\u00a097,444 \u00a0\u00a022,763 \u00a0\u00a0\u2014 \u00a0\u00a074,681 \u00a0\u00a00.37 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0(0.03) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(2,182) \u00a0\u00a0(3,244) \u00a0\u00a0\u2014 \u00a0\u00a01,062 \u00a0\u00a00.01 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,354,567 \u00a0$1,422,439 \u00a0$932,128 \u00a0$875,494 \u00a0$166,342 \u00a0$6,205 \u00a0$715,357 \u00a0$3.50 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP\n% change vs. ", "start_char_idx": 0, "end_char_idx": 1114, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c81751d0-3240-4f8c-ad5c-1e9d3a917823": {"__data__": {"id_": "c81751d0-3240-4f8c-ad5c-1e9d3a917823", "embedding": null, "metadata": {"window": "Turkey highly\ninflationary impact \u00a0\u00a04,855 \u00a0\u00a0\u2014 \u00a0\u00a04,855 \u00a0\u00a04,455 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a04,455 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a054,270 \u00a0\u00a0\u2014 \u00a0\u00a054,270 \u00a0\u00a054,270 \u00a0\u00a012,676 \u00a0\u00a0\u2014 \u00a0\u00a041,594 \u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(140,114) \u00a0\u00a0140,114 \u00a0\u00a0140,114 \u00a0\u00a032,727 \u00a0\u00a0(984) \u00a0\u00a0106,403 \u00a0\u00a00.52 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,813) \u00a0\u00a015,813 \u00a0\u00a015,813 \u00a0\u00a03,693 \u00a0\u00a0\u2014 \u00a0\u00a012,120 \u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(59,113) \u00a0\u00a059,113 \u00a0\u00a059,113 \u00a0\u00a013,808 \u00a0\u00a0\u2014 \u00a0\u00a045,305 \u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(97,444) \u00a0\u00a097,444 \u00a0\u00a097,444 \u00a0\u00a022,763 \u00a0\u00a0\u2014 \u00a0\u00a074,681 \u00a0\u00a00.37 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0(0.03) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(2,182) \u00a0\u00a0(3,244) \u00a0\u00a0\u2014 \u00a0\u00a01,062 \u00a0\u00a00.01 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,354,567 \u00a0$1,422,439 \u00a0$932,128 \u00a0$875,494 \u00a0$166,342 \u00a0$6,205 \u00a0$715,357 \u00a0$3.50 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP\n% change vs.  prior\nyear \u00a0\u00a06.2 % \u00a0\u00a09.4 % \u00a0\u00a01.7 % \u00a0\u00a00.9 % \u00a0\u00a0(8.5) % \u00a0\u00a0 \u00a0\u00a04.7 % \u00a0\u00a08.7 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.62% \u00a03.71%\nOperating expenses \u00a02.73% \u00a02.24%\n12", "original_text": "prior\nyear \u00a0\u00a06.2 % \u00a0\u00a09.4 % \u00a0\u00a01.7 % \u00a0\u00a00.9 % \u00a0\u00a0(8.5) % \u00a0\u00a0 \u00a0\u00a04.7 % \u00a0\u00a08.7 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.62% \u00a03.71%\nOperating expenses \u00a02.73% \u00a02.24%\n12", "page_label": "12", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cf471dd7-da88-4f99-af33-033da7024c63", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af84c62ccb0768ba0394a325d7dd25b57984c40f156c66a1199f309e0ebfe5ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d33315da-1936-4a5b-8462-3ddd7374d822", "node_type": "1", "metadata": {"window": "Turkey highly\ninflationary impact \u00a0\u00a04,855 \u00a0\u00a0\u2014 \u00a0\u00a04,855 \u00a0\u00a04,455 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a04,455 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a054,270 \u00a0\u00a0\u2014 \u00a0\u00a054,270 \u00a0\u00a054,270 \u00a0\u00a012,676 \u00a0\u00a0\u2014 \u00a0\u00a041,594 \u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(140,114) \u00a0\u00a0140,114 \u00a0\u00a0140,114 \u00a0\u00a032,727 \u00a0\u00a0(984) \u00a0\u00a0106,403 \u00a0\u00a00.52 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,813) \u00a0\u00a015,813 \u00a0\u00a015,813 \u00a0\u00a03,693 \u00a0\u00a0\u2014 \u00a0\u00a012,120 \u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(59,113) \u00a0\u00a059,113 \u00a0\u00a059,113 \u00a0\u00a013,808 \u00a0\u00a0\u2014 \u00a0\u00a045,305 \u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(97,444) \u00a0\u00a097,444 \u00a0\u00a097,444 \u00a0\u00a022,763 \u00a0\u00a0\u2014 \u00a0\u00a074,681 \u00a0\u00a00.37 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0(0.03) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(2,182) \u00a0\u00a0(3,244) \u00a0\u00a0\u2014 \u00a0\u00a01,062 \u00a0\u00a00.01 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,354,567 \u00a0$1,422,439 \u00a0$932,128 \u00a0$875,494 \u00a0$166,342 \u00a0$6,205 \u00a0$715,357 \u00a0$3.50 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP\n% change vs.  prior\nyear \u00a0\u00a06.2 % \u00a0\u00a09.4 % \u00a0\u00a01.7 % \u00a0\u00a00.9 % \u00a0\u00a0(8.5) % \u00a0\u00a0 \u00a0\u00a04.7 % \u00a0\u00a08.7 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.62% \u00a03.71%\nOperating expenses \u00a02.73% \u00a02.24%\n12", "original_text": "Turkey highly\ninflationary impact \u00a0\u00a04,855 \u00a0\u00a0\u2014 \u00a0\u00a04,855 \u00a0\u00a04,455 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a04,455 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a054,270 \u00a0\u00a0\u2014 \u00a0\u00a054,270 \u00a0\u00a054,270 \u00a0\u00a012,676 \u00a0\u00a0\u2014 \u00a0\u00a041,594 \u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(140,114) \u00a0\u00a0140,114 \u00a0\u00a0140,114 \u00a0\u00a032,727 \u00a0\u00a0(984) \u00a0\u00a0106,403 \u00a0\u00a00.52 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,813) \u00a0\u00a015,813 \u00a0\u00a015,813 \u00a0\u00a03,693 \u00a0\u00a0\u2014 \u00a0\u00a012,120 \u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(59,113) \u00a0\u00a059,113 \u00a0\u00a059,113 \u00a0\u00a013,808 \u00a0\u00a0\u2014 \u00a0\u00a045,305 \u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(97,444) \u00a0\u00a097,444 \u00a0\u00a097,444 \u00a0\u00a022,763 \u00a0\u00a0\u2014 \u00a0\u00a074,681 \u00a0\u00a00.37 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0(0.03) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(2,182) \u00a0\u00a0(3,244) \u00a0\u00a0\u2014 \u00a0\u00a01,062 \u00a0\u00a00.01 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,354,567 \u00a0$1,422,439 \u00a0$932,128 \u00a0$875,494 \u00a0$166,342 \u00a0$6,205 \u00a0$715,357 \u00a0$3.50 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP\n% change vs. ", "page_label": "12", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7207f496d486b0acc7d43c8c738e26157b6bc71da03b6e48984283a10859c1f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ffec9053-89ae-4749-84bb-8e08ccfe98cb", "node_type": "1", "metadata": {"window": "Operating income \u00a00.88% \u00a01.47%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,235,080 \u00a0$1,454,923 \u00a0$780,157 \u00a0$728,189 \u00a0$172,944 \u00a0$(7,231) \u00a0$548,014 \u00a0$2.59 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(16,059) \u00a0\u00a0\u2014 \u00a0\u00a0(16,059) \u00a0\u00a0(16,059) \u00a0\u00a0(3,897) \u00a0\u00a0\u2014 \u00a0\u00a0(12,162) \u00a0\u00a0(0.06) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(77,952) \u00a0\u00a077,952 \u00a0\u00a077,952 \u00a0\u00a018,431 \u00a0\u00a0(1,764) \u00a0\u00a057,757 \u00a0\u00a00.27 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(52,090) \u00a0\u00a052,090 \u00a0\u00a052,090 \u00a0\u00a05,298 \u00a0\u00a0\u2014 \u00a0\u00a046,792 \u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(11,790) \u00a0\u00a011,790 \u00a0\u00a011,790 \u00a0\u00a02,797 \u00a0\u00a0\u2014 \u00a0\u00a08,993 \u00a0\u00a00.04 \u00a0\n13", "original_text": "Operating income \u00a00.88% \u00a01.47%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n"}, "hash": "d31fe8b482fdaa2e0b3cb7685f1070956cea0efc86867ff17ad95374defbd8a6", "class_name": "RelatedNodeInfo"}}, "text": "prior\nyear \u00a0\u00a06.2 % \u00a0\u00a09.4 % \u00a0\u00a01.7 % \u00a0\u00a00.9 % \u00a0\u00a0(8.5) % \u00a0\u00a0 \u00a0\u00a04.7 % \u00a0\u00a08.7 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.62% \u00a03.71%\nOperating expenses \u00a02.73% \u00a02.24%\n12", "start_char_idx": 1114, "end_char_idx": 1301, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ffec9053-89ae-4749-84bb-8e08ccfe98cb": {"__data__": {"id_": "ffec9053-89ae-4749-84bb-8e08ccfe98cb", "embedding": null, "metadata": {"window": "Operating income \u00a00.88% \u00a01.47%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,235,080 \u00a0$1,454,923 \u00a0$780,157 \u00a0$728,189 \u00a0$172,944 \u00a0$(7,231) \u00a0$548,014 \u00a0$2.59 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(16,059) \u00a0\u00a0\u2014 \u00a0\u00a0(16,059) \u00a0\u00a0(16,059) \u00a0\u00a0(3,897) \u00a0\u00a0\u2014 \u00a0\u00a0(12,162) \u00a0\u00a0(0.06) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(77,952) \u00a0\u00a077,952 \u00a0\u00a077,952 \u00a0\u00a018,431 \u00a0\u00a0(1,764) \u00a0\u00a057,757 \u00a0\u00a00.27 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(52,090) \u00a0\u00a052,090 \u00a0\u00a052,090 \u00a0\u00a05,298 \u00a0\u00a0\u2014 \u00a0\u00a046,792 \u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(11,790) \u00a0\u00a011,790 \u00a0\u00a011,790 \u00a0\u00a02,797 \u00a0\u00a0\u2014 \u00a0\u00a08,993 \u00a0\u00a00.04 \u00a0\n13", "original_text": "Operating income \u00a00.88% \u00a01.47%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n", "page_label": "13", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b636a6e5-91b7-4a50-a4de-05c19f686131", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "252e2c0895dac4371510156367af02cd1a94fd650555a27dc279e3cf18196192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c81751d0-3240-4f8c-ad5c-1e9d3a917823", "node_type": "1", "metadata": {"window": "Turkey highly\ninflationary impact \u00a0\u00a04,855 \u00a0\u00a0\u2014 \u00a0\u00a04,855 \u00a0\u00a04,455 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a04,455 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a054,270 \u00a0\u00a0\u2014 \u00a0\u00a054,270 \u00a0\u00a054,270 \u00a0\u00a012,676 \u00a0\u00a0\u2014 \u00a0\u00a041,594 \u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(140,114) \u00a0\u00a0140,114 \u00a0\u00a0140,114 \u00a0\u00a032,727 \u00a0\u00a0(984) \u00a0\u00a0106,403 \u00a0\u00a00.52 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,813) \u00a0\u00a015,813 \u00a0\u00a015,813 \u00a0\u00a03,693 \u00a0\u00a0\u2014 \u00a0\u00a012,120 \u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(59,113) \u00a0\u00a059,113 \u00a0\u00a059,113 \u00a0\u00a013,808 \u00a0\u00a0\u2014 \u00a0\u00a045,305 \u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(97,444) \u00a0\u00a097,444 \u00a0\u00a097,444 \u00a0\u00a022,763 \u00a0\u00a0\u2014 \u00a0\u00a074,681 \u00a0\u00a00.37 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0(0.03) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(2,182) \u00a0\u00a0(3,244) \u00a0\u00a0\u2014 \u00a0\u00a01,062 \u00a0\u00a00.01 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,354,567 \u00a0$1,422,439 \u00a0$932,128 \u00a0$875,494 \u00a0$166,342 \u00a0$6,205 \u00a0$715,357 \u00a0$3.50 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP\n% change vs.  prior\nyear \u00a0\u00a06.2 % \u00a0\u00a09.4 % \u00a0\u00a01.7 % \u00a0\u00a00.9 % \u00a0\u00a0(8.5) % \u00a0\u00a0 \u00a0\u00a04.7 % \u00a0\u00a08.7 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.62% \u00a03.71%\nOperating expenses \u00a02.73% \u00a02.24%\n12", "original_text": "prior\nyear \u00a0\u00a06.2 % \u00a0\u00a09.4 % \u00a0\u00a01.7 % \u00a0\u00a00.9 % \u00a0\u00a0(8.5) % \u00a0\u00a0 \u00a0\u00a04.7 % \u00a0\u00a08.7 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.62% \u00a03.71%\nOperating expenses \u00a02.73% \u00a02.24%\n12", "page_label": "12", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "36d23b342dd285d3318aeef40bc0b4292b177cbdbf6f4a5bff9d340cd539eac0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4201620-ede3-440b-a0f5-370d8338a563", "node_type": "1", "metadata": {"window": "Operating income \u00a00.88% \u00a01.47%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,235,080 \u00a0$1,454,923 \u00a0$780,157 \u00a0$728,189 \u00a0$172,944 \u00a0$(7,231) \u00a0$548,014 \u00a0$2.59 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(16,059) \u00a0\u00a0\u2014 \u00a0\u00a0(16,059) \u00a0\u00a0(16,059) \u00a0\u00a0(3,897) \u00a0\u00a0\u2014 \u00a0\u00a0(12,162) \u00a0\u00a0(0.06) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(77,952) \u00a0\u00a077,952 \u00a0\u00a077,952 \u00a0\u00a018,431 \u00a0\u00a0(1,764) \u00a0\u00a057,757 \u00a0\u00a00.27 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(52,090) \u00a0\u00a052,090 \u00a0\u00a052,090 \u00a0\u00a05,298 \u00a0\u00a0\u2014 \u00a0\u00a046,792 \u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(11,790) \u00a0\u00a011,790 \u00a0\u00a011,790 \u00a0\u00a02,797 \u00a0\u00a0\u2014 \u00a0\u00a08,993 \u00a0\u00a00.04 \u00a0\n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n"}, "hash": "8c26d520691f343657f889235208e61fd99f86fbf5b981acfb8b60b8c92b97a7", "class_name": "RelatedNodeInfo"}}, "text": "Operating income \u00a00.88% \u00a01.47%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n", "start_char_idx": 0, "end_char_idx": 261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4201620-ede3-440b-a0f5-370d8338a563": {"__data__": {"id_": "e4201620-ede3-440b-a0f5-370d8338a563", "embedding": null, "metadata": {"window": "Operating income \u00a00.88% \u00a01.47%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,235,080 \u00a0$1,454,923 \u00a0$780,157 \u00a0$728,189 \u00a0$172,944 \u00a0$(7,231) \u00a0$548,014 \u00a0$2.59 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(16,059) \u00a0\u00a0\u2014 \u00a0\u00a0(16,059) \u00a0\u00a0(16,059) \u00a0\u00a0(3,897) \u00a0\u00a0\u2014 \u00a0\u00a0(12,162) \u00a0\u00a0(0.06) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(77,952) \u00a0\u00a077,952 \u00a0\u00a077,952 \u00a0\u00a018,431 \u00a0\u00a0(1,764) \u00a0\u00a057,757 \u00a0\u00a00.27 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(52,090) \u00a0\u00a052,090 \u00a0\u00a052,090 \u00a0\u00a05,298 \u00a0\u00a0\u2014 \u00a0\u00a046,792 \u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(11,790) \u00a0\u00a011,790 \u00a0\u00a011,790 \u00a0\u00a02,797 \u00a0\u00a0\u2014 \u00a0\u00a08,993 \u00a0\u00a00.04 \u00a0\n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "13", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b636a6e5-91b7-4a50-a4de-05c19f686131", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "252e2c0895dac4371510156367af02cd1a94fd650555a27dc279e3cf18196192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ffec9053-89ae-4749-84bb-8e08ccfe98cb", "node_type": "1", "metadata": {"window": "Operating income \u00a00.88% \u00a01.47%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,235,080 \u00a0$1,454,923 \u00a0$780,157 \u00a0$728,189 \u00a0$172,944 \u00a0$(7,231) \u00a0$548,014 \u00a0$2.59 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(16,059) \u00a0\u00a0\u2014 \u00a0\u00a0(16,059) \u00a0\u00a0(16,059) \u00a0\u00a0(3,897) \u00a0\u00a0\u2014 \u00a0\u00a0(12,162) \u00a0\u00a0(0.06) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(77,952) \u00a0\u00a077,952 \u00a0\u00a077,952 \u00a0\u00a018,431 \u00a0\u00a0(1,764) \u00a0\u00a057,757 \u00a0\u00a00.27 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(52,090) \u00a0\u00a052,090 \u00a0\u00a052,090 \u00a0\u00a05,298 \u00a0\u00a0\u2014 \u00a0\u00a046,792 \u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(11,790) \u00a0\u00a011,790 \u00a0\u00a011,790 \u00a0\u00a02,797 \u00a0\u00a0\u2014 \u00a0\u00a08,993 \u00a0\u00a00.04 \u00a0\n13", "original_text": "Operating income \u00a00.88% \u00a01.47%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n", "page_label": "13", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3afbe68315ef240e06263643906e3585b448226993c5b2e0248b5fbf7c3f2eff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f5b229c-1b24-4b23-8182-15e70925eff9", "node_type": "1", "metadata": {"window": "Operating income \u00a00.88% \u00a01.47%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,235,080 \u00a0$1,454,923 \u00a0$780,157 \u00a0$728,189 \u00a0$172,944 \u00a0$(7,231) \u00a0$548,014 \u00a0$2.59 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(16,059) \u00a0\u00a0\u2014 \u00a0\u00a0(16,059) \u00a0\u00a0(16,059) \u00a0\u00a0(3,897) \u00a0\u00a0\u2014 \u00a0\u00a0(12,162) \u00a0\u00a0(0.06) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(77,952) \u00a0\u00a077,952 \u00a0\u00a077,952 \u00a0\u00a018,431 \u00a0\u00a0(1,764) \u00a0\u00a057,757 \u00a0\u00a00.27 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(52,090) \u00a0\u00a052,090 \u00a0\u00a052,090 \u00a0\u00a05,298 \u00a0\u00a0\u2014 \u00a0\u00a046,792 \u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(11,790) \u00a0\u00a011,790 \u00a0\u00a011,790 \u00a0\u00a02,797 \u00a0\u00a0\u2014 \u00a0\u00a08,993 \u00a0\u00a00.04 \u00a0\n13", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,235,080 \u00a0$1,454,923 \u00a0$780,157 \u00a0$728,189 \u00a0$172,944 \u00a0$(7,231) \u00a0$548,014 \u00a0$2.59 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(16,059) \u00a0\u00a0\u2014 \u00a0\u00a0(16,059) \u00a0\u00a0(16,059) \u00a0\u00a0(3,897) \u00a0\u00a0\u2014 \u00a0\u00a0(12,162) \u00a0\u00a0(0.06) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(77,952) \u00a0\u00a077,952 \u00a0\u00a077,952 \u00a0\u00a018,431 \u00a0\u00a0(1,764) \u00a0\u00a057,757 \u00a0\u00a00.27 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(52,090) \u00a0\u00a052,090 \u00a0\u00a052,090 \u00a0\u00a05,298 \u00a0\u00a0\u2014 \u00a0\u00a046,792 \u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(11,790) \u00a0\u00a011,790 \u00a0\u00a011,790 \u00a0\u00a02,797 \u00a0\u00a0\u2014 \u00a0\u00a08,993 \u00a0\u00a00.04 \u00a0\n13"}, "hash": "5e1c36bb698985f8f987c9dcf79b952ceafec00e659e81459c4df97102aeea95", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "start_char_idx": 261, "end_char_idx": 438, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f5b229c-1b24-4b23-8182-15e70925eff9": {"__data__": {"id_": "2f5b229c-1b24-4b23-8182-15e70925eff9", "embedding": null, "metadata": {"window": "Operating income \u00a00.88% \u00a01.47%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,235,080 \u00a0$1,454,923 \u00a0$780,157 \u00a0$728,189 \u00a0$172,944 \u00a0$(7,231) \u00a0$548,014 \u00a0$2.59 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(16,059) \u00a0\u00a0\u2014 \u00a0\u00a0(16,059) \u00a0\u00a0(16,059) \u00a0\u00a0(3,897) \u00a0\u00a0\u2014 \u00a0\u00a0(12,162) \u00a0\u00a0(0.06) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(77,952) \u00a0\u00a077,952 \u00a0\u00a077,952 \u00a0\u00a018,431 \u00a0\u00a0(1,764) \u00a0\u00a057,757 \u00a0\u00a00.27 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(52,090) \u00a0\u00a052,090 \u00a0\u00a052,090 \u00a0\u00a05,298 \u00a0\u00a0\u2014 \u00a0\u00a046,792 \u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(11,790) \u00a0\u00a011,790 \u00a0\u00a011,790 \u00a0\u00a02,797 \u00a0\u00a0\u2014 \u00a0\u00a08,993 \u00a0\u00a00.04 \u00a0\n13", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,235,080 \u00a0$1,454,923 \u00a0$780,157 \u00a0$728,189 \u00a0$172,944 \u00a0$(7,231) \u00a0$548,014 \u00a0$2.59 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(16,059) \u00a0\u00a0\u2014 \u00a0\u00a0(16,059) \u00a0\u00a0(16,059) \u00a0\u00a0(3,897) \u00a0\u00a0\u2014 \u00a0\u00a0(12,162) \u00a0\u00a0(0.06) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(77,952) \u00a0\u00a077,952 \u00a0\u00a077,952 \u00a0\u00a018,431 \u00a0\u00a0(1,764) \u00a0\u00a057,757 \u00a0\u00a00.27 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(52,090) \u00a0\u00a052,090 \u00a0\u00a052,090 \u00a0\u00a05,298 \u00a0\u00a0\u2014 \u00a0\u00a046,792 \u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(11,790) \u00a0\u00a011,790 \u00a0\u00a011,790 \u00a0\u00a02,797 \u00a0\u00a0\u2014 \u00a0\u00a08,993 \u00a0\u00a00.04 \u00a0\n13", "page_label": "13", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b636a6e5-91b7-4a50-a4de-05c19f686131", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "252e2c0895dac4371510156367af02cd1a94fd650555a27dc279e3cf18196192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4201620-ede3-440b-a0f5-370d8338a563", "node_type": "1", "metadata": {"window": "Operating income \u00a00.88% \u00a01.47%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,235,080 \u00a0$1,454,923 \u00a0$780,157 \u00a0$728,189 \u00a0$172,944 \u00a0$(7,231) \u00a0$548,014 \u00a0$2.59 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(16,059) \u00a0\u00a0\u2014 \u00a0\u00a0(16,059) \u00a0\u00a0(16,059) \u00a0\u00a0(3,897) \u00a0\u00a0\u2014 \u00a0\u00a0(12,162) \u00a0\u00a0(0.06) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(77,952) \u00a0\u00a077,952 \u00a0\u00a077,952 \u00a0\u00a018,431 \u00a0\u00a0(1,764) \u00a0\u00a057,757 \u00a0\u00a00.27 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(52,090) \u00a0\u00a052,090 \u00a0\u00a052,090 \u00a0\u00a05,298 \u00a0\u00a0\u2014 \u00a0\u00a046,792 \u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(11,790) \u00a0\u00a011,790 \u00a0\u00a011,790 \u00a0\u00a02,797 \u00a0\u00a0\u2014 \u00a0\u00a08,993 \u00a0\u00a00.04 \u00a0\n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "13", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b037c9f2e41783c87545d949b2a901ef7b7dd8d12fef00a398450cac513aab2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4dd5f83-63f5-41b8-885c-a297b9053d44", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(12,515) \u00a0\u00a012,515 \u00a0\u00a012,515 \u00a0\u00a02,969 \u00a0\u00a0\u2014 \u00a0\u00a09,546 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(7,900) \u00a0\u00a06,840 \u00a0\u00a014,740 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,737 \u00a0\u00a0(8,329) \u00a0\u00a0\u2014 \u00a0\u00a011,066 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,217,186 \u00a0$1,300,576 \u00a0$916,610 \u00a0$867,379 \u00a0$181,886 \u00a0$(2,155) \u00a0$683,338 \u00a0$3.22\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,441,395 \u00a0$3,247,733 \u00a0$1,193,662 \u00a0$1,105,585 \u00a0$201,202 \u00a0$10,764 \u00a0$915,147 \u00a0$4.46 \u00a0\n14", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(12,515) \u00a0\u00a012,515 \u00a0\u00a012,515 \u00a0\u00a02,969 \u00a0\u00a0\u2014 \u00a0\u00a09,546 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(7,900) \u00a0\u00a06,840 \u00a0\u00a014,740 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,737 \u00a0\u00a0(8,329) \u00a0\u00a0\u2014 \u00a0\u00a011,066 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,217,186 \u00a0$1,300,576 \u00a0$916,610 \u00a0$867,379 \u00a0$181,886 \u00a0$(2,155) \u00a0$683,338 \u00a0$3.22\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net.\n"}, "hash": "4543941d75adcce6f17ff9ee9969f56e2b4eec2752761f23553b7df2e673baae", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,235,080 \u00a0$1,454,923 \u00a0$780,157 \u00a0$728,189 \u00a0$172,944 \u00a0$(7,231) \u00a0$548,014 \u00a0$2.59 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(16,059) \u00a0\u00a0\u2014 \u00a0\u00a0(16,059) \u00a0\u00a0(16,059) \u00a0\u00a0(3,897) \u00a0\u00a0\u2014 \u00a0\u00a0(12,162) \u00a0\u00a0(0.06) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(77,952) \u00a0\u00a077,952 \u00a0\u00a077,952 \u00a0\u00a018,431 \u00a0\u00a0(1,764) \u00a0\u00a057,757 \u00a0\u00a00.27 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(52,090) \u00a0\u00a052,090 \u00a0\u00a052,090 \u00a0\u00a05,298 \u00a0\u00a0\u2014 \u00a0\u00a046,792 \u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(11,790) \u00a0\u00a011,790 \u00a0\u00a011,790 \u00a0\u00a02,797 \u00a0\u00a0\u2014 \u00a0\u00a08,993 \u00a0\u00a00.04 \u00a0\n13", "start_char_idx": 438, "end_char_idx": 1575, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4dd5f83-63f5-41b8-885c-a297b9053d44": {"__data__": {"id_": "c4dd5f83-63f5-41b8-885c-a297b9053d44", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(12,515) \u00a0\u00a012,515 \u00a0\u00a012,515 \u00a0\u00a02,969 \u00a0\u00a0\u2014 \u00a0\u00a09,546 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(7,900) \u00a0\u00a06,840 \u00a0\u00a014,740 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,737 \u00a0\u00a0(8,329) \u00a0\u00a0\u2014 \u00a0\u00a011,066 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,217,186 \u00a0$1,300,576 \u00a0$916,610 \u00a0$867,379 \u00a0$181,886 \u00a0$(2,155) \u00a0$683,338 \u00a0$3.22\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,441,395 \u00a0$3,247,733 \u00a0$1,193,662 \u00a0$1,105,585 \u00a0$201,202 \u00a0$10,764 \u00a0$915,147 \u00a0$4.46 \u00a0\n14", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(12,515) \u00a0\u00a012,515 \u00a0\u00a012,515 \u00a0\u00a02,969 \u00a0\u00a0\u2014 \u00a0\u00a09,546 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(7,900) \u00a0\u00a06,840 \u00a0\u00a014,740 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,737 \u00a0\u00a0(8,329) \u00a0\u00a0\u2014 \u00a0\u00a011,066 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,217,186 \u00a0$1,300,576 \u00a0$916,610 \u00a0$867,379 \u00a0$181,886 \u00a0$(2,155) \u00a0$683,338 \u00a0$3.22\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net.\n", "page_label": "14", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8fd675f3-8941-48c4-9952-f93521529497", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dea946daff59d794eb171e159d368d5e8911cf7f435cdf90c202461230bef25b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f5b229c-1b24-4b23-8182-15e70925eff9", "node_type": "1", "metadata": {"window": "Operating income \u00a00.88% \u00a01.47%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,235,080 \u00a0$1,454,923 \u00a0$780,157 \u00a0$728,189 \u00a0$172,944 \u00a0$(7,231) \u00a0$548,014 \u00a0$2.59 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(16,059) \u00a0\u00a0\u2014 \u00a0\u00a0(16,059) \u00a0\u00a0(16,059) \u00a0\u00a0(3,897) \u00a0\u00a0\u2014 \u00a0\u00a0(12,162) \u00a0\u00a0(0.06) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(77,952) \u00a0\u00a077,952 \u00a0\u00a077,952 \u00a0\u00a018,431 \u00a0\u00a0(1,764) \u00a0\u00a057,757 \u00a0\u00a00.27 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(52,090) \u00a0\u00a052,090 \u00a0\u00a052,090 \u00a0\u00a05,298 \u00a0\u00a0\u2014 \u00a0\u00a046,792 \u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(11,790) \u00a0\u00a011,790 \u00a0\u00a011,790 \u00a0\u00a02,797 \u00a0\u00a0\u2014 \u00a0\u00a08,993 \u00a0\u00a00.04 \u00a0\n13", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,235,080 \u00a0$1,454,923 \u00a0$780,157 \u00a0$728,189 \u00a0$172,944 \u00a0$(7,231) \u00a0$548,014 \u00a0$2.59 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(16,059) \u00a0\u00a0\u2014 \u00a0\u00a0(16,059) \u00a0\u00a0(16,059) \u00a0\u00a0(3,897) \u00a0\u00a0\u2014 \u00a0\u00a0(12,162) \u00a0\u00a0(0.06) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(77,952) \u00a0\u00a077,952 \u00a0\u00a077,952 \u00a0\u00a018,431 \u00a0\u00a0(1,764) \u00a0\u00a057,757 \u00a0\u00a00.27 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(52,090) \u00a0\u00a052,090 \u00a0\u00a052,090 \u00a0\u00a05,298 \u00a0\u00a0\u2014 \u00a0\u00a046,792 \u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(11,790) \u00a0\u00a011,790 \u00a0\u00a011,790 \u00a0\u00a02,797 \u00a0\u00a0\u2014 \u00a0\u00a08,993 \u00a0\u00a00.04 \u00a0\n13", "page_label": "13", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63cf070d8c54d04bfd9cd2bbad0eb9ff29cc9dfd7d8d211750a1b769981e9305", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6bda1993-ed92-46d4-ae44-f7e48089d5ed", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(12,515) \u00a0\u00a012,515 \u00a0\u00a012,515 \u00a0\u00a02,969 \u00a0\u00a0\u2014 \u00a0\u00a09,546 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(7,900) \u00a0\u00a06,840 \u00a0\u00a014,740 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,737 \u00a0\u00a0(8,329) \u00a0\u00a0\u2014 \u00a0\u00a011,066 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,217,186 \u00a0$1,300,576 \u00a0$916,610 \u00a0$867,379 \u00a0$181,886 \u00a0$(2,155) \u00a0$683,338 \u00a0$3.22\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,441,395 \u00a0$3,247,733 \u00a0$1,193,662 \u00a0$1,105,585 \u00a0$201,202 \u00a0$10,764 \u00a0$915,147 \u00a0$4.46 \u00a0\n14", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n"}, "hash": "f7e684722ac58d8e96edef1b60549264d82cefc8a21913647e946173ed58e39a", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(12,515) \u00a0\u00a012,515 \u00a0\u00a012,515 \u00a0\u00a02,969 \u00a0\u00a0\u2014 \u00a0\u00a09,546 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(7,900) \u00a0\u00a06,840 \u00a0\u00a014,740 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,737 \u00a0\u00a0(8,329) \u00a0\u00a0\u2014 \u00a0\u00a011,066 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,217,186 \u00a0$1,300,576 \u00a0$916,610 \u00a0$867,379 \u00a0$181,886 \u00a0$(2,155) \u00a0$683,338 \u00a0$3.22\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net.\n", "start_char_idx": 0, "end_char_idx": 813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6bda1993-ed92-46d4-ae44-f7e48089d5ed": {"__data__": {"id_": "6bda1993-ed92-46d4-ae44-f7e48089d5ed", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(12,515) \u00a0\u00a012,515 \u00a0\u00a012,515 \u00a0\u00a02,969 \u00a0\u00a0\u2014 \u00a0\u00a09,546 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(7,900) \u00a0\u00a06,840 \u00a0\u00a014,740 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,737 \u00a0\u00a0(8,329) \u00a0\u00a0\u2014 \u00a0\u00a011,066 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,217,186 \u00a0$1,300,576 \u00a0$916,610 \u00a0$867,379 \u00a0$181,886 \u00a0$(2,155) \u00a0$683,338 \u00a0$3.22\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,441,395 \u00a0$3,247,733 \u00a0$1,193,662 \u00a0$1,105,585 \u00a0$201,202 \u00a0$10,764 \u00a0$915,147 \u00a0$4.46 \u00a0\n14", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "14", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8fd675f3-8941-48c4-9952-f93521529497", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dea946daff59d794eb171e159d368d5e8911cf7f435cdf90c202461230bef25b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4dd5f83-63f5-41b8-885c-a297b9053d44", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(12,515) \u00a0\u00a012,515 \u00a0\u00a012,515 \u00a0\u00a02,969 \u00a0\u00a0\u2014 \u00a0\u00a09,546 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(7,900) \u00a0\u00a06,840 \u00a0\u00a014,740 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,737 \u00a0\u00a0(8,329) \u00a0\u00a0\u2014 \u00a0\u00a011,066 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,217,186 \u00a0$1,300,576 \u00a0$916,610 \u00a0$867,379 \u00a0$181,886 \u00a0$(2,155) \u00a0$683,338 \u00a0$3.22\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,441,395 \u00a0$3,247,733 \u00a0$1,193,662 \u00a0$1,105,585 \u00a0$201,202 \u00a0$10,764 \u00a0$915,147 \u00a0$4.46 \u00a0\n14", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(12,515) \u00a0\u00a012,515 \u00a0\u00a012,515 \u00a0\u00a02,969 \u00a0\u00a0\u2014 \u00a0\u00a09,546 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(7,900) \u00a0\u00a06,840 \u00a0\u00a014,740 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,737 \u00a0\u00a0(8,329) \u00a0\u00a0\u2014 \u00a0\u00a011,066 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,217,186 \u00a0$1,300,576 \u00a0$916,610 \u00a0$867,379 \u00a0$181,886 \u00a0$(2,155) \u00a0$683,338 \u00a0$3.22\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net.\n", "page_label": "14", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f9aa16d815c5058a29e6622a459b371ac1a9df5b6c28e32c37e03f98c67d446", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2c538db-35f4-4ca7-8999-7a047397e60c", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(12,515) \u00a0\u00a012,515 \u00a0\u00a012,515 \u00a0\u00a02,969 \u00a0\u00a0\u2014 \u00a0\u00a09,546 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(7,900) \u00a0\u00a06,840 \u00a0\u00a014,740 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,737 \u00a0\u00a0(8,329) \u00a0\u00a0\u2014 \u00a0\u00a011,066 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,217,186 \u00a0$1,300,576 \u00a0$916,610 \u00a0$867,379 \u00a0$181,886 \u00a0$(2,155) \u00a0$683,338 \u00a0$3.22\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,441,395 \u00a0$3,247,733 \u00a0$1,193,662 \u00a0$1,105,585 \u00a0$201,202 \u00a0$10,764 \u00a0$915,147 \u00a0$4.46 \u00a0\n14", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,441,395 \u00a0$3,247,733 \u00a0$1,193,662 \u00a0$1,105,585 \u00a0$201,202 \u00a0$10,764 \u00a0$915,147 \u00a0$4.46 \u00a0\n14"}, "hash": "c84b1c67eade05a333264fa71a08b91672edf513d9deff95deb3603b9eb779d2", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "start_char_idx": 813, "end_char_idx": 990, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2c538db-35f4-4ca7-8999-7a047397e60c": {"__data__": {"id_": "f2c538db-35f4-4ca7-8999-7a047397e60c", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(12,515) \u00a0\u00a012,515 \u00a0\u00a012,515 \u00a0\u00a02,969 \u00a0\u00a0\u2014 \u00a0\u00a09,546 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(7,900) \u00a0\u00a06,840 \u00a0\u00a014,740 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,737 \u00a0\u00a0(8,329) \u00a0\u00a0\u2014 \u00a0\u00a011,066 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,217,186 \u00a0$1,300,576 \u00a0$916,610 \u00a0$867,379 \u00a0$181,886 \u00a0$(2,155) \u00a0$683,338 \u00a0$3.22\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,441,395 \u00a0$3,247,733 \u00a0$1,193,662 \u00a0$1,105,585 \u00a0$201,202 \u00a0$10,764 \u00a0$915,147 \u00a0$4.46 \u00a0\n14", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,441,395 \u00a0$3,247,733 \u00a0$1,193,662 \u00a0$1,105,585 \u00a0$201,202 \u00a0$10,764 \u00a0$915,147 \u00a0$4.46 \u00a0\n14", "page_label": "14", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8fd675f3-8941-48c4-9952-f93521529497", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dea946daff59d794eb171e159d368d5e8911cf7f435cdf90c202461230bef25b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6bda1993-ed92-46d4-ae44-f7e48089d5ed", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(12,515) \u00a0\u00a012,515 \u00a0\u00a012,515 \u00a0\u00a02,969 \u00a0\u00a0\u2014 \u00a0\u00a09,546 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(7,900) \u00a0\u00a06,840 \u00a0\u00a014,740 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,737 \u00a0\u00a0(8,329) \u00a0\u00a0\u2014 \u00a0\u00a011,066 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,217,186 \u00a0$1,300,576 \u00a0$916,610 \u00a0$867,379 \u00a0$181,886 \u00a0$(2,155) \u00a0$683,338 \u00a0$3.22\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,441,395 \u00a0$3,247,733 \u00a0$1,193,662 \u00a0$1,105,585 \u00a0$201,202 \u00a0$10,764 \u00a0$915,147 \u00a0$4.46 \u00a0\n14", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "14", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c9762bd4255a1bb00c8a7da81f9083e2c5fd23a34fa0dc0301681cf9451b9c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "514a09e2-e25a-4c16-a035-e1d20f5f9c8a", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0(49,899) \u00a0\u00a0\u2014 \u00a0\u00a0(49,899) \u00a0\u00a0(49,899) \u00a0\u00a0(11,657) \u00a0\u00a0\u2014 \u00a0\u00a0(38,242) \u00a0\u00a0(0.19) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a08,439 \u00a0\u00a0\u2014 \u00a0\u00a08,439 \u00a0\u00a08,441 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a08,441 \u00a0\u00a00.04 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a079,320 \u00a0\u00a0\u2014 \u00a0\u00a079,320 \u00a0\u00a079,320 \u00a0\u00a018,529 \u00a0\u00a0\u2014 \u00a0\u00a060,791 \u00a0\u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(211,992) \u00a0\u00a0211,992 \u00a0\u00a0211,992 \u00a0\u00a049,522 \u00a0\u00a0(2,142) \u00a0\u00a0160,328 \u00a0\u00a00.78 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(28,519) \u00a0\u00a028,519 \u00a0\u00a028,519 \u00a0\u00a06,662 \u00a0\u00a0\u2014 \u00a0\u00a021,857 \u00a0\u00a00.11 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(80,109) \u00a0\u00a080,109 \u00a0\u00a080,109 \u00a0\u00a018,714 \u00a0\u00a0\u2014 \u00a0\u00a061,395 \u00a0\u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(113,684) \u00a0\u00a0113,684 \u00a0\u00a0113,684 \u00a0\u00a026,557 \u00a0\u00a0\u2014 \u00a0\u00a087,127 \u00a0\u00a00.42 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0(0.03) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-\ncustomer note\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(1,148) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(1,148) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(6,639) \u00a0\u00a0(11,608) \u00a0\u00a0\u2014 \u00a0\u00a04,969 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,479,255 \u00a0$2,813,429 \u00a0$1,665,826 \u00a0$1,564,301 \u00a0$297,921 \u00a0$8,622 \u00a0$1,275,002 \u00a0$6.21 2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n15", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0(49,899) \u00a0\u00a0\u2014 \u00a0\u00a0(49,899) \u00a0\u00a0(49,899) \u00a0\u00a0(11,657) \u00a0\u00a0\u2014 \u00a0\u00a0(38,242) \u00a0\u00a0(0.19) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a08,439 \u00a0\u00a0\u2014 \u00a0\u00a08,439 \u00a0\u00a08,441 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a08,441 \u00a0\u00a00.04 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a079,320 \u00a0\u00a0\u2014 \u00a0\u00a079,320 \u00a0\u00a079,320 \u00a0\u00a018,529 \u00a0\u00a0\u2014 \u00a0\u00a060,791 \u00a0\u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(211,992) \u00a0\u00a0211,992 \u00a0\u00a0211,992 \u00a0\u00a049,522 \u00a0\u00a0(2,142) \u00a0\u00a0160,328 \u00a0\u00a00.78 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(28,519) \u00a0\u00a028,519 \u00a0\u00a028,519 \u00a0\u00a06,662 \u00a0\u00a0\u2014 \u00a0\u00a021,857 \u00a0\u00a00.11 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(80,109) \u00a0\u00a080,109 \u00a0\u00a080,109 \u00a0\u00a018,714 \u00a0\u00a0\u2014 \u00a0\u00a061,395 \u00a0\u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(113,684) \u00a0\u00a0113,684 \u00a0\u00a0113,684 \u00a0\u00a026,557 \u00a0\u00a0\u2014 \u00a0\u00a087,127 \u00a0\u00a00.42 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0(0.03) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-\ncustomer note\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(1,148) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(1,148) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(6,639) \u00a0\u00a0(11,608) \u00a0\u00a0\u2014 \u00a0\u00a04,969 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,479,255 \u00a0$2,813,429 \u00a0$1,665,826 \u00a0$1,564,301 \u00a0$297,921 \u00a0$8,622 \u00a0$1,275,002 \u00a0$6.21 2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n15"}, "hash": "af96b4bfd2004a2e15953ff40bd0842354c508c11db5b9bfae4aab9d2dc6a20b", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,441,395 \u00a0$3,247,733 \u00a0$1,193,662 \u00a0$1,105,585 \u00a0$201,202 \u00a0$10,764 \u00a0$915,147 \u00a0$4.46 \u00a0\n14", "start_char_idx": 990, "end_char_idx": 1467, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "514a09e2-e25a-4c16-a035-e1d20f5f9c8a": {"__data__": {"id_": "514a09e2-e25a-4c16-a035-e1d20f5f9c8a", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0(49,899) \u00a0\u00a0\u2014 \u00a0\u00a0(49,899) \u00a0\u00a0(49,899) \u00a0\u00a0(11,657) \u00a0\u00a0\u2014 \u00a0\u00a0(38,242) \u00a0\u00a0(0.19) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a08,439 \u00a0\u00a0\u2014 \u00a0\u00a08,439 \u00a0\u00a08,441 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a08,441 \u00a0\u00a00.04 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a079,320 \u00a0\u00a0\u2014 \u00a0\u00a079,320 \u00a0\u00a079,320 \u00a0\u00a018,529 \u00a0\u00a0\u2014 \u00a0\u00a060,791 \u00a0\u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(211,992) \u00a0\u00a0211,992 \u00a0\u00a0211,992 \u00a0\u00a049,522 \u00a0\u00a0(2,142) \u00a0\u00a0160,328 \u00a0\u00a00.78 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(28,519) \u00a0\u00a028,519 \u00a0\u00a028,519 \u00a0\u00a06,662 \u00a0\u00a0\u2014 \u00a0\u00a021,857 \u00a0\u00a00.11 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(80,109) \u00a0\u00a080,109 \u00a0\u00a080,109 \u00a0\u00a018,714 \u00a0\u00a0\u2014 \u00a0\u00a061,395 \u00a0\u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(113,684) \u00a0\u00a0113,684 \u00a0\u00a0113,684 \u00a0\u00a026,557 \u00a0\u00a0\u2014 \u00a0\u00a087,127 \u00a0\u00a00.42 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0(0.03) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-\ncustomer note\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(1,148) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(1,148) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(6,639) \u00a0\u00a0(11,608) \u00a0\u00a0\u2014 \u00a0\u00a04,969 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,479,255 \u00a0$2,813,429 \u00a0$1,665,826 \u00a0$1,564,301 \u00a0$297,921 \u00a0$8,622 \u00a0$1,275,002 \u00a0$6.21 2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n15", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0(49,899) \u00a0\u00a0\u2014 \u00a0\u00a0(49,899) \u00a0\u00a0(49,899) \u00a0\u00a0(11,657) \u00a0\u00a0\u2014 \u00a0\u00a0(38,242) \u00a0\u00a0(0.19) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a08,439 \u00a0\u00a0\u2014 \u00a0\u00a08,439 \u00a0\u00a08,441 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a08,441 \u00a0\u00a00.04 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a079,320 \u00a0\u00a0\u2014 \u00a0\u00a079,320 \u00a0\u00a079,320 \u00a0\u00a018,529 \u00a0\u00a0\u2014 \u00a0\u00a060,791 \u00a0\u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(211,992) \u00a0\u00a0211,992 \u00a0\u00a0211,992 \u00a0\u00a049,522 \u00a0\u00a0(2,142) \u00a0\u00a0160,328 \u00a0\u00a00.78 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(28,519) \u00a0\u00a028,519 \u00a0\u00a028,519 \u00a0\u00a06,662 \u00a0\u00a0\u2014 \u00a0\u00a021,857 \u00a0\u00a00.11 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(80,109) \u00a0\u00a080,109 \u00a0\u00a080,109 \u00a0\u00a018,714 \u00a0\u00a0\u2014 \u00a0\u00a061,395 \u00a0\u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(113,684) \u00a0\u00a0113,684 \u00a0\u00a0113,684 \u00a0\u00a026,557 \u00a0\u00a0\u2014 \u00a0\u00a087,127 \u00a0\u00a00.42 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0(0.03) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-\ncustomer note\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(1,148) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(1,148) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(6,639) \u00a0\u00a0(11,608) \u00a0\u00a0\u2014 \u00a0\u00a04,969 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,479,255 \u00a0$2,813,429 \u00a0$1,665,826 \u00a0$1,564,301 \u00a0$297,921 \u00a0$8,622 \u00a0$1,275,002 \u00a0$6.21 2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n15", "page_label": "15", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48d70c4d-35c4-4c7e-87a8-e96b3b10a00d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "424103f988e773120c3b812b2c23915b03856c9732f4d8b3bb83914b77158da6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2c538db-35f4-4ca7-8999-7a047397e60c", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(12,515) \u00a0\u00a012,515 \u00a0\u00a012,515 \u00a0\u00a02,969 \u00a0\u00a0\u2014 \u00a0\u00a09,546 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(7,900) \u00a0\u00a06,840 \u00a0\u00a014,740 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,737 \u00a0\u00a0(8,329) \u00a0\u00a0\u2014 \u00a0\u00a011,066 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,217,186 \u00a0$1,300,576 \u00a0$916,610 \u00a0$867,379 \u00a0$181,886 \u00a0$(2,155) \u00a0$683,338 \u00a0$3.22\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,441,395 \u00a0$3,247,733 \u00a0$1,193,662 \u00a0$1,105,585 \u00a0$201,202 \u00a0$10,764 \u00a0$915,147 \u00a0$4.46 \u00a0\n14", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,441,395 \u00a0$3,247,733 \u00a0$1,193,662 \u00a0$1,105,585 \u00a0$201,202 \u00a0$10,764 \u00a0$915,147 \u00a0$4.46 \u00a0\n14", "page_label": "14", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22e9e030014010babeb4ad9b802cd775905b52216275f4418d3e67ca6071e0ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d342622-e2a9-471c-bf4b-697b73edcf49", "node_type": "1", "metadata": {"window": "Adjusted Non-GAAP\n% change vs.  prior\nyear \u00a0\u00a05.8 % \u00a0\u00a09.6 % \u00a0\u00a0\u2014 % \u00a0\u00a00.1 % \u00a0\u00a0(9.7) % \u00a0 \u00a0\u00a03.8 % \u00a0\u00a06.9 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n________________________________________ \n 1 Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net. \n  2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "original_text": "Adjusted Non-GAAP\n% change vs. "}, "hash": "2c7c0d2975cd0e032ffc93422df2698d67e268046a951055320828c13afc9767", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0(49,899) \u00a0\u00a0\u2014 \u00a0\u00a0(49,899) \u00a0\u00a0(49,899) \u00a0\u00a0(11,657) \u00a0\u00a0\u2014 \u00a0\u00a0(38,242) \u00a0\u00a0(0.19) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a08,439 \u00a0\u00a0\u2014 \u00a0\u00a08,439 \u00a0\u00a08,441 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a08,441 \u00a0\u00a00.04 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a079,320 \u00a0\u00a0\u2014 \u00a0\u00a079,320 \u00a0\u00a079,320 \u00a0\u00a018,529 \u00a0\u00a0\u2014 \u00a0\u00a060,791 \u00a0\u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(211,992) \u00a0\u00a0211,992 \u00a0\u00a0211,992 \u00a0\u00a049,522 \u00a0\u00a0(2,142) \u00a0\u00a0160,328 \u00a0\u00a00.78 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(28,519) \u00a0\u00a028,519 \u00a0\u00a028,519 \u00a0\u00a06,662 \u00a0\u00a0\u2014 \u00a0\u00a021,857 \u00a0\u00a00.11 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(80,109) \u00a0\u00a080,109 \u00a0\u00a080,109 \u00a0\u00a018,714 \u00a0\u00a0\u2014 \u00a0\u00a061,395 \u00a0\u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(113,684) \u00a0\u00a0113,684 \u00a0\u00a0113,684 \u00a0\u00a026,557 \u00a0\u00a0\u2014 \u00a0\u00a087,127 \u00a0\u00a00.42 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0(0.03) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-\ncustomer note\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(1,148) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(1,148) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(6,639) \u00a0\u00a0(11,608) \u00a0\u00a0\u2014 \u00a0\u00a04,969 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,479,255 \u00a0$2,813,429 \u00a0$1,665,826 \u00a0$1,564,301 \u00a0$297,921 \u00a0$8,622 \u00a0$1,275,002 \u00a0$6.21 2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n15", "start_char_idx": 0, "end_char_idx": 1392, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d342622-e2a9-471c-bf4b-697b73edcf49": {"__data__": {"id_": "4d342622-e2a9-471c-bf4b-697b73edcf49", "embedding": null, "metadata": {"window": "Adjusted Non-GAAP\n% change vs.  prior\nyear \u00a0\u00a05.8 % \u00a0\u00a09.6 % \u00a0\u00a0\u2014 % \u00a0\u00a00.1 % \u00a0\u00a0(9.7) % \u00a0 \u00a0\u00a03.8 % \u00a0\u00a06.9 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n________________________________________ \n 1 Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net. \n  2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "original_text": "Adjusted Non-GAAP\n% change vs. ", "page_label": "16", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16633cac-2032-419d-bcd9-3517fad60db4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "981db0c44e811e4068f46b4756ae4c967755568832b26a466246cc7aba5b631b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "514a09e2-e25a-4c16-a035-e1d20f5f9c8a", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0(49,899) \u00a0\u00a0\u2014 \u00a0\u00a0(49,899) \u00a0\u00a0(49,899) \u00a0\u00a0(11,657) \u00a0\u00a0\u2014 \u00a0\u00a0(38,242) \u00a0\u00a0(0.19) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a08,439 \u00a0\u00a0\u2014 \u00a0\u00a08,439 \u00a0\u00a08,441 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a08,441 \u00a0\u00a00.04 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a079,320 \u00a0\u00a0\u2014 \u00a0\u00a079,320 \u00a0\u00a079,320 \u00a0\u00a018,529 \u00a0\u00a0\u2014 \u00a0\u00a060,791 \u00a0\u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(211,992) \u00a0\u00a0211,992 \u00a0\u00a0211,992 \u00a0\u00a049,522 \u00a0\u00a0(2,142) \u00a0\u00a0160,328 \u00a0\u00a00.78 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(28,519) \u00a0\u00a028,519 \u00a0\u00a028,519 \u00a0\u00a06,662 \u00a0\u00a0\u2014 \u00a0\u00a021,857 \u00a0\u00a00.11 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(80,109) \u00a0\u00a080,109 \u00a0\u00a080,109 \u00a0\u00a018,714 \u00a0\u00a0\u2014 \u00a0\u00a061,395 \u00a0\u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(113,684) \u00a0\u00a0113,684 \u00a0\u00a0113,684 \u00a0\u00a026,557 \u00a0\u00a0\u2014 \u00a0\u00a087,127 \u00a0\u00a00.42 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0(0.03) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-\ncustomer note\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(1,148) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(1,148) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(6,639) \u00a0\u00a0(11,608) \u00a0\u00a0\u2014 \u00a0\u00a04,969 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,479,255 \u00a0$2,813,429 \u00a0$1,665,826 \u00a0$1,564,301 \u00a0$297,921 \u00a0$8,622 \u00a0$1,275,002 \u00a0$6.21 2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n15", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0(49,899) \u00a0\u00a0\u2014 \u00a0\u00a0(49,899) \u00a0\u00a0(49,899) \u00a0\u00a0(11,657) \u00a0\u00a0\u2014 \u00a0\u00a0(38,242) \u00a0\u00a0(0.19) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a08,439 \u00a0\u00a0\u2014 \u00a0\u00a08,439 \u00a0\u00a08,441 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a08,441 \u00a0\u00a00.04 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a079,320 \u00a0\u00a0\u2014 \u00a0\u00a079,320 \u00a0\u00a079,320 \u00a0\u00a018,529 \u00a0\u00a0\u2014 \u00a0\u00a060,791 \u00a0\u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(211,992) \u00a0\u00a0211,992 \u00a0\u00a0211,992 \u00a0\u00a049,522 \u00a0\u00a0(2,142) \u00a0\u00a0160,328 \u00a0\u00a00.78 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(28,519) \u00a0\u00a028,519 \u00a0\u00a028,519 \u00a0\u00a06,662 \u00a0\u00a0\u2014 \u00a0\u00a021,857 \u00a0\u00a00.11 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(80,109) \u00a0\u00a080,109 \u00a0\u00a080,109 \u00a0\u00a018,714 \u00a0\u00a0\u2014 \u00a0\u00a061,395 \u00a0\u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(113,684) \u00a0\u00a0113,684 \u00a0\u00a0113,684 \u00a0\u00a026,557 \u00a0\u00a0\u2014 \u00a0\u00a087,127 \u00a0\u00a00.42 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0(0.03) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-\ncustomer note\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(1,148) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(1,148) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(6,639) \u00a0\u00a0(11,608) \u00a0\u00a0\u2014 \u00a0\u00a04,969 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,479,255 \u00a0$2,813,429 \u00a0$1,665,826 \u00a0$1,564,301 \u00a0$297,921 \u00a0$8,622 \u00a0$1,275,002 \u00a0$6.21 2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n15", "page_label": "15", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b98560a061a0f4ee073460acf6662a89e5856c2c066b532751296f4a7cc3540", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b91fc4e4-df44-40ac-8686-2845c88e8437", "node_type": "1", "metadata": {"window": "Adjusted Non-GAAP\n% change vs.  prior\nyear \u00a0\u00a05.8 % \u00a0\u00a09.6 % \u00a0\u00a0\u2014 % \u00a0\u00a00.1 % \u00a0\u00a0(9.7) % \u00a0 \u00a0\u00a03.8 % \u00a0\u00a06.9 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n________________________________________ \n 1 Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net. \n  2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0$2,870,877 \u00a0$1,424,562 \u00a0$1,324,394 \u00a0$319,733 \u00a0$(7,542) \u00a0$997,119 \u00a0$4.71 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738) \u00a0\u00a0\u2014 \u00a0\u00a0(60,738) \u00a0\u00a0(60,738) \u00a0\u00a0(14,142) \u00a0\u00a0\u2014 \u00a0\u00a0(46,596) \u00a0\u00a0(0.22) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(157,458) \u00a0\u00a0157,458 \u00a0\u00a0157,458 \u00a0\u00a036,661 \u00a0\u00a0(3,554) \u00a0\u00a0117,243 \u00a0\u00a00.55 \u00a0\n16", "original_text": "prior\nyear \u00a0\u00a05.8 % \u00a0\u00a09.6 % \u00a0\u00a0\u2014 % \u00a0\u00a00.1 % \u00a0\u00a0(9.7) % \u00a0 \u00a0\u00a03.8 % \u00a0\u00a06.9 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n________________________________________ \n 1 Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net. \n "}, "hash": "66876f396e4b21841b1c5c2ac8820b6c8aebc4c2a3850d24010c21522687131b", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Non-GAAP\n% change vs. ", "start_char_idx": 0, "end_char_idx": 31, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b91fc4e4-df44-40ac-8686-2845c88e8437": {"__data__": {"id_": "b91fc4e4-df44-40ac-8686-2845c88e8437", "embedding": null, "metadata": {"window": "Adjusted Non-GAAP\n% change vs.  prior\nyear \u00a0\u00a05.8 % \u00a0\u00a09.6 % \u00a0\u00a0\u2014 % \u00a0\u00a00.1 % \u00a0\u00a0(9.7) % \u00a0 \u00a0\u00a03.8 % \u00a0\u00a06.9 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n________________________________________ \n 1 Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net. \n  2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0$2,870,877 \u00a0$1,424,562 \u00a0$1,324,394 \u00a0$319,733 \u00a0$(7,542) \u00a0$997,119 \u00a0$4.71 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738) \u00a0\u00a0\u2014 \u00a0\u00a0(60,738) \u00a0\u00a0(60,738) \u00a0\u00a0(14,142) \u00a0\u00a0\u2014 \u00a0\u00a0(46,596) \u00a0\u00a0(0.22) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(157,458) \u00a0\u00a0157,458 \u00a0\u00a0157,458 \u00a0\u00a036,661 \u00a0\u00a0(3,554) \u00a0\u00a0117,243 \u00a0\u00a00.55 \u00a0\n16", "original_text": "prior\nyear \u00a0\u00a05.8 % \u00a0\u00a09.6 % \u00a0\u00a0\u2014 % \u00a0\u00a00.1 % \u00a0\u00a0(9.7) % \u00a0 \u00a0\u00a03.8 % \u00a0\u00a06.9 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n________________________________________ \n 1 Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net. \n ", "page_label": "16", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16633cac-2032-419d-bcd9-3517fad60db4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "981db0c44e811e4068f46b4756ae4c967755568832b26a466246cc7aba5b631b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d342622-e2a9-471c-bf4b-697b73edcf49", "node_type": "1", "metadata": {"window": "Adjusted Non-GAAP\n% change vs.  prior\nyear \u00a0\u00a05.8 % \u00a0\u00a09.6 % \u00a0\u00a0\u2014 % \u00a0\u00a00.1 % \u00a0\u00a0(9.7) % \u00a0 \u00a0\u00a03.8 % \u00a0\u00a06.9 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n________________________________________ \n 1 Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net. \n  2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "original_text": "Adjusted Non-GAAP\n% change vs. ", "page_label": "16", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a81602771c51b4efcf2d6e1a5cbc0c08edbc5c108f79fd775901bf1e1cbae79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c8420ff-9425-4b71-89b1-88f6b8449771", "node_type": "1", "metadata": {"window": "Adjusted Non-GAAP\n% change vs.  prior\nyear \u00a0\u00a05.8 % \u00a0\u00a09.6 % \u00a0\u00a0\u2014 % \u00a0\u00a00.1 % \u00a0\u00a0(9.7) % \u00a0 \u00a0\u00a03.8 % \u00a0\u00a06.9 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n________________________________________ \n 1 Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net. \n  2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0$2,870,877 \u00a0$1,424,562 \u00a0$1,324,394 \u00a0$319,733 \u00a0$(7,542) \u00a0$997,119 \u00a0$4.71 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738) \u00a0\u00a0\u2014 \u00a0\u00a0(60,738) \u00a0\u00a0(60,738) \u00a0\u00a0(14,142) \u00a0\u00a0\u2014 \u00a0\u00a0(46,596) \u00a0\u00a0(0.22) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(157,458) \u00a0\u00a0157,458 \u00a0\u00a0157,458 \u00a0\u00a036,661 \u00a0\u00a0(3,554) \u00a0\u00a0117,243 \u00a0\u00a00.55 \u00a0\n16", "original_text": "2 The sum of the components does not equal the total due to rounding.\n"}, "hash": "104cf5b3a568587c6b0e2c6bc3065c125204306e57c2de81ef33ed81e2afbf2d", "class_name": "RelatedNodeInfo"}}, "text": "prior\nyear \u00a0\u00a05.8 % \u00a0\u00a09.6 % \u00a0\u00a0\u2014 % \u00a0\u00a00.1 % \u00a0\u00a0(9.7) % \u00a0 \u00a0\u00a03.8 % \u00a0\u00a06.9 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n________________________________________ \n 1 Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net. \n ", "start_char_idx": 31, "end_char_idx": 472, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c8420ff-9425-4b71-89b1-88f6b8449771": {"__data__": {"id_": "1c8420ff-9425-4b71-89b1-88f6b8449771", "embedding": null, "metadata": {"window": "Adjusted Non-GAAP\n% change vs.  prior\nyear \u00a0\u00a05.8 % \u00a0\u00a09.6 % \u00a0\u00a0\u2014 % \u00a0\u00a00.1 % \u00a0\u00a0(9.7) % \u00a0 \u00a0\u00a03.8 % \u00a0\u00a06.9 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n________________________________________ \n 1 Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net. \n  2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0$2,870,877 \u00a0$1,424,562 \u00a0$1,324,394 \u00a0$319,733 \u00a0$(7,542) \u00a0$997,119 \u00a0$4.71 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738) \u00a0\u00a0\u2014 \u00a0\u00a0(60,738) \u00a0\u00a0(60,738) \u00a0\u00a0(14,142) \u00a0\u00a0\u2014 \u00a0\u00a0(46,596) \u00a0\u00a0(0.22) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(157,458) \u00a0\u00a0157,458 \u00a0\u00a0157,458 \u00a0\u00a036,661 \u00a0\u00a0(3,554) \u00a0\u00a0117,243 \u00a0\u00a00.55 \u00a0\n16", "original_text": "2 The sum of the components does not equal the total due to rounding.\n", "page_label": "16", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16633cac-2032-419d-bcd9-3517fad60db4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "981db0c44e811e4068f46b4756ae4c967755568832b26a466246cc7aba5b631b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b91fc4e4-df44-40ac-8686-2845c88e8437", "node_type": "1", "metadata": {"window": "Adjusted Non-GAAP\n% change vs.  prior\nyear \u00a0\u00a05.8 % \u00a0\u00a09.6 % \u00a0\u00a0\u2014 % \u00a0\u00a00.1 % \u00a0\u00a0(9.7) % \u00a0 \u00a0\u00a03.8 % \u00a0\u00a06.9 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n________________________________________ \n 1 Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net. \n  2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0$2,870,877 \u00a0$1,424,562 \u00a0$1,324,394 \u00a0$319,733 \u00a0$(7,542) \u00a0$997,119 \u00a0$4.71 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738) \u00a0\u00a0\u2014 \u00a0\u00a0(60,738) \u00a0\u00a0(60,738) \u00a0\u00a0(14,142) \u00a0\u00a0\u2014 \u00a0\u00a0(46,596) \u00a0\u00a0(0.22) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(157,458) \u00a0\u00a0157,458 \u00a0\u00a0157,458 \u00a0\u00a036,661 \u00a0\u00a0(3,554) \u00a0\u00a0117,243 \u00a0\u00a00.55 \u00a0\n16", "original_text": "prior\nyear \u00a0\u00a05.8 % \u00a0\u00a09.6 % \u00a0\u00a0\u2014 % \u00a0\u00a00.1 % \u00a0\u00a0(9.7) % \u00a0 \u00a0\u00a03.8 % \u00a0\u00a06.9 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n________________________________________ \n 1 Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net. \n ", "page_label": "16", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "894bafbe459c447afc623b764ac3b49bc4a8b3cb7358a89c1645d6d979d036f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b98622f-0457-493a-bc54-28a5a554dba6", "node_type": "1", "metadata": {"window": "Adjusted Non-GAAP\n% change vs.  prior\nyear \u00a0\u00a05.8 % \u00a0\u00a09.6 % \u00a0\u00a0\u2014 % \u00a0\u00a00.1 % \u00a0\u00a0(9.7) % \u00a0 \u00a0\u00a03.8 % \u00a0\u00a06.9 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n________________________________________ \n 1 Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net. \n  2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0$2,870,877 \u00a0$1,424,562 \u00a0$1,324,394 \u00a0$319,733 \u00a0$(7,542) \u00a0$997,119 \u00a0$4.71 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738) \u00a0\u00a0\u2014 \u00a0\u00a0(60,738) \u00a0\u00a0(60,738) \u00a0\u00a0(14,142) \u00a0\u00a0\u2014 \u00a0\u00a0(46,596) \u00a0\u00a0(0.22) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(157,458) \u00a0\u00a0157,458 \u00a0\u00a0157,458 \u00a0\u00a036,661 \u00a0\u00a0(3,554) \u00a0\u00a0117,243 \u00a0\u00a00.55 \u00a0\n16", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n"}, "hash": "467c5c1d2ee6f22f76423c606fb255bac780e34bf6aac884c3f7d212f837d440", "class_name": "RelatedNodeInfo"}}, "text": "2 The sum of the components does not equal the total due to rounding.\n", "start_char_idx": 472, "end_char_idx": 542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b98622f-0457-493a-bc54-28a5a554dba6": {"__data__": {"id_": "3b98622f-0457-493a-bc54-28a5a554dba6", "embedding": null, "metadata": {"window": "Adjusted Non-GAAP\n% change vs.  prior\nyear \u00a0\u00a05.8 % \u00a0\u00a09.6 % \u00a0\u00a0\u2014 % \u00a0\u00a00.1 % \u00a0\u00a0(9.7) % \u00a0 \u00a0\u00a03.8 % \u00a0\u00a06.9 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n________________________________________ \n 1 Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net. \n  2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0$2,870,877 \u00a0$1,424,562 \u00a0$1,324,394 \u00a0$319,733 \u00a0$(7,542) \u00a0$997,119 \u00a0$4.71 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738) \u00a0\u00a0\u2014 \u00a0\u00a0(60,738) \u00a0\u00a0(60,738) \u00a0\u00a0(14,142) \u00a0\u00a0\u2014 \u00a0\u00a0(46,596) \u00a0\u00a0(0.22) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(157,458) \u00a0\u00a0157,458 \u00a0\u00a0157,458 \u00a0\u00a036,661 \u00a0\u00a0(3,554) \u00a0\u00a0117,243 \u00a0\u00a00.55 \u00a0\n16", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "16", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16633cac-2032-419d-bcd9-3517fad60db4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "981db0c44e811e4068f46b4756ae4c967755568832b26a466246cc7aba5b631b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c8420ff-9425-4b71-89b1-88f6b8449771", "node_type": "1", "metadata": {"window": "Adjusted Non-GAAP\n% change vs.  prior\nyear \u00a0\u00a05.8 % \u00a0\u00a09.6 % \u00a0\u00a0\u2014 % \u00a0\u00a00.1 % \u00a0\u00a0(9.7) % \u00a0 \u00a0\u00a03.8 % \u00a0\u00a06.9 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n________________________________________ \n 1 Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net. \n  2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0$2,870,877 \u00a0$1,424,562 \u00a0$1,324,394 \u00a0$319,733 \u00a0$(7,542) \u00a0$997,119 \u00a0$4.71 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738) \u00a0\u00a0\u2014 \u00a0\u00a0(60,738) \u00a0\u00a0(60,738) \u00a0\u00a0(14,142) \u00a0\u00a0\u2014 \u00a0\u00a0(46,596) \u00a0\u00a0(0.22) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(157,458) \u00a0\u00a0157,458 \u00a0\u00a0157,458 \u00a0\u00a036,661 \u00a0\u00a0(3,554) \u00a0\u00a0117,243 \u00a0\u00a00.55 \u00a0\n16", "original_text": "2 The sum of the components does not equal the total due to rounding.\n", "page_label": "16", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c5b4f604e55875cbeb94da171bf38048fc2e2a05519c8fc0aec4841cf1e9601e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e470302-a3ed-4351-a6cb-5c72e106ce5b", "node_type": "1", "metadata": {"window": "prior\nyear \u00a0\u00a05.8 % \u00a0\u00a09.6 % \u00a0\u00a0\u2014 % \u00a0\u00a00.1 % \u00a0\u00a0(9.7) % \u00a0 \u00a0\u00a03.8 % \u00a0\u00a06.9 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n________________________________________ \n 1 Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net. \n  2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0$2,870,877 \u00a0$1,424,562 \u00a0$1,324,394 \u00a0$319,733 \u00a0$(7,542) \u00a0$997,119 \u00a0$4.71 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738) \u00a0\u00a0\u2014 \u00a0\u00a0(60,738) \u00a0\u00a0(60,738) \u00a0\u00a0(14,142) \u00a0\u00a0\u2014 \u00a0\u00a0(46,596) \u00a0\u00a0(0.22) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(157,458) \u00a0\u00a0157,458 \u00a0\u00a0157,458 \u00a0\u00a036,661 \u00a0\u00a0(3,554) \u00a0\u00a0117,243 \u00a0\u00a00.55 \u00a0\n16", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0$2,870,877 \u00a0$1,424,562 \u00a0$1,324,394 \u00a0$319,733 \u00a0$(7,542) \u00a0$997,119 \u00a0$4.71 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738) \u00a0\u00a0\u2014 \u00a0\u00a0(60,738) \u00a0\u00a0(60,738) \u00a0\u00a0(14,142) \u00a0\u00a0\u2014 \u00a0\u00a0(46,596) \u00a0\u00a0(0.22) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(157,458) \u00a0\u00a0157,458 \u00a0\u00a0157,458 \u00a0\u00a036,661 \u00a0\u00a0(3,554) \u00a0\u00a0117,243 \u00a0\u00a00.55 \u00a0\n16"}, "hash": "500314818e7c30de18098d1370568115834d70aae167ad754fb595e15061dfba", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "start_char_idx": 542, "end_char_idx": 719, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e470302-a3ed-4351-a6cb-5c72e106ce5b": {"__data__": {"id_": "5e470302-a3ed-4351-a6cb-5c72e106ce5b", "embedding": null, "metadata": {"window": "prior\nyear \u00a0\u00a05.8 % \u00a0\u00a09.6 % \u00a0\u00a0\u2014 % \u00a0\u00a00.1 % \u00a0\u00a0(9.7) % \u00a0 \u00a0\u00a03.8 % \u00a0\u00a06.9 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n________________________________________ \n 1 Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net. \n  2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0$2,870,877 \u00a0$1,424,562 \u00a0$1,324,394 \u00a0$319,733 \u00a0$(7,542) \u00a0$997,119 \u00a0$4.71 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738) \u00a0\u00a0\u2014 \u00a0\u00a0(60,738) \u00a0\u00a0(60,738) \u00a0\u00a0(14,142) \u00a0\u00a0\u2014 \u00a0\u00a0(46,596) \u00a0\u00a0(0.22) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(157,458) \u00a0\u00a0157,458 \u00a0\u00a0157,458 \u00a0\u00a036,661 \u00a0\u00a0(3,554) \u00a0\u00a0117,243 \u00a0\u00a00.55 \u00a0\n16", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0$2,870,877 \u00a0$1,424,562 \u00a0$1,324,394 \u00a0$319,733 \u00a0$(7,542) \u00a0$997,119 \u00a0$4.71 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738) \u00a0\u00a0\u2014 \u00a0\u00a0(60,738) \u00a0\u00a0(60,738) \u00a0\u00a0(14,142) \u00a0\u00a0\u2014 \u00a0\u00a0(46,596) \u00a0\u00a0(0.22) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(157,458) \u00a0\u00a0157,458 \u00a0\u00a0157,458 \u00a0\u00a036,661 \u00a0\u00a0(3,554) \u00a0\u00a0117,243 \u00a0\u00a00.55 \u00a0\n16", "page_label": "16", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16633cac-2032-419d-bcd9-3517fad60db4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "981db0c44e811e4068f46b4756ae4c967755568832b26a466246cc7aba5b631b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b98622f-0457-493a-bc54-28a5a554dba6", "node_type": "1", "metadata": {"window": "Adjusted Non-GAAP\n% change vs.  prior\nyear \u00a0\u00a05.8 % \u00a0\u00a09.6 % \u00a0\u00a0\u2014 % \u00a0\u00a00.1 % \u00a0\u00a0(9.7) % \u00a0 \u00a0\u00a03.8 % \u00a0\u00a06.9 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n________________________________________ \n 1 Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net. \n  2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0$2,870,877 \u00a0$1,424,562 \u00a0$1,324,394 \u00a0$319,733 \u00a0$(7,542) \u00a0$997,119 \u00a0$4.71 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738) \u00a0\u00a0\u2014 \u00a0\u00a0(60,738) \u00a0\u00a0(60,738) \u00a0\u00a0(14,142) \u00a0\u00a0\u2014 \u00a0\u00a0(46,596) \u00a0\u00a0(0.22) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(157,458) \u00a0\u00a0157,458 \u00a0\u00a0157,458 \u00a0\u00a036,661 \u00a0\u00a0(3,554) \u00a0\u00a0117,243 \u00a0\u00a00.55 \u00a0\n16", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "16", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "120013ff0ba8fbb1d689ec228f3e0e9a4babc0a1a4cd4d463cf96cb1c3c67b93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9d502b2-0c38-40d5-980d-f6b357eeeca7", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(84,725) \u00a0\u00a084,725 \u00a0\u00a084,725 \u00a0\u00a011,210 \u00a0\u00a0\u2014 \u00a0\u00a073,515 \u00a0\u00a00.35 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(33,140) \u00a0\u00a033,140 \u00a0\u00a033,140 \u00a0\u00a07,716 \u00a0\u00a0\u2014 \u00a0\u00a025,424 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(23,499) \u00a0\u00a023,499 \u00a0\u00a023,499 \u00a0\u00a05,471 \u00a0\u00a0\u2014 \u00a0\u00a018,028 \u00a0\u00a00.09 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a04,946 \u00a0\u00a04,946 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a04,946 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(18,979) \u00a0\u00a06,840 \u00a0\u00a025,819 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(2,570) \u00a0\u00a0(17,204) \u00a0\u00a0\u2014 \u00a0\u00a014,634 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$4,232,866 \u00a0$2,567,109 \u00a0$1,665,757 \u00a0$1,563,019 \u00a0$330,039 \u00a0$(4,256) \u00a0$1,228,724 \u00a0$5.81 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.66% \u00a03.61%\nOperating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net. \n  2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\n17", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(84,725) \u00a0\u00a084,725 \u00a0\u00a084,725 \u00a0\u00a011,210 \u00a0\u00a0\u2014 \u00a0\u00a073,515 \u00a0\u00a00.35 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(33,140) \u00a0\u00a033,140 \u00a0\u00a033,140 \u00a0\u00a07,716 \u00a0\u00a0\u2014 \u00a0\u00a025,424 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(23,499) \u00a0\u00a023,499 \u00a0\u00a023,499 \u00a0\u00a05,471 \u00a0\u00a0\u2014 \u00a0\u00a018,028 \u00a0\u00a00.09 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a04,946 \u00a0\u00a04,946 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a04,946 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(18,979) \u00a0\u00a06,840 \u00a0\u00a025,819 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(2,570) \u00a0\u00a0(17,204) \u00a0\u00a0\u2014 \u00a0\u00a014,634 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$4,232,866 \u00a0$2,567,109 \u00a0$1,665,757 \u00a0$1,563,019 \u00a0$330,039 \u00a0$(4,256) \u00a0$1,228,724 \u00a0$5.81 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.66% \u00a03.61%\nOperating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net. \n "}, "hash": "75192e6ae412dfde0eeba0e0c4366243449ddb012c5852900f48cdfe543e2874", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0$2,870,877 \u00a0$1,424,562 \u00a0$1,324,394 \u00a0$319,733 \u00a0$(7,542) \u00a0$997,119 \u00a0$4.71 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738) \u00a0\u00a0\u2014 \u00a0\u00a0(60,738) \u00a0\u00a0(60,738) \u00a0\u00a0(14,142) \u00a0\u00a0\u2014 \u00a0\u00a0(46,596) \u00a0\u00a0(0.22) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(157,458) \u00a0\u00a0157,458 \u00a0\u00a0157,458 \u00a0\u00a036,661 \u00a0\u00a0(3,554) \u00a0\u00a0117,243 \u00a0\u00a00.55 \u00a0\n16", "start_char_idx": 719, "end_char_idx": 1593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9d502b2-0c38-40d5-980d-f6b357eeeca7": {"__data__": {"id_": "f9d502b2-0c38-40d5-980d-f6b357eeeca7", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(84,725) \u00a0\u00a084,725 \u00a0\u00a084,725 \u00a0\u00a011,210 \u00a0\u00a0\u2014 \u00a0\u00a073,515 \u00a0\u00a00.35 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(33,140) \u00a0\u00a033,140 \u00a0\u00a033,140 \u00a0\u00a07,716 \u00a0\u00a0\u2014 \u00a0\u00a025,424 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(23,499) \u00a0\u00a023,499 \u00a0\u00a023,499 \u00a0\u00a05,471 \u00a0\u00a0\u2014 \u00a0\u00a018,028 \u00a0\u00a00.09 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a04,946 \u00a0\u00a04,946 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a04,946 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(18,979) \u00a0\u00a06,840 \u00a0\u00a025,819 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(2,570) \u00a0\u00a0(17,204) \u00a0\u00a0\u2014 \u00a0\u00a014,634 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$4,232,866 \u00a0$2,567,109 \u00a0$1,665,757 \u00a0$1,563,019 \u00a0$330,039 \u00a0$(4,256) \u00a0$1,228,724 \u00a0$5.81 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.66% \u00a03.61%\nOperating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net. \n  2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\n17", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(84,725) \u00a0\u00a084,725 \u00a0\u00a084,725 \u00a0\u00a011,210 \u00a0\u00a0\u2014 \u00a0\u00a073,515 \u00a0\u00a00.35 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(33,140) \u00a0\u00a033,140 \u00a0\u00a033,140 \u00a0\u00a07,716 \u00a0\u00a0\u2014 \u00a0\u00a025,424 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(23,499) \u00a0\u00a023,499 \u00a0\u00a023,499 \u00a0\u00a05,471 \u00a0\u00a0\u2014 \u00a0\u00a018,028 \u00a0\u00a00.09 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a04,946 \u00a0\u00a04,946 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a04,946 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(18,979) \u00a0\u00a06,840 \u00a0\u00a025,819 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(2,570) \u00a0\u00a0(17,204) \u00a0\u00a0\u2014 \u00a0\u00a014,634 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$4,232,866 \u00a0$2,567,109 \u00a0$1,665,757 \u00a0$1,563,019 \u00a0$330,039 \u00a0$(4,256) \u00a0$1,228,724 \u00a0$5.81 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.66% \u00a03.61%\nOperating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net. \n ", "page_label": "17", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ffab077b-dbe7-4d72-b99b-ca6b09c298f2", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bfc4adbd0aa4730f31d2ea8765181ffc98cd2aa80ffd29caf7c1fbc420cf3ea3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e470302-a3ed-4351-a6cb-5c72e106ce5b", "node_type": "1", "metadata": {"window": "prior\nyear \u00a0\u00a05.8 % \u00a0\u00a09.6 % \u00a0\u00a0\u2014 % \u00a0\u00a00.1 % \u00a0\u00a0(9.7) % \u00a0 \u00a0\u00a03.8 % \u00a0\u00a06.9 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n________________________________________ \n 1 Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net. \n  2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0$2,870,877 \u00a0$1,424,562 \u00a0$1,324,394 \u00a0$319,733 \u00a0$(7,542) \u00a0$997,119 \u00a0$4.71 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738) \u00a0\u00a0\u2014 \u00a0\u00a0(60,738) \u00a0\u00a0(60,738) \u00a0\u00a0(14,142) \u00a0\u00a0\u2014 \u00a0\u00a0(46,596) \u00a0\u00a0(0.22) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(157,458) \u00a0\u00a0157,458 \u00a0\u00a0157,458 \u00a0\u00a036,661 \u00a0\u00a0(3,554) \u00a0\u00a0117,243 \u00a0\u00a00.55 \u00a0\n16", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0$2,870,877 \u00a0$1,424,562 \u00a0$1,324,394 \u00a0$319,733 \u00a0$(7,542) \u00a0$997,119 \u00a0$4.71 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738) \u00a0\u00a0\u2014 \u00a0\u00a0(60,738) \u00a0\u00a0(60,738) \u00a0\u00a0(14,142) \u00a0\u00a0\u2014 \u00a0\u00a0(46,596) \u00a0\u00a0(0.22) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(157,458) \u00a0\u00a0157,458 \u00a0\u00a0157,458 \u00a0\u00a036,661 \u00a0\u00a0(3,554) \u00a0\u00a0117,243 \u00a0\u00a00.55 \u00a0\n16", "page_label": "16", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32bb8019c62350027aad90ce37c1af2246bcdb788773709782ae269d05f33e85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8abab408-129a-4391-a888-3557d4315c97", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(84,725) \u00a0\u00a084,725 \u00a0\u00a084,725 \u00a0\u00a011,210 \u00a0\u00a0\u2014 \u00a0\u00a073,515 \u00a0\u00a00.35 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(33,140) \u00a0\u00a033,140 \u00a0\u00a033,140 \u00a0\u00a07,716 \u00a0\u00a0\u2014 \u00a0\u00a025,424 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(23,499) \u00a0\u00a023,499 \u00a0\u00a023,499 \u00a0\u00a05,471 \u00a0\u00a0\u2014 \u00a0\u00a018,028 \u00a0\u00a00.09 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a04,946 \u00a0\u00a04,946 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a04,946 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(18,979) \u00a0\u00a06,840 \u00a0\u00a025,819 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(2,570) \u00a0\u00a0(17,204) \u00a0\u00a0\u2014 \u00a0\u00a014,634 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$4,232,866 \u00a0$2,567,109 \u00a0$1,665,757 \u00a0$1,563,019 \u00a0$330,039 \u00a0$(4,256) \u00a0$1,228,724 \u00a0$5.81 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.66% \u00a03.61%\nOperating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net. \n  2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\n17", "original_text": "2 The sum of the components does not equal the total due to rounding.\n"}, "hash": "c2aa9733f0ba6bd4875c89657bb6d05c6134673bdef112cac1384b9bccd99bb3", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(84,725) \u00a0\u00a084,725 \u00a0\u00a084,725 \u00a0\u00a011,210 \u00a0\u00a0\u2014 \u00a0\u00a073,515 \u00a0\u00a00.35 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(33,140) \u00a0\u00a033,140 \u00a0\u00a033,140 \u00a0\u00a07,716 \u00a0\u00a0\u2014 \u00a0\u00a025,424 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(23,499) \u00a0\u00a023,499 \u00a0\u00a023,499 \u00a0\u00a05,471 \u00a0\u00a0\u2014 \u00a0\u00a018,028 \u00a0\u00a00.09 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a04,946 \u00a0\u00a04,946 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a04,946 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(18,979) \u00a0\u00a06,840 \u00a0\u00a025,819 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(2,570) \u00a0\u00a0(17,204) \u00a0\u00a0\u2014 \u00a0\u00a014,634 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$4,232,866 \u00a0$2,567,109 \u00a0$1,665,757 \u00a0$1,563,019 \u00a0$330,039 \u00a0$(4,256) \u00a0$1,228,724 \u00a0$5.81 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.66% \u00a03.61%\nOperating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net. \n ", "start_char_idx": 0, "end_char_idx": 1203, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8abab408-129a-4391-a888-3557d4315c97": {"__data__": {"id_": "8abab408-129a-4391-a888-3557d4315c97", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(84,725) \u00a0\u00a084,725 \u00a0\u00a084,725 \u00a0\u00a011,210 \u00a0\u00a0\u2014 \u00a0\u00a073,515 \u00a0\u00a00.35 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(33,140) \u00a0\u00a033,140 \u00a0\u00a033,140 \u00a0\u00a07,716 \u00a0\u00a0\u2014 \u00a0\u00a025,424 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(23,499) \u00a0\u00a023,499 \u00a0\u00a023,499 \u00a0\u00a05,471 \u00a0\u00a0\u2014 \u00a0\u00a018,028 \u00a0\u00a00.09 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a04,946 \u00a0\u00a04,946 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a04,946 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(18,979) \u00a0\u00a06,840 \u00a0\u00a025,819 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(2,570) \u00a0\u00a0(17,204) \u00a0\u00a0\u2014 \u00a0\u00a014,634 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$4,232,866 \u00a0$2,567,109 \u00a0$1,665,757 \u00a0$1,563,019 \u00a0$330,039 \u00a0$(4,256) \u00a0$1,228,724 \u00a0$5.81 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.66% \u00a03.61%\nOperating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net. \n  2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\n17", "original_text": "2 The sum of the components does not equal the total due to rounding.\n", "page_label": "17", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ffab077b-dbe7-4d72-b99b-ca6b09c298f2", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bfc4adbd0aa4730f31d2ea8765181ffc98cd2aa80ffd29caf7c1fbc420cf3ea3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9d502b2-0c38-40d5-980d-f6b357eeeca7", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(84,725) \u00a0\u00a084,725 \u00a0\u00a084,725 \u00a0\u00a011,210 \u00a0\u00a0\u2014 \u00a0\u00a073,515 \u00a0\u00a00.35 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(33,140) \u00a0\u00a033,140 \u00a0\u00a033,140 \u00a0\u00a07,716 \u00a0\u00a0\u2014 \u00a0\u00a025,424 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(23,499) \u00a0\u00a023,499 \u00a0\u00a023,499 \u00a0\u00a05,471 \u00a0\u00a0\u2014 \u00a0\u00a018,028 \u00a0\u00a00.09 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a04,946 \u00a0\u00a04,946 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a04,946 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(18,979) \u00a0\u00a06,840 \u00a0\u00a025,819 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(2,570) \u00a0\u00a0(17,204) \u00a0\u00a0\u2014 \u00a0\u00a014,634 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$4,232,866 \u00a0$2,567,109 \u00a0$1,665,757 \u00a0$1,563,019 \u00a0$330,039 \u00a0$(4,256) \u00a0$1,228,724 \u00a0$5.81 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.66% \u00a03.61%\nOperating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net. \n  2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\n17", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(84,725) \u00a0\u00a084,725 \u00a0\u00a084,725 \u00a0\u00a011,210 \u00a0\u00a0\u2014 \u00a0\u00a073,515 \u00a0\u00a00.35 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(33,140) \u00a0\u00a033,140 \u00a0\u00a033,140 \u00a0\u00a07,716 \u00a0\u00a0\u2014 \u00a0\u00a025,424 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(23,499) \u00a0\u00a023,499 \u00a0\u00a023,499 \u00a0\u00a05,471 \u00a0\u00a0\u2014 \u00a0\u00a018,028 \u00a0\u00a00.09 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a04,946 \u00a0\u00a04,946 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a04,946 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(18,979) \u00a0\u00a06,840 \u00a0\u00a025,819 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(2,570) \u00a0\u00a0(17,204) \u00a0\u00a0\u2014 \u00a0\u00a014,634 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$4,232,866 \u00a0$2,567,109 \u00a0$1,665,757 \u00a0$1,563,019 \u00a0$330,039 \u00a0$(4,256) \u00a0$1,228,724 \u00a0$5.81 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.66% \u00a03.61%\nOperating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net. \n ", "page_label": "17", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4038aba9f588a84930568d624224633f79b7c757563d2f933c740648985430bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bd0b50d-e4d7-41d4-9e5e-4ad0215b9db1", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(84,725) \u00a0\u00a084,725 \u00a0\u00a084,725 \u00a0\u00a011,210 \u00a0\u00a0\u2014 \u00a0\u00a073,515 \u00a0\u00a00.35 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(33,140) \u00a0\u00a033,140 \u00a0\u00a033,140 \u00a0\u00a07,716 \u00a0\u00a0\u2014 \u00a0\u00a025,424 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(23,499) \u00a0\u00a023,499 \u00a0\u00a023,499 \u00a0\u00a05,471 \u00a0\u00a0\u2014 \u00a0\u00a018,028 \u00a0\u00a00.09 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a04,946 \u00a0\u00a04,946 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a04,946 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(18,979) \u00a0\u00a06,840 \u00a0\u00a025,819 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(2,570) \u00a0\u00a0(17,204) \u00a0\u00a0\u2014 \u00a0\u00a014,634 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$4,232,866 \u00a0$2,567,109 \u00a0$1,665,757 \u00a0$1,563,019 \u00a0$330,039 \u00a0$(4,256) \u00a0$1,228,724 \u00a0$5.81 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.66% \u00a03.61%\nOperating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net. \n  2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\n17", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\n17"}, "hash": "ee6cd8d5510ee9d599a7b0384766e76d7735b3082364b17fe49e01d7b9869bee", "class_name": "RelatedNodeInfo"}}, "text": "2 The sum of the components does not equal the total due to rounding.\n", "start_char_idx": 1203, "end_char_idx": 1273, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bd0b50d-e4d7-41d4-9e5e-4ad0215b9db1": {"__data__": {"id_": "8bd0b50d-e4d7-41d4-9e5e-4ad0215b9db1", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(84,725) \u00a0\u00a084,725 \u00a0\u00a084,725 \u00a0\u00a011,210 \u00a0\u00a0\u2014 \u00a0\u00a073,515 \u00a0\u00a00.35 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(33,140) \u00a0\u00a033,140 \u00a0\u00a033,140 \u00a0\u00a07,716 \u00a0\u00a0\u2014 \u00a0\u00a025,424 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(23,499) \u00a0\u00a023,499 \u00a0\u00a023,499 \u00a0\u00a05,471 \u00a0\u00a0\u2014 \u00a0\u00a018,028 \u00a0\u00a00.09 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a04,946 \u00a0\u00a04,946 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a04,946 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(18,979) \u00a0\u00a06,840 \u00a0\u00a025,819 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(2,570) \u00a0\u00a0(17,204) \u00a0\u00a0\u2014 \u00a0\u00a014,634 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$4,232,866 \u00a0$2,567,109 \u00a0$1,665,757 \u00a0$1,563,019 \u00a0$330,039 \u00a0$(4,256) \u00a0$1,228,724 \u00a0$5.81 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.66% \u00a03.61%\nOperating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net. \n  2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\n17", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\n17", "page_label": "17", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ffab077b-dbe7-4d72-b99b-ca6b09c298f2", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bfc4adbd0aa4730f31d2ea8765181ffc98cd2aa80ffd29caf7c1fbc420cf3ea3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8abab408-129a-4391-a888-3557d4315c97", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(84,725) \u00a0\u00a084,725 \u00a0\u00a084,725 \u00a0\u00a011,210 \u00a0\u00a0\u2014 \u00a0\u00a073,515 \u00a0\u00a00.35 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(33,140) \u00a0\u00a033,140 \u00a0\u00a033,140 \u00a0\u00a07,716 \u00a0\u00a0\u2014 \u00a0\u00a025,424 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(23,499) \u00a0\u00a023,499 \u00a0\u00a023,499 \u00a0\u00a05,471 \u00a0\u00a0\u2014 \u00a0\u00a018,028 \u00a0\u00a00.09 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a04,946 \u00a0\u00a04,946 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a04,946 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(18,979) \u00a0\u00a06,840 \u00a0\u00a025,819 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(2,570) \u00a0\u00a0(17,204) \u00a0\u00a0\u2014 \u00a0\u00a014,634 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$4,232,866 \u00a0$2,567,109 \u00a0$1,665,757 \u00a0$1,563,019 \u00a0$330,039 \u00a0$(4,256) \u00a0$1,228,724 \u00a0$5.81 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.66% \u00a03.61%\nOperating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net. \n  2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\n17", "original_text": "2 The sum of the components does not equal the total due to rounding.\n", "page_label": "17", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b002259eb562bc83d9069bb2ef3020b00513b11dfd6aec17ed243c6b7a399a22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2cadb71-ec5d-46c6-899e-d084ceb78d1d", "node_type": "1", "metadata": {"window": "Regarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$56,693,456 \u00a0$50,942,763 \u00a011.3%\nInternational Healthcare Solutions \u00a0\u00a06,764,935 \u00a0\u00a06,777,691 \u00a0(0.2)%\nIntersegment eliminations \u00a0\u00a0(1,186) \u00a0\u00a0(1,008) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$63,457,205 \u00a0$57,719,446 \u00a09.9%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$756,137 \u00a0$729,542 \u00a03.6%\nInternational Healthcare Solutions \u00a0\u00a0175,991 \u00a0\u00a0187,068 \u00a0(5.9)%\nTotal segment operating income \u00a0\u00a0932,128 \u00a0\u00a0916,610 \u00a01.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(4,855) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(54,270) \u00a0\u00a016,059 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(140,114) \u00a0\u00a0(77,952) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,813) \u00a0\u00a0(52,090) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(59,113) \u00a0\u00a0(11,790) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(97,444) \u00a0\u00a0(12,515) \u00a0\u00a0\n18", "original_text": "Regarding Non-GAAP Financial Measures\u201d of this release.\n"}, "hash": "d99ddb18eebfd6ed92ade99d427ad51c34cdf4191106547473158fb2cbe9a4a5", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\n17", "start_char_idx": 1273, "end_char_idx": 1396, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2cadb71-ec5d-46c6-899e-d084ceb78d1d": {"__data__": {"id_": "e2cadb71-ec5d-46c6-899e-d084ceb78d1d", "embedding": null, "metadata": {"window": "Regarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$56,693,456 \u00a0$50,942,763 \u00a011.3%\nInternational Healthcare Solutions \u00a0\u00a06,764,935 \u00a0\u00a06,777,691 \u00a0(0.2)%\nIntersegment eliminations \u00a0\u00a0(1,186) \u00a0\u00a0(1,008) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$63,457,205 \u00a0$57,719,446 \u00a09.9%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$756,137 \u00a0$729,542 \u00a03.6%\nInternational Healthcare Solutions \u00a0\u00a0175,991 \u00a0\u00a0187,068 \u00a0(5.9)%\nTotal segment operating income \u00a0\u00a0932,128 \u00a0\u00a0916,610 \u00a01.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(4,855) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(54,270) \u00a0\u00a016,059 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(140,114) \u00a0\u00a0(77,952) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,813) \u00a0\u00a0(52,090) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(59,113) \u00a0\u00a0(11,790) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(97,444) \u00a0\u00a0(12,515) \u00a0\u00a0\n18", "original_text": "Regarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "18", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "18c50b95-a0e6-4159-abc8-a85289142737", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dfc86982e35d7b7dcf58f4fcdd4442cdb2d5f5b03fab2537a94bb13a8c1b7431", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bd0b50d-e4d7-41d4-9e5e-4ad0215b9db1", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(84,725) \u00a0\u00a084,725 \u00a0\u00a084,725 \u00a0\u00a011,210 \u00a0\u00a0\u2014 \u00a0\u00a073,515 \u00a0\u00a00.35 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(33,140) \u00a0\u00a033,140 \u00a0\u00a033,140 \u00a0\u00a07,716 \u00a0\u00a0\u2014 \u00a0\u00a025,424 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(23,499) \u00a0\u00a023,499 \u00a0\u00a023,499 \u00a0\u00a05,471 \u00a0\u00a0\u2014 \u00a0\u00a018,028 \u00a0\u00a00.09 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a04,946 \u00a0\u00a04,946 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a04,946 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(18,979) \u00a0\u00a06,840 \u00a0\u00a025,819 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(2,570) \u00a0\u00a0(17,204) \u00a0\u00a0\u2014 \u00a0\u00a014,634 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$4,232,866 \u00a0$2,567,109 \u00a0$1,665,757 \u00a0$1,563,019 \u00a0$330,039 \u00a0$(4,256) \u00a0$1,228,724 \u00a0$5.81 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.66% \u00a03.61%\nOperating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net. \n  2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\n17", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\n17", "page_label": "17", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "517caa98c245a7d7ddcbf0b705222b78bde30c6d0a1b42123b4f879d8262dc88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d7d54a3-dc4a-4996-aa6f-76c884f758c1", "node_type": "1", "metadata": {"window": "Regarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$56,693,456 \u00a0$50,942,763 \u00a011.3%\nInternational Healthcare Solutions \u00a0\u00a06,764,935 \u00a0\u00a06,777,691 \u00a0(0.2)%\nIntersegment eliminations \u00a0\u00a0(1,186) \u00a0\u00a0(1,008) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$63,457,205 \u00a0$57,719,446 \u00a09.9%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$756,137 \u00a0$729,542 \u00a03.6%\nInternational Healthcare Solutions \u00a0\u00a0175,991 \u00a0\u00a0187,068 \u00a0(5.9)%\nTotal segment operating income \u00a0\u00a0932,128 \u00a0\u00a0916,610 \u00a01.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(4,855) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(54,270) \u00a0\u00a016,059 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(140,114) \u00a0\u00a0(77,952) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,813) \u00a0\u00a0(52,090) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(59,113) \u00a0\u00a0(11,790) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(97,444) \u00a0\u00a0(12,515) \u00a0\u00a0\n18", "original_text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S. "}, "hash": "42814398c37d3de96fa1fe67d31cc3fe55674d4acc6c1a853e9c7a6e5db7186c", "class_name": "RelatedNodeInfo"}}, "text": "Regarding Non-GAAP Financial Measures\u201d of this release.\n", "start_char_idx": 0, "end_char_idx": 56, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d7d54a3-dc4a-4996-aa6f-76c884f758c1": {"__data__": {"id_": "9d7d54a3-dc4a-4996-aa6f-76c884f758c1", "embedding": null, "metadata": {"window": "Regarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$56,693,456 \u00a0$50,942,763 \u00a011.3%\nInternational Healthcare Solutions \u00a0\u00a06,764,935 \u00a0\u00a06,777,691 \u00a0(0.2)%\nIntersegment eliminations \u00a0\u00a0(1,186) \u00a0\u00a0(1,008) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$63,457,205 \u00a0$57,719,446 \u00a09.9%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$756,137 \u00a0$729,542 \u00a03.6%\nInternational Healthcare Solutions \u00a0\u00a0175,991 \u00a0\u00a0187,068 \u00a0(5.9)%\nTotal segment operating income \u00a0\u00a0932,128 \u00a0\u00a0916,610 \u00a01.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(4,855) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(54,270) \u00a0\u00a016,059 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(140,114) \u00a0\u00a0(77,952) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,813) \u00a0\u00a0(52,090) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(59,113) \u00a0\u00a0(11,790) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(97,444) \u00a0\u00a0(12,515) \u00a0\u00a0\n18", "original_text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S. ", "page_label": "18", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "18c50b95-a0e6-4159-abc8-a85289142737", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dfc86982e35d7b7dcf58f4fcdd4442cdb2d5f5b03fab2537a94bb13a8c1b7431", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2cadb71-ec5d-46c6-899e-d084ceb78d1d", "node_type": "1", "metadata": {"window": "Regarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$56,693,456 \u00a0$50,942,763 \u00a011.3%\nInternational Healthcare Solutions \u00a0\u00a06,764,935 \u00a0\u00a06,777,691 \u00a0(0.2)%\nIntersegment eliminations \u00a0\u00a0(1,186) \u00a0\u00a0(1,008) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$63,457,205 \u00a0$57,719,446 \u00a09.9%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$756,137 \u00a0$729,542 \u00a03.6%\nInternational Healthcare Solutions \u00a0\u00a0175,991 \u00a0\u00a0187,068 \u00a0(5.9)%\nTotal segment operating income \u00a0\u00a0932,128 \u00a0\u00a0916,610 \u00a01.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(4,855) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(54,270) \u00a0\u00a016,059 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(140,114) \u00a0\u00a0(77,952) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,813) \u00a0\u00a0(52,090) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(59,113) \u00a0\u00a0(11,790) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(97,444) \u00a0\u00a0(12,515) \u00a0\u00a0\n18", "original_text": "Regarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "18", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8cb29de181e0a6f44abbab20fbb2f0ca92008b549c3a9c1807723e8da3b0006", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2e6fb57-7441-4946-bea5-4460bdf1bf2d", "node_type": "1", "metadata": {"window": "Regarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$56,693,456 \u00a0$50,942,763 \u00a011.3%\nInternational Healthcare Solutions \u00a0\u00a06,764,935 \u00a0\u00a06,777,691 \u00a0(0.2)%\nIntersegment eliminations \u00a0\u00a0(1,186) \u00a0\u00a0(1,008) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$63,457,205 \u00a0$57,719,446 \u00a09.9%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$756,137 \u00a0$729,542 \u00a03.6%\nInternational Healthcare Solutions \u00a0\u00a0175,991 \u00a0\u00a0187,068 \u00a0(5.9)%\nTotal segment operating income \u00a0\u00a0932,128 \u00a0\u00a0916,610 \u00a01.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(4,855) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(54,270) \u00a0\u00a016,059 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(140,114) \u00a0\u00a0(77,952) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,813) \u00a0\u00a0(52,090) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(59,113) \u00a0\u00a0(11,790) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(97,444) \u00a0\u00a0(12,515) \u00a0\u00a0\n18", "original_text": "Healthcare Solutions \u00a0$56,693,456 \u00a0$50,942,763 \u00a011.3%\nInternational Healthcare Solutions \u00a0\u00a06,764,935 \u00a0\u00a06,777,691 \u00a0(0.2)%\nIntersegment eliminations \u00a0\u00a0(1,186) \u00a0\u00a0(1,008) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$63,457,205 \u00a0$57,719,446 \u00a09.9%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S. "}, "hash": "133180bc98c502939c8ebe42721eda6ec528b9cb9276d760b07bfed7294d2fcf", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S. ", "start_char_idx": 56, "end_char_idx": 217, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2e6fb57-7441-4946-bea5-4460bdf1bf2d": {"__data__": {"id_": "c2e6fb57-7441-4946-bea5-4460bdf1bf2d", "embedding": null, "metadata": {"window": "Regarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$56,693,456 \u00a0$50,942,763 \u00a011.3%\nInternational Healthcare Solutions \u00a0\u00a06,764,935 \u00a0\u00a06,777,691 \u00a0(0.2)%\nIntersegment eliminations \u00a0\u00a0(1,186) \u00a0\u00a0(1,008) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$63,457,205 \u00a0$57,719,446 \u00a09.9%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$756,137 \u00a0$729,542 \u00a03.6%\nInternational Healthcare Solutions \u00a0\u00a0175,991 \u00a0\u00a0187,068 \u00a0(5.9)%\nTotal segment operating income \u00a0\u00a0932,128 \u00a0\u00a0916,610 \u00a01.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(4,855) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(54,270) \u00a0\u00a016,059 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(140,114) \u00a0\u00a0(77,952) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,813) \u00a0\u00a0(52,090) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(59,113) \u00a0\u00a0(11,790) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(97,444) \u00a0\u00a0(12,515) \u00a0\u00a0\n18", "original_text": "Healthcare Solutions \u00a0$56,693,456 \u00a0$50,942,763 \u00a011.3%\nInternational Healthcare Solutions \u00a0\u00a06,764,935 \u00a0\u00a06,777,691 \u00a0(0.2)%\nIntersegment eliminations \u00a0\u00a0(1,186) \u00a0\u00a0(1,008) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$63,457,205 \u00a0$57,719,446 \u00a09.9%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S. ", "page_label": "18", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "18c50b95-a0e6-4159-abc8-a85289142737", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dfc86982e35d7b7dcf58f4fcdd4442cdb2d5f5b03fab2537a94bb13a8c1b7431", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d7d54a3-dc4a-4996-aa6f-76c884f758c1", "node_type": "1", "metadata": {"window": "Regarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$56,693,456 \u00a0$50,942,763 \u00a011.3%\nInternational Healthcare Solutions \u00a0\u00a06,764,935 \u00a0\u00a06,777,691 \u00a0(0.2)%\nIntersegment eliminations \u00a0\u00a0(1,186) \u00a0\u00a0(1,008) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$63,457,205 \u00a0$57,719,446 \u00a09.9%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$756,137 \u00a0$729,542 \u00a03.6%\nInternational Healthcare Solutions \u00a0\u00a0175,991 \u00a0\u00a0187,068 \u00a0(5.9)%\nTotal segment operating income \u00a0\u00a0932,128 \u00a0\u00a0916,610 \u00a01.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(4,855) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(54,270) \u00a0\u00a016,059 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(140,114) \u00a0\u00a0(77,952) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,813) \u00a0\u00a0(52,090) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(59,113) \u00a0\u00a0(11,790) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(97,444) \u00a0\u00a0(12,515) \u00a0\u00a0\n18", "original_text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S. ", "page_label": "18", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a014eacbb97eee4017ea0e8fca4f2cdb5e7a9b355ac5628b11ec189096ef3667", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b44e530d-e562-49b3-908c-9110fd21d718", "node_type": "1", "metadata": {"window": "Regarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$56,693,456 \u00a0$50,942,763 \u00a011.3%\nInternational Healthcare Solutions \u00a0\u00a06,764,935 \u00a0\u00a06,777,691 \u00a0(0.2)%\nIntersegment eliminations \u00a0\u00a0(1,186) \u00a0\u00a0(1,008) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$63,457,205 \u00a0$57,719,446 \u00a09.9%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$756,137 \u00a0$729,542 \u00a03.6%\nInternational Healthcare Solutions \u00a0\u00a0175,991 \u00a0\u00a0187,068 \u00a0(5.9)%\nTotal segment operating income \u00a0\u00a0932,128 \u00a0\u00a0916,610 \u00a01.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(4,855) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(54,270) \u00a0\u00a016,059 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(140,114) \u00a0\u00a0(77,952) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,813) \u00a0\u00a0(52,090) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(59,113) \u00a0\u00a0(11,790) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(97,444) \u00a0\u00a0(12,515) \u00a0\u00a0\n18", "original_text": "Healthcare Solutions \u00a0$756,137 \u00a0$729,542 \u00a03.6%\nInternational Healthcare Solutions \u00a0\u00a0175,991 \u00a0\u00a0187,068 \u00a0(5.9)%\nTotal segment operating income \u00a0\u00a0932,128 \u00a0\u00a0916,610 \u00a01.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(4,855) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(54,270) \u00a0\u00a016,059 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(140,114) \u00a0\u00a0(77,952) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,813) \u00a0\u00a0(52,090) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(59,113) \u00a0\u00a0(11,790) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(97,444) \u00a0\u00a0(12,515) \u00a0\u00a0\n18"}, "hash": "a7b9fee4ae0f347a5a6c3852c65e36e0a82bf4564eddd61fc9c8040936a7cd9a", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$56,693,456 \u00a0$50,942,763 \u00a011.3%\nInternational Healthcare Solutions \u00a0\u00a06,764,935 \u00a0\u00a06,777,691 \u00a0(0.2)%\nIntersegment eliminations \u00a0\u00a0(1,186) \u00a0\u00a0(1,008) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$63,457,205 \u00a0$57,719,446 \u00a09.9%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S. ", "start_char_idx": 217, "end_char_idx": 517, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b44e530d-e562-49b3-908c-9110fd21d718": {"__data__": {"id_": "b44e530d-e562-49b3-908c-9110fd21d718", "embedding": null, "metadata": {"window": "Regarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$56,693,456 \u00a0$50,942,763 \u00a011.3%\nInternational Healthcare Solutions \u00a0\u00a06,764,935 \u00a0\u00a06,777,691 \u00a0(0.2)%\nIntersegment eliminations \u00a0\u00a0(1,186) \u00a0\u00a0(1,008) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$63,457,205 \u00a0$57,719,446 \u00a09.9%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$756,137 \u00a0$729,542 \u00a03.6%\nInternational Healthcare Solutions \u00a0\u00a0175,991 \u00a0\u00a0187,068 \u00a0(5.9)%\nTotal segment operating income \u00a0\u00a0932,128 \u00a0\u00a0916,610 \u00a01.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(4,855) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(54,270) \u00a0\u00a016,059 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(140,114) \u00a0\u00a0(77,952) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,813) \u00a0\u00a0(52,090) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(59,113) \u00a0\u00a0(11,790) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(97,444) \u00a0\u00a0(12,515) \u00a0\u00a0\n18", "original_text": "Healthcare Solutions \u00a0$756,137 \u00a0$729,542 \u00a03.6%\nInternational Healthcare Solutions \u00a0\u00a0175,991 \u00a0\u00a0187,068 \u00a0(5.9)%\nTotal segment operating income \u00a0\u00a0932,128 \u00a0\u00a0916,610 \u00a01.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(4,855) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(54,270) \u00a0\u00a016,059 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(140,114) \u00a0\u00a0(77,952) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,813) \u00a0\u00a0(52,090) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(59,113) \u00a0\u00a0(11,790) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(97,444) \u00a0\u00a0(12,515) \u00a0\u00a0\n18", "page_label": "18", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "18c50b95-a0e6-4159-abc8-a85289142737", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dfc86982e35d7b7dcf58f4fcdd4442cdb2d5f5b03fab2537a94bb13a8c1b7431", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2e6fb57-7441-4946-bea5-4460bdf1bf2d", "node_type": "1", "metadata": {"window": "Regarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$56,693,456 \u00a0$50,942,763 \u00a011.3%\nInternational Healthcare Solutions \u00a0\u00a06,764,935 \u00a0\u00a06,777,691 \u00a0(0.2)%\nIntersegment eliminations \u00a0\u00a0(1,186) \u00a0\u00a0(1,008) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$63,457,205 \u00a0$57,719,446 \u00a09.9%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$756,137 \u00a0$729,542 \u00a03.6%\nInternational Healthcare Solutions \u00a0\u00a0175,991 \u00a0\u00a0187,068 \u00a0(5.9)%\nTotal segment operating income \u00a0\u00a0932,128 \u00a0\u00a0916,610 \u00a01.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(4,855) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(54,270) \u00a0\u00a016,059 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(140,114) \u00a0\u00a0(77,952) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,813) \u00a0\u00a0(52,090) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(59,113) \u00a0\u00a0(11,790) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(97,444) \u00a0\u00a0(12,515) \u00a0\u00a0\n18", "original_text": "Healthcare Solutions \u00a0$56,693,456 \u00a0$50,942,763 \u00a011.3%\nInternational Healthcare Solutions \u00a0\u00a06,764,935 \u00a0\u00a06,777,691 \u00a0(0.2)%\nIntersegment eliminations \u00a0\u00a0(1,186) \u00a0\u00a0(1,008) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$63,457,205 \u00a0$57,719,446 \u00a09.9%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S. ", "page_label": "18", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a5e5a444dd4c3d6d762f3691fcee5eca29dc374e243f8b619c23b19d77c0a0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8657904c-114f-429c-b8f2-ef46c033eebe", "node_type": "1", "metadata": {"window": "Operating income \u00a0$560,519 \u00a0$780,157 \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74% \u00a0\u00a02.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.40% \u00a0\u00a01.44% \u00a0\u00a0\nOperating income \u00a0\u00a01.33% \u00a0\u00a01.43% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.88% \u00a0\u00a011.15% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.28% \u00a0\u00a08.39% \u00a0\u00a0\nOperating income \u00a0\u00a02.60% \u00a0\u00a02.76% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.62% \u00a0\u00a03.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.73% \u00a0\u00a02.52% \u00a0\u00a0\nOperating income \u00a0\u00a00.88% \u00a0\u00a01.35% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.71% \u00a0\u00a03.84% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.24% \u00a0\u00a02.25% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.47% \u00a0\u00a01.59% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n19", "original_text": "Operating income \u00a0$560,519 \u00a0$780,157 \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. "}, "hash": "cf4d739b8cce56ea2db0672b5472d1cfd1e4372b27acddb299e2227cf268df3d", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$756,137 \u00a0$729,542 \u00a03.6%\nInternational Healthcare Solutions \u00a0\u00a0175,991 \u00a0\u00a0187,068 \u00a0(5.9)%\nTotal segment operating income \u00a0\u00a0932,128 \u00a0\u00a0916,610 \u00a01.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(4,855) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(54,270) \u00a0\u00a016,059 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(140,114) \u00a0\u00a0(77,952) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,813) \u00a0\u00a0(52,090) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(59,113) \u00a0\u00a0(11,790) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(97,444) \u00a0\u00a0(12,515) \u00a0\u00a0\n18", "start_char_idx": 517, "end_char_idx": 1120, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8657904c-114f-429c-b8f2-ef46c033eebe": {"__data__": {"id_": "8657904c-114f-429c-b8f2-ef46c033eebe", "embedding": null, "metadata": {"window": "Operating income \u00a0$560,519 \u00a0$780,157 \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74% \u00a0\u00a02.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.40% \u00a0\u00a01.44% \u00a0\u00a0\nOperating income \u00a0\u00a01.33% \u00a0\u00a01.43% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.88% \u00a0\u00a011.15% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.28% \u00a0\u00a08.39% \u00a0\u00a0\nOperating income \u00a0\u00a02.60% \u00a0\u00a02.76% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.62% \u00a0\u00a03.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.73% \u00a0\u00a02.52% \u00a0\u00a0\nOperating income \u00a0\u00a00.88% \u00a0\u00a01.35% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.71% \u00a0\u00a03.84% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.24% \u00a0\u00a02.25% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.47% \u00a0\u00a01.59% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n19", "original_text": "Operating income \u00a0$560,519 \u00a0$780,157 \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "19", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25d07277-3739-4196-bfcd-8f796d392da4", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50ec5e5a2021b5468278744979e5c0e2dc1a1b83650d48871016fe19e31c1ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b44e530d-e562-49b3-908c-9110fd21d718", "node_type": "1", "metadata": {"window": "Regarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$56,693,456 \u00a0$50,942,763 \u00a011.3%\nInternational Healthcare Solutions \u00a0\u00a06,764,935 \u00a0\u00a06,777,691 \u00a0(0.2)%\nIntersegment eliminations \u00a0\u00a0(1,186) \u00a0\u00a0(1,008) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$63,457,205 \u00a0$57,719,446 \u00a09.9%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$756,137 \u00a0$729,542 \u00a03.6%\nInternational Healthcare Solutions \u00a0\u00a0175,991 \u00a0\u00a0187,068 \u00a0(5.9)%\nTotal segment operating income \u00a0\u00a0932,128 \u00a0\u00a0916,610 \u00a01.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(4,855) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(54,270) \u00a0\u00a016,059 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(140,114) \u00a0\u00a0(77,952) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,813) \u00a0\u00a0(52,090) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(59,113) \u00a0\u00a0(11,790) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(97,444) \u00a0\u00a0(12,515) \u00a0\u00a0\n18", "original_text": "Healthcare Solutions \u00a0$756,137 \u00a0$729,542 \u00a03.6%\nInternational Healthcare Solutions \u00a0\u00a0175,991 \u00a0\u00a0187,068 \u00a0(5.9)%\nTotal segment operating income \u00a0\u00a0932,128 \u00a0\u00a0916,610 \u00a01.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(4,855) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(54,270) \u00a0\u00a016,059 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(140,114) \u00a0\u00a0(77,952) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,813) \u00a0\u00a0(52,090) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(59,113) \u00a0\u00a0(11,790) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(97,444) \u00a0\u00a0(12,515) \u00a0\u00a0\n18", "page_label": "18", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb401635d860749cc7e3c46b523b0362a25866c9f1d5df01233e9b966383a980", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47fd3b06-3139-4ecf-a53f-53eed305d51b", "node_type": "1", "metadata": {"window": "Operating income \u00a0$560,519 \u00a0$780,157 \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74% \u00a0\u00a02.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.40% \u00a0\u00a01.44% \u00a0\u00a0\nOperating income \u00a0\u00a01.33% \u00a0\u00a01.43% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.88% \u00a0\u00a011.15% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.28% \u00a0\u00a08.39% \u00a0\u00a0\nOperating income \u00a0\u00a02.60% \u00a0\u00a02.76% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.62% \u00a0\u00a03.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.73% \u00a0\u00a02.52% \u00a0\u00a0\nOperating income \u00a0\u00a00.88% \u00a0\u00a01.35% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.71% \u00a0\u00a03.84% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.24% \u00a0\u00a02.25% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.47% \u00a0\u00a01.59% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n19", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74% \u00a0\u00a02.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.40% \u00a0\u00a01.44% \u00a0\u00a0\nOperating income \u00a0\u00a01.33% \u00a0\u00a01.43% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.88% \u00a0\u00a011.15% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.28% \u00a0\u00a08.39% \u00a0\u00a0\nOperating income \u00a0\u00a02.60% \u00a0\u00a02.76% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.62% \u00a0\u00a03.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.73% \u00a0\u00a02.52% \u00a0\u00a0\nOperating income \u00a0\u00a00.88% \u00a0\u00a01.35% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.71% \u00a0\u00a03.84% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.24% \u00a0\u00a02.25% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.47% \u00a0\u00a01.59% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n"}, "hash": "f985b066c4eb218b9a5106a41e4ddf0f06a7729d3b4b160d0169d02564897bda", "class_name": "RelatedNodeInfo"}}, "text": "Operating income \u00a0$560,519 \u00a0$780,157 \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "start_char_idx": 0, "end_char_idx": 106, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47fd3b06-3139-4ecf-a53f-53eed305d51b": {"__data__": {"id_": "47fd3b06-3139-4ecf-a53f-53eed305d51b", "embedding": null, "metadata": {"window": "Operating income \u00a0$560,519 \u00a0$780,157 \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74% \u00a0\u00a02.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.40% \u00a0\u00a01.44% \u00a0\u00a0\nOperating income \u00a0\u00a01.33% \u00a0\u00a01.43% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.88% \u00a0\u00a011.15% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.28% \u00a0\u00a08.39% \u00a0\u00a0\nOperating income \u00a0\u00a02.60% \u00a0\u00a02.76% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.62% \u00a0\u00a03.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.73% \u00a0\u00a02.52% \u00a0\u00a0\nOperating income \u00a0\u00a00.88% \u00a0\u00a01.35% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.71% \u00a0\u00a03.84% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.24% \u00a0\u00a02.25% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.47% \u00a0\u00a01.59% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n19", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74% \u00a0\u00a02.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.40% \u00a0\u00a01.44% \u00a0\u00a0\nOperating income \u00a0\u00a01.33% \u00a0\u00a01.43% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.88% \u00a0\u00a011.15% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.28% \u00a0\u00a08.39% \u00a0\u00a0\nOperating income \u00a0\u00a02.60% \u00a0\u00a02.76% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.62% \u00a0\u00a03.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.73% \u00a0\u00a02.52% \u00a0\u00a0\nOperating income \u00a0\u00a00.88% \u00a0\u00a01.35% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.71% \u00a0\u00a03.84% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.24% \u00a0\u00a02.25% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.47% \u00a0\u00a01.59% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "19", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25d07277-3739-4196-bfcd-8f796d392da4", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50ec5e5a2021b5468278744979e5c0e2dc1a1b83650d48871016fe19e31c1ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8657904c-114f-429c-b8f2-ef46c033eebe", "node_type": "1", "metadata": {"window": "Operating income \u00a0$560,519 \u00a0$780,157 \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74% \u00a0\u00a02.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.40% \u00a0\u00a01.44% \u00a0\u00a0\nOperating income \u00a0\u00a01.33% \u00a0\u00a01.43% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.88% \u00a0\u00a011.15% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.28% \u00a0\u00a08.39% \u00a0\u00a0\nOperating income \u00a0\u00a02.60% \u00a0\u00a02.76% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.62% \u00a0\u00a03.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.73% \u00a0\u00a02.52% \u00a0\u00a0\nOperating income \u00a0\u00a00.88% \u00a0\u00a01.35% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.71% \u00a0\u00a03.84% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.24% \u00a0\u00a02.25% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.47% \u00a0\u00a01.59% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n19", "original_text": "Operating income \u00a0$560,519 \u00a0$780,157 \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "19", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dbaf090b16554fcbb6b037bc475c0bd2e875e0e1e007252ee35c85e748eff750", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb6990ef-f748-4f48-8f7e-89fe735989be", "node_type": "1", "metadata": {"window": "Operating income \u00a0$560,519 \u00a0$780,157 \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74% \u00a0\u00a02.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.40% \u00a0\u00a01.44% \u00a0\u00a0\nOperating income \u00a0\u00a01.33% \u00a0\u00a01.43% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.88% \u00a0\u00a011.15% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.28% \u00a0\u00a08.39% \u00a0\u00a0\nOperating income \u00a0\u00a02.60% \u00a0\u00a02.76% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.62% \u00a0\u00a03.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.73% \u00a0\u00a02.52% \u00a0\u00a0\nOperating income \u00a0\u00a00.88% \u00a0\u00a01.35% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.71% \u00a0\u00a03.84% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.24% \u00a0\u00a02.25% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.47% \u00a0\u00a01.59% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n19", "original_text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n19"}, "hash": "666d5322d8cba0f7fd38fe475829b7f282f0726104644e4f6af7e80e873e585e", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74% \u00a0\u00a02.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.40% \u00a0\u00a01.44% \u00a0\u00a0\nOperating income \u00a0\u00a01.33% \u00a0\u00a01.43% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.88% \u00a0\u00a011.15% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.28% \u00a0\u00a08.39% \u00a0\u00a0\nOperating income \u00a0\u00a02.60% \u00a0\u00a02.76% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.62% \u00a0\u00a03.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.73% \u00a0\u00a02.52% \u00a0\u00a0\nOperating income \u00a0\u00a00.88% \u00a0\u00a01.35% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.71% \u00a0\u00a03.84% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.24% \u00a0\u00a02.25% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.47% \u00a0\u00a01.59% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "start_char_idx": 106, "end_char_idx": 939, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb6990ef-f748-4f48-8f7e-89fe735989be": {"__data__": {"id_": "eb6990ef-f748-4f48-8f7e-89fe735989be", "embedding": null, "metadata": {"window": "Operating income \u00a0$560,519 \u00a0$780,157 \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74% \u00a0\u00a02.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.40% \u00a0\u00a01.44% \u00a0\u00a0\nOperating income \u00a0\u00a01.33% \u00a0\u00a01.43% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.88% \u00a0\u00a011.15% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.28% \u00a0\u00a08.39% \u00a0\u00a0\nOperating income \u00a0\u00a02.60% \u00a0\u00a02.76% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.62% \u00a0\u00a03.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.73% \u00a0\u00a02.52% \u00a0\u00a0\nOperating income \u00a0\u00a00.88% \u00a0\u00a01.35% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.71% \u00a0\u00a03.84% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.24% \u00a0\u00a02.25% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.47% \u00a0\u00a01.59% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n19", "original_text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n19", "page_label": "19", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25d07277-3739-4196-bfcd-8f796d392da4", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50ec5e5a2021b5468278744979e5c0e2dc1a1b83650d48871016fe19e31c1ea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47fd3b06-3139-4ecf-a53f-53eed305d51b", "node_type": "1", "metadata": {"window": "Operating income \u00a0$560,519 \u00a0$780,157 \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74% \u00a0\u00a02.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.40% \u00a0\u00a01.44% \u00a0\u00a0\nOperating income \u00a0\u00a01.33% \u00a0\u00a01.43% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.88% \u00a0\u00a011.15% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.28% \u00a0\u00a08.39% \u00a0\u00a0\nOperating income \u00a0\u00a02.60% \u00a0\u00a02.76% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.62% \u00a0\u00a03.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.73% \u00a0\u00a02.52% \u00a0\u00a0\nOperating income \u00a0\u00a00.88% \u00a0\u00a01.35% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.71% \u00a0\u00a03.84% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.24% \u00a0\u00a02.25% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.47% \u00a0\u00a01.59% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n19", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74% \u00a0\u00a02.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.40% \u00a0\u00a01.44% \u00a0\u00a0\nOperating income \u00a0\u00a01.33% \u00a0\u00a01.43% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.88% \u00a0\u00a011.15% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.28% \u00a0\u00a08.39% \u00a0\u00a0\nOperating income \u00a0\u00a02.60% \u00a0\u00a02.76% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.62% \u00a0\u00a03.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.73% \u00a0\u00a02.52% \u00a0\u00a0\nOperating income \u00a0\u00a00.88% \u00a0\u00a01.35% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.71% \u00a0\u00a03.84% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.24% \u00a0\u00a02.25% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.47% \u00a0\u00a01.59% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "19", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40d6ac732b03139faa0256342c6272afd448d751d5d880b811668af9c63feeda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d6d9744-4328-48d7-98f2-e765d82db6ef", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$112,930,035 \u00a0$103,922,410 \u00a08.7%\nInternational Healthcare Solutions \u00a0\u00a013,376,213 \u00a0\u00a013,427,473 \u00a0(0.4)%\nIntersegment eliminations \u00a0\u00a0(2,211) \u00a0\u00a0(1,627) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$126,304,037 \u00a0$117,348,256 \u00a07.6%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,328,553 \u00a0$1,298,629 \u00a02.3%\nInternational Healthcare Solutions \u00a0\u00a0337,273 \u00a0\u00a0367,128 \u00a0(8.1)%\nTotal segment operating income \u00a0\u00a01,665,826 \u00a0\u00a01,665,757 \u00a0\u2014%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(8,439) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(79,320) \u00a0\u00a060,738 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(211,992) \u00a0\u00a0(157,458) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(28,519) \u00a0\u00a0(84,725) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(80,109) \u00a0\u00a0(33,140) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(113,684) \u00a0\u00a0(23,499) \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a0\nOperating income \u00a0$1,193,662 \u00a0$1,424,562 \u00a0(16.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20", "original_text": "\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S. "}, "hash": "b710f5e76bebce237adf3fd9634e91c95185a7ed534b8ac720d50856c08750fc", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n19", "start_char_idx": 939, "end_char_idx": 1032, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d6d9744-4328-48d7-98f2-e765d82db6ef": {"__data__": {"id_": "3d6d9744-4328-48d7-98f2-e765d82db6ef", "embedding": null, "metadata": {"window": "\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$112,930,035 \u00a0$103,922,410 \u00a08.7%\nInternational Healthcare Solutions \u00a0\u00a013,376,213 \u00a0\u00a013,427,473 \u00a0(0.4)%\nIntersegment eliminations \u00a0\u00a0(2,211) \u00a0\u00a0(1,627) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$126,304,037 \u00a0$117,348,256 \u00a07.6%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,328,553 \u00a0$1,298,629 \u00a02.3%\nInternational Healthcare Solutions \u00a0\u00a0337,273 \u00a0\u00a0367,128 \u00a0(8.1)%\nTotal segment operating income \u00a0\u00a01,665,826 \u00a0\u00a01,665,757 \u00a0\u2014%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(8,439) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(79,320) \u00a0\u00a060,738 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(211,992) \u00a0\u00a0(157,458) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(28,519) \u00a0\u00a0(84,725) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(80,109) \u00a0\u00a0(33,140) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(113,684) \u00a0\u00a0(23,499) \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a0\nOperating income \u00a0$1,193,662 \u00a0$1,424,562 \u00a0(16.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20", "original_text": "\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S. ", "page_label": "20", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8fcc4cbd-0eac-491e-a5b1-e4b4e05c1251", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fef7bcb8217a71cf7bbf94404ae44b60ec49b6e29eca47353da99b99e177a56f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb6990ef-f748-4f48-8f7e-89fe735989be", "node_type": "1", "metadata": {"window": "Operating income \u00a0$560,519 \u00a0$780,157 \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74% \u00a0\u00a02.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.40% \u00a0\u00a01.44% \u00a0\u00a0\nOperating income \u00a0\u00a01.33% \u00a0\u00a01.43% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.88% \u00a0\u00a011.15% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.28% \u00a0\u00a08.39% \u00a0\u00a0\nOperating income \u00a0\u00a02.60% \u00a0\u00a02.76% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.62% \u00a0\u00a03.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.73% \u00a0\u00a02.52% \u00a0\u00a0\nOperating income \u00a0\u00a00.88% \u00a0\u00a01.35% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.71% \u00a0\u00a03.84% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.24% \u00a0\u00a02.25% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.47% \u00a0\u00a01.59% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n19", "original_text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n19", "page_label": "19", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "105740aa83c1b420b3e80e60238130a9189e6ed8a9b0c958467c6aecc8fa41d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "923071aa-73c5-4598-b2c4-52931edb8a36", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$112,930,035 \u00a0$103,922,410 \u00a08.7%\nInternational Healthcare Solutions \u00a0\u00a013,376,213 \u00a0\u00a013,427,473 \u00a0(0.4)%\nIntersegment eliminations \u00a0\u00a0(2,211) \u00a0\u00a0(1,627) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$126,304,037 \u00a0$117,348,256 \u00a07.6%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,328,553 \u00a0$1,298,629 \u00a02.3%\nInternational Healthcare Solutions \u00a0\u00a0337,273 \u00a0\u00a0367,128 \u00a0(8.1)%\nTotal segment operating income \u00a0\u00a01,665,826 \u00a0\u00a01,665,757 \u00a0\u2014%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(8,439) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(79,320) \u00a0\u00a060,738 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(211,992) \u00a0\u00a0(157,458) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(28,519) \u00a0\u00a0(84,725) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(80,109) \u00a0\u00a0(33,140) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(113,684) \u00a0\u00a0(23,499) \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a0\nOperating income \u00a0$1,193,662 \u00a0$1,424,562 \u00a0(16.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20", "original_text": "Healthcare Solutions \u00a0$112,930,035 \u00a0$103,922,410 \u00a08.7%\nInternational Healthcare Solutions \u00a0\u00a013,376,213 \u00a0\u00a013,427,473 \u00a0(0.4)%\nIntersegment eliminations \u00a0\u00a0(2,211) \u00a0\u00a0(1,627) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$126,304,037 \u00a0$117,348,256 \u00a07.6%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S. "}, "hash": "c662d410cf75a8631b3ed530218ff8080424ded0530740f2c30e587ead0cbb51", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S. ", "start_char_idx": 0, "end_char_idx": 68, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "923071aa-73c5-4598-b2c4-52931edb8a36": {"__data__": {"id_": "923071aa-73c5-4598-b2c4-52931edb8a36", "embedding": null, "metadata": {"window": "\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$112,930,035 \u00a0$103,922,410 \u00a08.7%\nInternational Healthcare Solutions \u00a0\u00a013,376,213 \u00a0\u00a013,427,473 \u00a0(0.4)%\nIntersegment eliminations \u00a0\u00a0(2,211) \u00a0\u00a0(1,627) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$126,304,037 \u00a0$117,348,256 \u00a07.6%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,328,553 \u00a0$1,298,629 \u00a02.3%\nInternational Healthcare Solutions \u00a0\u00a0337,273 \u00a0\u00a0367,128 \u00a0(8.1)%\nTotal segment operating income \u00a0\u00a01,665,826 \u00a0\u00a01,665,757 \u00a0\u2014%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(8,439) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(79,320) \u00a0\u00a060,738 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(211,992) \u00a0\u00a0(157,458) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(28,519) \u00a0\u00a0(84,725) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(80,109) \u00a0\u00a0(33,140) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(113,684) \u00a0\u00a0(23,499) \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a0\nOperating income \u00a0$1,193,662 \u00a0$1,424,562 \u00a0(16.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20", "original_text": "Healthcare Solutions \u00a0$112,930,035 \u00a0$103,922,410 \u00a08.7%\nInternational Healthcare Solutions \u00a0\u00a013,376,213 \u00a0\u00a013,427,473 \u00a0(0.4)%\nIntersegment eliminations \u00a0\u00a0(2,211) \u00a0\u00a0(1,627) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$126,304,037 \u00a0$117,348,256 \u00a07.6%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S. ", "page_label": "20", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8fcc4cbd-0eac-491e-a5b1-e4b4e05c1251", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fef7bcb8217a71cf7bbf94404ae44b60ec49b6e29eca47353da99b99e177a56f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d6d9744-4328-48d7-98f2-e765d82db6ef", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$112,930,035 \u00a0$103,922,410 \u00a08.7%\nInternational Healthcare Solutions \u00a0\u00a013,376,213 \u00a0\u00a013,427,473 \u00a0(0.4)%\nIntersegment eliminations \u00a0\u00a0(2,211) \u00a0\u00a0(1,627) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$126,304,037 \u00a0$117,348,256 \u00a07.6%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,328,553 \u00a0$1,298,629 \u00a02.3%\nInternational Healthcare Solutions \u00a0\u00a0337,273 \u00a0\u00a0367,128 \u00a0(8.1)%\nTotal segment operating income \u00a0\u00a01,665,826 \u00a0\u00a01,665,757 \u00a0\u2014%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(8,439) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(79,320) \u00a0\u00a060,738 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(211,992) \u00a0\u00a0(157,458) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(28,519) \u00a0\u00a0(84,725) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(80,109) \u00a0\u00a0(33,140) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(113,684) \u00a0\u00a0(23,499) \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a0\nOperating income \u00a0$1,193,662 \u00a0$1,424,562 \u00a0(16.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20", "original_text": "\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S. ", "page_label": "20", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b5c74ded3e427f91fb5834824cd3e740509f5a0d575f742996581abb9f3e59ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bd9556b-5d6e-4198-b7b5-09785b79add0", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$112,930,035 \u00a0$103,922,410 \u00a08.7%\nInternational Healthcare Solutions \u00a0\u00a013,376,213 \u00a0\u00a013,427,473 \u00a0(0.4)%\nIntersegment eliminations \u00a0\u00a0(2,211) \u00a0\u00a0(1,627) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$126,304,037 \u00a0$117,348,256 \u00a07.6%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,328,553 \u00a0$1,298,629 \u00a02.3%\nInternational Healthcare Solutions \u00a0\u00a0337,273 \u00a0\u00a0367,128 \u00a0(8.1)%\nTotal segment operating income \u00a0\u00a01,665,826 \u00a0\u00a01,665,757 \u00a0\u2014%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(8,439) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(79,320) \u00a0\u00a060,738 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(211,992) \u00a0\u00a0(157,458) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(28,519) \u00a0\u00a0(84,725) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(80,109) \u00a0\u00a0(33,140) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(113,684) \u00a0\u00a0(23,499) \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a0\nOperating income \u00a0$1,193,662 \u00a0$1,424,562 \u00a0(16.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20", "original_text": "Healthcare Solutions \u00a0$1,328,553 \u00a0$1,298,629 \u00a02.3%\nInternational Healthcare Solutions \u00a0\u00a0337,273 \u00a0\u00a0367,128 \u00a0(8.1)%\nTotal segment operating income \u00a0\u00a01,665,826 \u00a0\u00a01,665,757 \u00a0\u2014%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(8,439) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(79,320) \u00a0\u00a060,738 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(211,992) \u00a0\u00a0(157,458) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(28,519) \u00a0\u00a0(84,725) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(80,109) \u00a0\u00a0(33,140) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(113,684) \u00a0\u00a0(23,499) \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a0\nOperating income \u00a0$1,193,662 \u00a0$1,424,562 \u00a0(16.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20"}, "hash": "623b265d93121e1ee82e642f69ba10a33c4d068b1b56c8b7e95a7be8172925e5", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$112,930,035 \u00a0$103,922,410 \u00a08.7%\nInternational Healthcare Solutions \u00a0\u00a013,376,213 \u00a0\u00a013,427,473 \u00a0(0.4)%\nIntersegment eliminations \u00a0\u00a0(2,211) \u00a0\u00a0(1,627) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$126,304,037 \u00a0$117,348,256 \u00a07.6%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S. ", "start_char_idx": 68, "end_char_idx": 371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bd9556b-5d6e-4198-b7b5-09785b79add0": {"__data__": {"id_": "8bd9556b-5d6e-4198-b7b5-09785b79add0", "embedding": null, "metadata": {"window": "\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$112,930,035 \u00a0$103,922,410 \u00a08.7%\nInternational Healthcare Solutions \u00a0\u00a013,376,213 \u00a0\u00a013,427,473 \u00a0(0.4)%\nIntersegment eliminations \u00a0\u00a0(2,211) \u00a0\u00a0(1,627) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$126,304,037 \u00a0$117,348,256 \u00a07.6%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,328,553 \u00a0$1,298,629 \u00a02.3%\nInternational Healthcare Solutions \u00a0\u00a0337,273 \u00a0\u00a0367,128 \u00a0(8.1)%\nTotal segment operating income \u00a0\u00a01,665,826 \u00a0\u00a01,665,757 \u00a0\u2014%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(8,439) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(79,320) \u00a0\u00a060,738 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(211,992) \u00a0\u00a0(157,458) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(28,519) \u00a0\u00a0(84,725) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(80,109) \u00a0\u00a0(33,140) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(113,684) \u00a0\u00a0(23,499) \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a0\nOperating income \u00a0$1,193,662 \u00a0$1,424,562 \u00a0(16.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20", "original_text": "Healthcare Solutions \u00a0$1,328,553 \u00a0$1,298,629 \u00a02.3%\nInternational Healthcare Solutions \u00a0\u00a0337,273 \u00a0\u00a0367,128 \u00a0(8.1)%\nTotal segment operating income \u00a0\u00a01,665,826 \u00a0\u00a01,665,757 \u00a0\u2014%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(8,439) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(79,320) \u00a0\u00a060,738 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(211,992) \u00a0\u00a0(157,458) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(28,519) \u00a0\u00a0(84,725) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(80,109) \u00a0\u00a0(33,140) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(113,684) \u00a0\u00a0(23,499) \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a0\nOperating income \u00a0$1,193,662 \u00a0$1,424,562 \u00a0(16.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20", "page_label": "20", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8fcc4cbd-0eac-491e-a5b1-e4b4e05c1251", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fef7bcb8217a71cf7bbf94404ae44b60ec49b6e29eca47353da99b99e177a56f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "923071aa-73c5-4598-b2c4-52931edb8a36", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$112,930,035 \u00a0$103,922,410 \u00a08.7%\nInternational Healthcare Solutions \u00a0\u00a013,376,213 \u00a0\u00a013,427,473 \u00a0(0.4)%\nIntersegment eliminations \u00a0\u00a0(2,211) \u00a0\u00a0(1,627) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$126,304,037 \u00a0$117,348,256 \u00a07.6%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,328,553 \u00a0$1,298,629 \u00a02.3%\nInternational Healthcare Solutions \u00a0\u00a0337,273 \u00a0\u00a0367,128 \u00a0(8.1)%\nTotal segment operating income \u00a0\u00a01,665,826 \u00a0\u00a01,665,757 \u00a0\u2014%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(8,439) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(79,320) \u00a0\u00a060,738 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(211,992) \u00a0\u00a0(157,458) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(28,519) \u00a0\u00a0(84,725) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(80,109) \u00a0\u00a0(33,140) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(113,684) \u00a0\u00a0(23,499) \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a0\nOperating income \u00a0$1,193,662 \u00a0$1,424,562 \u00a0(16.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20", "original_text": "Healthcare Solutions \u00a0$112,930,035 \u00a0$103,922,410 \u00a08.7%\nInternational Healthcare Solutions \u00a0\u00a013,376,213 \u00a0\u00a013,427,473 \u00a0(0.4)%\nIntersegment eliminations \u00a0\u00a0(2,211) \u00a0\u00a0(1,627) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$126,304,037 \u00a0$117,348,256 \u00a07.6%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S. ", "page_label": "20", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f978b928896ad42ae50986da5df384e3ac15fc3ea9799f799e762b79dfa9be76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bff4d05-67f4-4ce1-89f4-e93e90db1346", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.60% \u00a0\u00a02.64% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.42% \u00a0\u00a01.39% \u00a0\u00a0\nOperating income \u00a0\u00a01.18% \u00a0\u00a01.25% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.53% \u00a0\u00a011.12% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.01% \u00a0\u00a08.38% \u00a0\u00a0\nOperating income \u00a0\u00a02.52% \u00a0\u00a02.73% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.52% \u00a0\u00a03.66% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.57% \u00a0\u00a02.45% \u00a0\u00a0\nOperating income \u00a0\u00a00.95% \u00a0\u00a01.21% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55% \u00a0\u00a03.61% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23% \u00a0\u00a02.19% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.32% \u00a0\u00a01.42% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0 March 31, \u00a0September 30,\n21", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. "}, "hash": "0724a6dca922f9e0c00a463b4949320e60c563a1154b6ff62ae3c28851e21433", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$1,328,553 \u00a0$1,298,629 \u00a02.3%\nInternational Healthcare Solutions \u00a0\u00a0337,273 \u00a0\u00a0367,128 \u00a0(8.1)%\nTotal segment operating income \u00a0\u00a01,665,826 \u00a0\u00a01,665,757 \u00a0\u2014%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(8,439) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(79,320) \u00a0\u00a060,738 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(211,992) \u00a0\u00a0(157,458) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(28,519) \u00a0\u00a0(84,725) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(80,109) \u00a0\u00a0(33,140) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(113,684) \u00a0\u00a0(23,499) \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a0\nOperating income \u00a0$1,193,662 \u00a0$1,424,562 \u00a0(16.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20", "start_char_idx": 371, "end_char_idx": 1119, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bff4d05-67f4-4ce1-89f4-e93e90db1346": {"__data__": {"id_": "5bff4d05-67f4-4ce1-89f4-e93e90db1346", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.60% \u00a0\u00a02.64% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.42% \u00a0\u00a01.39% \u00a0\u00a0\nOperating income \u00a0\u00a01.18% \u00a0\u00a01.25% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.53% \u00a0\u00a011.12% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.01% \u00a0\u00a08.38% \u00a0\u00a0\nOperating income \u00a0\u00a02.52% \u00a0\u00a02.73% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.52% \u00a0\u00a03.66% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.57% \u00a0\u00a02.45% \u00a0\u00a0\nOperating income \u00a0\u00a00.95% \u00a0\u00a01.21% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55% \u00a0\u00a03.61% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23% \u00a0\u00a02.19% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.32% \u00a0\u00a01.42% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0 March 31, \u00a0September 30,\n21", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "21", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "098c5ca1-2c88-4bec-a459-b6f22556d52e", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eb32df56e6abbcc331f94ecfb281472f6ed2687ae7c568e25a868db6c2638994", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bd9556b-5d6e-4198-b7b5-09785b79add0", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$112,930,035 \u00a0$103,922,410 \u00a08.7%\nInternational Healthcare Solutions \u00a0\u00a013,376,213 \u00a0\u00a013,427,473 \u00a0(0.4)%\nIntersegment eliminations \u00a0\u00a0(2,211) \u00a0\u00a0(1,627) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$126,304,037 \u00a0$117,348,256 \u00a07.6%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,328,553 \u00a0$1,298,629 \u00a02.3%\nInternational Healthcare Solutions \u00a0\u00a0337,273 \u00a0\u00a0367,128 \u00a0(8.1)%\nTotal segment operating income \u00a0\u00a01,665,826 \u00a0\u00a01,665,757 \u00a0\u2014%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(8,439) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(79,320) \u00a0\u00a060,738 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(211,992) \u00a0\u00a0(157,458) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(28,519) \u00a0\u00a0(84,725) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(80,109) \u00a0\u00a0(33,140) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(113,684) \u00a0\u00a0(23,499) \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a0\nOperating income \u00a0$1,193,662 \u00a0$1,424,562 \u00a0(16.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20", "original_text": "Healthcare Solutions \u00a0$1,328,553 \u00a0$1,298,629 \u00a02.3%\nInternational Healthcare Solutions \u00a0\u00a0337,273 \u00a0\u00a0367,128 \u00a0(8.1)%\nTotal segment operating income \u00a0\u00a01,665,826 \u00a0\u00a01,665,757 \u00a0\u2014%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(8,439) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(79,320) \u00a0\u00a060,738 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(211,992) \u00a0\u00a0(157,458) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(28,519) \u00a0\u00a0(84,725) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(80,109) \u00a0\u00a0(33,140) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(113,684) \u00a0\u00a0(23,499) \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a0\nOperating income \u00a0$1,193,662 \u00a0$1,424,562 \u00a0(16.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20", "page_label": "20", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4630fd810d33b0d8870ba1624cfe2333b6d414115cbcc595aa61b3823693137", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ee887a4-8828-4837-8f2a-f08691c364f2", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.60% \u00a0\u00a02.64% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.42% \u00a0\u00a01.39% \u00a0\u00a0\nOperating income \u00a0\u00a01.18% \u00a0\u00a01.25% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.53% \u00a0\u00a011.12% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.01% \u00a0\u00a08.38% \u00a0\u00a0\nOperating income \u00a0\u00a02.52% \u00a0\u00a02.73% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.52% \u00a0\u00a03.66% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.57% \u00a0\u00a02.45% \u00a0\u00a0\nOperating income \u00a0\u00a00.95% \u00a0\u00a01.21% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55% \u00a0\u00a03.61% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23% \u00a0\u00a02.19% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.32% \u00a0\u00a01.42% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0 March 31, \u00a0September 30,\n21", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.60% \u00a0\u00a02.64% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.42% \u00a0\u00a01.39% \u00a0\u00a0\nOperating income \u00a0\u00a01.18% \u00a0\u00a01.25% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.53% \u00a0\u00a011.12% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.01% \u00a0\u00a08.38% \u00a0\u00a0\nOperating income \u00a0\u00a02.52% \u00a0\u00a02.73% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.52% \u00a0\u00a03.66% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.57% \u00a0\u00a02.45% \u00a0\u00a0\nOperating income \u00a0\u00a00.95% \u00a0\u00a01.21% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55% \u00a0\u00a03.61% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23% \u00a0\u00a02.19% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.32% \u00a0\u00a01.42% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n"}, "hash": "29620959c0ed291d332439c775343fffee960fe37cce31faa5c32a76d6a08a85", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ee887a4-8828-4837-8f2a-f08691c364f2": {"__data__": {"id_": "0ee887a4-8828-4837-8f2a-f08691c364f2", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.60% \u00a0\u00a02.64% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.42% \u00a0\u00a01.39% \u00a0\u00a0\nOperating income \u00a0\u00a01.18% \u00a0\u00a01.25% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.53% \u00a0\u00a011.12% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.01% \u00a0\u00a08.38% \u00a0\u00a0\nOperating income \u00a0\u00a02.52% \u00a0\u00a02.73% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.52% \u00a0\u00a03.66% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.57% \u00a0\u00a02.45% \u00a0\u00a0\nOperating income \u00a0\u00a00.95% \u00a0\u00a01.21% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55% \u00a0\u00a03.61% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23% \u00a0\u00a02.19% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.32% \u00a0\u00a01.42% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0 March 31, \u00a0September 30,\n21", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.60% \u00a0\u00a02.64% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.42% \u00a0\u00a01.39% \u00a0\u00a0\nOperating income \u00a0\u00a01.18% \u00a0\u00a01.25% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.53% \u00a0\u00a011.12% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.01% \u00a0\u00a08.38% \u00a0\u00a0\nOperating income \u00a0\u00a02.52% \u00a0\u00a02.73% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.52% \u00a0\u00a03.66% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.57% \u00a0\u00a02.45% \u00a0\u00a0\nOperating income \u00a0\u00a00.95% \u00a0\u00a01.21% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55% \u00a0\u00a03.61% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23% \u00a0\u00a02.19% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.32% \u00a0\u00a01.42% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "21", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "098c5ca1-2c88-4bec-a459-b6f22556d52e", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eb32df56e6abbcc331f94ecfb281472f6ed2687ae7c568e25a868db6c2638994", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bff4d05-67f4-4ce1-89f4-e93e90db1346", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.60% \u00a0\u00a02.64% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.42% \u00a0\u00a01.39% \u00a0\u00a0\nOperating income \u00a0\u00a01.18% \u00a0\u00a01.25% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.53% \u00a0\u00a011.12% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.01% \u00a0\u00a08.38% \u00a0\u00a0\nOperating income \u00a0\u00a02.52% \u00a0\u00a02.73% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.52% \u00a0\u00a03.66% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.57% \u00a0\u00a02.45% \u00a0\u00a0\nOperating income \u00a0\u00a00.95% \u00a0\u00a01.21% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55% \u00a0\u00a03.61% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23% \u00a0\u00a02.19% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.32% \u00a0\u00a01.42% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0 March 31, \u00a0September 30,\n21", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "21", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7830b5add898de496e8327aa8f1567edd6499922ee9ec77baae47020df494a3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c11240c0-51d3-4d62-8a94-a8d2989a6729", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.60% \u00a0\u00a02.64% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.42% \u00a0\u00a01.39% \u00a0\u00a0\nOperating income \u00a0\u00a01.18% \u00a0\u00a01.25% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.53% \u00a0\u00a011.12% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.01% \u00a0\u00a08.38% \u00a0\u00a0\nOperating income \u00a0\u00a02.52% \u00a0\u00a02.73% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.52% \u00a0\u00a03.66% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.57% \u00a0\u00a02.45% \u00a0\u00a0\nOperating income \u00a0\u00a00.95% \u00a0\u00a01.21% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55% \u00a0\u00a03.61% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23% \u00a0\u00a02.19% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.32% \u00a0\u00a01.42% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0 March 31, \u00a0September 30,\n21", "original_text": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0 March 31, \u00a0September 30,\n21"}, "hash": "1c2bbcceedd7cfac79c668024d72200613951b6715c4ff1b9b31cb017fd2dfce", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.60% \u00a0\u00a02.64% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.42% \u00a0\u00a01.39% \u00a0\u00a0\nOperating income \u00a0\u00a01.18% \u00a0\u00a01.25% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.53% \u00a0\u00a011.12% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.01% \u00a0\u00a08.38% \u00a0\u00a0\nOperating income \u00a0\u00a02.52% \u00a0\u00a02.73% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.52% \u00a0\u00a03.66% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.57% \u00a0\u00a02.45% \u00a0\u00a0\nOperating income \u00a0\u00a00.95% \u00a0\u00a01.21% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55% \u00a0\u00a03.61% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23% \u00a0\u00a02.19% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.32% \u00a0\u00a01.42% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "start_char_idx": 16, "end_char_idx": 849, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c11240c0-51d3-4d62-8a94-a8d2989a6729": {"__data__": {"id_": "c11240c0-51d3-4d62-8a94-a8d2989a6729", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.60% \u00a0\u00a02.64% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.42% \u00a0\u00a01.39% \u00a0\u00a0\nOperating income \u00a0\u00a01.18% \u00a0\u00a01.25% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.53% \u00a0\u00a011.12% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.01% \u00a0\u00a08.38% \u00a0\u00a0\nOperating income \u00a0\u00a02.52% \u00a0\u00a02.73% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.52% \u00a0\u00a03.66% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.57% \u00a0\u00a02.45% \u00a0\u00a0\nOperating income \u00a0\u00a00.95% \u00a0\u00a01.21% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55% \u00a0\u00a03.61% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23% \u00a0\u00a02.19% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.32% \u00a0\u00a01.42% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0 March 31, \u00a0September 30,\n21", "original_text": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0 March 31, \u00a0September 30,\n21", "page_label": "21", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "098c5ca1-2c88-4bec-a459-b6f22556d52e", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eb32df56e6abbcc331f94ecfb281472f6ed2687ae7c568e25a868db6c2638994", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ee887a4-8828-4837-8f2a-f08691c364f2", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.60% \u00a0\u00a02.64% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.42% \u00a0\u00a01.39% \u00a0\u00a0\nOperating income \u00a0\u00a01.18% \u00a0\u00a01.25% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.53% \u00a0\u00a011.12% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.01% \u00a0\u00a08.38% \u00a0\u00a0\nOperating income \u00a0\u00a02.52% \u00a0\u00a02.73% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.52% \u00a0\u00a03.66% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.57% \u00a0\u00a02.45% \u00a0\u00a0\nOperating income \u00a0\u00a00.95% \u00a0\u00a01.21% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55% \u00a0\u00a03.61% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23% \u00a0\u00a02.19% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.32% \u00a0\u00a01.42% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0 March 31, \u00a0September 30,\n21", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.60% \u00a0\u00a02.64% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.42% \u00a0\u00a01.39% \u00a0\u00a0\nOperating income \u00a0\u00a01.18% \u00a0\u00a01.25% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.53% \u00a0\u00a011.12% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.01% \u00a0\u00a08.38% \u00a0\u00a0\nOperating income \u00a0\u00a02.52% \u00a0\u00a02.73% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.52% \u00a0\u00a03.66% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.57% \u00a0\u00a02.45% \u00a0\u00a0\nOperating income \u00a0\u00a00.95% \u00a0\u00a01.21% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55% \u00a0\u00a03.61% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23% \u00a0\u00a02.19% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.32% \u00a0\u00a01.42% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "21", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cbf8ef3fc89b596194c69558b78f0f8fe8bf9bbbdfdf1ef927a0198037f851f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a968815-008f-4b6d-8342-c72bcee134b9", "node_type": "1", "metadata": {"window": "\u00a0 \u00a02023 \u00a0\u00a02022\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,539,406 \u00a0$3,388,189\nAccounts receivable, net \u00a019,491,097 \u00a0\u00a018,452,675\nInventories \u00a016,955,245 \u00a0\u00a015,556,394\nRight to recover assets \u00a01,480,545 \u00a0\u00a01,532,061\nPrepaid expenses and other \u00a0523,348 \u00a0\u00a0660,439\nTotal current assets \u00a039,989,641 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,149,937 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a014,518,383 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0228,524 \u00a0\u00a0237,571\nOther long-term assets \u00a01,879,698 \u00a0\u00a01,761,661\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $58,766,183 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $42,734,822 \u00a0$40,192,890\nOther current liabilities \u00a02,069,996 \u00a0\u00a02,214,592\nShort-term debt \u00a0266,279 \u00a0\u00a01,070,473\nTotal current liabilities \u00a045,071,097 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,666,532 \u00a0\u00a04,632,360\n22", "original_text": "\u00a0 \u00a02023 \u00a0\u00a02022\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,539,406 \u00a0$3,388,189\nAccounts receivable, net \u00a019,491,097 \u00a0\u00a018,452,675\nInventories \u00a016,955,245 \u00a0\u00a015,556,394\nRight to recover assets \u00a01,480,545 \u00a0\u00a01,532,061\nPrepaid expenses and other \u00a0523,348 \u00a0\u00a0660,439\nTotal current assets \u00a039,989,641 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,149,937 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a014,518,383 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0228,524 \u00a0\u00a0237,571\nOther long-term assets \u00a01,879,698 \u00a0\u00a01,761,661\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $58,766,183 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $42,734,822 \u00a0$40,192,890\nOther current liabilities \u00a02,069,996 \u00a0\u00a02,214,592\nShort-term debt \u00a0266,279 \u00a0\u00a01,070,473\nTotal current liabilities \u00a045,071,097 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,666,532 \u00a0\u00a04,632,360\n22"}, "hash": "5d60eabdd930e31ccb6bc07cdbd70fd86db47eaf3c52112c85ac83d9bf44ea78", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0 March 31, \u00a0September 30,\n21", "start_char_idx": 849, "end_char_idx": 979, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a968815-008f-4b6d-8342-c72bcee134b9": {"__data__": {"id_": "5a968815-008f-4b6d-8342-c72bcee134b9", "embedding": null, "metadata": {"window": "\u00a0 \u00a02023 \u00a0\u00a02022\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,539,406 \u00a0$3,388,189\nAccounts receivable, net \u00a019,491,097 \u00a0\u00a018,452,675\nInventories \u00a016,955,245 \u00a0\u00a015,556,394\nRight to recover assets \u00a01,480,545 \u00a0\u00a01,532,061\nPrepaid expenses and other \u00a0523,348 \u00a0\u00a0660,439\nTotal current assets \u00a039,989,641 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,149,937 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a014,518,383 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0228,524 \u00a0\u00a0237,571\nOther long-term assets \u00a01,879,698 \u00a0\u00a01,761,661\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $58,766,183 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $42,734,822 \u00a0$40,192,890\nOther current liabilities \u00a02,069,996 \u00a0\u00a02,214,592\nShort-term debt \u00a0266,279 \u00a0\u00a01,070,473\nTotal current liabilities \u00a045,071,097 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,666,532 \u00a0\u00a04,632,360\n22", "original_text": "\u00a0 \u00a02023 \u00a0\u00a02022\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,539,406 \u00a0$3,388,189\nAccounts receivable, net \u00a019,491,097 \u00a0\u00a018,452,675\nInventories \u00a016,955,245 \u00a0\u00a015,556,394\nRight to recover assets \u00a01,480,545 \u00a0\u00a01,532,061\nPrepaid expenses and other \u00a0523,348 \u00a0\u00a0660,439\nTotal current assets \u00a039,989,641 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,149,937 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a014,518,383 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0228,524 \u00a0\u00a0237,571\nOther long-term assets \u00a01,879,698 \u00a0\u00a01,761,661\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $58,766,183 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $42,734,822 \u00a0$40,192,890\nOther current liabilities \u00a02,069,996 \u00a0\u00a02,214,592\nShort-term debt \u00a0266,279 \u00a0\u00a01,070,473\nTotal current liabilities \u00a045,071,097 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,666,532 \u00a0\u00a04,632,360\n22", "page_label": "22", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "368884fa-8c24-4580-9d20-e4b1e224b1ed", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d603ee576a467b40bb92618f3cedf7cfbe72040fdf3e9cf06bdec2994bf0db9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c11240c0-51d3-4d62-8a94-a8d2989a6729", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.60% \u00a0\u00a02.64% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.42% \u00a0\u00a01.39% \u00a0\u00a0\nOperating income \u00a0\u00a01.18% \u00a0\u00a01.25% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.53% \u00a0\u00a011.12% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.01% \u00a0\u00a08.38% \u00a0\u00a0\nOperating income \u00a0\u00a02.52% \u00a0\u00a02.73% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.52% \u00a0\u00a03.66% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.57% \u00a0\u00a02.45% \u00a0\u00a0\nOperating income \u00a0\u00a00.95% \u00a0\u00a01.21% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55% \u00a0\u00a03.61% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23% \u00a0\u00a02.19% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.32% \u00a0\u00a01.42% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0 March 31, \u00a0September 30,\n21", "original_text": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0 March 31, \u00a0September 30,\n21", "page_label": "21", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc5ccef324802d9777ebdc412616e7f382dac73cf2e9f1621d8deb56041e6193", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbc1e5b9-4452-463f-8125-8a4f650a3355", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0272,292 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,741,795 \u00a0\u00a01,620,413\nOther long-term liabilities \u00a01,055,255 \u00a0\u00a0976,583\nAccrued litigation liability \u00a05,448,075 \u00a0\u00a05,461,758\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0511,137 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $58,766,183 \u00a0$56,560,616\nAMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0Six Months Ended\nMarch 31,\n\u00a0 \u00a02023 \u00a0\u00a02022\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $904,383 \u00a0$1,004,661\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0527,840 \u00a0\u00a0423,420\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(861,202) \u00a0\u00a0(527,521)\nInventories \u00a0(1,413,515) \u00a0\u00a0(215,479)\nAccounts payable \u00a02,391,172 \u00a0\u00a0598,411\nOther, net \u00a0(209,090) \u00a0\u00a0(153,496)\nNet cash provided by operating activities \u00a01,339,588 \u00a0\u00a01,129,996\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(178,581) \u00a0\u00a0(209,343)\n23", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0272,292 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,741,795 \u00a0\u00a01,620,413\nOther long-term liabilities \u00a01,055,255 \u00a0\u00a0976,583\nAccrued litigation liability \u00a05,448,075 \u00a0\u00a05,461,758\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0511,137 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $58,766,183 \u00a0$56,560,616\nAMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0Six Months Ended\nMarch 31,\n\u00a0 \u00a02023 \u00a0\u00a02022\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $904,383 \u00a0$1,004,661\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0527,840 \u00a0\u00a0423,420\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(861,202) \u00a0\u00a0(527,521)\nInventories \u00a0(1,413,515) \u00a0\u00a0(215,479)\nAccounts payable \u00a02,391,172 \u00a0\u00a0598,411\nOther, net \u00a0(209,090) \u00a0\u00a0(153,496)\nNet cash provided by operating activities \u00a01,339,588 \u00a0\u00a01,129,996\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(178,581) \u00a0\u00a0(209,343)\n23"}, "hash": "0ee5af24464dd52a5ab3bddaa81f0fea4c7e85b1c4aabe90b56903b282abbbc0", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a02023 \u00a0\u00a02022\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,539,406 \u00a0$3,388,189\nAccounts receivable, net \u00a019,491,097 \u00a0\u00a018,452,675\nInventories \u00a016,955,245 \u00a0\u00a015,556,394\nRight to recover assets \u00a01,480,545 \u00a0\u00a01,532,061\nPrepaid expenses and other \u00a0523,348 \u00a0\u00a0660,439\nTotal current assets \u00a039,989,641 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,149,937 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a014,518,383 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0228,524 \u00a0\u00a0237,571\nOther long-term assets \u00a01,879,698 \u00a0\u00a01,761,661\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $58,766,183 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $42,734,822 \u00a0$40,192,890\nOther current liabilities \u00a02,069,996 \u00a0\u00a02,214,592\nShort-term debt \u00a0266,279 \u00a0\u00a01,070,473\nTotal current liabilities \u00a045,071,097 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,666,532 \u00a0\u00a04,632,360\n22", "start_char_idx": 0, "end_char_idx": 890, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbc1e5b9-4452-463f-8125-8a4f650a3355": {"__data__": {"id_": "bbc1e5b9-4452-463f-8125-8a4f650a3355", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0272,292 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,741,795 \u00a0\u00a01,620,413\nOther long-term liabilities \u00a01,055,255 \u00a0\u00a0976,583\nAccrued litigation liability \u00a05,448,075 \u00a0\u00a05,461,758\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0511,137 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $58,766,183 \u00a0$56,560,616\nAMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0Six Months Ended\nMarch 31,\n\u00a0 \u00a02023 \u00a0\u00a02022\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $904,383 \u00a0$1,004,661\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0527,840 \u00a0\u00a0423,420\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(861,202) \u00a0\u00a0(527,521)\nInventories \u00a0(1,413,515) \u00a0\u00a0(215,479)\nAccounts payable \u00a02,391,172 \u00a0\u00a0598,411\nOther, net \u00a0(209,090) \u00a0\u00a0(153,496)\nNet cash provided by operating activities \u00a01,339,588 \u00a0\u00a01,129,996\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(178,581) \u00a0\u00a0(209,343)\n23", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0272,292 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,741,795 \u00a0\u00a01,620,413\nOther long-term liabilities \u00a01,055,255 \u00a0\u00a0976,583\nAccrued litigation liability \u00a05,448,075 \u00a0\u00a05,461,758\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0511,137 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $58,766,183 \u00a0$56,560,616\nAMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0Six Months Ended\nMarch 31,\n\u00a0 \u00a02023 \u00a0\u00a02022\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $904,383 \u00a0$1,004,661\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0527,840 \u00a0\u00a0423,420\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(861,202) \u00a0\u00a0(527,521)\nInventories \u00a0(1,413,515) \u00a0\u00a0(215,479)\nAccounts payable \u00a02,391,172 \u00a0\u00a0598,411\nOther, net \u00a0(209,090) \u00a0\u00a0(153,496)\nNet cash provided by operating activities \u00a01,339,588 \u00a0\u00a01,129,996\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(178,581) \u00a0\u00a0(209,343)\n23", "page_label": "23", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "552c9223-006f-4978-9615-5ff41f28d8d1", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35eb9649b1782447cce64918171168afa5df33797beae63d19ee63180c05de9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a968815-008f-4b6d-8342-c72bcee134b9", "node_type": "1", "metadata": {"window": "\u00a0 \u00a02023 \u00a0\u00a02022\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,539,406 \u00a0$3,388,189\nAccounts receivable, net \u00a019,491,097 \u00a0\u00a018,452,675\nInventories \u00a016,955,245 \u00a0\u00a015,556,394\nRight to recover assets \u00a01,480,545 \u00a0\u00a01,532,061\nPrepaid expenses and other \u00a0523,348 \u00a0\u00a0660,439\nTotal current assets \u00a039,989,641 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,149,937 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a014,518,383 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0228,524 \u00a0\u00a0237,571\nOther long-term assets \u00a01,879,698 \u00a0\u00a01,761,661\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $58,766,183 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $42,734,822 \u00a0$40,192,890\nOther current liabilities \u00a02,069,996 \u00a0\u00a02,214,592\nShort-term debt \u00a0266,279 \u00a0\u00a01,070,473\nTotal current liabilities \u00a045,071,097 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,666,532 \u00a0\u00a04,632,360\n22", "original_text": "\u00a0 \u00a02023 \u00a0\u00a02022\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,539,406 \u00a0$3,388,189\nAccounts receivable, net \u00a019,491,097 \u00a0\u00a018,452,675\nInventories \u00a016,955,245 \u00a0\u00a015,556,394\nRight to recover assets \u00a01,480,545 \u00a0\u00a01,532,061\nPrepaid expenses and other \u00a0523,348 \u00a0\u00a0660,439\nTotal current assets \u00a039,989,641 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,149,937 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a014,518,383 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0228,524 \u00a0\u00a0237,571\nOther long-term assets \u00a01,879,698 \u00a0\u00a01,761,661\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $58,766,183 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $42,734,822 \u00a0$40,192,890\nOther current liabilities \u00a02,069,996 \u00a0\u00a02,214,592\nShort-term debt \u00a0266,279 \u00a0\u00a01,070,473\nTotal current liabilities \u00a045,071,097 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,666,532 \u00a0\u00a04,632,360\n22", "page_label": "22", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e6088ed548a31527fedfaae059d112bc9a8c09fbe7e044f86bca6d059402e050", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eef444bc-bb42-4857-98f7-8d51aad2c7bc", "node_type": "1", "metadata": {"window": "Cost of acquired companies, net of cash acquired 1 \u00a0(1,409,681) \u00a0\u00a0(124,158)\nOther, net \u00a0(11,633) \u00a0\u00a0(3,663)\nNet cash used in investing activities \u00a0(1,599,895) \u00a0\u00a0(337,164)\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(685,101) \u00a0\u00a0(208,790)\nPurchases of common stock 2 \u00a0(807,214) \u00a0\u00a0(11,396)\nExercises of stock options \u00a031,712 \u00a0\u00a072,973\nCash dividends on common stock \u00a0(201,479) \u00a0\u00a0(197,923)\nEmployee tax withholdings related to restricted share vesting \u00a0(67,954) \u00a0\u00a0(35,200)\nOther, net \u00a0(3,355) \u00a0\u00a0(4,251)\nNet cash used in financing activities \u00a0(1,733,391) \u00a0\u00a0(384,587)\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a088,822 \u00a0\u00a0(5,055)\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within assets\nheld for sale \u00a0(1,904,876) \u00a0\u00a0403,190\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0(516)\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,904,876) \u00a0\u00a0402,674\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3 \u00a03,593,539 \u00a0\u00a03,070,128\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3 $1,688,663 \u00a0$3,472,802\n________________________________________\n1 Includes $1,406.3 million for the acquisition of PharmaLex. \n  2 Includes $28.4 million of purchases in September 2022 that cash settled in October 2022. \n  3 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n24", "original_text": "Cost of acquired companies, net of cash acquired 1 \u00a0(1,409,681) \u00a0\u00a0(124,158)\nOther, net \u00a0(11,633) \u00a0\u00a0(3,663)\nNet cash used in investing activities \u00a0(1,599,895) \u00a0\u00a0(337,164)\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(685,101) \u00a0\u00a0(208,790)\nPurchases of common stock 2 \u00a0(807,214) \u00a0\u00a0(11,396)\nExercises of stock options \u00a031,712 \u00a0\u00a072,973\nCash dividends on common stock \u00a0(201,479) \u00a0\u00a0(197,923)\nEmployee tax withholdings related to restricted share vesting \u00a0(67,954) \u00a0\u00a0(35,200)\nOther, net \u00a0(3,355) \u00a0\u00a0(4,251)\nNet cash used in financing activities \u00a0(1,733,391) \u00a0\u00a0(384,587)\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a088,822 \u00a0\u00a0(5,055)\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within assets\nheld for sale \u00a0(1,904,876) \u00a0\u00a0403,190\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0(516)\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,904,876) \u00a0\u00a0402,674\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3 \u00a03,593,539 \u00a0\u00a03,070,128\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3 $1,688,663 \u00a0$3,472,802\n________________________________________\n1 Includes $1,406.3 million for the acquisition of PharmaLex. \n "}, "hash": "6875d8312e61a7a4246d7930bf466588ae4cfaff59f12cce4978e8f9e4762962", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0272,292 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,741,795 \u00a0\u00a01,620,413\nOther long-term liabilities \u00a01,055,255 \u00a0\u00a0976,583\nAccrued litigation liability \u00a05,448,075 \u00a0\u00a05,461,758\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0511,137 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $58,766,183 \u00a0$56,560,616\nAMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0Six Months Ended\nMarch 31,\n\u00a0 \u00a02023 \u00a0\u00a02022\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $904,383 \u00a0$1,004,661\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0527,840 \u00a0\u00a0423,420\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(861,202) \u00a0\u00a0(527,521)\nInventories \u00a0(1,413,515) \u00a0\u00a0(215,479)\nAccounts payable \u00a02,391,172 \u00a0\u00a0598,411\nOther, net \u00a0(209,090) \u00a0\u00a0(153,496)\nNet cash provided by operating activities \u00a01,339,588 \u00a0\u00a01,129,996\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(178,581) \u00a0\u00a0(209,343)\n23", "start_char_idx": 0, "end_char_idx": 1005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eef444bc-bb42-4857-98f7-8d51aad2c7bc": {"__data__": {"id_": "eef444bc-bb42-4857-98f7-8d51aad2c7bc", "embedding": null, "metadata": {"window": "Cost of acquired companies, net of cash acquired 1 \u00a0(1,409,681) \u00a0\u00a0(124,158)\nOther, net \u00a0(11,633) \u00a0\u00a0(3,663)\nNet cash used in investing activities \u00a0(1,599,895) \u00a0\u00a0(337,164)\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(685,101) \u00a0\u00a0(208,790)\nPurchases of common stock 2 \u00a0(807,214) \u00a0\u00a0(11,396)\nExercises of stock options \u00a031,712 \u00a0\u00a072,973\nCash dividends on common stock \u00a0(201,479) \u00a0\u00a0(197,923)\nEmployee tax withholdings related to restricted share vesting \u00a0(67,954) \u00a0\u00a0(35,200)\nOther, net \u00a0(3,355) \u00a0\u00a0(4,251)\nNet cash used in financing activities \u00a0(1,733,391) \u00a0\u00a0(384,587)\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a088,822 \u00a0\u00a0(5,055)\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within assets\nheld for sale \u00a0(1,904,876) \u00a0\u00a0403,190\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0(516)\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,904,876) \u00a0\u00a0402,674\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3 \u00a03,593,539 \u00a0\u00a03,070,128\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3 $1,688,663 \u00a0$3,472,802\n________________________________________\n1 Includes $1,406.3 million for the acquisition of PharmaLex. \n  2 Includes $28.4 million of purchases in September 2022 that cash settled in October 2022. \n  3 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n24", "original_text": "Cost of acquired companies, net of cash acquired 1 \u00a0(1,409,681) \u00a0\u00a0(124,158)\nOther, net \u00a0(11,633) \u00a0\u00a0(3,663)\nNet cash used in investing activities \u00a0(1,599,895) \u00a0\u00a0(337,164)\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(685,101) \u00a0\u00a0(208,790)\nPurchases of common stock 2 \u00a0(807,214) \u00a0\u00a0(11,396)\nExercises of stock options \u00a031,712 \u00a0\u00a072,973\nCash dividends on common stock \u00a0(201,479) \u00a0\u00a0(197,923)\nEmployee tax withholdings related to restricted share vesting \u00a0(67,954) \u00a0\u00a0(35,200)\nOther, net \u00a0(3,355) \u00a0\u00a0(4,251)\nNet cash used in financing activities \u00a0(1,733,391) \u00a0\u00a0(384,587)\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a088,822 \u00a0\u00a0(5,055)\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within assets\nheld for sale \u00a0(1,904,876) \u00a0\u00a0403,190\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0(516)\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,904,876) \u00a0\u00a0402,674\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3 \u00a03,593,539 \u00a0\u00a03,070,128\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3 $1,688,663 \u00a0$3,472,802\n________________________________________\n1 Includes $1,406.3 million for the acquisition of PharmaLex. \n ", "page_label": "24", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42c6c531-bc0a-4846-8dee-a086f06147b8", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd3f01c97dcbcdf9a53d615ee5f22b7f1074f86586f168890eec3ab7035a461b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbc1e5b9-4452-463f-8125-8a4f650a3355", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0272,292 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,741,795 \u00a0\u00a01,620,413\nOther long-term liabilities \u00a01,055,255 \u00a0\u00a0976,583\nAccrued litigation liability \u00a05,448,075 \u00a0\u00a05,461,758\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0511,137 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $58,766,183 \u00a0$56,560,616\nAMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0Six Months Ended\nMarch 31,\n\u00a0 \u00a02023 \u00a0\u00a02022\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $904,383 \u00a0$1,004,661\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0527,840 \u00a0\u00a0423,420\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(861,202) \u00a0\u00a0(527,521)\nInventories \u00a0(1,413,515) \u00a0\u00a0(215,479)\nAccounts payable \u00a02,391,172 \u00a0\u00a0598,411\nOther, net \u00a0(209,090) \u00a0\u00a0(153,496)\nNet cash provided by operating activities \u00a01,339,588 \u00a0\u00a01,129,996\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(178,581) \u00a0\u00a0(209,343)\n23", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0272,292 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,741,795 \u00a0\u00a01,620,413\nOther long-term liabilities \u00a01,055,255 \u00a0\u00a0976,583\nAccrued litigation liability \u00a05,448,075 \u00a0\u00a05,461,758\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0511,137 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $58,766,183 \u00a0$56,560,616\nAMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0Six Months Ended\nMarch 31,\n\u00a0 \u00a02023 \u00a0\u00a02022\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $904,383 \u00a0$1,004,661\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0527,840 \u00a0\u00a0423,420\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(861,202) \u00a0\u00a0(527,521)\nInventories \u00a0(1,413,515) \u00a0\u00a0(215,479)\nAccounts payable \u00a02,391,172 \u00a0\u00a0598,411\nOther, net \u00a0(209,090) \u00a0\u00a0(153,496)\nNet cash provided by operating activities \u00a01,339,588 \u00a0\u00a01,129,996\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(178,581) \u00a0\u00a0(209,343)\n23", "page_label": "23", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c68eef0763d9930f3fe844d3328effe641d59bf8ddb373866f16c1ff81982a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbb30748-962e-4282-903e-1160d57593f0", "node_type": "1", "metadata": {"window": "Cost of acquired companies, net of cash acquired 1 \u00a0(1,409,681) \u00a0\u00a0(124,158)\nOther, net \u00a0(11,633) \u00a0\u00a0(3,663)\nNet cash used in investing activities \u00a0(1,599,895) \u00a0\u00a0(337,164)\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(685,101) \u00a0\u00a0(208,790)\nPurchases of common stock 2 \u00a0(807,214) \u00a0\u00a0(11,396)\nExercises of stock options \u00a031,712 \u00a0\u00a072,973\nCash dividends on common stock \u00a0(201,479) \u00a0\u00a0(197,923)\nEmployee tax withholdings related to restricted share vesting \u00a0(67,954) \u00a0\u00a0(35,200)\nOther, net \u00a0(3,355) \u00a0\u00a0(4,251)\nNet cash used in financing activities \u00a0(1,733,391) \u00a0\u00a0(384,587)\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a088,822 \u00a0\u00a0(5,055)\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within assets\nheld for sale \u00a0(1,904,876) \u00a0\u00a0403,190\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0(516)\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,904,876) \u00a0\u00a0402,674\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3 \u00a03,593,539 \u00a0\u00a03,070,128\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3 $1,688,663 \u00a0$3,472,802\n________________________________________\n1 Includes $1,406.3 million for the acquisition of PharmaLex. \n  2 Includes $28.4 million of purchases in September 2022 that cash settled in October 2022. \n  3 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n24", "original_text": "2 Includes $28.4 million of purchases in September 2022 that cash settled in October 2022. \n "}, "hash": "ce47e4cbac374a5e91011070d5d1ee9e86acfc07519e0556deaa1a62f468e511", "class_name": "RelatedNodeInfo"}}, "text": "Cost of acquired companies, net of cash acquired 1 \u00a0(1,409,681) \u00a0\u00a0(124,158)\nOther, net \u00a0(11,633) \u00a0\u00a0(3,663)\nNet cash used in investing activities \u00a0(1,599,895) \u00a0\u00a0(337,164)\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(685,101) \u00a0\u00a0(208,790)\nPurchases of common stock 2 \u00a0(807,214) \u00a0\u00a0(11,396)\nExercises of stock options \u00a031,712 \u00a0\u00a072,973\nCash dividends on common stock \u00a0(201,479) \u00a0\u00a0(197,923)\nEmployee tax withholdings related to restricted share vesting \u00a0(67,954) \u00a0\u00a0(35,200)\nOther, net \u00a0(3,355) \u00a0\u00a0(4,251)\nNet cash used in financing activities \u00a0(1,733,391) \u00a0\u00a0(384,587)\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a088,822 \u00a0\u00a0(5,055)\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within assets\nheld for sale \u00a0(1,904,876) \u00a0\u00a0403,190\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0(516)\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,904,876) \u00a0\u00a0402,674\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3 \u00a03,593,539 \u00a0\u00a03,070,128\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3 $1,688,663 \u00a0$3,472,802\n________________________________________\n1 Includes $1,406.3 million for the acquisition of PharmaLex. \n ", "start_char_idx": 0, "end_char_idx": 1287, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbb30748-962e-4282-903e-1160d57593f0": {"__data__": {"id_": "cbb30748-962e-4282-903e-1160d57593f0", "embedding": null, "metadata": {"window": "Cost of acquired companies, net of cash acquired 1 \u00a0(1,409,681) \u00a0\u00a0(124,158)\nOther, net \u00a0(11,633) \u00a0\u00a0(3,663)\nNet cash used in investing activities \u00a0(1,599,895) \u00a0\u00a0(337,164)\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(685,101) \u00a0\u00a0(208,790)\nPurchases of common stock 2 \u00a0(807,214) \u00a0\u00a0(11,396)\nExercises of stock options \u00a031,712 \u00a0\u00a072,973\nCash dividends on common stock \u00a0(201,479) \u00a0\u00a0(197,923)\nEmployee tax withholdings related to restricted share vesting \u00a0(67,954) \u00a0\u00a0(35,200)\nOther, net \u00a0(3,355) \u00a0\u00a0(4,251)\nNet cash used in financing activities \u00a0(1,733,391) \u00a0\u00a0(384,587)\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a088,822 \u00a0\u00a0(5,055)\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within assets\nheld for sale \u00a0(1,904,876) \u00a0\u00a0403,190\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0(516)\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,904,876) \u00a0\u00a0402,674\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3 \u00a03,593,539 \u00a0\u00a03,070,128\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3 $1,688,663 \u00a0$3,472,802\n________________________________________\n1 Includes $1,406.3 million for the acquisition of PharmaLex. \n  2 Includes $28.4 million of purchases in September 2022 that cash settled in October 2022. \n  3 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n24", "original_text": "2 Includes $28.4 million of purchases in September 2022 that cash settled in October 2022. \n ", "page_label": "24", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42c6c531-bc0a-4846-8dee-a086f06147b8", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd3f01c97dcbcdf9a53d615ee5f22b7f1074f86586f168890eec3ab7035a461b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eef444bc-bb42-4857-98f7-8d51aad2c7bc", "node_type": "1", "metadata": {"window": "Cost of acquired companies, net of cash acquired 1 \u00a0(1,409,681) \u00a0\u00a0(124,158)\nOther, net \u00a0(11,633) \u00a0\u00a0(3,663)\nNet cash used in investing activities \u00a0(1,599,895) \u00a0\u00a0(337,164)\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(685,101) \u00a0\u00a0(208,790)\nPurchases of common stock 2 \u00a0(807,214) \u00a0\u00a0(11,396)\nExercises of stock options \u00a031,712 \u00a0\u00a072,973\nCash dividends on common stock \u00a0(201,479) \u00a0\u00a0(197,923)\nEmployee tax withholdings related to restricted share vesting \u00a0(67,954) \u00a0\u00a0(35,200)\nOther, net \u00a0(3,355) \u00a0\u00a0(4,251)\nNet cash used in financing activities \u00a0(1,733,391) \u00a0\u00a0(384,587)\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a088,822 \u00a0\u00a0(5,055)\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within assets\nheld for sale \u00a0(1,904,876) \u00a0\u00a0403,190\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0(516)\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,904,876) \u00a0\u00a0402,674\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3 \u00a03,593,539 \u00a0\u00a03,070,128\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3 $1,688,663 \u00a0$3,472,802\n________________________________________\n1 Includes $1,406.3 million for the acquisition of PharmaLex. \n  2 Includes $28.4 million of purchases in September 2022 that cash settled in October 2022. \n  3 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n24", "original_text": "Cost of acquired companies, net of cash acquired 1 \u00a0(1,409,681) \u00a0\u00a0(124,158)\nOther, net \u00a0(11,633) \u00a0\u00a0(3,663)\nNet cash used in investing activities \u00a0(1,599,895) \u00a0\u00a0(337,164)\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(685,101) \u00a0\u00a0(208,790)\nPurchases of common stock 2 \u00a0(807,214) \u00a0\u00a0(11,396)\nExercises of stock options \u00a031,712 \u00a0\u00a072,973\nCash dividends on common stock \u00a0(201,479) \u00a0\u00a0(197,923)\nEmployee tax withholdings related to restricted share vesting \u00a0(67,954) \u00a0\u00a0(35,200)\nOther, net \u00a0(3,355) \u00a0\u00a0(4,251)\nNet cash used in financing activities \u00a0(1,733,391) \u00a0\u00a0(384,587)\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a088,822 \u00a0\u00a0(5,055)\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within assets\nheld for sale \u00a0(1,904,876) \u00a0\u00a0403,190\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0(516)\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,904,876) \u00a0\u00a0402,674\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3 \u00a03,593,539 \u00a0\u00a03,070,128\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3 $1,688,663 \u00a0$3,472,802\n________________________________________\n1 Includes $1,406.3 million for the acquisition of PharmaLex. \n ", "page_label": "24", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d07419a62f7958587f8d0b5ff4c9c9af654801ced1d895470d872397d86a508", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "beda0a27-823d-4e70-85e2-209790d00459", "node_type": "1", "metadata": {"window": "Cost of acquired companies, net of cash acquired 1 \u00a0(1,409,681) \u00a0\u00a0(124,158)\nOther, net \u00a0(11,633) \u00a0\u00a0(3,663)\nNet cash used in investing activities \u00a0(1,599,895) \u00a0\u00a0(337,164)\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(685,101) \u00a0\u00a0(208,790)\nPurchases of common stock 2 \u00a0(807,214) \u00a0\u00a0(11,396)\nExercises of stock options \u00a031,712 \u00a0\u00a072,973\nCash dividends on common stock \u00a0(201,479) \u00a0\u00a0(197,923)\nEmployee tax withholdings related to restricted share vesting \u00a0(67,954) \u00a0\u00a0(35,200)\nOther, net \u00a0(3,355) \u00a0\u00a0(4,251)\nNet cash used in financing activities \u00a0(1,733,391) \u00a0\u00a0(384,587)\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a088,822 \u00a0\u00a0(5,055)\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within assets\nheld for sale \u00a0(1,904,876) \u00a0\u00a0403,190\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0(516)\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,904,876) \u00a0\u00a0402,674\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3 \u00a03,593,539 \u00a0\u00a03,070,128\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3 $1,688,663 \u00a0$3,472,802\n________________________________________\n1 Includes $1,406.3 million for the acquisition of PharmaLex. \n  2 Includes $28.4 million of purchases in September 2022 that cash settled in October 2022. \n  3 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n24", "original_text": "3 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n24"}, "hash": "56ce7c7410c7c7633fdd8e8321055bd970d89e15a476264f850328686fa46c20", "class_name": "RelatedNodeInfo"}}, "text": "2 Includes $28.4 million of purchases in September 2022 that cash settled in October 2022. \n ", "start_char_idx": 1287, "end_char_idx": 1380, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "beda0a27-823d-4e70-85e2-209790d00459": {"__data__": {"id_": "beda0a27-823d-4e70-85e2-209790d00459", "embedding": null, "metadata": {"window": "Cost of acquired companies, net of cash acquired 1 \u00a0(1,409,681) \u00a0\u00a0(124,158)\nOther, net \u00a0(11,633) \u00a0\u00a0(3,663)\nNet cash used in investing activities \u00a0(1,599,895) \u00a0\u00a0(337,164)\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(685,101) \u00a0\u00a0(208,790)\nPurchases of common stock 2 \u00a0(807,214) \u00a0\u00a0(11,396)\nExercises of stock options \u00a031,712 \u00a0\u00a072,973\nCash dividends on common stock \u00a0(201,479) \u00a0\u00a0(197,923)\nEmployee tax withholdings related to restricted share vesting \u00a0(67,954) \u00a0\u00a0(35,200)\nOther, net \u00a0(3,355) \u00a0\u00a0(4,251)\nNet cash used in financing activities \u00a0(1,733,391) \u00a0\u00a0(384,587)\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a088,822 \u00a0\u00a0(5,055)\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within assets\nheld for sale \u00a0(1,904,876) \u00a0\u00a0403,190\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0(516)\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,904,876) \u00a0\u00a0402,674\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3 \u00a03,593,539 \u00a0\u00a03,070,128\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3 $1,688,663 \u00a0$3,472,802\n________________________________________\n1 Includes $1,406.3 million for the acquisition of PharmaLex. \n  2 Includes $28.4 million of purchases in September 2022 that cash settled in October 2022. \n  3 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n24", "original_text": "3 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n24", "page_label": "24", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42c6c531-bc0a-4846-8dee-a086f06147b8", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd3f01c97dcbcdf9a53d615ee5f22b7f1074f86586f168890eec3ab7035a461b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbb30748-962e-4282-903e-1160d57593f0", "node_type": "1", "metadata": {"window": "Cost of acquired companies, net of cash acquired 1 \u00a0(1,409,681) \u00a0\u00a0(124,158)\nOther, net \u00a0(11,633) \u00a0\u00a0(3,663)\nNet cash used in investing activities \u00a0(1,599,895) \u00a0\u00a0(337,164)\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(685,101) \u00a0\u00a0(208,790)\nPurchases of common stock 2 \u00a0(807,214) \u00a0\u00a0(11,396)\nExercises of stock options \u00a031,712 \u00a0\u00a072,973\nCash dividends on common stock \u00a0(201,479) \u00a0\u00a0(197,923)\nEmployee tax withholdings related to restricted share vesting \u00a0(67,954) \u00a0\u00a0(35,200)\nOther, net \u00a0(3,355) \u00a0\u00a0(4,251)\nNet cash used in financing activities \u00a0(1,733,391) \u00a0\u00a0(384,587)\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a088,822 \u00a0\u00a0(5,055)\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within assets\nheld for sale \u00a0(1,904,876) \u00a0\u00a0403,190\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0(516)\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,904,876) \u00a0\u00a0402,674\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3 \u00a03,593,539 \u00a0\u00a03,070,128\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3 $1,688,663 \u00a0$3,472,802\n________________________________________\n1 Includes $1,406.3 million for the acquisition of PharmaLex. \n  2 Includes $28.4 million of purchases in September 2022 that cash settled in October 2022. \n  3 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n24", "original_text": "2 Includes $28.4 million of purchases in September 2022 that cash settled in October 2022. \n ", "page_label": "24", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "044e55ddb119cebf9548f56feecb9c4f46e12bb5268767d90f4892689d12f769", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3bd1824e-1d27-4e6f-a619-d37f0aff50dc", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0March 31, \n2023 \u00a0September\n30, \n2022 \u00a0March 31, \n2022 \u00a0September\n30, \n2021\nCash and cash equivalents \u00a0$1,539,406 \u00a0$3,388,189 \u00a0$2,960,759 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a087,740 \u00a0\u00a0144,980 \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a061,517 \u00a0\u00a060,370 \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,688,663 \u00a0$3,593,539 \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "\u00a0 \u00a0March 31, \n2023 \u00a0September\n30, \n2022 \u00a0March 31, \n2022 \u00a0September\n30, \n2021\nCash and cash equivalents \u00a0$1,539,406 \u00a0$3,388,189 \u00a0$2,960,759 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a087,740 \u00a0\u00a0144,980 \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a061,517 \u00a0\u00a060,370 \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,688,663 \u00a0$3,593,539 \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. "}, "hash": "ae4c6f3d8875a937cf60ad6a731f911c1396f6ee03431ada2905834533520dc7", "class_name": "RelatedNodeInfo"}}, "text": "3 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n24", "start_char_idx": 1380, "end_char_idx": 1608, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3bd1824e-1d27-4e6f-a619-d37f0aff50dc": {"__data__": {"id_": "3bd1824e-1d27-4e6f-a619-d37f0aff50dc", "embedding": null, "metadata": {"window": "\u00a0 \u00a0March 31, \n2023 \u00a0September\n30, \n2022 \u00a0March 31, \n2022 \u00a0September\n30, \n2021\nCash and cash equivalents \u00a0$1,539,406 \u00a0$3,388,189 \u00a0$2,960,759 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a087,740 \u00a0\u00a0144,980 \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a061,517 \u00a0\u00a060,370 \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,688,663 \u00a0$3,593,539 \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "\u00a0 \u00a0March 31, \n2023 \u00a0September\n30, \n2022 \u00a0March 31, \n2022 \u00a0September\n30, \n2021\nCash and cash equivalents \u00a0$1,539,406 \u00a0$3,388,189 \u00a0$2,960,759 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a087,740 \u00a0\u00a0144,980 \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a061,517 \u00a0\u00a060,370 \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,688,663 \u00a0$3,593,539 \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee046645-a402-466b-bb1a-bb5f0f792a30", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2afdf66ba72a5392bd27182dc35bd4e0ccc46f2da91dc8718e4953f72482c92a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "beda0a27-823d-4e70-85e2-209790d00459", "node_type": "1", "metadata": {"window": "Cost of acquired companies, net of cash acquired 1 \u00a0(1,409,681) \u00a0\u00a0(124,158)\nOther, net \u00a0(11,633) \u00a0\u00a0(3,663)\nNet cash used in investing activities \u00a0(1,599,895) \u00a0\u00a0(337,164)\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(685,101) \u00a0\u00a0(208,790)\nPurchases of common stock 2 \u00a0(807,214) \u00a0\u00a0(11,396)\nExercises of stock options \u00a031,712 \u00a0\u00a072,973\nCash dividends on common stock \u00a0(201,479) \u00a0\u00a0(197,923)\nEmployee tax withholdings related to restricted share vesting \u00a0(67,954) \u00a0\u00a0(35,200)\nOther, net \u00a0(3,355) \u00a0\u00a0(4,251)\nNet cash used in financing activities \u00a0(1,733,391) \u00a0\u00a0(384,587)\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a088,822 \u00a0\u00a0(5,055)\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within assets\nheld for sale \u00a0(1,904,876) \u00a0\u00a0403,190\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0(516)\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,904,876) \u00a0\u00a0402,674\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3 \u00a03,593,539 \u00a0\u00a03,070,128\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3 $1,688,663 \u00a0$3,472,802\n________________________________________\n1 Includes $1,406.3 million for the acquisition of PharmaLex. \n  2 Includes $28.4 million of purchases in September 2022 that cash settled in October 2022. \n  3 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n24", "original_text": "3 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n24", "page_label": "24", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "071f2f84da95ddb64164d5f035322fb2f3571a401882bd829fb05d5db413d60f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb547f50-97a8-4e90-aebf-636289a27e38", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0March 31, \n2023 \u00a0September\n30, \n2022 \u00a0March 31, \n2022 \u00a0September\n30, \n2021\nCash and cash equivalents \u00a0$1,539,406 \u00a0$3,388,189 \u00a0$2,960,759 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a087,740 \u00a0\u00a0144,980 \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a061,517 \u00a0\u00a060,370 \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,688,663 \u00a0$3,593,539 \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. "}, "hash": "b8c8b3bdef6ae7cabff9d63d814ba48b658269ae2a312521948f487a79c6c152", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0March 31, \n2023 \u00a0September\n30, \n2022 \u00a0March 31, \n2022 \u00a0September\n30, \n2021\nCash and cash equivalents \u00a0$1,539,406 \u00a0$3,388,189 \u00a0$2,960,759 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a087,740 \u00a0\u00a0144,980 \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a061,517 \u00a0\u00a060,370 \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,688,663 \u00a0$3,593,539 \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "start_char_idx": 0, "end_char_idx": 570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb547f50-97a8-4e90-aebf-636289a27e38": {"__data__": {"id_": "cb547f50-97a8-4e90-aebf-636289a27e38", "embedding": null, "metadata": {"window": "\u00a0 \u00a0March 31, \n2023 \u00a0September\n30, \n2022 \u00a0March 31, \n2022 \u00a0September\n30, \n2021\nCash and cash equivalents \u00a0$1,539,406 \u00a0$3,388,189 \u00a0$2,960,759 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a087,740 \u00a0\u00a0144,980 \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a061,517 \u00a0\u00a060,370 \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,688,663 \u00a0$3,593,539 \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee046645-a402-466b-bb1a-bb5f0f792a30", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2afdf66ba72a5392bd27182dc35bd4e0ccc46f2da91dc8718e4953f72482c92a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3bd1824e-1d27-4e6f-a619-d37f0aff50dc", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0March 31, \n2023 \u00a0September\n30, \n2022 \u00a0March 31, \n2022 \u00a0September\n30, \n2021\nCash and cash equivalents \u00a0$1,539,406 \u00a0$3,388,189 \u00a0$2,960,759 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a087,740 \u00a0\u00a0144,980 \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a061,517 \u00a0\u00a060,370 \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,688,663 \u00a0$3,593,539 \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "\u00a0 \u00a0March 31, \n2023 \u00a0September\n30, \n2022 \u00a0March 31, \n2022 \u00a0September\n30, \n2021\nCash and cash equivalents \u00a0$1,539,406 \u00a0$3,388,189 \u00a0$2,960,759 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a087,740 \u00a0\u00a0144,980 \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a061,517 \u00a0\u00a060,370 \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,688,663 \u00a0$3,593,539 \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ed9d4f95fc6e82d9134b5a9e94233938be5377ba22f64087135c4b701ba0ffc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48034cb2-dd85-4d2c-baff-c2d776e3119f", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0March 31, \n2023 \u00a0September\n30, \n2022 \u00a0March 31, \n2022 \u00a0September\n30, \n2021\nCash and cash equivalents \u00a0$1,539,406 \u00a0$3,388,189 \u00a0$2,960,759 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a087,740 \u00a0\u00a0144,980 \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a061,517 \u00a0\u00a060,370 \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,688,663 \u00a0$3,593,539 \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. "}, "hash": "64db272bad86732c32cff797a55667601df336b549e7b7003c9a62f595951775", "class_name": "RelatedNodeInfo"}}, "text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "start_char_idx": 570, "end_char_idx": 685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48034cb2-dd85-4d2c-baff-c2d776e3119f": {"__data__": {"id_": "48034cb2-dd85-4d2c-baff-c2d776e3119f", "embedding": null, "metadata": {"window": "\u00a0 \u00a0March 31, \n2023 \u00a0September\n30, \n2022 \u00a0March 31, \n2022 \u00a0September\n30, \n2021\nCash and cash equivalents \u00a0$1,539,406 \u00a0$3,388,189 \u00a0$2,960,759 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a087,740 \u00a0\u00a0144,980 \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a061,517 \u00a0\u00a060,370 \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,688,663 \u00a0$3,593,539 \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee046645-a402-466b-bb1a-bb5f0f792a30", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2afdf66ba72a5392bd27182dc35bd4e0ccc46f2da91dc8718e4953f72482c92a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb547f50-97a8-4e90-aebf-636289a27e38", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0March 31, \n2023 \u00a0September\n30, \n2022 \u00a0March 31, \n2022 \u00a0September\n30, \n2021\nCash and cash equivalents \u00a0$1,539,406 \u00a0$3,388,189 \u00a0$2,960,759 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a087,740 \u00a0\u00a0144,980 \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a061,517 \u00a0\u00a060,370 \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,688,663 \u00a0$3,593,539 \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "688d9145f4f33f515299fa79028f2e7a80f5431acc429a289cf5b0c01b0c8ffd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0acfc997-ba63-4a15-9a2c-e9aa3d3a5452", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0March 31, \n2023 \u00a0September\n30, \n2022 \u00a0March 31, \n2022 \u00a0September\n30, \n2021\nCash and cash equivalents \u00a0$1,539,406 \u00a0$3,388,189 \u00a0$2,960,759 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a087,740 \u00a0\u00a0144,980 \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a061,517 \u00a0\u00a060,370 \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,688,663 \u00a0$3,593,539 \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n"}, "hash": "df8046b388a6a7cf2601e8178320c90356acb6fe0e8ead84984b6c94f12cace9", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "start_char_idx": 685, "end_char_idx": 825, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0acfc997-ba63-4a15-9a2c-e9aa3d3a5452": {"__data__": {"id_": "0acfc997-ba63-4a15-9a2c-e9aa3d3a5452", "embedding": null, "metadata": {"window": "\u00a0 \u00a0March 31, \n2023 \u00a0September\n30, \n2022 \u00a0March 31, \n2022 \u00a0September\n30, \n2021\nCash and cash equivalents \u00a0$1,539,406 \u00a0$3,388,189 \u00a0$2,960,759 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a087,740 \u00a0\u00a0144,980 \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a061,517 \u00a0\u00a060,370 \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,688,663 \u00a0$3,593,539 \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee046645-a402-466b-bb1a-bb5f0f792a30", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2afdf66ba72a5392bd27182dc35bd4e0ccc46f2da91dc8718e4953f72482c92a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48034cb2-dd85-4d2c-baff-c2d776e3119f", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0March 31, \n2023 \u00a0September\n30, \n2022 \u00a0March 31, \n2022 \u00a0September\n30, \n2021\nCash and cash equivalents \u00a0$1,539,406 \u00a0$3,388,189 \u00a0$2,960,759 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a087,740 \u00a0\u00a0144,980 \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a061,517 \u00a0\u00a060,370 \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,688,663 \u00a0$3,593,539 \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d56e799017db4f7d355ce81589cee772607e9ac96b743dd2895ff4d5effcf39a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de202494-c94f-4af4-a438-26f66d13da97", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. "}, "hash": "d113664708c03fc0a6c2229c426458b573bef21ce3cf83a08bbfce49e8922f67", "class_name": "RelatedNodeInfo"}}, "text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "start_char_idx": 825, "end_char_idx": 944, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de202494-c94f-4af4-a438-26f66d13da97": {"__data__": {"id_": "de202494-c94f-4af4-a438-26f66d13da97", "embedding": null, "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee046645-a402-466b-bb1a-bb5f0f792a30", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2afdf66ba72a5392bd27182dc35bd4e0ccc46f2da91dc8718e4953f72482c92a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0acfc997-ba63-4a15-9a2c-e9aa3d3a5452", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0March 31, \n2023 \u00a0September\n30, \n2022 \u00a0March 31, \n2022 \u00a0September\n30, \n2021\nCash and cash equivalents \u00a0$1,539,406 \u00a0$3,388,189 \u00a0$2,960,759 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a087,740 \u00a0\u00a0144,980 \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a061,517 \u00a0\u00a060,370 \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,688,663 \u00a0$3,593,539 \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "234c71a6d0e307970ebef3c06839fcd8ab86903e4a574b48080f9837254a558a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b71e5118-d76f-47fd-958b-ee4d12cd83a3", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. "}, "hash": "65ff579b1e75b5197ff977bc43ffe26ebd1bd7363482d7718bcebe8350fd5e7f", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "start_char_idx": 944, "end_char_idx": 1163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b71e5118-d76f-47fd-958b-ee4d12cd83a3": {"__data__": {"id_": "b71e5118-d76f-47fd-958b-ee4d12cd83a3", "embedding": null, "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee046645-a402-466b-bb1a-bb5f0f792a30", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2afdf66ba72a5392bd27182dc35bd4e0ccc46f2da91dc8718e4953f72482c92a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de202494-c94f-4af4-a438-26f66d13da97", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a94b04a24fd90d376cceca2adc70bdb7736ec582f2c4dc252ad65f6fc5f5da8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd076787-9e8c-49e5-89ec-fc2e53dc6d75", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. "}, "hash": "6a6d15663c95e237e8ed656b559fec9dd658a7a8d3bf6c8243c843072885e13b", "class_name": "RelatedNodeInfo"}}, "text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "start_char_idx": 1163, "end_char_idx": 1345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd076787-9e8c-49e5-89ec-fc2e53dc6d75": {"__data__": {"id_": "cd076787-9e8c-49e5-89ec-fc2e53dc6d75", "embedding": null, "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee046645-a402-466b-bb1a-bb5f0f792a30", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2afdf66ba72a5392bd27182dc35bd4e0ccc46f2da91dc8718e4953f72482c92a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b71e5118-d76f-47fd-958b-ee4d12cd83a3", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a53544b0cce18fa924cec651f9d0c0fc828e6dd276756eee8e412a8273b0425", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ce1ed0f-4c05-4137-905d-9a5074082f61", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit). "}, "hash": "6e4e1e2227bdeecf2b35eef5df8f1cbfa64a218491da18c1e12380e5861a21ef", "class_name": "RelatedNodeInfo"}}, "text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "start_char_idx": 1345, "end_char_idx": 1626, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ce1ed0f-4c05-4137-905d-9a5074082f61": {"__data__": {"id_": "6ce1ed0f-4c05-4137-905d-9a5074082f61", "embedding": null, "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit). ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee046645-a402-466b-bb1a-bb5f0f792a30", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2afdf66ba72a5392bd27182dc35bd4e0ccc46f2da91dc8718e4953f72482c92a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd076787-9e8c-49e5-89ec-fc2e53dc6d75", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b768c50991bba5c8ff2a493c6ab76a1671840dbe1c5e49370924e0deee428642", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f19e3c6-d67b-4d4e-ba48-ca198e3ba775", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "original_text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. "}, "hash": "974a7f52fd1507db628ef4ec3055120c300927ee8c500a470702ac30e7f3ae78", "class_name": "RelatedNodeInfo"}}, "text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit). ", "start_char_idx": 1626, "end_char_idx": 1951, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f19e3c6-d67b-4d4e-ba48-ca198e3ba775": {"__data__": {"id_": "7f19e3c6-d67b-4d4e-ba48-ca198e3ba775", "embedding": null, "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "original_text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee046645-a402-466b-bb1a-bb5f0f792a30", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2afdf66ba72a5392bd27182dc35bd4e0ccc46f2da91dc8718e4953f72482c92a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ce1ed0f-4c05-4137-905d-9a5074082f61", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit). ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c72873de8b4a6b011e26515ec9d38eea3bdd9662550ee7fd2dd08769247d25d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cac545f6-e45a-4d17-b33d-5acda567295b", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "original_text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. "}, "hash": "7d2a6b93ae3d73ed5864deb026bc2da4691d6fd3afcbcf6049e4643440390c2c", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "start_char_idx": 1951, "end_char_idx": 2036, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cac545f6-e45a-4d17-b33d-5acda567295b": {"__data__": {"id_": "cac545f6-e45a-4d17-b33d-5acda567295b", "embedding": null, "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "original_text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee046645-a402-466b-bb1a-bb5f0f792a30", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2afdf66ba72a5392bd27182dc35bd4e0ccc46f2da91dc8718e4953f72482c92a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f19e3c6-d67b-4d4e-ba48-ca198e3ba775", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "original_text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d3d7f9bc378a33fbaeb6f604e8ba973d23681e705007de32093799ee8f7b1c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02a982a6-3c49-489d-94e3-6b51a086f508", "node_type": "1", "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition-related\ndeal and integration expenses; restructuring and other expenses; and impairment of assets. ", "original_text": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. "}, "hash": "256fe5638707eb246c35c3750dcf9a977a740adb6ad982e9aa240e386f3eb6d1", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "start_char_idx": 2036, "end_char_idx": 2193, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02a982a6-3c49-489d-94e3-6b51a086f508": {"__data__": {"id_": "02a982a6-3c49-489d-94e3-6b51a086f508", "embedding": null, "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition-related\ndeal and integration expenses; restructuring and other expenses; and impairment of assets. ", "original_text": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee046645-a402-466b-bb1a-bb5f0f792a30", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2afdf66ba72a5392bd27182dc35bd4e0ccc46f2da91dc8718e4953f72482c92a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cac545f6-e45a-4d17-b33d-5acda567295b", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "original_text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "716d669ea2daf376314f5c9ecf1916a6a60bb29c01f05a97965b792df2ad9625", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88adbd8f-4b47-4beb-8f5c-a97614f4f38c", "node_type": "1", "metadata": {"window": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition-related\ndeal and integration expenses; restructuring and other expenses; and impairment of assets.  Adjusted operating expense\nmargin is the ratio of adjusted operating expenses to total revenue. ", "original_text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. "}, "hash": "52aa31ed94f74704447c19dfe6c61ee4401e24094a110b08176b72fb0c6a1df2", "class_name": "RelatedNodeInfo"}}, "text": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "start_char_idx": 2193, "end_char_idx": 2396, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88adbd8f-4b47-4beb-8f5c-a97614f4f38c": {"__data__": {"id_": "88adbd8f-4b47-4beb-8f5c-a97614f4f38c", "embedding": null, "metadata": {"window": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition-related\ndeal and integration expenses; restructuring and other expenses; and impairment of assets.  Adjusted operating expense\nmargin is the ratio of adjusted operating expenses to total revenue. ", "original_text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee046645-a402-466b-bb1a-bb5f0f792a30", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2afdf66ba72a5392bd27182dc35bd4e0ccc46f2da91dc8718e4953f72482c92a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02a982a6-3c49-489d-94e3-6b51a086f508", "node_type": "1", "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact, and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition-related\ndeal and integration expenses; restructuring and other expenses; and impairment of assets. ", "original_text": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f42d272f19e87119a603a0a20df487f157eed6211b0188e6fab07b0efba4d91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a15de15-ef42-404b-b43e-8ddaffda031e", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition-related\ndeal and integration expenses; restructuring and other expenses; and impairment of assets.  Adjusted operating expense\nmargin is the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded\nbecause it is a non-cash item and does not reflect the operating performance of the acquired companies. ", "original_text": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n"}, "hash": "722c90426e04cd2c375c43433cb5e6029e734b36cfdfaa820c6f20041a289d27", "class_name": "RelatedNodeInfo"}}, "text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "start_char_idx": 2396, "end_char_idx": 2692, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a15de15-ef42-404b-b43e-8ddaffda031e": {"__data__": {"id_": "5a15de15-ef42-404b-b43e-8ddaffda031e", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition-related\ndeal and integration expenses; restructuring and other expenses; and impairment of assets.  Adjusted operating expense\nmargin is the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded\nbecause it is a non-cash item and does not reflect the operating performance of the acquired companies. ", "original_text": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee046645-a402-466b-bb1a-bb5f0f792a30", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2afdf66ba72a5392bd27182dc35bd4e0ccc46f2da91dc8718e4953f72482c92a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88adbd8f-4b47-4beb-8f5c-a97614f4f38c", "node_type": "1", "metadata": {"window": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition-related\ndeal and integration expenses; restructuring and other expenses; and impairment of assets.  Adjusted operating expense\nmargin is the ratio of adjusted operating expenses to total revenue. ", "original_text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e60a8bce3eeca3855cdaef33d1ccd8d9d5ddfd5b4eb8ad8d5e310049746ed11a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09265200-330a-4ec5-8582-5dd90953f47c", "node_type": "1", "metadata": {"window": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition-related\ndeal and integration expenses; restructuring and other expenses; and impairment of assets.  Adjusted operating expense\nmargin is the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded\nbecause it is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude\nacquisition-related deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or\nnon-recurring business activities. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition-related\ndeal and integration expenses; restructuring and other expenses; and impairment of assets. "}, "hash": "e7e360328802ebb008c3cb17cae591966aac98ca5c08ca3a44b5a25b8a844ad1", "class_name": "RelatedNodeInfo"}}, "text": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "start_char_idx": 2692, "end_char_idx": 2874, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09265200-330a-4ec5-8582-5dd90953f47c": {"__data__": {"id_": "09265200-330a-4ec5-8582-5dd90953f47c", "embedding": null, "metadata": {"window": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition-related\ndeal and integration expenses; restructuring and other expenses; and impairment of assets.  Adjusted operating expense\nmargin is the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded\nbecause it is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude\nacquisition-related deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or\nnon-recurring business activities. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition-related\ndeal and integration expenses; restructuring and other expenses; and impairment of assets. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee046645-a402-466b-bb1a-bb5f0f792a30", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2afdf66ba72a5392bd27182dc35bd4e0ccc46f2da91dc8718e4953f72482c92a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a15de15-ef42-404b-b43e-8ddaffda031e", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition-related\ndeal and integration expenses; restructuring and other expenses; and impairment of assets.  Adjusted operating expense\nmargin is the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded\nbecause it is a non-cash item and does not reflect the operating performance of the acquired companies. ", "original_text": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a69cabd71e704401733109c6712f650fd6737f3001d41e71b225fd9147262e9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "675a98fa-7930-4554-8629-212e8fb751d3", "node_type": "1", "metadata": {"window": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition-related\ndeal and integration expenses; restructuring and other expenses; and impairment of assets.  Adjusted operating expense\nmargin is the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded\nbecause it is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude\nacquisition-related deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or\nnon-recurring business activities.  We exclude the amount of litigation and opioid-related expenses, and the impairment of\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n", "original_text": "Adjusted operating expense\nmargin is the ratio of adjusted operating expenses to total revenue. "}, "hash": "1a7653eda84be908fa0d05ac5fceba503f7446be00cac0069b79c36799e68f36", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition-related\ndeal and integration expenses; restructuring and other expenses; and impairment of assets. ", "start_char_idx": 2874, "end_char_idx": 3212, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "675a98fa-7930-4554-8629-212e8fb751d3": {"__data__": {"id_": "675a98fa-7930-4554-8629-212e8fb751d3", "embedding": null, "metadata": {"window": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition-related\ndeal and integration expenses; restructuring and other expenses; and impairment of assets.  Adjusted operating expense\nmargin is the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded\nbecause it is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude\nacquisition-related deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or\nnon-recurring business activities.  We exclude the amount of litigation and opioid-related expenses, and the impairment of\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n", "original_text": "Adjusted operating expense\nmargin is the ratio of adjusted operating expenses to total revenue. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee046645-a402-466b-bb1a-bb5f0f792a30", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2afdf66ba72a5392bd27182dc35bd4e0ccc46f2da91dc8718e4953f72482c92a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09265200-330a-4ec5-8582-5dd90953f47c", "node_type": "1", "metadata": {"window": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact, and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition-related\ndeal and integration expenses; restructuring and other expenses; and impairment of assets.  Adjusted operating expense\nmargin is the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded\nbecause it is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude\nacquisition-related deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or\nnon-recurring business activities. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition-related\ndeal and integration expenses; restructuring and other expenses; and impairment of assets. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38845e570fb37a600abf97f467feaaadf43454f9a43e0cfd5680869cfdd2e86b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "149a6d34-fb26-463f-9202-51826495a1ed", "node_type": "1", "metadata": {"window": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition-related\ndeal and integration expenses; restructuring and other expenses; and impairment of assets.  Adjusted operating expense\nmargin is the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded\nbecause it is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude\nacquisition-related deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or\nnon-recurring business activities.  We exclude the amount of litigation and opioid-related expenses, and the impairment of\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-related intangibles amortization is excluded\nbecause it is a non-cash item and does not reflect the operating performance of the acquired companies. "}, "hash": "05bb38ac77197b4b0cee0b5f3387008d53f245e174884f156a55ca86e2281347", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expense\nmargin is the ratio of adjusted operating expenses to total revenue. ", "start_char_idx": 3212, "end_char_idx": 3308, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "149a6d34-fb26-463f-9202-51826495a1ed": {"__data__": {"id_": "149a6d34-fb26-463f-9202-51826495a1ed", "embedding": null, "metadata": {"window": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition-related\ndeal and integration expenses; restructuring and other expenses; and impairment of assets.  Adjusted operating expense\nmargin is the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded\nbecause it is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude\nacquisition-related deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or\nnon-recurring business activities.  We exclude the amount of litigation and opioid-related expenses, and the impairment of\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-related intangibles amortization is excluded\nbecause it is a non-cash item and does not reflect the operating performance of the acquired companies. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee046645-a402-466b-bb1a-bb5f0f792a30", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2afdf66ba72a5392bd27182dc35bd4e0ccc46f2da91dc8718e4953f72482c92a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "675a98fa-7930-4554-8629-212e8fb751d3", "node_type": "1", "metadata": {"window": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition-related\ndeal and integration expenses; restructuring and other expenses; and impairment of assets.  Adjusted operating expense\nmargin is the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded\nbecause it is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude\nacquisition-related deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or\nnon-recurring business activities.  We exclude the amount of litigation and opioid-related expenses, and the impairment of\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n", "original_text": "Adjusted operating expense\nmargin is the ratio of adjusted operating expenses to total revenue. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f94cd3f145178637419abcd50dfedcd5195a92ff2ac1624ac4430734ec95762", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5391c3f-27ed-42ad-b330-d43be4e7a941", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition-related\ndeal and integration expenses; restructuring and other expenses; and impairment of assets.  Adjusted operating expense\nmargin is the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded\nbecause it is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude\nacquisition-related deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or\nnon-recurring business activities.  We exclude the amount of litigation and opioid-related expenses, and the impairment of\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude\nacquisition-related deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or\nnon-recurring business activities. "}, "hash": "42b6cd964bd05a5bdd7ef1f52c624146974b304840e148d296112e683072fec5", "class_name": "RelatedNodeInfo"}}, "text": "Acquisition-related intangibles amortization is excluded\nbecause it is a non-cash item and does not reflect the operating performance of the acquired companies. ", "start_char_idx": 3308, "end_char_idx": 3469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5391c3f-27ed-42ad-b330-d43be4e7a941": {"__data__": {"id_": "f5391c3f-27ed-42ad-b330-d43be4e7a941", "embedding": null, "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition-related\ndeal and integration expenses; restructuring and other expenses; and impairment of assets.  Adjusted operating expense\nmargin is the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded\nbecause it is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude\nacquisition-related deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or\nnon-recurring business activities.  We exclude the amount of litigation and opioid-related expenses, and the impairment of\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude\nacquisition-related deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or\nnon-recurring business activities. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee046645-a402-466b-bb1a-bb5f0f792a30", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2afdf66ba72a5392bd27182dc35bd4e0ccc46f2da91dc8718e4953f72482c92a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "149a6d34-fb26-463f-9202-51826495a1ed", "node_type": "1", "metadata": {"window": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition-related\ndeal and integration expenses; restructuring and other expenses; and impairment of assets.  Adjusted operating expense\nmargin is the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded\nbecause it is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude\nacquisition-related deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or\nnon-recurring business activities.  We exclude the amount of litigation and opioid-related expenses, and the impairment of\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-related intangibles amortization is excluded\nbecause it is a non-cash item and does not reflect the operating performance of the acquired companies. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f959beadec3f2027c520cc6110823337ef632da1026f0f0481c6ec586f166ed9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95ebc054-9b60-4e84-a4d6-00fb0323b2c6", "node_type": "1", "metadata": {"window": "Adjusted operating expense\nmargin is the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded\nbecause it is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude\nacquisition-related deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or\nnon-recurring business activities.  We exclude the amount of litigation and opioid-related expenses, and the impairment of\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n 25", "original_text": "We exclude the amount of litigation and opioid-related expenses, and the impairment of\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n"}, "hash": "7d3cb948ff4f58a5f4a8f82563bae539485eb344b92fedab7f50b078183b1568", "class_name": "RelatedNodeInfo"}}, "text": "We exclude\nacquisition-related deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or\nnon-recurring business activities. ", "start_char_idx": 3469, "end_char_idx": 3638, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95ebc054-9b60-4e84-a4d6-00fb0323b2c6": {"__data__": {"id_": "95ebc054-9b60-4e84-a4d6-00fb0323b2c6", "embedding": null, "metadata": {"window": "Adjusted operating expense\nmargin is the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded\nbecause it is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude\nacquisition-related deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or\nnon-recurring business activities.  We exclude the amount of litigation and opioid-related expenses, and the impairment of\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n 25", "original_text": "We exclude the amount of litigation and opioid-related expenses, and the impairment of\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee046645-a402-466b-bb1a-bb5f0f792a30", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2afdf66ba72a5392bd27182dc35bd4e0ccc46f2da91dc8718e4953f72482c92a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5391c3f-27ed-42ad-b330-d43be4e7a941", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition-related\ndeal and integration expenses; restructuring and other expenses; and impairment of assets.  Adjusted operating expense\nmargin is the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded\nbecause it is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude\nacquisition-related deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or\nnon-recurring business activities.  We exclude the amount of litigation and opioid-related expenses, and the impairment of\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude\nacquisition-related deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or\nnon-recurring business activities. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d878444c468982e6c76934f296b4433d221eb00f62dff442d908f1545af96158", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e81820cb-8bdb-4624-ad2a-103b7839eb5f", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization is excluded\nbecause it is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude\nacquisition-related deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or\nnon-recurring business activities.  We exclude the amount of litigation and opioid-related expenses, and the impairment of\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n 25", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. "}, "hash": "a7670d531b89a342b1871df52fede4a1f706af9764a5e2cbf736ddee95593abd", "class_name": "RelatedNodeInfo"}}, "text": "We exclude the amount of litigation and opioid-related expenses, and the impairment of\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n", "start_char_idx": 3638, "end_char_idx": 3917, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e81820cb-8bdb-4624-ad2a-103b7839eb5f": {"__data__": {"id_": "e81820cb-8bdb-4624-ad2a-103b7839eb5f", "embedding": null, "metadata": {"window": "Acquisition-related intangibles amortization is excluded\nbecause it is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude\nacquisition-related deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or\nnon-recurring business activities.  We exclude the amount of litigation and opioid-related expenses, and the impairment of\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n 25", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee046645-a402-466b-bb1a-bb5f0f792a30", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2afdf66ba72a5392bd27182dc35bd4e0ccc46f2da91dc8718e4953f72482c92a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95ebc054-9b60-4e84-a4d6-00fb0323b2c6", "node_type": "1", "metadata": {"window": "Adjusted operating expense\nmargin is the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded\nbecause it is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude\nacquisition-related deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or\nnon-recurring business activities.  We exclude the amount of litigation and opioid-related expenses, and the impairment of\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n 25", "original_text": "We exclude the amount of litigation and opioid-related expenses, and the impairment of\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b4dbc142361b43f4603989470fcece5d46e96bf4bf13c793623c78a8685fe253", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc499630-bb64-4ac3-acc3-34e9d5abb2e4", "node_type": "1", "metadata": {"window": "We exclude\nacquisition-related deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or\nnon-recurring business activities.  We exclude the amount of litigation and opioid-related expenses, and the impairment of\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n 25", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n"}, "hash": "044eb0b6918a32ae9fd21a32773c6823a6af2768c29ebe93186402c668c24d41", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "start_char_idx": 3917, "end_char_idx": 4166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc499630-bb64-4ac3-acc3-34e9d5abb2e4": {"__data__": {"id_": "fc499630-bb64-4ac3-acc3-34e9d5abb2e4", "embedding": null, "metadata": {"window": "We exclude\nacquisition-related deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or\nnon-recurring business activities.  We exclude the amount of litigation and opioid-related expenses, and the impairment of\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n 25", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee046645-a402-466b-bb1a-bb5f0f792a30", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2afdf66ba72a5392bd27182dc35bd4e0ccc46f2da91dc8718e4953f72482c92a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e81820cb-8bdb-4624-ad2a-103b7839eb5f", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization is excluded\nbecause it is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude\nacquisition-related deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or\nnon-recurring business activities.  We exclude the amount of litigation and opioid-related expenses, and the impairment of\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n 25", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52ef6743296c04c20cb435ae74f6f4e356af84fcf0fcfcaccc32b4085aa08803", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8be5db23-7493-4ac3-aedb-84cff14f8063", "node_type": "1", "metadata": {"window": "We exclude the amount of litigation and opioid-related expenses, and the impairment of\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n 25", "original_text": "25"}, "hash": "49d34dfca834274de900e69e8034393438843b86acbd13064d325c49c952f836", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "start_char_idx": 4166, "end_char_idx": 4259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8be5db23-7493-4ac3-aedb-84cff14f8063": {"__data__": {"id_": "8be5db23-7493-4ac3-aedb-84cff14f8063", "embedding": null, "metadata": {"window": "We exclude the amount of litigation and opioid-related expenses, and the impairment of\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n 25", "original_text": "25", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee046645-a402-466b-bb1a-bb5f0f792a30", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2afdf66ba72a5392bd27182dc35bd4e0ccc46f2da91dc8718e4953f72482c92a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc499630-bb64-4ac3-acc3-34e9d5abb2e4", "node_type": "1", "metadata": {"window": "We exclude\nacquisition-related deal and integration expenses and restructuring and other expenses that relate to unpredictable and/or\nnon-recurring business activities.  We exclude the amount of litigation and opioid-related expenses, and the impairment of\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n 25", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f2d15764531b96a35c1655948765f07c6bf74fffd9f958381d5271ff72282262", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc5e9606-cf52-4384-8e32-f5e88271c1de", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, and the gain (loss) on the currency remeasurement of the deferred tax\nasset relating to Swiss tax reform are excluded from adjusted income before income taxes because these amounts are\nunusual, non-operating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors\nbecause it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n"}, "hash": "e990c905fd9ee7202d8a32bd3aa8964f2bc62ee8a64dcad120c5ac8904ec76b3", "class_name": "RelatedNodeInfo"}}, "text": "25", "start_char_idx": 4259, "end_char_idx": 4261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc5e9606-cf52-4384-8e32-f5e88271c1de": {"__data__": {"id_": "dc5e9606-cf52-4384-8e32-f5e88271c1de", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, and the gain (loss) on the currency remeasurement of the deferred tax\nasset relating to Swiss tax reform are excluded from adjusted income before income taxes because these amounts are\nunusual, non-operating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors\nbecause it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a987d23b-8858-4688-baaf-029e2c3bd9be", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aed9e60f525d4e794568abc3693b6966b8a1b8d03bf37550017f943c5217f94d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8be5db23-7493-4ac3-aedb-84cff14f8063", "node_type": "1", "metadata": {"window": "We exclude the amount of litigation and opioid-related expenses, and the impairment of\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n 25", "original_text": "25", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed2bb570a2589f16d3b908f2db82ffce440e5c054bca0c27ee1c34a613b43c1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf19bdd2-48a8-4a6d-bacd-87c814b4e41c", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, and the gain (loss) on the currency remeasurement of the deferred tax\nasset relating to Swiss tax reform are excluded from adjusted income before income taxes because these amounts are\nunusual, non-operating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors\nbecause it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. "}, "hash": "ec0ce772f9d87562aa74813fca7135bca5346930fe0e3ec54f4003548c26571b", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "start_char_idx": 0, "end_char_idx": 247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf19bdd2-48a8-4a6d-bacd-87c814b4e41c": {"__data__": {"id_": "cf19bdd2-48a8-4a6d-bacd-87c814b4e41c", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, and the gain (loss) on the currency remeasurement of the deferred tax\nasset relating to Swiss tax reform are excluded from adjusted income before income taxes because these amounts are\nunusual, non-operating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors\nbecause it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a987d23b-8858-4688-baaf-029e2c3bd9be", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aed9e60f525d4e794568abc3693b6966b8a1b8d03bf37550017f943c5217f94d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc5e9606-cf52-4384-8e32-f5e88271c1de", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, and the gain (loss) on the currency remeasurement of the deferred tax\nasset relating to Swiss tax reform are excluded from adjusted income before income taxes because these amounts are\nunusual, non-operating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors\nbecause it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebd9c14e2e8ad13c56fed7e6c81f935b082ce7b4a040a5b6d9c58262ba9d6b39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c35762f9-d1d9-4a9f-bbea-e81d30f019fd", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, and the gain (loss) on the currency remeasurement of the deferred tax\nasset relating to Swiss tax reform are excluded from adjusted income before income taxes because these amounts are\nunusual, non-operating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors\nbecause it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, and the gain (loss) on the currency remeasurement of the deferred tax\nasset relating to Swiss tax reform are excluded from adjusted income before income taxes because these amounts are\nunusual, non-operating, and non-recurring. "}, "hash": "ed8f20781a81ccdb7599ea61bf9ce372aeb364fa6ff7e12f70d107ba92255b23", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "start_char_idx": 247, "end_char_idx": 452, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c35762f9-d1d9-4a9f-bbea-e81d30f019fd": {"__data__": {"id_": "c35762f9-d1d9-4a9f-bbea-e81d30f019fd", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, and the gain (loss) on the currency remeasurement of the deferred tax\nasset relating to Swiss tax reform are excluded from adjusted income before income taxes because these amounts are\nunusual, non-operating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors\nbecause it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, and the gain (loss) on the currency remeasurement of the deferred tax\nasset relating to Swiss tax reform are excluded from adjusted income before income taxes because these amounts are\nunusual, non-operating, and non-recurring. ", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a987d23b-8858-4688-baaf-029e2c3bd9be", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aed9e60f525d4e794568abc3693b6966b8a1b8d03bf37550017f943c5217f94d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf19bdd2-48a8-4a6d-bacd-87c814b4e41c", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, and the gain (loss) on the currency remeasurement of the deferred tax\nasset relating to Swiss tax reform are excluded from adjusted income before income taxes because these amounts are\nunusual, non-operating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors\nbecause it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "05ee739b1be1b3a79c03fef8eb89de659d7f08561e666dbe47426bec972912d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20713742-60f5-4f4c-b86a-b7be54d26e82", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, and the gain (loss) on the currency remeasurement of the deferred tax\nasset relating to Swiss tax reform are excluded from adjusted income before income taxes because these amounts are\nunusual, non-operating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors\nbecause it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to investors\nbecause it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n"}, "hash": "e103ad1a54848c598ecd70c28c9f71460106459b3affb43c9358b0308e9f7137", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, and the gain (loss) on the currency remeasurement of the deferred tax\nasset relating to Swiss tax reform are excluded from adjusted income before income taxes because these amounts are\nunusual, non-operating, and non-recurring. ", "start_char_idx": 452, "end_char_idx": 767, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20713742-60f5-4f4c-b86a-b7be54d26e82": {"__data__": {"id_": "20713742-60f5-4f4c-b86a-b7be54d26e82", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, and the gain (loss) on the currency remeasurement of the deferred tax\nasset relating to Swiss tax reform are excluded from adjusted income before income taxes because these amounts are\nunusual, non-operating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors\nbecause it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to investors\nbecause it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a987d23b-8858-4688-baaf-029e2c3bd9be", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aed9e60f525d4e794568abc3693b6966b8a1b8d03bf37550017f943c5217f94d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c35762f9-d1d9-4a9f-bbea-e81d30f019fd", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, and the gain (loss) on the currency remeasurement of the deferred tax\nasset relating to Swiss tax reform are excluded from adjusted income before income taxes because these amounts are\nunusual, non-operating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors\nbecause it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, and the gain (loss) on the currency remeasurement of the deferred tax\nasset relating to Swiss tax reform are excluded from adjusted income before income taxes because these amounts are\nunusual, non-operating, and non-recurring. ", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d16f85502e84e12028c9393105b62e710cfad113154974f8064a2606a84da69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2cdbe09c-0a5e-47bc-9ee4-ea983b1e2bb3", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, and the gain (loss) on the currency remeasurement of the deferred tax\nasset relating to Swiss tax reform are excluded from adjusted income before income taxes because these amounts are\nunusual, non-operating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors\nbecause it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the six months\nended March 31, 2022 are also excluded from adjusted income tax expense. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. "}, "hash": "ad62a3dcf163c74c45ee78025d97a971b9b26743d9b31daa8a0c1ec4bb52a323", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors\nbecause it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n", "start_char_idx": 767, "end_char_idx": 932, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2cdbe09c-0a5e-47bc-9ee4-ea983b1e2bb3": {"__data__": {"id_": "2cdbe09c-0a5e-47bc-9ee4-ea983b1e2bb3", "embedding": null, "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, and the gain (loss) on the currency remeasurement of the deferred tax\nasset relating to Swiss tax reform are excluded from adjusted income before income taxes because these amounts are\nunusual, non-operating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors\nbecause it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the six months\nended March 31, 2022 are also excluded from adjusted income tax expense. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a987d23b-8858-4688-baaf-029e2c3bd9be", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aed9e60f525d4e794568abc3693b6966b8a1b8d03bf37550017f943c5217f94d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20713742-60f5-4f4c-b86a-b7be54d26e82", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, and the gain (loss) on the currency remeasurement of the deferred tax\nasset relating to Swiss tax reform are excluded from adjusted income before income taxes because these amounts are\nunusual, non-operating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors\nbecause it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to investors\nbecause it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcb558ebf7cabff053c4b3ad6448986de8b0c0686c4032678a30b65fa97c77a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d75522d-4d17-4d32-bd6e-57bc5ce4ce5e", "node_type": "1", "metadata": {"window": "In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, and the gain (loss) on the currency remeasurement of the deferred tax\nasset relating to Swiss tax reform are excluded from adjusted income before income taxes because these amounts are\nunusual, non-operating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors\nbecause it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the six months\nended March 31, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the six months ended March 31, 2023 and 2022.\n", "original_text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n"}, "hash": "d5a12570753c4c7343110859708c30a274bbb5133dd17264b69cf801d6fe6c2c", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "start_char_idx": 932, "end_char_idx": 1121, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d75522d-4d17-4d32-bd6e-57bc5ce4ce5e": {"__data__": {"id_": "3d75522d-4d17-4d32-bd6e-57bc5ce4ce5e", "embedding": null, "metadata": {"window": "In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, and the gain (loss) on the currency remeasurement of the deferred tax\nasset relating to Swiss tax reform are excluded from adjusted income before income taxes because these amounts are\nunusual, non-operating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors\nbecause it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the six months\nended March 31, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the six months ended March 31, 2023 and 2022.\n", "original_text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a987d23b-8858-4688-baaf-029e2c3bd9be", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aed9e60f525d4e794568abc3693b6966b8a1b8d03bf37550017f943c5217f94d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2cdbe09c-0a5e-47bc-9ee4-ea983b1e2bb3", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, and the gain (loss) on the currency remeasurement of the deferred tax\nasset relating to Swiss tax reform are excluded from adjusted income before income taxes because these amounts are\nunusual, non-operating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors\nbecause it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the six months\nended March 31, 2022 are also excluded from adjusted income tax expense. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "72745385ceb2b573d2c5da2b117be1e7ba28b7382fed1b1e7bb5202da5bbb4b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3bcaeac-10b7-42cd-8451-8659894b0d96", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors\nbecause it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the six months\nended March 31, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the six months ended March 31, 2023 and 2022.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n"}, "hash": "768110c5317720f83d5a0be579f5cb63a125c85a92f2f8e7da0cc49553cf18d9", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "start_char_idx": 1121, "end_char_idx": 1394, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3bcaeac-10b7-42cd-8451-8659894b0d96": {"__data__": {"id_": "e3bcaeac-10b7-42cd-8451-8659894b0d96", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors\nbecause it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the six months\nended March 31, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the six months ended March 31, 2023 and 2022.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a987d23b-8858-4688-baaf-029e2c3bd9be", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aed9e60f525d4e794568abc3693b6966b8a1b8d03bf37550017f943c5217f94d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d75522d-4d17-4d32-bd6e-57bc5ce4ce5e", "node_type": "1", "metadata": {"window": "In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, and the gain (loss) on the currency remeasurement of the deferred tax\nasset relating to Swiss tax reform are excluded from adjusted income before income taxes because these amounts are\nunusual, non-operating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors\nbecause it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the six months\nended March 31, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the six months ended March 31, 2023 and 2022.\n", "original_text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "987144a160b4629992127c836d4417a17a5be16717c3cd0ea4da20587db34a7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f93c21b1-db84-4a30-ba7c-929c8688fc05", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the six months\nended March 31, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the six months ended March 31, 2023 and 2022.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "original_text": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the six months\nended March 31, 2022 are also excluded from adjusted income tax expense. "}, "hash": "3ae061551194fdfeb176f4f5a5186d8f073ab18090dbcdae69a283dcc4651700", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "start_char_idx": 1394, "end_char_idx": 1632, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f93c21b1-db84-4a30-ba7c-929c8688fc05": {"__data__": {"id_": "f93c21b1-db84-4a30-ba7c-929c8688fc05", "embedding": null, "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the six months\nended March 31, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the six months ended March 31, 2023 and 2022.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "original_text": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the six months\nended March 31, 2022 are also excluded from adjusted income tax expense. ", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a987d23b-8858-4688-baaf-029e2c3bd9be", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aed9e60f525d4e794568abc3693b6966b8a1b8d03bf37550017f943c5217f94d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3bcaeac-10b7-42cd-8451-8659894b0d96", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors\nbecause it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the six months\nended March 31, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the six months ended March 31, 2023 and 2022.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f5794fb3094bf0dad316ba5feef98a686340bfa78073c51e2b4e910c61694cb6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9fe768f-31e3-481c-adc8-99d9ef943842", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the six months\nended March 31, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the six months ended March 31, 2023 and 2022.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "original_text": "Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the six months ended March 31, 2023 and 2022.\n"}, "hash": "231b27c2c6ae95221f68535d85f5ec0c6ff283a7e2aae9b00e31c021e079412f", "class_name": "RelatedNodeInfo"}}, "text": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the six months\nended March 31, 2022 are also excluded from adjusted income tax expense. ", "start_char_idx": 1632, "end_char_idx": 1830, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9fe768f-31e3-481c-adc8-99d9ef943842": {"__data__": {"id_": "f9fe768f-31e3-481c-adc8-99d9ef943842", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the six months\nended March 31, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the six months ended March 31, 2023 and 2022.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "original_text": "Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the six months ended March 31, 2023 and 2022.\n", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a987d23b-8858-4688-baaf-029e2c3bd9be", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aed9e60f525d4e794568abc3693b6966b8a1b8d03bf37550017f943c5217f94d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f93c21b1-db84-4a30-ba7c-929c8688fc05", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the six months\nended March 31, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the six months ended March 31, 2023 and 2022.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "original_text": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the six months\nended March 31, 2022 are also excluded from adjusted income tax expense. ", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "241bb868e36c8fa8e5efc35623c8186021453d2a91ea9734125e9fb8cb5bc08a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1117b6e6-8db1-4a12-8519-0f952d735a34", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the six months\nended March 31, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the six months ended March 31, 2023 and 2022.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n"}, "hash": "36b62ed4ad00d31c5c81915ad09c369dc4406f4bfeccb5c5bb6808a9a61612c3", "class_name": "RelatedNodeInfo"}}, "text": "Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the six months ended March 31, 2023 and 2022.\n", "start_char_idx": 1830, "end_char_idx": 1990, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1117b6e6-8db1-4a12-8519-0f952d735a34": {"__data__": {"id_": "1117b6e6-8db1-4a12-8519-0f952d735a34", "embedding": null, "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the six months\nended March 31, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the six months ended March 31, 2023 and 2022.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a987d23b-8858-4688-baaf-029e2c3bd9be", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aed9e60f525d4e794568abc3693b6966b8a1b8d03bf37550017f943c5217f94d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9fe768f-31e3-481c-adc8-99d9ef943842", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the six months\nended March 31, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the six months ended March 31, 2023 and 2022.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "original_text": "Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the six months ended March 31, 2023 and 2022.\n", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6220cc3d200cbbcbc007791a7caa6e9588f14d2f756295038d4361b3dcc701e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aaeb1452-24fa-4708-be4e-1eb1683d928a", "node_type": "1", "metadata": {"window": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the six months\nended March 31, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the six months ended March 31, 2023 and 2022.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. "}, "hash": "9d84f61c94cc71e9348daadf0fbe22b4908436fcf333804e3e5886639e191779", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "start_char_idx": 1990, "end_char_idx": 2234, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aaeb1452-24fa-4708-be4e-1eb1683d928a": {"__data__": {"id_": "aaeb1452-24fa-4708-be4e-1eb1683d928a", "embedding": null, "metadata": {"window": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the six months\nended March 31, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the six months ended March 31, 2023 and 2022.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a987d23b-8858-4688-baaf-029e2c3bd9be", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aed9e60f525d4e794568abc3693b6966b8a1b8d03bf37550017f943c5217f94d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1117b6e6-8db1-4a12-8519-0f952d735a34", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the six months\nended March 31, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the six months ended March 31, 2023 and 2022.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "109c33eafb3801d24db9a830c5b36f15e328faa676f2f8d87f374afecf2e0da8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0774fa4d-38cb-4855-a576-98ca28aca4d3", "node_type": "1", "metadata": {"window": "Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the six months ended March 31, 2023 and 2022.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition-related deal and integration expenses;\nrestructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment of assets;\nand the gain (loss) on the currency remeasurement related to Swiss tax reform, in each case net of the tax effect calculated\nusing the applicable effective tax rate for those items. ", "original_text": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n"}, "hash": "e6e232e72a1f8831a4036263adce2938c742dd3f3d0fc3fae62cca69565d6374", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "start_char_idx": 2234, "end_char_idx": 2448, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0774fa4d-38cb-4855-a576-98ca28aca4d3": {"__data__": {"id_": "0774fa4d-38cb-4855-a576-98ca28aca4d3", "embedding": null, "metadata": {"window": "Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the six months ended March 31, 2023 and 2022.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition-related deal and integration expenses;\nrestructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment of assets;\nand the gain (loss) on the currency remeasurement related to Swiss tax reform, in each case net of the tax effect calculated\nusing the applicable effective tax rate for those items. ", "original_text": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a987d23b-8858-4688-baaf-029e2c3bd9be", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aed9e60f525d4e794568abc3693b6966b8a1b8d03bf37550017f943c5217f94d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aaeb1452-24fa-4708-be4e-1eb1683d928a", "node_type": "1", "metadata": {"window": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the six months\nended March 31, 2022 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the six months ended March 31, 2023 and 2022.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c5f86fe574557dbf530f5a17976bbb43e02dfc897b51e99f4e2d3f54d0db3a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "303a2539-fb13-4145-9619-915e4ef9ce1b", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition-related deal and integration expenses;\nrestructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment of assets;\nand the gain (loss) on the currency remeasurement related to Swiss tax reform, in each case net of the tax effect calculated\nusing the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax expense\nprimarily attributable to foreign valuation allowance adjustments for the six months ended March 31, 2022, and the per share\nimpact of certain expenses relating to tax reform in Switzerland for the six months ended March 31, 2023 and 2022 are also\nexcluded from adjusted diluted earnings per share. ", "original_text": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. "}, "hash": "899ce474a5f9e69d122d0c098b3fbfc0eaa2023220a010c00dd1b6a0b4398779", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "start_char_idx": 2448, "end_char_idx": 2619, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "303a2539-fb13-4145-9619-915e4ef9ce1b": {"__data__": {"id_": "303a2539-fb13-4145-9619-915e4ef9ce1b", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition-related deal and integration expenses;\nrestructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment of assets;\nand the gain (loss) on the currency remeasurement related to Swiss tax reform, in each case net of the tax effect calculated\nusing the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax expense\nprimarily attributable to foreign valuation allowance adjustments for the six months ended March 31, 2022, and the per share\nimpact of certain expenses relating to tax reform in Switzerland for the six months ended March 31, 2023 and 2022 are also\nexcluded from adjusted diluted earnings per share. ", "original_text": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a987d23b-8858-4688-baaf-029e2c3bd9be", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aed9e60f525d4e794568abc3693b6966b8a1b8d03bf37550017f943c5217f94d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0774fa4d-38cb-4855-a576-98ca28aca4d3", "node_type": "1", "metadata": {"window": "Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the six months ended March 31, 2023 and 2022.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition-related deal and integration expenses;\nrestructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment of assets;\nand the gain (loss) on the currency remeasurement related to Swiss tax reform, in each case net of the tax effect calculated\nusing the applicable effective tax rate for those items. ", "original_text": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "916256a93d473a0fab03fd30f93548f9b6af9790c3f5a7464a93b04592102f17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "381fa99f-09bb-4b27-bcc5-2b1e4949219e", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition-related deal and integration expenses;\nrestructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment of assets;\nand the gain (loss) on the currency remeasurement related to Swiss tax reform, in each case net of the tax effect calculated\nusing the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax expense\nprimarily attributable to foreign valuation allowance adjustments for the six months ended March 31, 2022, and the per share\nimpact of certain expenses relating to tax reform in Switzerland for the six months ended March 31, 2023 and 2022 are also\nexcluded from adjusted diluted earnings per share.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n"}, "hash": "a2e9ba9bf88a1c0add7e6f27f3c36c1f978021662c6d0037bb8a24a1eb220444", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "start_char_idx": 2619, "end_char_idx": 2804, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "381fa99f-09bb-4b27-bcc5-2b1e4949219e": {"__data__": {"id_": "381fa99f-09bb-4b27-bcc5-2b1e4949219e", "embedding": null, "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition-related deal and integration expenses;\nrestructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment of assets;\nand the gain (loss) on the currency remeasurement related to Swiss tax reform, in each case net of the tax effect calculated\nusing the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax expense\nprimarily attributable to foreign valuation allowance adjustments for the six months ended March 31, 2022, and the per share\nimpact of certain expenses relating to tax reform in Switzerland for the six months ended March 31, 2023 and 2022 are also\nexcluded from adjusted diluted earnings per share.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a987d23b-8858-4688-baaf-029e2c3bd9be", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aed9e60f525d4e794568abc3693b6966b8a1b8d03bf37550017f943c5217f94d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "303a2539-fb13-4145-9619-915e4ef9ce1b", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition-related deal and integration expenses;\nrestructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment of assets;\nand the gain (loss) on the currency remeasurement related to Swiss tax reform, in each case net of the tax effect calculated\nusing the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax expense\nprimarily attributable to foreign valuation allowance adjustments for the six months ended March 31, 2022, and the per share\nimpact of certain expenses relating to tax reform in Switzerland for the six months ended March 31, 2023 and 2022 are also\nexcluded from adjusted diluted earnings per share. ", "original_text": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8891962509ecad7960f47b9686757bd3ccaf7caa8f52be5a9d9c0f675156a85f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07608cd4-15d9-4686-8f00-14fadc66b6b5", "node_type": "1", "metadata": {"window": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition-related deal and integration expenses;\nrestructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment of assets;\nand the gain (loss) on the currency remeasurement related to Swiss tax reform, in each case net of the tax effect calculated\nusing the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax expense\nprimarily attributable to foreign valuation allowance adjustments for the six months ended March 31, 2022, and the per share\nimpact of certain expenses relating to tax reform in Switzerland for the six months ended March 31, 2023 and 2022 are also\nexcluded from adjusted diluted earnings per share.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition-related deal and integration expenses;\nrestructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment of assets;\nand the gain (loss) on the currency remeasurement related to Swiss tax reform, in each case net of the tax effect calculated\nusing the applicable effective tax rate for those items. "}, "hash": "db2e64c67c07c219330d35ea1aa06f9da6dd3a676ccce7f688d6d770ef4c19d9", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "start_char_idx": 2804, "end_char_idx": 3048, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07608cd4-15d9-4686-8f00-14fadc66b6b5": {"__data__": {"id_": "07608cd4-15d9-4686-8f00-14fadc66b6b5", "embedding": null, "metadata": {"window": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition-related deal and integration expenses;\nrestructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment of assets;\nand the gain (loss) on the currency remeasurement related to Swiss tax reform, in each case net of the tax effect calculated\nusing the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax expense\nprimarily attributable to foreign valuation allowance adjustments for the six months ended March 31, 2022, and the per share\nimpact of certain expenses relating to tax reform in Switzerland for the six months ended March 31, 2023 and 2022 are also\nexcluded from adjusted diluted earnings per share.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition-related deal and integration expenses;\nrestructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment of assets;\nand the gain (loss) on the currency remeasurement related to Swiss tax reform, in each case net of the tax effect calculated\nusing the applicable effective tax rate for those items. ", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a987d23b-8858-4688-baaf-029e2c3bd9be", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aed9e60f525d4e794568abc3693b6966b8a1b8d03bf37550017f943c5217f94d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "381fa99f-09bb-4b27-bcc5-2b1e4949219e", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition-related deal and integration expenses;\nrestructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment of assets;\nand the gain (loss) on the currency remeasurement related to Swiss tax reform, in each case net of the tax effect calculated\nusing the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax expense\nprimarily attributable to foreign valuation allowance adjustments for the six months ended March 31, 2022, and the per share\nimpact of certain expenses relating to tax reform in Switzerland for the six months ended March 31, 2023 and 2022 are also\nexcluded from adjusted diluted earnings per share.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d0204983dec9cc633c151d1d5b0dfb58bfcbe5650b5d43a6e30933b8f67b6d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acc19a3f-8a0e-48a8-bc11-6f2ab1c2eea8", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition-related deal and integration expenses;\nrestructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment of assets;\nand the gain (loss) on the currency remeasurement related to Swiss tax reform, in each case net of the tax effect calculated\nusing the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax expense\nprimarily attributable to foreign valuation allowance adjustments for the six months ended March 31, 2022, and the per share\nimpact of certain expenses relating to tax reform in Switzerland for the six months ended March 31, 2023 and 2022 are also\nexcluded from adjusted diluted earnings per share.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "original_text": "In addition, the per share impact of certain discrete tax expense\nprimarily attributable to foreign valuation allowance adjustments for the six months ended March 31, 2022, and the per share\nimpact of certain expenses relating to tax reform in Switzerland for the six months ended March 31, 2023 and 2022 are also\nexcluded from adjusted diluted earnings per share. "}, "hash": "1040d0e0f074ca027fd18bff74646d96a007cb0d66d57f3ac62361f394b4fbb3", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition-related deal and integration expenses;\nrestructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment of assets;\nand the gain (loss) on the currency remeasurement related to Swiss tax reform, in each case net of the tax effect calculated\nusing the applicable effective tax rate for those items. ", "start_char_idx": 3048, "end_char_idx": 3724, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acc19a3f-8a0e-48a8-bc11-6f2ab1c2eea8": {"__data__": {"id_": "acc19a3f-8a0e-48a8-bc11-6f2ab1c2eea8", "embedding": null, "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition-related deal and integration expenses;\nrestructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment of assets;\nand the gain (loss) on the currency remeasurement related to Swiss tax reform, in each case net of the tax effect calculated\nusing the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax expense\nprimarily attributable to foreign valuation allowance adjustments for the six months ended March 31, 2022, and the per share\nimpact of certain expenses relating to tax reform in Switzerland for the six months ended March 31, 2023 and 2022 are also\nexcluded from adjusted diluted earnings per share.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "original_text": "In addition, the per share impact of certain discrete tax expense\nprimarily attributable to foreign valuation allowance adjustments for the six months ended March 31, 2022, and the per share\nimpact of certain expenses relating to tax reform in Switzerland for the six months ended March 31, 2023 and 2022 are also\nexcluded from adjusted diluted earnings per share. ", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a987d23b-8858-4688-baaf-029e2c3bd9be", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aed9e60f525d4e794568abc3693b6966b8a1b8d03bf37550017f943c5217f94d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07608cd4-15d9-4686-8f00-14fadc66b6b5", "node_type": "1", "metadata": {"window": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition-related deal and integration expenses;\nrestructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment of assets;\nand the gain (loss) on the currency remeasurement related to Swiss tax reform, in each case net of the tax effect calculated\nusing the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax expense\nprimarily attributable to foreign valuation allowance adjustments for the six months ended March 31, 2022, and the per share\nimpact of certain expenses relating to tax reform in Switzerland for the six months ended March 31, 2023 and 2022 are also\nexcluded from adjusted diluted earnings per share.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition-related deal and integration expenses;\nrestructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment of assets;\nand the gain (loss) on the currency remeasurement related to Swiss tax reform, in each case net of the tax effect calculated\nusing the applicable effective tax rate for those items. ", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac21db4051b91e928e53e5294851a3da59971048ed27046a72b3a12043b0eae0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d8e64ce-dfeb-4eff-9175-b72950e0452e", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition-related deal and integration expenses;\nrestructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment of assets;\nand the gain (loss) on the currency remeasurement related to Swiss tax reform, in each case net of the tax effect calculated\nusing the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax expense\nprimarily attributable to foreign valuation allowance adjustments for the six months ended March 31, 2022, and the per share\nimpact of certain expenses relating to tax reform in Switzerland for the six months ended March 31, 2023 and 2022 are also\nexcluded from adjusted diluted earnings per share.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n"}, "hash": "1b7b35d98cc45a37bf28714e49f46c31823b113736d4b0094ae8dba78a577b4a", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the per share impact of certain discrete tax expense\nprimarily attributable to foreign valuation allowance adjustments for the six months ended March 31, 2022, and the per share\nimpact of certain expenses relating to tax reform in Switzerland for the six months ended March 31, 2023 and 2022 are also\nexcluded from adjusted diluted earnings per share. ", "start_char_idx": 3724, "end_char_idx": 4089, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d8e64ce-dfeb-4eff-9175-b72950e0452e": {"__data__": {"id_": "0d8e64ce-dfeb-4eff-9175-b72950e0452e", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition-related deal and integration expenses;\nrestructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment of assets;\nand the gain (loss) on the currency remeasurement related to Swiss tax reform, in each case net of the tax effect calculated\nusing the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax expense\nprimarily attributable to foreign valuation allowance adjustments for the six months ended March 31, 2022, and the per share\nimpact of certain expenses relating to tax reform in Switzerland for the six months ended March 31, 2023 and 2022 are also\nexcluded from adjusted diluted earnings per share.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a987d23b-8858-4688-baaf-029e2c3bd9be", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aed9e60f525d4e794568abc3693b6966b8a1b8d03bf37550017f943c5217f94d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acc19a3f-8a0e-48a8-bc11-6f2ab1c2eea8", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition-related deal and integration expenses;\nrestructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment of assets;\nand the gain (loss) on the currency remeasurement related to Swiss tax reform, in each case net of the tax effect calculated\nusing the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax expense\nprimarily attributable to foreign valuation allowance adjustments for the six months ended March 31, 2022, and the per share\nimpact of certain expenses relating to tax reform in Switzerland for the six months ended March 31, 2023 and 2022 are also\nexcluded from adjusted diluted earnings per share.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "original_text": "In addition, the per share impact of certain discrete tax expense\nprimarily attributable to foreign valuation allowance adjustments for the six months ended March 31, 2022, and the per share\nimpact of certain expenses relating to tax reform in Switzerland for the six months ended March 31, 2023 and 2022 are also\nexcluded from adjusted diluted earnings per share. ", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c519db17db1075a4a71d8efb7c40f0685e94b6c4712e509a27dd6eed66000808", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a7b5840-dc0f-4484-bfd4-54f37a1bae36", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition-related deal and integration expenses;\nrestructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment of assets;\nand the gain (loss) on the currency remeasurement related to Swiss tax reform, in each case net of the tax effect calculated\nusing the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax expense\nprimarily attributable to foreign valuation allowance adjustments for the six months ended March 31, 2022, and the per share\nimpact of certain expenses relating to tax reform in Switzerland for the six months ended March 31, 2023 and 2022 are also\nexcluded from adjusted diluted earnings per share.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\n26", "original_text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. "}, "hash": "3b744781daaee8103c3491e049e3adbb9aa1ef1cc5fb71a1af1c1f7bf79e8680", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n", "start_char_idx": 4089, "end_char_idx": 4443, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a7b5840-dc0f-4484-bfd4-54f37a1bae36": {"__data__": {"id_": "3a7b5840-dc0f-4484-bfd4-54f37a1bae36", "embedding": null, "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition-related deal and integration expenses;\nrestructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment of assets;\nand the gain (loss) on the currency remeasurement related to Swiss tax reform, in each case net of the tax effect calculated\nusing the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax expense\nprimarily attributable to foreign valuation allowance adjustments for the six months ended March 31, 2022, and the per share\nimpact of certain expenses relating to tax reform in Switzerland for the six months ended March 31, 2023 and 2022 are also\nexcluded from adjusted diluted earnings per share.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\n26", "original_text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a987d23b-8858-4688-baaf-029e2c3bd9be", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aed9e60f525d4e794568abc3693b6966b8a1b8d03bf37550017f943c5217f94d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d8e64ce-dfeb-4eff-9175-b72950e0452e", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition-related deal and integration expenses;\nrestructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment of assets;\nand the gain (loss) on the currency remeasurement related to Swiss tax reform, in each case net of the tax effect calculated\nusing the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax expense\nprimarily attributable to foreign valuation allowance adjustments for the six months ended March 31, 2022, and the per share\nimpact of certain expenses relating to tax reform in Switzerland for the six months ended March 31, 2023 and 2022 are also\nexcluded from adjusted diluted earnings per share.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03674dfc52fb34807d1e61e67f645bebb2073a7266e0ee8f52f7b5d5f808e794", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f09e9ad0-49be-4e3a-8dbf-6680f8bf620b", "node_type": "1", "metadata": {"window": "In addition, the per share impact of certain discrete tax expense\nprimarily attributable to foreign valuation allowance adjustments for the six months ended March 31, 2022, and the per share\nimpact of certain expenses relating to tax reform in Switzerland for the six months ended March 31, 2023 and 2022 are also\nexcluded from adjusted diluted earnings per share.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\n26", "original_text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. "}, "hash": "a4792eda9ef763c4b79245878e83182a84c7eafd268ff13f65dbc961e0b09bdd", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "start_char_idx": 4443, "end_char_idx": 4716, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f09e9ad0-49be-4e3a-8dbf-6680f8bf620b": {"__data__": {"id_": "f09e9ad0-49be-4e3a-8dbf-6680f8bf620b", "embedding": null, "metadata": {"window": "In addition, the per share impact of certain discrete tax expense\nprimarily attributable to foreign valuation allowance adjustments for the six months ended March 31, 2022, and the per share\nimpact of certain expenses relating to tax reform in Switzerland for the six months ended March 31, 2023 and 2022 are also\nexcluded from adjusted diluted earnings per share.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\n26", "original_text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a987d23b-8858-4688-baaf-029e2c3bd9be", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aed9e60f525d4e794568abc3693b6966b8a1b8d03bf37550017f943c5217f94d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a7b5840-dc0f-4484-bfd4-54f37a1bae36", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition-related deal and integration expenses;\nrestructuring and other expenses; recovery of a non-customer note receivable; a foreign currency gain; impairment of assets;\nand the gain (loss) on the currency remeasurement related to Swiss tax reform, in each case net of the tax effect calculated\nusing the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax expense\nprimarily attributable to foreign valuation allowance adjustments for the six months ended March 31, 2022, and the per share\nimpact of certain expenses relating to tax reform in Switzerland for the six months ended March 31, 2023 and 2022 are also\nexcluded from adjusted diluted earnings per share.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\n26", "original_text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6108213aabb7ed23b8edd8e6ccead904b65f4978a25182b24ee3db5e043f7f05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a405dff4-a395-4fad-a622-042253319e18", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\n26", "original_text": "The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n"}, "hash": "16034a18a9470963318ef6b912a833f4818b1eaf9fc950e28c1c457e4a1ed334", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "start_char_idx": 4716, "end_char_idx": 4954, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a405dff4-a395-4fad-a622-042253319e18": {"__data__": {"id_": "a405dff4-a395-4fad-a622-042253319e18", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\n26", "original_text": "The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a987d23b-8858-4688-baaf-029e2c3bd9be", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aed9e60f525d4e794568abc3693b6966b8a1b8d03bf37550017f943c5217f94d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f09e9ad0-49be-4e3a-8dbf-6680f8bf620b", "node_type": "1", "metadata": {"window": "In addition, the per share impact of certain discrete tax expense\nprimarily attributable to foreign valuation allowance adjustments for the six months ended March 31, 2022, and the per share\nimpact of certain expenses relating to tax reform in Switzerland for the six months ended March 31, 2023 and 2022 are also\nexcluded from adjusted diluted earnings per share.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\n26", "original_text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ed17d27325ec39e5ccd2a55154cba493d3b85827d0ba11da2543cb6d873610", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "095eb7e6-b986-467f-a0bd-ad4f8d898f86", "node_type": "1", "metadata": {"window": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\n26", "original_text": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\n26"}, "hash": "ddba64b01fc68e588ea96d86d44403b3318b1e4b8846742cbaa51b4b38d84231", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n", "start_char_idx": 4954, "end_char_idx": 5250, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "095eb7e6-b986-467f-a0bd-ad4f8d898f86": {"__data__": {"id_": "095eb7e6-b986-467f-a0bd-ad4f8d898f86", "embedding": null, "metadata": {"window": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\n26", "original_text": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\n26", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a987d23b-8858-4688-baaf-029e2c3bd9be", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aed9e60f525d4e794568abc3693b6966b8a1b8d03bf37550017f943c5217f94d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a405dff4-a395-4fad-a622-042253319e18", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\n26", "original_text": "The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62e4718fcba2614497cc237ba41044fda265e77db4e97cb27c2bdc43eba2d8db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd812978-96ad-4d91-9f78-556450ed5596", "node_type": "1", "metadata": {"window": "GAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. ", "original_text": "GAAP financial measure. "}, "hash": "a2cac06373070964754eb6244b1456010d480a5596293221907e3a66186a0bca", "class_name": "RelatedNodeInfo"}}, "text": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\n26", "start_char_idx": 5250, "end_char_idx": 5382, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd812978-96ad-4d91-9f78-556450ed5596": {"__data__": {"id_": "dd812978-96ad-4d91-9f78-556450ed5596", "embedding": null, "metadata": {"window": "GAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. ", "original_text": "GAAP financial measure. ", "page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0424d274-5fca-4e18-8a4d-973d57f1117e", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c21ad58b64594179631f31d34f5d887edd5ab0edfdf0cb05961f4c1fcbb47d02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "095eb7e6-b986-467f-a0bd-ad4f8d898f86", "node_type": "1", "metadata": {"window": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\n26", "original_text": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\n26", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a5c9a4ba40f349a26104a23158618e253580098ef67557e6c86be1497055a59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d38f63d-7b2c-46e2-a3f6-b23b70a2bc23", "node_type": "1", "metadata": {"window": "GAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6.8 billion was negatively impacted\nby foreign currency translation of $818 million, resulting in revenue on a constant currency basis of $7.6 billion, and (ii) operating\nincome of $176 million was negatively impacted by foreign currency translation of $25 million, resulting in operating income on a\nconstant currency basis of $201 million.\n", "original_text": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. "}, "hash": "12c189f0f6f1ffa1fd85fa180dbc89f754e000b3bca2af79a0c25cec163db922", "class_name": "RelatedNodeInfo"}}, "text": "GAAP financial measure. ", "start_char_idx": 0, "end_char_idx": 24, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d38f63d-7b2c-46e2-a3f6-b23b70a2bc23": {"__data__": {"id_": "1d38f63d-7b2c-46e2-a3f6-b23b70a2bc23", "embedding": null, "metadata": {"window": "GAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6.8 billion was negatively impacted\nby foreign currency translation of $818 million, resulting in revenue on a constant currency basis of $7.6 billion, and (ii) operating\nincome of $176 million was negatively impacted by foreign currency translation of $25 million, resulting in operating income on a\nconstant currency basis of $201 million.\n", "original_text": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0424d274-5fca-4e18-8a4d-973d57f1117e", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c21ad58b64594179631f31d34f5d887edd5ab0edfdf0cb05961f4c1fcbb47d02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd812978-96ad-4d91-9f78-556450ed5596", "node_type": "1", "metadata": {"window": "GAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. ", "original_text": "GAAP financial measure. ", "page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "393d565da7fe176adff0ae1e00331dad827fde82579b0a066bfc6b21452eb4df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6275d57-0f30-485b-8937-78d333327af0", "node_type": "1", "metadata": {"window": "GAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6.8 billion was negatively impacted\nby foreign currency translation of $818 million, resulting in revenue on a constant currency basis of $7.6 billion, and (ii) operating\nincome of $176 million was negatively impacted by foreign currency translation of $25 million, resulting in operating income on a\nconstant currency basis of $201 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S. "}, "hash": "f9c9906cb0380937980a03bc34fdd49cf7f2653be460873d1b84ac33906427a1", "class_name": "RelatedNodeInfo"}}, "text": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "start_char_idx": 24, "end_char_idx": 179, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6275d57-0f30-485b-8937-78d333327af0": {"__data__": {"id_": "d6275d57-0f30-485b-8937-78d333327af0", "embedding": null, "metadata": {"window": "GAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6.8 billion was negatively impacted\nby foreign currency translation of $818 million, resulting in revenue on a constant currency basis of $7.6 billion, and (ii) operating\nincome of $176 million was negatively impacted by foreign currency translation of $25 million, resulting in operating income on a\nconstant currency basis of $201 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S. ", "page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0424d274-5fca-4e18-8a4d-973d57f1117e", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c21ad58b64594179631f31d34f5d887edd5ab0edfdf0cb05961f4c1fcbb47d02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d38f63d-7b2c-46e2-a3f6-b23b70a2bc23", "node_type": "1", "metadata": {"window": "GAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6.8 billion was negatively impacted\nby foreign currency translation of $818 million, resulting in revenue on a constant currency basis of $7.6 billion, and (ii) operating\nincome of $176 million was negatively impacted by foreign currency translation of $25 million, resulting in operating income on a\nconstant currency basis of $201 million.\n", "original_text": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "593f5cc531a9010f754af34a2a7bc9cde3813dcfa983b01a8bcca5b87450b56e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a32c172d-d905-463e-a71c-55e3040c8457", "node_type": "1", "metadata": {"window": "GAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6.8 billion was negatively impacted\nby foreign currency translation of $818 million, resulting in revenue on a constant currency basis of $7.6 billion, and (ii) operating\nincome of $176 million was negatively impacted by foreign currency translation of $25 million, resulting in operating income on a\nconstant currency basis of $201 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "original_text": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. "}, "hash": "ffe33d0a5a6f61c73a1bd2e10e8254bf3903f5b26dc7b90392478e7ac03455d2", "class_name": "RelatedNodeInfo"}}, "text": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S. ", "start_char_idx": 179, "end_char_idx": 356, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a32c172d-d905-463e-a71c-55e3040c8457": {"__data__": {"id_": "a32c172d-d905-463e-a71c-55e3040c8457", "embedding": null, "metadata": {"window": "GAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6.8 billion was negatively impacted\nby foreign currency translation of $818 million, resulting in revenue on a constant currency basis of $7.6 billion, and (ii) operating\nincome of $176 million was negatively impacted by foreign currency translation of $25 million, resulting in operating income on a\nconstant currency basis of $201 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "original_text": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. ", "page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0424d274-5fca-4e18-8a4d-973d57f1117e", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c21ad58b64594179631f31d34f5d887edd5ab0edfdf0cb05961f4c1fcbb47d02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6275d57-0f30-485b-8937-78d333327af0", "node_type": "1", "metadata": {"window": "GAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6.8 billion was negatively impacted\nby foreign currency translation of $818 million, resulting in revenue on a constant currency basis of $7.6 billion, and (ii) operating\nincome of $176 million was negatively impacted by foreign currency translation of $25 million, resulting in operating income on a\nconstant currency basis of $201 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S. ", "page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d7bb8c89365a56b8ea1565138dda3e8ed47c61ba925d7b59c67c2f5bbb178275", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a367bfe-4315-4db3-ba2b-83401b7f4c64", "node_type": "1", "metadata": {"window": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6.8 billion was negatively impacted\nby foreign currency translation of $818 million, resulting in revenue on a constant currency basis of $7.6 billion, and (ii) operating\nincome of $176 million was negatively impacted by foreign currency translation of $25 million, resulting in operating income on a\nconstant currency basis of $201 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "For the\nsecond quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6.8 billion was negatively impacted\nby foreign currency translation of $818 million, resulting in revenue on a constant currency basis of $7.6 billion, and (ii) operating\nincome of $176 million was negatively impacted by foreign currency translation of $25 million, resulting in operating income on a\nconstant currency basis of $201 million.\n"}, "hash": "c194785ef4650177f6206d87ed1823584624cf6869a1ceee9175a1b348aeca1b", "class_name": "RelatedNodeInfo"}}, "text": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. ", "start_char_idx": 356, "end_char_idx": 512, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a367bfe-4315-4db3-ba2b-83401b7f4c64": {"__data__": {"id_": "1a367bfe-4315-4db3-ba2b-83401b7f4c64", "embedding": null, "metadata": {"window": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6.8 billion was negatively impacted\nby foreign currency translation of $818 million, resulting in revenue on a constant currency basis of $7.6 billion, and (ii) operating\nincome of $176 million was negatively impacted by foreign currency translation of $25 million, resulting in operating income on a\nconstant currency basis of $201 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "For the\nsecond quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6.8 billion was negatively impacted\nby foreign currency translation of $818 million, resulting in revenue on a constant currency basis of $7.6 billion, and (ii) operating\nincome of $176 million was negatively impacted by foreign currency translation of $25 million, resulting in operating income on a\nconstant currency basis of $201 million.\n", "page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0424d274-5fca-4e18-8a4d-973d57f1117e", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c21ad58b64594179631f31d34f5d887edd5ab0edfdf0cb05961f4c1fcbb47d02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a32c172d-d905-463e-a71c-55e3040c8457", "node_type": "1", "metadata": {"window": "GAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6.8 billion was negatively impacted\nby foreign currency translation of $818 million, resulting in revenue on a constant currency basis of $7.6 billion, and (ii) operating\nincome of $176 million was negatively impacted by foreign currency translation of $25 million, resulting in operating income on a\nconstant currency basis of $201 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "original_text": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. ", "page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31afd69f567ecf309bb2c2d8683f21e9f316f9610ce3bc8e318dd417b9958100", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7c01f88-ed76-4605-9a3f-d0c57e7c275f", "node_type": "1", "metadata": {"window": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6.8 billion was negatively impacted\nby foreign currency translation of $818 million, resulting in revenue on a constant currency basis of $7.6 billion, and (ii) operating\nincome of $176 million was negatively impacted by foreign currency translation of $25 million, resulting in operating income on a\nconstant currency basis of $201 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. "}, "hash": "aea4a6f5e9f76b263f482461c0b85d699a6be5cb63961ecf20a99ff18ad22f1e", "class_name": "RelatedNodeInfo"}}, "text": "For the\nsecond quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6.8 billion was negatively impacted\nby foreign currency translation of $818 million, resulting in revenue on a constant currency basis of $7.6 billion, and (ii) operating\nincome of $176 million was negatively impacted by foreign currency translation of $25 million, resulting in operating income on a\nconstant currency basis of $201 million.\n", "start_char_idx": 512, "end_char_idx": 959, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7c01f88-ed76-4605-9a3f-d0c57e7c275f": {"__data__": {"id_": "a7c01f88-ed76-4605-9a3f-d0c57e7c275f", "embedding": null, "metadata": {"window": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6.8 billion was negatively impacted\nby foreign currency translation of $818 million, resulting in revenue on a constant currency basis of $7.6 billion, and (ii) operating\nincome of $176 million was negatively impacted by foreign currency translation of $25 million, resulting in operating income on a\nconstant currency basis of $201 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0424d274-5fca-4e18-8a4d-973d57f1117e", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c21ad58b64594179631f31d34f5d887edd5ab0edfdf0cb05961f4c1fcbb47d02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a367bfe-4315-4db3-ba2b-83401b7f4c64", "node_type": "1", "metadata": {"window": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6.8 billion was negatively impacted\nby foreign currency translation of $818 million, resulting in revenue on a constant currency basis of $7.6 billion, and (ii) operating\nincome of $176 million was negatively impacted by foreign currency translation of $25 million, resulting in operating income on a\nconstant currency basis of $201 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "For the\nsecond quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6.8 billion was negatively impacted\nby foreign currency translation of $818 million, resulting in revenue on a constant currency basis of $7.6 billion, and (ii) operating\nincome of $176 million was negatively impacted by foreign currency translation of $25 million, resulting in operating income on a\nconstant currency basis of $201 million.\n", "page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f156d3a3ecd0c194f7a0014c6dfb75e753139bbebe9c1c1b821398deb940c47c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49ea5a94-dc1d-4d55-b7c0-52e173fca5b8", "node_type": "1", "metadata": {"window": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6.8 billion was negatively impacted\nby foreign currency translation of $818 million, resulting in revenue on a constant currency basis of $7.6 billion, and (ii) operating\nincome of $176 million was negatively impacted by foreign currency translation of $25 million, resulting in operating income on a\nconstant currency basis of $201 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n27", "original_text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. "}, "hash": "32057e0aae74b758863a3017785c3d27a3b860ee2a7de93aee22c8336c41a8a8", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "start_char_idx": 959, "end_char_idx": 1409, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49ea5a94-dc1d-4d55-b7c0-52e173fca5b8": {"__data__": {"id_": "49ea5a94-dc1d-4d55-b7c0-52e173fca5b8", "embedding": null, "metadata": {"window": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6.8 billion was negatively impacted\nby foreign currency translation of $818 million, resulting in revenue on a constant currency basis of $7.6 billion, and (ii) operating\nincome of $176 million was negatively impacted by foreign currency translation of $25 million, resulting in operating income on a\nconstant currency basis of $201 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n27", "original_text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0424d274-5fca-4e18-8a4d-973d57f1117e", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c21ad58b64594179631f31d34f5d887edd5ab0edfdf0cb05961f4c1fcbb47d02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7c01f88-ed76-4605-9a3f-d0c57e7c275f", "node_type": "1", "metadata": {"window": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6.8 billion was negatively impacted\nby foreign currency translation of $818 million, resulting in revenue on a constant currency basis of $7.6 billion, and (ii) operating\nincome of $176 million was negatively impacted by foreign currency translation of $25 million, resulting in operating income on a\nconstant currency basis of $201 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d71988ed139048b6397fdbf4a37c6dea9519d4418926185bc7b1a6361d00e8be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06cb0dbc-6b7a-4e8b-9432-a00e1b45b12d", "node_type": "1", "metadata": {"window": "For the\nsecond quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6.8 billion was negatively impacted\nby foreign currency translation of $818 million, resulting in revenue on a constant currency basis of $7.6 billion, and (ii) operating\nincome of $176 million was negatively impacted by foreign currency translation of $25 million, resulting in operating income on a\nconstant currency basis of $201 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n27", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. "}, "hash": "9319fdcd8d714cf5ebda2bde021c2009c4a9cd1cfe6f061224bf61c1891c81c3", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "start_char_idx": 1409, "end_char_idx": 1645, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06cb0dbc-6b7a-4e8b-9432-a00e1b45b12d": {"__data__": {"id_": "06cb0dbc-6b7a-4e8b-9432-a00e1b45b12d", "embedding": null, "metadata": {"window": "For the\nsecond quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6.8 billion was negatively impacted\nby foreign currency translation of $818 million, resulting in revenue on a constant currency basis of $7.6 billion, and (ii) operating\nincome of $176 million was negatively impacted by foreign currency translation of $25 million, resulting in operating income on a\nconstant currency basis of $201 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n27", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0424d274-5fca-4e18-8a4d-973d57f1117e", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c21ad58b64594179631f31d34f5d887edd5ab0edfdf0cb05961f4c1fcbb47d02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49ea5a94-dc1d-4d55-b7c0-52e173fca5b8", "node_type": "1", "metadata": {"window": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.  For the\nsecond quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6.8 billion was negatively impacted\nby foreign currency translation of $818 million, resulting in revenue on a constant currency basis of $7.6 billion, and (ii) operating\nincome of $176 million was negatively impacted by foreign currency translation of $25 million, resulting in operating income on a\nconstant currency basis of $201 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n27", "original_text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f8c11809f2c7507c2a2df21c335c980a415491469307c52f89b31de33cb3ad47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "023ce815-ae13-40ab-a1df-1c9d8d31dc39", "node_type": "1", "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n27", "original_text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n"}, "hash": "410da25922cd733dee01fafb5d49e3cd9b10b2af9dbd3359d754fa2384a1b639", "class_name": "RelatedNodeInfo"}}, "text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "start_char_idx": 1645, "end_char_idx": 1961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "023ce815-ae13-40ab-a1df-1c9d8d31dc39": {"__data__": {"id_": "023ce815-ae13-40ab-a1df-1c9d8d31dc39", "embedding": null, "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n27", "original_text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0424d274-5fca-4e18-8a4d-973d57f1117e", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c21ad58b64594179631f31d34f5d887edd5ab0edfdf0cb05961f4c1fcbb47d02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06cb0dbc-6b7a-4e8b-9432-a00e1b45b12d", "node_type": "1", "metadata": {"window": "For the\nsecond quarter of fiscal 2023 in the International Healthcare Solutions segment, (i) revenue of $6.8 billion was negatively impacted\nby foreign currency translation of $818 million, resulting in revenue on a constant currency basis of $7.6 billion, and (ii) operating\nincome of $176 million was negatively impacted by foreign currency translation of $25 million, resulting in operating income on a\nconstant currency basis of $201 million.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n27", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "102375468c6a558ae11c6f9d6ab61270b20a2fb328653b6a5a649fedf2560226", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2cdcf985-051c-4433-8d3f-395748d61003", "node_type": "1", "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n27", "original_text": "Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n27"}, "hash": "9b608f1717dc405f17791d8a4227d8664318d2aa3bc8709de635ea45c55a2ae8", "class_name": "RelatedNodeInfo"}}, "text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "start_char_idx": 1961, "end_char_idx": 2145, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2cdcf985-051c-4433-8d3f-395748d61003": {"__data__": {"id_": "2cdcf985-051c-4433-8d3f-395748d61003", "embedding": null, "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n27", "original_text": "Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n27", "page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0424d274-5fca-4e18-8a4d-973d57f1117e", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c21ad58b64594179631f31d34f5d887edd5ab0edfdf0cb05961f4c1fcbb47d02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "023ce815-ae13-40ab-a1df-1c9d8d31dc39", "node_type": "1", "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n27", "original_text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7c3dd06f6a60bde16828e41c4950f6e8f7f60821111750ffd9c34624359b284", "class_name": "RelatedNodeInfo"}}, "text": "Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n27", "start_char_idx": 2145, "end_char_idx": 2318, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"2be5c252-7555-49ff-bc1c-f643c74108ff": {"doc_hash": "df0eb9c0fa17d6f9c6460b4985e4f77eddccefb96744a052cec12b9605e9c364", "ref_doc_id": "1be8a049-344b-4ace-8a28-85686b68389d"}, "abfeb62b-55e3-4b4d-98a6-ff1f7837bd46": {"doc_hash": "ec4f9774e67fadbed3450a1de7c17fb22a4bc4192ff6a2a41162520dd96333ae", "ref_doc_id": "1be8a049-344b-4ace-8a28-85686b68389d"}, "7d885ad9-2d2e-4f7a-afd9-8b9dabb5c15a": {"doc_hash": "bbbd927b8ff10e012458ad9caa6ad4858d9c74c022dad0f824f18a73e14303a5", "ref_doc_id": "1be8a049-344b-4ace-8a28-85686b68389d"}, "32fbe827-672d-4810-9e64-56b2bb44dd85": {"doc_hash": "c2fe399b183cbd33c285a535d60abe9691b62a53cdced35049cd454c6c3c8385", "ref_doc_id": "1be8a049-344b-4ace-8a28-85686b68389d"}, "58388f55-3720-4b1c-800a-248f0bc82fb9": {"doc_hash": "ccaeef1b13473af9a257aab9f767f85b3e85adffe2e2605dd9ddab69657b0f4b", "ref_doc_id": "1be8a049-344b-4ace-8a28-85686b68389d"}, "e5cbce75-cbf0-41a8-8ccb-2bbbf0831c30": {"doc_hash": "6ac9e9fcb28e2f26e01d0b6ab21e64abe0ffa25e77456927c890fc8dd1bb0a33", "ref_doc_id": "1be8a049-344b-4ace-8a28-85686b68389d"}, "df4eda42-e666-4ace-9b30-17df1f1a338d": {"doc_hash": "133d05c095f2b501ed64427193493c6f7569a477e3cf58211bf306076ed67d26", "ref_doc_id": "1be8a049-344b-4ace-8a28-85686b68389d"}, "d741694b-cb99-4ac4-851c-763703850446": {"doc_hash": "1c7c110ffa11b413dff52303258b8daab2247fbd0e0f66bf6120bc5b740fbc82", "ref_doc_id": "1be8a049-344b-4ace-8a28-85686b68389d"}, "9ff5b05b-d238-46ac-abee-d4af7f7f08e9": {"doc_hash": "204b6536b338798f89e93f4cf4b9dededae6b28f3bf508556b301d3662aa597b", "ref_doc_id": "1be8a049-344b-4ace-8a28-85686b68389d"}, "2b6835bb-c491-4995-8485-6fbfe7ce1c4f": {"doc_hash": "f847fe29dcc5973707c3cdbf6c57d58c474af9402e0133377ee786340e9e9ff9", "ref_doc_id": "1be8a049-344b-4ace-8a28-85686b68389d"}, "644503db-33c0-4041-81b5-ecaaf4301ea4": {"doc_hash": "5ca633a9fde7ff0424d40bc1f4ef3837d215896e9471ed961ef9dc6ab6a5b595", "ref_doc_id": "1be8a049-344b-4ace-8a28-85686b68389d"}, "c17ba48c-7ab4-45f6-941e-b116774ef499": {"doc_hash": "69c656810f6cc2936b6629ff1efac9226961b4e490e399ef36b00aae4dd11214", "ref_doc_id": "1be8a049-344b-4ace-8a28-85686b68389d"}, "3bbdac0f-2d1d-480d-b4b8-e9b9a75e3c70": {"doc_hash": "234835ce1f0b816c8920a6fa830d63d63061ea394ddb736c21233b351c4cc135", "ref_doc_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4"}, "e5de0544-2670-4070-b748-6e5c09d0e2da": {"doc_hash": "808fb0ca87d29c6072555e28d6e71fc8258eccb71f8c2f6d4e46ea165110351b", "ref_doc_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4"}, "f564c843-b5ae-4ccc-8766-a774aa292514": {"doc_hash": "b2d289f7983568edb487387053964228be1b91a89d35df5e3ba0f60d189e000d", "ref_doc_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4"}, "4e8b6623-9569-4ae0-98eb-b7fa51c5ffb2": {"doc_hash": "33c25c423a569e2ee1babaa1cc6e79e5d3223a2ef4bf445230d9f7cac7b084ca", "ref_doc_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4"}, "1fe8d39a-2f83-4084-9bd6-5a8fe30d4c55": {"doc_hash": "e777f104bbbcf3bd726b5526af6e1914a89f145edb3c4c3627bdbecaeabe65d6", "ref_doc_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4"}, "9019e039-d6a4-4fd2-93c9-ac4a1b3c633c": {"doc_hash": "577c8475eafed08ede79a028c21a67ac39000308ff267ebb9c481c20a40b1b55", "ref_doc_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4"}, "266653f0-f52f-4023-863a-7154f6ab1155": {"doc_hash": "a1cd6d0b3ca0506a141b3c8d3644c4e9763f624598481f4acc1d740f35de3c4f", "ref_doc_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4"}, "c9238917-5bc2-4e91-b85d-af881ebba971": {"doc_hash": "fa1c1fd43ee5acf3400d21d0f9db793aad4355805cdb24dae37c6449986e1f25", "ref_doc_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4"}, "76185ba7-db6a-49af-b34e-c4148db1778d": {"doc_hash": "4a3d76f44e8dfef9bdb4d3dfa3e93dafa7ab70381642f0586f4594ef640e9509", "ref_doc_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4"}, "5a4d5613-6a63-4969-aabb-7f163240ad47": {"doc_hash": "42dd228549e25fbc34d74ed1bf9d71bb3d1e4423ccbea81b187f5e6df91c66a3", "ref_doc_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4"}, "19f5dc5d-443a-4f1e-927c-2675277b362a": {"doc_hash": "c28baa1a09106cc30f2e09caa0f7e6c523e14f9c93f12355e2861481c23acad8", "ref_doc_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4"}, "03da905a-591c-4ce7-95e2-bcd5ae8c191a": {"doc_hash": "e6275468b0e23e308f0803453e4daa1c6853adae1653ddf25e64f5bad56dbbd3", "ref_doc_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4"}, "7ed60717-183c-4bf7-aeeb-0e6ecd24553a": {"doc_hash": "427288b2bbe6cbc59c5ff47961fdac5427415895990cf1befd934300dfb9bb5f", "ref_doc_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4"}, "dd18b0a6-d283-4ccc-8ba2-72083c4bb391": {"doc_hash": "f886c1b4d51c25ef2e737341d1cf35a152ad08cc2be6b316f0a72e00c6ceca10", "ref_doc_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4"}, "d5fdfe2b-02d7-4c13-b559-8207a94295c1": {"doc_hash": "e8ec34a84150822edbe8d8096157920eea835750cbe28f46f5198685d6311d21", "ref_doc_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4"}, "af33271f-e531-46b6-beec-b14e6055e3e1": {"doc_hash": "48bcb208076ca6ce39bdbc8a2b8a1fbd45d717cf4143e7e54122f8a657a41895", "ref_doc_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4"}, "e266e7e7-2523-4dce-b735-798efce6cc5b": {"doc_hash": "ddedecec10b98df9f18c02064c440a8af8a64cbfa48db932d711894c3961d7ef", "ref_doc_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4"}, "815a9878-af3c-482c-a607-65aa2ce0ddac": {"doc_hash": "e0a2f5d4ff1477e6f5794c4e49370661c24e3641edb6e3cbf583c994d8d0b1e0", "ref_doc_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4"}, "67466426-f58b-425e-a50c-8da4769e59dd": {"doc_hash": "27f6bc8a63a9dec90e641d81fc139b657a27d3f6f7aadfb5e32b634662400b89", "ref_doc_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4"}, "01f0683a-7c0d-4a69-9cce-19f0cc927188": {"doc_hash": "18855b512d8d9b0b6a124ea1a64db173103b9604ff9265c9787ed335d34fc9a5", "ref_doc_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4"}, "8c3aa4c2-9213-4f15-8cec-637ab6bcc139": {"doc_hash": "3fb30b34572aa949fd1b869dd18ea2ba43c1def0087beb5543a2122fb5fd881b", "ref_doc_id": "a86db333-a14d-40e3-8d0a-74faa62f01e4"}, "a7a09a98-ec97-467f-be34-8d252768727c": {"doc_hash": "7a64b030d80e45366c15321a31cd7204f66950a9e91e6dd536f342e39b335944", "ref_doc_id": "27e2e724-303c-4a3c-a394-4f851829c7bc"}, "a29eb57a-664e-42e2-b183-38d25402e53c": {"doc_hash": "b08d83fecb9e7135cc48dd96b35730da509c05e2d347d48aa2ded0ab8c2907bc", "ref_doc_id": "27e2e724-303c-4a3c-a394-4f851829c7bc"}, "f7fc5adb-f448-4377-a1f7-42d0e2b121af": {"doc_hash": "ed5bf9cc2c1b17477357009b3850c95d839f793302b97b816c12ee7dc573b477", "ref_doc_id": "27e2e724-303c-4a3c-a394-4f851829c7bc"}, "c3da5c0e-b712-4d8f-a1ef-1a27f827be65": {"doc_hash": "c8da99aed5ffe79fa32f57bd46d3ec2d52208b2e36f9abbf46d8c6745e8896b4", "ref_doc_id": "27e2e724-303c-4a3c-a394-4f851829c7bc"}, "31ddcb6a-e3f3-44af-9f51-d9f7fec4636e": {"doc_hash": "993af1ad076785ad4c61e12d58f02c0769a555ec3188d84a13be4b8ef0ffa61a", "ref_doc_id": "27e2e724-303c-4a3c-a394-4f851829c7bc"}, "7e2f8188-3449-4588-9b15-45a6b1253ab0": {"doc_hash": "0d722f56db9a2e51e0d41e1adf24b6d552430822d5c88b2506dc21cfdbaaae2b", "ref_doc_id": "27e2e724-303c-4a3c-a394-4f851829c7bc"}, "219bd29e-7f9b-4af9-8e30-b290926fb587": {"doc_hash": "1a295d23de15ca3ca2be3e54946951de329153be5f592e286f20164993e150ad", "ref_doc_id": "27e2e724-303c-4a3c-a394-4f851829c7bc"}, "168f6baf-a5b4-47c1-8f45-4a7464ba0f09": {"doc_hash": "f3502253a771f14c69307707cf26eee47548f9b0ba296e8f879945fc32683bfe", "ref_doc_id": "27e2e724-303c-4a3c-a394-4f851829c7bc"}, "94dacbd4-6937-4c5e-b48d-538cbbae7d33": {"doc_hash": "a934ca2a50430549fe5f0464fadde199da87baafa865ad3e5e67af2400599cbe", "ref_doc_id": "27e2e724-303c-4a3c-a394-4f851829c7bc"}, "199e38b8-d6f7-4052-a216-5080c7979d69": {"doc_hash": "6a934526b3b072a601dab3f64720c52398191e2c8cdd4ec3b05cbaec9bc1c37b", "ref_doc_id": "27e2e724-303c-4a3c-a394-4f851829c7bc"}, "62660e88-ea6b-484f-89fa-ff84f0a620f1": {"doc_hash": "8ce4579e08a9edb631069637163f193c296cf7b6648ef1a5b20efe47f188eccd", "ref_doc_id": "27e2e724-303c-4a3c-a394-4f851829c7bc"}, "ae4d5271-9f17-4cad-82e5-9690991fd840": {"doc_hash": "51fc755457df36f21163b98f269737e90f3a99a410311987324136ce850bc204", "ref_doc_id": "27e2e724-303c-4a3c-a394-4f851829c7bc"}, "74c302f1-4d44-4f3b-9f94-e32decd05c95": {"doc_hash": "3d3ac229e4d1602722635a0722f4a9c54e5310bc87c41c4e1b15447eff883c9c", "ref_doc_id": "27e2e724-303c-4a3c-a394-4f851829c7bc"}, "77348027-7b24-4989-8a4f-0a3866fac559": {"doc_hash": "264587c4ecd3c3933b856a31e7b8b1b411704201f7bd8d6f1b8f8e24976b6a36", "ref_doc_id": "27e2e724-303c-4a3c-a394-4f851829c7bc"}, "833c4bf9-f693-4659-bf04-0734d22d4b88": {"doc_hash": "93a0f42176ce25b09093c6299f05269a1a2e1c701ceab99eda864a656bafbb50", "ref_doc_id": "27e2e724-303c-4a3c-a394-4f851829c7bc"}, "05400520-791d-41f8-9c1c-e74b7473a104": {"doc_hash": "d9066844aebd42a96bdda492896d41e96097d87b85b1f24c60f21414bf8cf68d", "ref_doc_id": "27e2e724-303c-4a3c-a394-4f851829c7bc"}, "490f2417-a24b-4cee-9261-afdcf7ecff5b": {"doc_hash": "745f5bc1c5ee0f5084d1a621b2a25eeb24041f835a94797ee1f0a7cf0e5b379c", "ref_doc_id": "27e2e724-303c-4a3c-a394-4f851829c7bc"}, "1fa9961b-0205-4640-885a-032ea5cb9f86": {"doc_hash": "be26aaf5f6157154726fc7943d834540acdf364afbe73ec3144f0aa207da072b", "ref_doc_id": "27e2e724-303c-4a3c-a394-4f851829c7bc"}, "1248b045-1dad-4160-b9f0-5b9ebfa7c9f6": {"doc_hash": "31beefeb05218d363dffa09201fb523e4343ef1af78e5fa1f07c97514fc18dd0", "ref_doc_id": "27e2e724-303c-4a3c-a394-4f851829c7bc"}, "cfad33d0-737c-460d-9571-2ba295447fe5": {"doc_hash": "65ec9f888c92d08bb6a2d68054a2b5f2749a5c57c432f08b9162bc7c05947c2f", "ref_doc_id": "27e2e724-303c-4a3c-a394-4f851829c7bc"}, "5e5978b1-1906-48c4-92b4-a0110942b184": {"doc_hash": "cb2021901d699353a5e90ca219a20d551a30e14c88f08f3fdcf45f193cd982d7", "ref_doc_id": "27e2e724-303c-4a3c-a394-4f851829c7bc"}, "d79cba85-a093-4acb-9328-a1898f2fdc06": {"doc_hash": "10bc2e1b4164a4a0639ef355e2ca3b3eba21e2133d23991b21359d24eb69f207", "ref_doc_id": "27e2e724-303c-4a3c-a394-4f851829c7bc"}, "bb8837da-caef-495e-a0f9-499ac0bc5b92": {"doc_hash": "44d7e89a515744833d70f9083293353133232172768996ccefd094376895141f", "ref_doc_id": "27e2e724-303c-4a3c-a394-4f851829c7bc"}, "d1210e7b-b36a-482e-9312-59fb895a4cb1": {"doc_hash": "666c8e99f374a9b4f9b429233500e097ef1808d5491f88ae015a97298305ab60", "ref_doc_id": "27e2e724-303c-4a3c-a394-4f851829c7bc"}, "74663052-5d3a-4131-8de6-e6d8e007744e": {"doc_hash": "0f8208fbff315ac85b89284f8dfbcf17705cbf61dfd7dd0430abf1bb254b3021", "ref_doc_id": "27e2e724-303c-4a3c-a394-4f851829c7bc"}, "a438fcd9-2945-4e36-8de5-d7fc9f354d68": {"doc_hash": "1e27466b28df66b2dc11ad9b21cbc0149b79bde53a7bf5260540fe8092b95a32", "ref_doc_id": "27e2e724-303c-4a3c-a394-4f851829c7bc"}, "b1717eba-3a66-4c74-a0c3-df019208e2db": {"doc_hash": "237cc7dcd4cda63dde123adc153494000a66069ec750e6542fdfb6fcc06914f2", "ref_doc_id": "7129ecf3-7586-4969-be47-487cdb63cac3"}, "a403200a-bc9c-4f8b-856f-a692a7d6b174": {"doc_hash": "e01877e8246beeb8ae81b98b34a08eff607a47c497c35bb63b9341fd22638d84", "ref_doc_id": "7129ecf3-7586-4969-be47-487cdb63cac3"}, "ae6acd26-380f-44b0-b49d-43bf6f716bbe": {"doc_hash": "b0b633b4652f1e34379dd91d0e5b682b6c297f7757716d50411a02e242d6b103", "ref_doc_id": "7129ecf3-7586-4969-be47-487cdb63cac3"}, "e0c84da1-8f08-4a1a-92c3-8b95725609a7": {"doc_hash": "d7f520a0c251c94f4944b0c26527e15ec84451c583e7d6be7f449ae8cc3c6ae4", "ref_doc_id": "7129ecf3-7586-4969-be47-487cdb63cac3"}, "83086610-76a7-49de-b3ce-6bf31086cd53": {"doc_hash": "7b6aa14ad195f13d74b71d7f328eefddb8b9f4d53f8cc54892c1a1921c249609", "ref_doc_id": "7129ecf3-7586-4969-be47-487cdb63cac3"}, "8e4f9bac-e48f-4480-9f64-4e990a1b8890": {"doc_hash": "a303c4a6ccfeaa6fad74fb6057cc10becf6a03db39269139b21368112021f285", "ref_doc_id": "7129ecf3-7586-4969-be47-487cdb63cac3"}, "5da72bf4-ef5f-4463-a5bd-3bc7f9abb205": {"doc_hash": "3fa94b78de583b2d18fe81326dfd5bc7dbb15795ff3f291c21a6456a381d294c", "ref_doc_id": "7129ecf3-7586-4969-be47-487cdb63cac3"}, "44450600-dfa3-437a-af3a-a8c4c238d2ae": {"doc_hash": "fa2647e8c7e6826b22a6571b1d7dd09c6fcc2af1666bdfe74e189254ab53881d", "ref_doc_id": "7129ecf3-7586-4969-be47-487cdb63cac3"}, "1340242b-90ab-4594-855f-a593a5f48bac": {"doc_hash": "929fba019c33001d072e2f72d1d22cab6487bdb6e14ab679d54909c53459cf56", "ref_doc_id": "7129ecf3-7586-4969-be47-487cdb63cac3"}, "a52f9b2c-6c02-4cb9-9022-a04bb200f913": {"doc_hash": "a1821b2b744f7e7e558ee64fbaeec7d215ced22da919475c522256ee99316293", "ref_doc_id": "7129ecf3-7586-4969-be47-487cdb63cac3"}, "366d93fc-c2bc-488a-91ed-8026ed62f635": {"doc_hash": "e39910ca68fdb70c43b14d41957bc5b399628e17ca96308adacd2a6630fc8e78", "ref_doc_id": "7129ecf3-7586-4969-be47-487cdb63cac3"}, "3b4db343-bdcf-4042-bcdc-a637411b9b12": {"doc_hash": "69123a20bfa3fe7e2886231e33dcc3a890d7292305e22ae38105ae73e19628d4", "ref_doc_id": "7129ecf3-7586-4969-be47-487cdb63cac3"}, "1ff9fc40-f568-44e0-8470-b64b743373e5": {"doc_hash": "905652f2c662fb3567fa1bf18453d7dc32762defc1fc64a9599dfad4b1182025", "ref_doc_id": "7129ecf3-7586-4969-be47-487cdb63cac3"}, "2e653783-8ebf-4ddf-8125-27a1fb37edd8": {"doc_hash": "f387ef9a3891fe38bb90eec49eeab7be1ad3bde63540c9ae6f54e8c2b424abd9", "ref_doc_id": "7129ecf3-7586-4969-be47-487cdb63cac3"}, "7b584290-4f8b-47b9-b0f4-14be7baa3e2c": {"doc_hash": "65d0b2bcd626b3d0abd9ef95096fd978300f1e6d3980eb43afce82bcc19f8063", "ref_doc_id": "7129ecf3-7586-4969-be47-487cdb63cac3"}, "207dc282-f542-497a-a357-153f1347b913": {"doc_hash": "382808bd6ae9f02bd6faeb88f3e71c5feeab627a3ff154ba350e85b440d87397", "ref_doc_id": "7129ecf3-7586-4969-be47-487cdb63cac3"}, "8d548d5d-1f59-4671-9b15-213eac1001f2": {"doc_hash": "7262fc04f741dd04bba1b1f75661ba6941b4ff5176bf26cf33838bbdd7c6f9c8", "ref_doc_id": "09858b6e-6f03-4927-8378-7b281265574e"}, "03d779dc-9735-49b4-a529-708437b390de": {"doc_hash": "bea62003b38d608b9b95b2fa43d7c1e6081540071f4ec1af6bef89267b959e03", "ref_doc_id": "09858b6e-6f03-4927-8378-7b281265574e"}, "77d1c990-cdc9-4509-b103-8c080d9960cd": {"doc_hash": "3847cf502cea77cb247e3d20af3b2e2b9fe3dd871b6f6474e36bf73fe1df508b", "ref_doc_id": "09858b6e-6f03-4927-8378-7b281265574e"}, "25fc97ed-1cad-459a-ab4d-fea617d55e1a": {"doc_hash": "d00a18c4415fa5e1794eefbaa70e7abd2ce41e5f9315085eda394144b5331ec4", "ref_doc_id": "09858b6e-6f03-4927-8378-7b281265574e"}, "184afaea-e1cb-4a62-9278-67bd4d9bbdf2": {"doc_hash": "f0c7ddd84077a77806b5b87a7089dfe1f186a30b0143c936ca71abf4f1585412", "ref_doc_id": "09858b6e-6f03-4927-8378-7b281265574e"}, "127ce416-9c4a-4a5e-8c07-082d70636218": {"doc_hash": "9811d6af5872431bacc96f898d23c886f4c0618f897a2778e6791455292de537", "ref_doc_id": "09858b6e-6f03-4927-8378-7b281265574e"}, "57b5047f-2b89-4baa-9edb-abc87239fcf4": {"doc_hash": "6c0c982b45f75c75fbf2de4558f1e72f01c3e32e9be3627b28020dd5fed3f503", "ref_doc_id": "09858b6e-6f03-4927-8378-7b281265574e"}, "8ac65456-4a5f-4a40-89c0-d24e15e07a03": {"doc_hash": "3f1a1c11ae4acc83b1b885ba38b7b6de3810123e1cb8b3eb5b95216a56087207", "ref_doc_id": "09858b6e-6f03-4927-8378-7b281265574e"}, "31ae8181-b0fa-4e7e-80eb-4ca666ede20d": {"doc_hash": "7b2541fb8b56f89066464f82712a367332226523709d7a5462ca34eab6816de2", "ref_doc_id": "09858b6e-6f03-4927-8378-7b281265574e"}, "c9cc3448-51c9-43b5-b448-3f1d765cac8b": {"doc_hash": "f04fb3e2527745d21cc03576dbca0d78ea681b0bce9c7acf4c7d2c4478371fc5", "ref_doc_id": "09858b6e-6f03-4927-8378-7b281265574e"}, "b2282575-55dc-4217-b030-84f5ee3dd149": {"doc_hash": "0e8394bb5003e3af371496a7f2257756e4f0f0ec44f236a390802ee1815cfb89", "ref_doc_id": "09858b6e-6f03-4927-8378-7b281265574e"}, "eecdaadd-ddaf-42de-902b-2b1c14076857": {"doc_hash": "cdff5bc77086d4f02930edbc7d470ef4f3a62baada88e117a6112abdd9965ab4", "ref_doc_id": "09858b6e-6f03-4927-8378-7b281265574e"}, "0162d3e6-5409-4c77-a92a-a4638189705a": {"doc_hash": "439f84c3c9f8e318726ffa48544af00ab9e01028efa304adf3b2e05227322d31", "ref_doc_id": "09858b6e-6f03-4927-8378-7b281265574e"}, "43e9388d-392c-4fed-8c7a-4f7854225096": {"doc_hash": "2a19b5b0d19bcdab5f66429ae2ae49368b6721d499c77a6ffe0352b84974eb7a", "ref_doc_id": "09858b6e-6f03-4927-8378-7b281265574e"}, "412b50b1-6c5b-456e-ae65-eb3702e99dee": {"doc_hash": "9f30b5c4552156b59da6dae5102beaa029c00be1b3d8e61ca3720058488e2348", "ref_doc_id": "09858b6e-6f03-4927-8378-7b281265574e"}, "ea311a20-290e-48f3-ae76-5928e5710ab7": {"doc_hash": "7cca61015659b37ceb7590127ae2b0db73d78f00beddf988f9504b51de0fca96", "ref_doc_id": "09858b6e-6f03-4927-8378-7b281265574e"}, "45fb4dec-22e5-4e7f-8576-3f35259ef2fe": {"doc_hash": "b01bb6b8aff08981170b4c0aa5d25f14447b47a78fdcf8770a0f7e5007340525", "ref_doc_id": "09858b6e-6f03-4927-8378-7b281265574e"}, "e7f6cb07-3e73-4dbc-a245-28cddd411def": {"doc_hash": "be05fcc5aa584ae6bc4e468882c4480645820b2d205dbc3658cfebb12f13ed60", "ref_doc_id": "09858b6e-6f03-4927-8378-7b281265574e"}, "29b82857-1aff-481a-87f0-2818aeb39fa1": {"doc_hash": "510c83286cf8d046fe1dbf708703cceeb002faccfdbd1a52254ef18adb7d5bbd", "ref_doc_id": "09858b6e-6f03-4927-8378-7b281265574e"}, "93618fd6-3ddf-46ab-9d7c-90dcefec4a45": {"doc_hash": "5403b54e4df3cb1218155c70038f8a1ebdc79435dc2e7310290259b5523dc600", "ref_doc_id": "09858b6e-6f03-4927-8378-7b281265574e"}, "b6a60497-f25d-46fc-8e91-500598cb5346": {"doc_hash": "61d2baf24e6cfa8396011a7712d21e3dce6a5d53c733a352f42cde98e1a4f0e9", "ref_doc_id": "09858b6e-6f03-4927-8378-7b281265574e"}, "11920c85-0ba8-4427-b5e4-5cd0317eac2d": {"doc_hash": "1601e12e584ede02c3f41495b83fc36715ebb17a0e65cd2d5e15a63bbe808b34", "ref_doc_id": "09858b6e-6f03-4927-8378-7b281265574e"}, "71ceb11f-a3cb-4817-8f1f-a0d8574117c0": {"doc_hash": "5fa87583a663a4acac7cb1c29955c7cb8283c257d4f6efa56685f8d9e9c7b00f", "ref_doc_id": "09858b6e-6f03-4927-8378-7b281265574e"}, "0aa52601-bcc4-447f-bd6f-cd0853f2566a": {"doc_hash": "bac122434942a3275e22db87e9ebae6c55895f4880be737d44262e170a65c3d3", "ref_doc_id": "09858b6e-6f03-4927-8378-7b281265574e"}, "c4e2e62c-1fd0-4c23-9d81-dcd10d18506c": {"doc_hash": "5b6bcf4b1f5b231afa65d2854eeb58d5de81cb9fa08723ec0a94a98d0aa2e8b2", "ref_doc_id": "cfd904d4-27a2-44eb-86a3-80c14449c264"}, "c30088e4-f8dd-41ca-8643-66646218c12a": {"doc_hash": "262f1072e09be76c269756352b2354a5e1bd1b4fccaed8a7d1c15c84d53be206", "ref_doc_id": "cfd904d4-27a2-44eb-86a3-80c14449c264"}, "d0bcae8c-544c-4937-8357-0740606a094f": {"doc_hash": "c9c499f6952d0c94e5d43e591efd41c8fab73c1f61d7e15c84e9187ceaff9f26", "ref_doc_id": "cfd904d4-27a2-44eb-86a3-80c14449c264"}, "cacde9be-25a7-4e9e-ae0d-43b911eef2e0": {"doc_hash": "8163d66e5bf23564726c330005f7a4efba687d68077f7d9aaa80b1180e50f543", "ref_doc_id": "cfd904d4-27a2-44eb-86a3-80c14449c264"}, "85b8b537-01b2-439c-939e-d86f81aeec20": {"doc_hash": "c99b16afe059f1735469861d4a91ef5f2818ef369243f390b40a70ca725627ae", "ref_doc_id": "cfd904d4-27a2-44eb-86a3-80c14449c264"}, "164ef264-1039-4f33-a735-2ad587f4ffaa": {"doc_hash": "2211526b95eb69f8430ddeb6d535c6bb670efe6e58e9450236b62dec01c0b5d6", "ref_doc_id": "cfd904d4-27a2-44eb-86a3-80c14449c264"}, "f007cac8-fbfd-4e5e-a72a-75113e1568cd": {"doc_hash": "149edd48e5869835fb233e0d53af9a51242bf44ad60ef52f85d632850983ad8f", "ref_doc_id": "cfd904d4-27a2-44eb-86a3-80c14449c264"}, "0201e0ea-6163-4ed3-a3d1-a3091e36af0d": {"doc_hash": "677625a79457ba0c965b22da51b91853934064c2e1bd5909639f67beb8933d9c", "ref_doc_id": "cfd904d4-27a2-44eb-86a3-80c14449c264"}, "0632d3bd-3e2b-4802-ad61-79891039b026": {"doc_hash": "f9ccb46b787008d889daba9cb8e599ca4ceb0f57ce3fd7c38d7dc5230aa9ab36", "ref_doc_id": "cfd904d4-27a2-44eb-86a3-80c14449c264"}, "5c45d857-cfeb-4cd1-9345-36ca2789755b": {"doc_hash": "d454fcd6bc61fb0a7877fe4c91974b3f0389ae55845e8b0246931b4ed4cdb831", "ref_doc_id": "cfd904d4-27a2-44eb-86a3-80c14449c264"}, "f06b64b7-fdad-4662-bf21-70652b94f9db": {"doc_hash": "0aeb19511699f4db99c42bc1751c2349adad060bb6943bd2218d44d4aac44f11", "ref_doc_id": "cfd904d4-27a2-44eb-86a3-80c14449c264"}, "5baeb4d0-6160-470b-97f6-8bbbe851923a": {"doc_hash": "a0af19aa03c9f404525ebbb91b0dd26bde559b27bc91b24dd7aef278f8767bc9", "ref_doc_id": "8d137db6-3360-4408-8451-4f38761e2b23"}, "52ef53ef-53a8-4fef-9e8d-572392013414": {"doc_hash": "b195b284538b3ba453a600fafffb1681dac1d1b0031ff5a31f5790294fa72795", "ref_doc_id": "8d137db6-3360-4408-8451-4f38761e2b23"}, "12d4fc00-9c7c-468a-b5b2-92cdf9888d55": {"doc_hash": "1937a4710fd5511694a50c1ab7d9f387467d0e6a7cbcce2fe06cb2266aeb334a", "ref_doc_id": "8d137db6-3360-4408-8451-4f38761e2b23"}, "a5c51f15-21f4-46db-980f-62fdb0c975e4": {"doc_hash": "25f0d9d300aa2ce148865af443ffdce7a646a22158b5d050119bedf1de654157", "ref_doc_id": "5d629b4d-da68-46db-9b09-ded3bdf928c2"}, "c37f560a-fe7b-4ebf-9a78-676ad4932aa0": {"doc_hash": "cfd8367f5b1863f72e6ebb12f86bc1276628c88a731e0ce3ec7cf99416e9fb4c", "ref_doc_id": "5d629b4d-da68-46db-9b09-ded3bdf928c2"}, "d9e70527-4a16-4b3f-9a4e-5d580ce50b8b": {"doc_hash": "a894ab2614409a30395a34fdc97134558a10589576b9fe8eaf25e7bb39b87fba", "ref_doc_id": "5d629b4d-da68-46db-9b09-ded3bdf928c2"}, "a91697a3-fd02-418f-a1e1-0b5b1a5e7d33": {"doc_hash": "cde385a76d238b915235ec223bc8f4dd31c039a3faec2481487e35994973bae1", "ref_doc_id": "5d629b4d-da68-46db-9b09-ded3bdf928c2"}, "c34477e8-da40-4366-87ec-f83824234c05": {"doc_hash": "67918300fac90869418403dcf0075a359f3e2b84f10648ac475434fb71c49cb1", "ref_doc_id": "37177a96-950b-40f8-b0fd-e9f26ad4974a"}, "d909fccf-e2d1-412d-92bd-98153fa872c9": {"doc_hash": "f75ba50de518ea2011b7189b6a541a2ba7cc48a12e0029faa1f7af026fc50097", "ref_doc_id": "37177a96-950b-40f8-b0fd-e9f26ad4974a"}, "0d2ab4c7-6354-4c88-929b-a4355e9b70d2": {"doc_hash": "8755d7e8b2858a122743656f3ed851f065616c67e07c23ea2663fb8bd5b6c62b", "ref_doc_id": "7f1c344d-531d-4d97-8f84-76bd8391b766"}, "b2960218-5cc7-4893-a326-eb062e7d6b5c": {"doc_hash": "fc24d3dd166948264f504a2905da2b007ce43fce781cfed0470642db7f956756", "ref_doc_id": "1bb47096-a02d-4d23-85cc-7b9438626f38"}, "283efd3c-6c39-43e4-aa17-28f15cb63d7e": {"doc_hash": "6d51e2a0ecd4c589d3bdafedae6a5bb3f9a007a9571c2a07fd4e65888a01258d", "ref_doc_id": "1bb47096-a02d-4d23-85cc-7b9438626f38"}, "01c3d115-1cd7-41df-a191-cd67779d1837": {"doc_hash": "924de0197119b4f523c089b466ae152acb2cb232c2f782bdf5431a446ee75225", "ref_doc_id": "1bb47096-a02d-4d23-85cc-7b9438626f38"}, "d33315da-1936-4a5b-8462-3ddd7374d822": {"doc_hash": "7207f496d486b0acc7d43c8c738e26157b6bc71da03b6e48984283a10859c1f2", "ref_doc_id": "cf471dd7-da88-4f99-af33-033da7024c63"}, "c81751d0-3240-4f8c-ad5c-1e9d3a917823": {"doc_hash": "36d23b342dd285d3318aeef40bc0b4292b177cbdbf6f4a5bff9d340cd539eac0", "ref_doc_id": "cf471dd7-da88-4f99-af33-033da7024c63"}, "ffec9053-89ae-4749-84bb-8e08ccfe98cb": {"doc_hash": "3afbe68315ef240e06263643906e3585b448226993c5b2e0248b5fbf7c3f2eff", "ref_doc_id": "b636a6e5-91b7-4a50-a4de-05c19f686131"}, "e4201620-ede3-440b-a0f5-370d8338a563": {"doc_hash": "b037c9f2e41783c87545d949b2a901ef7b7dd8d12fef00a398450cac513aab2c", "ref_doc_id": "b636a6e5-91b7-4a50-a4de-05c19f686131"}, "2f5b229c-1b24-4b23-8182-15e70925eff9": {"doc_hash": "63cf070d8c54d04bfd9cd2bbad0eb9ff29cc9dfd7d8d211750a1b769981e9305", "ref_doc_id": "b636a6e5-91b7-4a50-a4de-05c19f686131"}, "c4dd5f83-63f5-41b8-885c-a297b9053d44": {"doc_hash": "5f9aa16d815c5058a29e6622a459b371ac1a9df5b6c28e32c37e03f98c67d446", "ref_doc_id": "8fd675f3-8941-48c4-9952-f93521529497"}, "6bda1993-ed92-46d4-ae44-f7e48089d5ed": {"doc_hash": "4c9762bd4255a1bb00c8a7da81f9083e2c5fd23a34fa0dc0301681cf9451b9c6", "ref_doc_id": "8fd675f3-8941-48c4-9952-f93521529497"}, "f2c538db-35f4-4ca7-8999-7a047397e60c": {"doc_hash": "22e9e030014010babeb4ad9b802cd775905b52216275f4418d3e67ca6071e0ac", "ref_doc_id": "8fd675f3-8941-48c4-9952-f93521529497"}, "514a09e2-e25a-4c16-a035-e1d20f5f9c8a": {"doc_hash": "8b98560a061a0f4ee073460acf6662a89e5856c2c066b532751296f4a7cc3540", "ref_doc_id": "48d70c4d-35c4-4c7e-87a8-e96b3b10a00d"}, "4d342622-e2a9-471c-bf4b-697b73edcf49": {"doc_hash": "0a81602771c51b4efcf2d6e1a5cbc0c08edbc5c108f79fd775901bf1e1cbae79", "ref_doc_id": "16633cac-2032-419d-bcd9-3517fad60db4"}, "b91fc4e4-df44-40ac-8686-2845c88e8437": {"doc_hash": "894bafbe459c447afc623b764ac3b49bc4a8b3cb7358a89c1645d6d979d036f8", "ref_doc_id": "16633cac-2032-419d-bcd9-3517fad60db4"}, "1c8420ff-9425-4b71-89b1-88f6b8449771": {"doc_hash": "c5b4f604e55875cbeb94da171bf38048fc2e2a05519c8fc0aec4841cf1e9601e", "ref_doc_id": "16633cac-2032-419d-bcd9-3517fad60db4"}, "3b98622f-0457-493a-bc54-28a5a554dba6": {"doc_hash": "120013ff0ba8fbb1d689ec228f3e0e9a4babc0a1a4cd4d463cf96cb1c3c67b93", "ref_doc_id": "16633cac-2032-419d-bcd9-3517fad60db4"}, "5e470302-a3ed-4351-a6cb-5c72e106ce5b": {"doc_hash": "32bb8019c62350027aad90ce37c1af2246bcdb788773709782ae269d05f33e85", "ref_doc_id": "16633cac-2032-419d-bcd9-3517fad60db4"}, "f9d502b2-0c38-40d5-980d-f6b357eeeca7": {"doc_hash": "4038aba9f588a84930568d624224633f79b7c757563d2f933c740648985430bb", "ref_doc_id": "ffab077b-dbe7-4d72-b99b-ca6b09c298f2"}, "8abab408-129a-4391-a888-3557d4315c97": {"doc_hash": "b002259eb562bc83d9069bb2ef3020b00513b11dfd6aec17ed243c6b7a399a22", "ref_doc_id": "ffab077b-dbe7-4d72-b99b-ca6b09c298f2"}, "8bd0b50d-e4d7-41d4-9e5e-4ad0215b9db1": {"doc_hash": "517caa98c245a7d7ddcbf0b705222b78bde30c6d0a1b42123b4f879d8262dc88", "ref_doc_id": "ffab077b-dbe7-4d72-b99b-ca6b09c298f2"}, "e2cadb71-ec5d-46c6-899e-d084ceb78d1d": {"doc_hash": "a8cb29de181e0a6f44abbab20fbb2f0ca92008b549c3a9c1807723e8da3b0006", "ref_doc_id": "18c50b95-a0e6-4159-abc8-a85289142737"}, "9d7d54a3-dc4a-4996-aa6f-76c884f758c1": {"doc_hash": "a014eacbb97eee4017ea0e8fca4f2cdb5e7a9b355ac5628b11ec189096ef3667", "ref_doc_id": "18c50b95-a0e6-4159-abc8-a85289142737"}, "c2e6fb57-7441-4946-bea5-4460bdf1bf2d": {"doc_hash": "0a5e5a444dd4c3d6d762f3691fcee5eca29dc374e243f8b619c23b19d77c0a0b", "ref_doc_id": "18c50b95-a0e6-4159-abc8-a85289142737"}, "b44e530d-e562-49b3-908c-9110fd21d718": {"doc_hash": "cb401635d860749cc7e3c46b523b0362a25866c9f1d5df01233e9b966383a980", "ref_doc_id": "18c50b95-a0e6-4159-abc8-a85289142737"}, "8657904c-114f-429c-b8f2-ef46c033eebe": {"doc_hash": "dbaf090b16554fcbb6b037bc475c0bd2e875e0e1e007252ee35c85e748eff750", "ref_doc_id": "25d07277-3739-4196-bfcd-8f796d392da4"}, "47fd3b06-3139-4ecf-a53f-53eed305d51b": {"doc_hash": "40d6ac732b03139faa0256342c6272afd448d751d5d880b811668af9c63feeda", "ref_doc_id": "25d07277-3739-4196-bfcd-8f796d392da4"}, "eb6990ef-f748-4f48-8f7e-89fe735989be": {"doc_hash": "105740aa83c1b420b3e80e60238130a9189e6ed8a9b0c958467c6aecc8fa41d4", "ref_doc_id": "25d07277-3739-4196-bfcd-8f796d392da4"}, "3d6d9744-4328-48d7-98f2-e765d82db6ef": {"doc_hash": "b5c74ded3e427f91fb5834824cd3e740509f5a0d575f742996581abb9f3e59ad", "ref_doc_id": "8fcc4cbd-0eac-491e-a5b1-e4b4e05c1251"}, "923071aa-73c5-4598-b2c4-52931edb8a36": {"doc_hash": "f978b928896ad42ae50986da5df384e3ac15fc3ea9799f799e762b79dfa9be76", "ref_doc_id": "8fcc4cbd-0eac-491e-a5b1-e4b4e05c1251"}, "8bd9556b-5d6e-4198-b7b5-09785b79add0": {"doc_hash": "a4630fd810d33b0d8870ba1624cfe2333b6d414115cbcc595aa61b3823693137", "ref_doc_id": "8fcc4cbd-0eac-491e-a5b1-e4b4e05c1251"}, "5bff4d05-67f4-4ce1-89f4-e93e90db1346": {"doc_hash": "7830b5add898de496e8327aa8f1567edd6499922ee9ec77baae47020df494a3b", "ref_doc_id": "098c5ca1-2c88-4bec-a459-b6f22556d52e"}, "0ee887a4-8828-4837-8f2a-f08691c364f2": {"doc_hash": "cbf8ef3fc89b596194c69558b78f0f8fe8bf9bbbdfdf1ef927a0198037f851f0", "ref_doc_id": "098c5ca1-2c88-4bec-a459-b6f22556d52e"}, "c11240c0-51d3-4d62-8a94-a8d2989a6729": {"doc_hash": "bc5ccef324802d9777ebdc412616e7f382dac73cf2e9f1621d8deb56041e6193", "ref_doc_id": "098c5ca1-2c88-4bec-a459-b6f22556d52e"}, "5a968815-008f-4b6d-8342-c72bcee134b9": {"doc_hash": "e6088ed548a31527fedfaae059d112bc9a8c09fbe7e044f86bca6d059402e050", "ref_doc_id": "368884fa-8c24-4580-9d20-e4b1e224b1ed"}, "bbc1e5b9-4452-463f-8125-8a4f650a3355": {"doc_hash": "4c68eef0763d9930f3fe844d3328effe641d59bf8ddb373866f16c1ff81982a9", "ref_doc_id": "552c9223-006f-4978-9615-5ff41f28d8d1"}, "eef444bc-bb42-4857-98f7-8d51aad2c7bc": {"doc_hash": "6d07419a62f7958587f8d0b5ff4c9c9af654801ced1d895470d872397d86a508", "ref_doc_id": "42c6c531-bc0a-4846-8dee-a086f06147b8"}, "cbb30748-962e-4282-903e-1160d57593f0": {"doc_hash": "044e55ddb119cebf9548f56feecb9c4f46e12bb5268767d90f4892689d12f769", "ref_doc_id": "42c6c531-bc0a-4846-8dee-a086f06147b8"}, "beda0a27-823d-4e70-85e2-209790d00459": {"doc_hash": "071f2f84da95ddb64164d5f035322fb2f3571a401882bd829fb05d5db413d60f", "ref_doc_id": "42c6c531-bc0a-4846-8dee-a086f06147b8"}, "3bd1824e-1d27-4e6f-a619-d37f0aff50dc": {"doc_hash": "0ed9d4f95fc6e82d9134b5a9e94233938be5377ba22f64087135c4b701ba0ffc", "ref_doc_id": "ee046645-a402-466b-bb1a-bb5f0f792a30"}, "cb547f50-97a8-4e90-aebf-636289a27e38": {"doc_hash": "688d9145f4f33f515299fa79028f2e7a80f5431acc429a289cf5b0c01b0c8ffd", "ref_doc_id": "ee046645-a402-466b-bb1a-bb5f0f792a30"}, "48034cb2-dd85-4d2c-baff-c2d776e3119f": {"doc_hash": "d56e799017db4f7d355ce81589cee772607e9ac96b743dd2895ff4d5effcf39a", "ref_doc_id": "ee046645-a402-466b-bb1a-bb5f0f792a30"}, "0acfc997-ba63-4a15-9a2c-e9aa3d3a5452": {"doc_hash": "234c71a6d0e307970ebef3c06839fcd8ab86903e4a574b48080f9837254a558a", "ref_doc_id": "ee046645-a402-466b-bb1a-bb5f0f792a30"}, "de202494-c94f-4af4-a438-26f66d13da97": {"doc_hash": "a94b04a24fd90d376cceca2adc70bdb7736ec582f2c4dc252ad65f6fc5f5da8f", "ref_doc_id": "ee046645-a402-466b-bb1a-bb5f0f792a30"}, "b71e5118-d76f-47fd-958b-ee4d12cd83a3": {"doc_hash": "6a53544b0cce18fa924cec651f9d0c0fc828e6dd276756eee8e412a8273b0425", "ref_doc_id": "ee046645-a402-466b-bb1a-bb5f0f792a30"}, "cd076787-9e8c-49e5-89ec-fc2e53dc6d75": {"doc_hash": "b768c50991bba5c8ff2a493c6ab76a1671840dbe1c5e49370924e0deee428642", "ref_doc_id": "ee046645-a402-466b-bb1a-bb5f0f792a30"}, "6ce1ed0f-4c05-4137-905d-9a5074082f61": {"doc_hash": "5c72873de8b4a6b011e26515ec9d38eea3bdd9662550ee7fd2dd08769247d25d", "ref_doc_id": "ee046645-a402-466b-bb1a-bb5f0f792a30"}, "7f19e3c6-d67b-4d4e-ba48-ca198e3ba775": {"doc_hash": "2d3d7f9bc378a33fbaeb6f604e8ba973d23681e705007de32093799ee8f7b1c9", "ref_doc_id": "ee046645-a402-466b-bb1a-bb5f0f792a30"}, "cac545f6-e45a-4d17-b33d-5acda567295b": {"doc_hash": "716d669ea2daf376314f5c9ecf1916a6a60bb29c01f05a97965b792df2ad9625", "ref_doc_id": "ee046645-a402-466b-bb1a-bb5f0f792a30"}, "02a982a6-3c49-489d-94e3-6b51a086f508": {"doc_hash": "7f42d272f19e87119a603a0a20df487f157eed6211b0188e6fab07b0efba4d91", "ref_doc_id": "ee046645-a402-466b-bb1a-bb5f0f792a30"}, "88adbd8f-4b47-4beb-8f5c-a97614f4f38c": {"doc_hash": "e60a8bce3eeca3855cdaef33d1ccd8d9d5ddfd5b4eb8ad8d5e310049746ed11a", "ref_doc_id": "ee046645-a402-466b-bb1a-bb5f0f792a30"}, "5a15de15-ef42-404b-b43e-8ddaffda031e": {"doc_hash": "a69cabd71e704401733109c6712f650fd6737f3001d41e71b225fd9147262e9b", "ref_doc_id": "ee046645-a402-466b-bb1a-bb5f0f792a30"}, "09265200-330a-4ec5-8582-5dd90953f47c": {"doc_hash": "38845e570fb37a600abf97f467feaaadf43454f9a43e0cfd5680869cfdd2e86b", "ref_doc_id": "ee046645-a402-466b-bb1a-bb5f0f792a30"}, "675a98fa-7930-4554-8629-212e8fb751d3": {"doc_hash": "2f94cd3f145178637419abcd50dfedcd5195a92ff2ac1624ac4430734ec95762", "ref_doc_id": "ee046645-a402-466b-bb1a-bb5f0f792a30"}, "149a6d34-fb26-463f-9202-51826495a1ed": {"doc_hash": "f959beadec3f2027c520cc6110823337ef632da1026f0f0481c6ec586f166ed9", "ref_doc_id": "ee046645-a402-466b-bb1a-bb5f0f792a30"}, "f5391c3f-27ed-42ad-b330-d43be4e7a941": {"doc_hash": "d878444c468982e6c76934f296b4433d221eb00f62dff442d908f1545af96158", "ref_doc_id": "ee046645-a402-466b-bb1a-bb5f0f792a30"}, "95ebc054-9b60-4e84-a4d6-00fb0323b2c6": {"doc_hash": "b4dbc142361b43f4603989470fcece5d46e96bf4bf13c793623c78a8685fe253", "ref_doc_id": "ee046645-a402-466b-bb1a-bb5f0f792a30"}, "e81820cb-8bdb-4624-ad2a-103b7839eb5f": {"doc_hash": "52ef6743296c04c20cb435ae74f6f4e356af84fcf0fcfcaccc32b4085aa08803", "ref_doc_id": "ee046645-a402-466b-bb1a-bb5f0f792a30"}, "fc499630-bb64-4ac3-acc3-34e9d5abb2e4": {"doc_hash": "f2d15764531b96a35c1655948765f07c6bf74fffd9f958381d5271ff72282262", "ref_doc_id": "ee046645-a402-466b-bb1a-bb5f0f792a30"}, "8be5db23-7493-4ac3-aedb-84cff14f8063": {"doc_hash": "ed2bb570a2589f16d3b908f2db82ffce440e5c054bca0c27ee1c34a613b43c1f", "ref_doc_id": "ee046645-a402-466b-bb1a-bb5f0f792a30"}, "dc5e9606-cf52-4384-8e32-f5e88271c1de": {"doc_hash": "ebd9c14e2e8ad13c56fed7e6c81f935b082ce7b4a040a5b6d9c58262ba9d6b39", "ref_doc_id": "a987d23b-8858-4688-baaf-029e2c3bd9be"}, "cf19bdd2-48a8-4a6d-bacd-87c814b4e41c": {"doc_hash": "05ee739b1be1b3a79c03fef8eb89de659d7f08561e666dbe47426bec972912d4", "ref_doc_id": "a987d23b-8858-4688-baaf-029e2c3bd9be"}, "c35762f9-d1d9-4a9f-bbea-e81d30f019fd": {"doc_hash": "8d16f85502e84e12028c9393105b62e710cfad113154974f8064a2606a84da69", "ref_doc_id": "a987d23b-8858-4688-baaf-029e2c3bd9be"}, "20713742-60f5-4f4c-b86a-b7be54d26e82": {"doc_hash": "cfcb558ebf7cabff053c4b3ad6448986de8b0c0686c4032678a30b65fa97c77a", "ref_doc_id": "a987d23b-8858-4688-baaf-029e2c3bd9be"}, "2cdbe09c-0a5e-47bc-9ee4-ea983b1e2bb3": {"doc_hash": "72745385ceb2b573d2c5da2b117be1e7ba28b7382fed1b1e7bb5202da5bbb4b9", "ref_doc_id": "a987d23b-8858-4688-baaf-029e2c3bd9be"}, "3d75522d-4d17-4d32-bd6e-57bc5ce4ce5e": {"doc_hash": "987144a160b4629992127c836d4417a17a5be16717c3cd0ea4da20587db34a7b", "ref_doc_id": "a987d23b-8858-4688-baaf-029e2c3bd9be"}, "e3bcaeac-10b7-42cd-8451-8659894b0d96": {"doc_hash": "f5794fb3094bf0dad316ba5feef98a686340bfa78073c51e2b4e910c61694cb6", "ref_doc_id": "a987d23b-8858-4688-baaf-029e2c3bd9be"}, "f93c21b1-db84-4a30-ba7c-929c8688fc05": {"doc_hash": "241bb868e36c8fa8e5efc35623c8186021453d2a91ea9734125e9fb8cb5bc08a", "ref_doc_id": "a987d23b-8858-4688-baaf-029e2c3bd9be"}, "f9fe768f-31e3-481c-adc8-99d9ef943842": {"doc_hash": "6220cc3d200cbbcbc007791a7caa6e9588f14d2f756295038d4361b3dcc701e1", "ref_doc_id": "a987d23b-8858-4688-baaf-029e2c3bd9be"}, "1117b6e6-8db1-4a12-8519-0f952d735a34": {"doc_hash": "109c33eafb3801d24db9a830c5b36f15e328faa676f2f8d87f374afecf2e0da8", "ref_doc_id": "a987d23b-8858-4688-baaf-029e2c3bd9be"}, "aaeb1452-24fa-4708-be4e-1eb1683d928a": {"doc_hash": "9c5f86fe574557dbf530f5a17976bbb43e02dfc897b51e99f4e2d3f54d0db3a9", "ref_doc_id": "a987d23b-8858-4688-baaf-029e2c3bd9be"}, "0774fa4d-38cb-4855-a576-98ca28aca4d3": {"doc_hash": "916256a93d473a0fab03fd30f93548f9b6af9790c3f5a7464a93b04592102f17", "ref_doc_id": "a987d23b-8858-4688-baaf-029e2c3bd9be"}, "303a2539-fb13-4145-9619-915e4ef9ce1b": {"doc_hash": "8891962509ecad7960f47b9686757bd3ccaf7caa8f52be5a9d9c0f675156a85f", "ref_doc_id": "a987d23b-8858-4688-baaf-029e2c3bd9be"}, "381fa99f-09bb-4b27-bcc5-2b1e4949219e": {"doc_hash": "7d0204983dec9cc633c151d1d5b0dfb58bfcbe5650b5d43a6e30933b8f67b6d7", "ref_doc_id": "a987d23b-8858-4688-baaf-029e2c3bd9be"}, "07608cd4-15d9-4686-8f00-14fadc66b6b5": {"doc_hash": "ac21db4051b91e928e53e5294851a3da59971048ed27046a72b3a12043b0eae0", "ref_doc_id": "a987d23b-8858-4688-baaf-029e2c3bd9be"}, "acc19a3f-8a0e-48a8-bc11-6f2ab1c2eea8": {"doc_hash": "c519db17db1075a4a71d8efb7c40f0685e94b6c4712e509a27dd6eed66000808", "ref_doc_id": "a987d23b-8858-4688-baaf-029e2c3bd9be"}, "0d8e64ce-dfeb-4eff-9175-b72950e0452e": {"doc_hash": "03674dfc52fb34807d1e61e67f645bebb2073a7266e0ee8f52f7b5d5f808e794", "ref_doc_id": "a987d23b-8858-4688-baaf-029e2c3bd9be"}, "3a7b5840-dc0f-4484-bfd4-54f37a1bae36": {"doc_hash": "6108213aabb7ed23b8edd8e6ccead904b65f4978a25182b24ee3db5e043f7f05", "ref_doc_id": "a987d23b-8858-4688-baaf-029e2c3bd9be"}, "f09e9ad0-49be-4e3a-8dbf-6680f8bf620b": {"doc_hash": "b1ed17d27325ec39e5ccd2a55154cba493d3b85827d0ba11da2543cb6d873610", "ref_doc_id": "a987d23b-8858-4688-baaf-029e2c3bd9be"}, "a405dff4-a395-4fad-a622-042253319e18": {"doc_hash": "62e4718fcba2614497cc237ba41044fda265e77db4e97cb27c2bdc43eba2d8db", "ref_doc_id": "a987d23b-8858-4688-baaf-029e2c3bd9be"}, "095eb7e6-b986-467f-a0bd-ad4f8d898f86": {"doc_hash": "6a5c9a4ba40f349a26104a23158618e253580098ef67557e6c86be1497055a59", "ref_doc_id": "a987d23b-8858-4688-baaf-029e2c3bd9be"}, "dd812978-96ad-4d91-9f78-556450ed5596": {"doc_hash": "393d565da7fe176adff0ae1e00331dad827fde82579b0a066bfc6b21452eb4df", "ref_doc_id": "0424d274-5fca-4e18-8a4d-973d57f1117e"}, "1d38f63d-7b2c-46e2-a3f6-b23b70a2bc23": {"doc_hash": "593f5cc531a9010f754af34a2a7bc9cde3813dcfa983b01a8bcca5b87450b56e", "ref_doc_id": "0424d274-5fca-4e18-8a4d-973d57f1117e"}, "d6275d57-0f30-485b-8937-78d333327af0": {"doc_hash": "d7bb8c89365a56b8ea1565138dda3e8ed47c61ba925d7b59c67c2f5bbb178275", "ref_doc_id": "0424d274-5fca-4e18-8a4d-973d57f1117e"}, "a32c172d-d905-463e-a71c-55e3040c8457": {"doc_hash": "31afd69f567ecf309bb2c2d8683f21e9f316f9610ce3bc8e318dd417b9958100", "ref_doc_id": "0424d274-5fca-4e18-8a4d-973d57f1117e"}, "1a367bfe-4315-4db3-ba2b-83401b7f4c64": {"doc_hash": "f156d3a3ecd0c194f7a0014c6dfb75e753139bbebe9c1c1b821398deb940c47c", "ref_doc_id": "0424d274-5fca-4e18-8a4d-973d57f1117e"}, "a7c01f88-ed76-4605-9a3f-d0c57e7c275f": {"doc_hash": "d71988ed139048b6397fdbf4a37c6dea9519d4418926185bc7b1a6361d00e8be", "ref_doc_id": "0424d274-5fca-4e18-8a4d-973d57f1117e"}, "49ea5a94-dc1d-4d55-b7c0-52e173fca5b8": {"doc_hash": "f8c11809f2c7507c2a2df21c335c980a415491469307c52f89b31de33cb3ad47", "ref_doc_id": "0424d274-5fca-4e18-8a4d-973d57f1117e"}, "06cb0dbc-6b7a-4e8b-9432-a00e1b45b12d": {"doc_hash": "102375468c6a558ae11c6f9d6ab61270b20a2fb328653b6a5a649fedf2560226", "ref_doc_id": "0424d274-5fca-4e18-8a4d-973d57f1117e"}, "023ce815-ae13-40ab-a1df-1c9d8d31dc39": {"doc_hash": "b7c3dd06f6a60bde16828e41c4950f6e8f7f60821111750ffd9c34624359b284", "ref_doc_id": "0424d274-5fca-4e18-8a4d-973d57f1117e"}, "2cdcf985-051c-4433-8d3f-395748d61003": {"doc_hash": "2e99644efbeaf17fc9147eb5a2d82fa50a8caecd2b5dcddd85e6e2545ae33a55", "ref_doc_id": "0424d274-5fca-4e18-8a4d-973d57f1117e"}}, "docstore/ref_doc_info": {"1be8a049-344b-4ace-8a28-85686b68389d": {"node_ids": ["2be5c252-7555-49ff-bc1c-f643c74108ff", "abfeb62b-55e3-4b4d-98a6-ff1f7837bd46", "7d885ad9-2d2e-4f7a-afd9-8b9dabb5c15a", "32fbe827-672d-4810-9e64-56b2bb44dd85", "58388f55-3720-4b1c-800a-248f0bc82fb9", "e5cbce75-cbf0-41a8-8ccb-2bbbf0831c30", "df4eda42-e666-4ace-9b30-17df1f1a338d", "d741694b-cb99-4ac4-851c-763703850446", "9ff5b05b-d238-46ac-abee-d4af7f7f08e9", "2b6835bb-c491-4995-8485-6fbfe7ce1c4f", "644503db-33c0-4041-81b5-ecaaf4301ea4", "c17ba48c-7ab4-45f6-941e-b116774ef499"], "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Second Quar ter Results\n5/2/2023\nRevenue of $63.5 billion for the Second Quarter, a 9.9 Percent Increase Year-Over-Year\nSecond  Quarter GAAP Diluted EPS of $2.13 and Adjusted Diluted EPS of $3.50\nAdjusted Diluted EPS Guidance Range Raised to $11.70 to $11.90 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nsecond quarter ended March 31, 2023, revenue increased 9.9 percent year-over-year to $63.5 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.13 for the second quarter of fiscal 2023 compared to\n$2.59 in the prior year second quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 8.7 percent to $3.50 in the fiscal second quarter from $3.22 in the prior year second quarter.\n", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2023 Second Quar ter Results\n5/2/2023\nRevenue of $63.5 billion for the Second Quarter, a 9.9 Percent Increase Year-Over-Year\nSecond  Quarter GAAP Diluted EPS of $2.13 and Adjusted Diluted EPS of $3.50\nAdjusted Diluted EPS Guidance Range Raised to $11.70 to $11.90 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nsecond quarter ended March 31, 2023, revenue increased 9.9 percent year-over-year to $63.5 billion. ", "page_label": "1", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a86db333-a14d-40e3-8d0a-74faa62f01e4": {"node_ids": ["3bbdac0f-2d1d-480d-b4b8-e9b9a75e3c70", "e5de0544-2670-4070-b748-6e5c09d0e2da", "f564c843-b5ae-4ccc-8766-a774aa292514", "4e8b6623-9569-4ae0-98eb-b7fa51c5ffb2", "1fe8d39a-2f83-4084-9bd6-5a8fe30d4c55", "9019e039-d6a4-4fd2-93c9-ac4a1b3c633c", "266653f0-f52f-4023-863a-7154f6ab1155", "c9238917-5bc2-4e91-b85d-af881ebba971", "76185ba7-db6a-49af-b34e-c4148db1778d", "5a4d5613-6a63-4969-aabb-7f163240ad47", "19f5dc5d-443a-4f1e-927c-2675277b362a", "03da905a-591c-4ce7-95e2-bcd5ae8c191a", "7ed60717-183c-4bf7-aeeb-0e6ecd24553a", "dd18b0a6-d283-4ccc-8ba2-72083c4bb391", "d5fdfe2b-02d7-4c13-b559-8207a94295c1", "af33271f-e531-46b6-beec-b14e6055e3e1", "e266e7e7-2523-4dce-b735-798efce6cc5b", "815a9878-af3c-482c-a607-65aa2ce0ddac", "67466426-f58b-425e-a50c-8da4769e59dd", "01f0683a-7c0d-4a69-9cce-19f0cc927188", "8c3aa4c2-9213-4f15-8cec-637ab6bcc139"], "metadata": {"window": "Effectiv e Tax Rat e 16.4% 19.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $435M $715M\nDilut ed Earnings P er Shar e $2.13 $3.50\nDilut ed Shar es Outstanding 204.3M 204.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2023, revenue was $63.5 billion, up 9.9 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 11.3 percent increase in revenue within U.S. ", "original_text": "Effectiv e Tax Rat e 16.4% 19.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $435M $715M\nDilut ed Earnings P er Shar e $2.13 $3.50\nDilut ed Shar es Outstanding 204.3M 204.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "27e2e724-303c-4a3c-a394-4f851829c7bc": {"node_ids": ["a7a09a98-ec97-467f-be34-8d252768727c", "a29eb57a-664e-42e2-b183-38d25402e53c", "f7fc5adb-f448-4377-a1f7-42d0e2b121af", "c3da5c0e-b712-4d8f-a1ef-1a27f827be65", "31ddcb6a-e3f3-44af-9f51-d9f7fec4636e", "7e2f8188-3449-4588-9b15-45a6b1253ab0", "219bd29e-7f9b-4af9-8e30-b290926fb587", "168f6baf-a5b4-47c1-8f45-4a7464ba0f09", "94dacbd4-6937-4c5e-b48d-538cbbae7d33", "199e38b8-d6f7-4052-a216-5080c7979d69", "62660e88-ea6b-484f-89fa-ff84f0a620f1", "ae4d5271-9f17-4cad-82e5-9690991fd840", "74c302f1-4d44-4f3b-9f94-e32decd05c95", "77348027-7b24-4989-8a4f-0a3866fac559", "833c4bf9-f693-4659-bf04-0734d22d4b88", "05400520-791d-41f8-9c1c-e74b7473a104", "490f2417-a24b-4cee-9261-afdcf7ecff5b", "1fa9961b-0205-4640-885a-032ea5cb9f86", "1248b045-1dad-4160-b9f0-5b9ebfa7c9f6", "cfad33d0-737c-460d-9571-2ba295447fe5", "5e5978b1-1906-48c4-92b4-a0110942b184", "d79cba85-a093-4acb-9328-a1898f2fdc06", "bb8837da-caef-495e-a0f9-499ac0bc5b92", "d1210e7b-b36a-482e-9312-59fb895a4cb1", "74663052-5d3a-4131-8de6-e6d8e007744e", "a438fcd9-2945-4e36-8de5-d7fc9f354d68"], "metadata": {"window": "year quarter in comparison to the prior year quarter.  On a constant currency basis, revenue was up 11.4 percent, reflecting\n11.9 percent constant currency growth in International Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2023 was $2.4 billion, a 6.2 percent increase\ncompared to the same period in the previous fiscal year due to an increase in gross profit in both reportable segments.\n Adjusted gross profit as a percentage of revenue was 3.71 percent in the fiscal 2023 second quarter, a decrease of 13 basis\npoints from the prior year quarter.\n", "original_text": "year quarter in comparison to the prior year quarter. ", "page_label": "3", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "7129ecf3-7586-4969-be47-487cdb63cac3": {"node_ids": ["b1717eba-3a66-4c74-a0c3-df019208e2db", "a403200a-bc9c-4f8b-856f-a692a7d6b174", "ae6acd26-380f-44b0-b49d-43bf6f716bbe", "e0c84da1-8f08-4a1a-92c3-8b95725609a7", "83086610-76a7-49de-b3ce-6bf31086cd53", "8e4f9bac-e48f-4480-9f64-4e990a1b8890", "5da72bf4-ef5f-4463-a5bd-3bc7f9abb205", "44450600-dfa3-437a-af3a-a8c4c238d2ae", "1340242b-90ab-4594-855f-a593a5f48bac", "a52f9b2c-6c02-4cb9-9022-a04bb200f913", "366d93fc-c2bc-488a-91ed-8026ed62f635", "3b4db343-bdcf-4042-bcdc-a637411b9b12", "1ff9fc40-f568-44e0-8470-b64b743373e5", "2e653783-8ebf-4ddf-8125-27a1fb37edd8", "7b584290-4f8b-47b9-b0f4-14be7baa3e2c", "207dc282-f542-497a-a357-153f1347b913"], "metadata": {"window": "decrease of 5.9 percent.  The period over period declines were due to the June 2022 divestiture of our Brazil specialty business and\nunfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter.  On a constant\ncurrency basis, International Healthcare Solutions revenue and operating income increased by 11.9 percent and 7.3 percent,\nrespectively.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and TPG announced an agreement to acquire OneOncology, a network of leading oncology practices.\n", "original_text": "decrease of 5.9 percent. ", "page_label": "4", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "09858b6e-6f03-4927-8378-7b281265574e": {"node_ids": ["8d548d5d-1f59-4671-9b15-213eac1001f2", "03d779dc-9735-49b4-a529-708437b390de", "77d1c990-cdc9-4509-b103-8c080d9960cd", "25fc97ed-1cad-459a-ab4d-fea617d55e1a", "184afaea-e1cb-4a62-9278-67bd4d9bbdf2", "127ce416-9c4a-4a5e-8c07-082d70636218", "57b5047f-2b89-4baa-9edb-abc87239fcf4", "8ac65456-4a5f-4a40-89c0-d24e15e07a03", "31ae8181-b0fa-4e7e-80eb-4ca666ede20d", "c9cc3448-51c9-43b5-b448-3f1d765cac8b", "b2282575-55dc-4217-b030-84f5ee3dd149", "eecdaadd-ddaf-42de-902b-2b1c14076857", "0162d3e6-5409-4c77-a92a-a4638189705a", "43e9388d-392c-4fed-8c7a-4f7854225096", "412b50b1-6c5b-456e-ae65-eb3702e99dee", "ea311a20-290e-48f3-ae76-5928e5710ab7", "45fb4dec-22e5-4e7f-8576-3f35259ef2fe", "e7f6cb07-3e73-4dbc-a245-28cddd411def", "29b82857-1aff-481a-87f0-2818aeb39fa1", "93618fd6-3ddf-46ab-9d7c-90dcefec4a45", "b6a60497-f25d-46fc-8e91-500598cb5346", "11920c85-0ba8-4427-b5e4-5cd0317eac2d", "71ceb11f-a3cb-4817-8f1f-a0d8574117c0", "0aa52601-bcc4-447f-bd6f-cd0853f2566a"], "metadata": {"window": "percent.  Excluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 5 to 7\npercent, up from the previous range of 4 to 6 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 3 percent to 5 percent, up from the\nprevious range of 1 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions have been raised to growth of 6 to 8 percent, up from the previous range of 5 to 7 percent;\nWeighted average diluted shares to be approximately 205 million shares for the fiscal year, lowered from the previous range\nof approximately 206 million shares; and\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis, please refer to our slide presentation for investors.\n", "original_text": "percent. ", "page_label": "5", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "cfd904d4-27a2-44eb-86a3-80c14449c264": {"node_ids": ["c4e2e62c-1fd0-4c23-9d81-dcd10d18506c", "c30088e4-f8dd-41ca-8643-66646218c12a", "d0bcae8c-544c-4937-8357-0740606a094f", "cacde9be-25a7-4e9e-ae0d-43b911eef2e0", "85b8b537-01b2-439c-939e-d86f81aeec20", "164ef264-1039-4f33-a735-2ad587f4ffaa", "f007cac8-fbfd-4e5e-a72a-75113e1568cd", "0201e0ea-6163-4ed3-a3d1-a3091e36af0d", "0632d3bd-3e2b-4802-ad61-79891039b026", "5c45d857-cfeb-4cd1-9345-36ca2789755b", "f06b64b7-fdad-4662-bf21-70652b94f9db"], "metadata": {"window": "around the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures. ", "original_text": "around the world. ", "page_label": "6", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8d137db6-3360-4408-8451-4f38761e2b23": {"node_ids": ["5baeb4d0-6160-470b-97f6-8bbbe851923a", "52ef53ef-53a8-4fef-9e8d-572392013414", "12d4fc00-9c7c-468a-b5b2-92cdf9888d55"], "metadata": {"window": "the possibility that various conditions to the consummation of the acquisition of OneOncology may not be satisfied or that\ntheir satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of OneOncology;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\nAlliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nwith respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nmanaging foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations;\nour ability to respond to financial market volatility and disruption;\nchanges in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax positions and/or the Company\u2019s tax\nliabilities or adverse resolution of challenges to the Company\u2019s tax positions;\nthe loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by\nor the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19;\nfinancial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix;\nmalfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated\nwith cybersecurity;\nrisks generally associated with data privacy regulation and the protection and international transfer of personal data;\nregulatory and legal implications relating to the March 2023 cybersecurity event sustained by one of the Company\u2019s foreign\nbusiness units in one country;\nfinancial and other impacts of macroeconomic and geopolitical trends and events, including the unfolding situation in Russia\nand Ukraine and its regional and global ramifications;\nnatural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations;\nthe impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings;\nthe Company\u2019s ability to manage and complete divestitures;\nthe disruption of the Company\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices;\ninterest rate and foreign currency exchange rate fluctuations;\ndeclining economic conditions and increases in inflation in the United States and abroad; and\n7", "original_text": "the possibility that various conditions to the consummation of the acquisition of OneOncology may not be satisfied or that\ntheir satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of OneOncology;\nunexpected costs, charges or expenses resulting from the acquisitions of PharmaLex and OneOncology;\nthe integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming\nor costly than expected;\nthe Company\u2019s, Alliance Healthcare\u2019s, PharmaLex\u2019s or OneOncology\u2019s failure to achieve expected or targeted future financial\nand operating performance and results;\nthe effects of disruption from acquisitions and related strategic transactions on the respective businesses of the Company,\nAlliance Healthcare, PharmaLex and OneOncology, and the fact that acquisitions and related strategic transactions may make\nit more difficult to establish or maintain relationships with employees, suppliers and other business partners;\nthe acquisition of businesses, including the acquisitions of the Alliance Healthcare, PharmaLex and OneOncology businesses\nand related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability\nto capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time\nperiod;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. ", "page_label": "7", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "5d629b4d-da68-46db-9b09-ded3bdf928c2": {"node_ids": ["a5c51f15-21f4-46db-980f-62fdb0c975e4", "c37f560a-fe7b-4ebf-9a78-676ad4932aa0", "d9e70527-4a16-4b3f-9a4e-5d580ce50b8b", "a91697a3-fd02-418f-a1e1-0b5b1a5e7d33"], "metadata": {"window": "other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three\nMonths\nEnded \nMarch 31,\n2023 \u00a0% of\nRevenue \u00a0Three\nMonths\nEnded \nMarch 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$63,457,205 \u00a0\u00a0 \u00a0$57,719,446 \u00a0\u00a0 \u00a09.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a061,161,763 \u00a0\u00a0 \u00a0\u00a055,484,366 \u00a0\u00a0 \u00a010.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,295,442 \u00a03.62% \u00a0\u00a02,235,080 \u00a03.87% \u00a02.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,321,087 \u00a02.08% \u00a0\u00a01,203,238 \u00a02.08% \u00a09.8%\nDepreciation and amortization \u00a0\u00a0241,466 \u00a00.38% \u00a0\u00a0175,290 \u00a00.30% \u00a037.8%\nLitigation and opioid-related expenses \u00a0\u00a015,813 \u00a0\u00a0 \u00a0\u00a052,090 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a059,113 \u00a0\u00a0 \u00a0\u00a011,790 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a097,444 \u00a0\u00a0 \u00a0\u00a012,515 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,734,923 \u00a02.73% \u00a0\u00a01,454,923 \u00a02.52% \u00a019.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0560,519 \u00a00.88% \u00a0\u00a0780,157 \u00a01.35% \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business\ngenerally.\n", "page_label": "8", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "37177a96-950b-40f8-b0fd-e9f26ad4974a": {"node_ids": ["c34477e8-da40-4366-87ec-f83824234c05", "d909fccf-e2d1-412d-92bd-98153fa872c9"], "metadata": {"window": "Other income, net \u00a0\u00a0(15,720) \u00a0\u00a0 \u00a0\u00a0(948) \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a064,109 \u00a0\u00a0 \u00a0\u00a052,916 \u00a0\u00a0 \u00a021.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0512,130 \u00a00.81% \u00a0\u00a0728,189 \u00a01.26% \u00a0(29.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,917 \u00a0\u00a0 \u00a0\u00a0172,944 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0428,213 \u00a00.67% \u00a0\u00a0555,245 \u00a00.96% \u00a0(22.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a07,189 \u00a0\u00a0 \u00a0\u00a0(7,231) \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$435,402 \u00a00.69% \u00a0$548,014 \u00a00.95% \u00a0(20.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.15 \u00a0\u00a0 \u00a0$2.62 \u00a0\u00a0 \u00a0(17.9)%\nDiluted \u00a0$2.13 \u00a0\u00a0 \u00a0$2.59 \u00a0\u00a0 \u00a0(17.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,316 \u00a0\u00a0 \u00a0\u00a0209,244 \u00a0\u00a0 \u00a0(3.3)%\nDiluted \u00a0\u00a0204,256 \u00a0\u00a0 \u00a0\u00a0211,991 \u00a0\u00a0 \u00a0(3.6)%\n________________________________________ \n 1 Includes a $54.3 million LIFO expense in the three months ended March 31, 2023 and a $16.1 million LIFO credit in the three\nmonths ended March 31, 2022.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n9", "original_text": "Other income, net \u00a0\u00a0(15,720) \u00a0\u00a0 \u00a0\u00a0(948) \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a064,109 \u00a0\u00a0 \u00a0\u00a052,916 \u00a0\u00a0 \u00a021.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0512,130 \u00a00.81% \u00a0\u00a0728,189 \u00a01.26% \u00a0(29.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,917 \u00a0\u00a0 \u00a0\u00a0172,944 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0428,213 \u00a00.67% \u00a0\u00a0555,245 \u00a00.96% \u00a0(22.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a07,189 \u00a0\u00a0 \u00a0\u00a0(7,231) \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$435,402 \u00a00.69% \u00a0$548,014 \u00a00.95% \u00a0(20.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.15 \u00a0\u00a0 \u00a0$2.62 \u00a0\u00a0 \u00a0(17.9)%\nDiluted \u00a0$2.13 \u00a0\u00a0 \u00a0$2.59 \u00a0\u00a0 \u00a0(17.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0202,316 \u00a0\u00a0 \u00a0\u00a0209,244 \u00a0\u00a0 \u00a0(3.3)%\nDiluted \u00a0\u00a0204,256 \u00a0\u00a0 \u00a0\u00a0211,991 \u00a0\u00a0 \u00a0(3.6)%\n________________________________________ \n 1 Includes a $54.3 million LIFO expense in the three months ended March 31, 2023 and a $16.1 million LIFO credit in the three\nmonths ended March 31, 2022.\n", "page_label": "9", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "7f1c344d-531d-4d97-8f84-76bd8391b766": {"node_ids": ["0d2ab4c7-6354-4c88-929b-a4355e9b70d2"], "metadata": {"window": "\u00a0 \u00a0Six Months\nEnded \nMarch 31,\n2023 \u00a0% of\nRevenue \u00a0Six Months\nEnded \nMarch 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$126,304,037 \u00a0\u00a0 \u00a0$117,348,256 \u00a0\u00a0 \u00a07.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0121,862,642 \u00a0\u00a0 \u00a0\u00a0113,052,817 \u00a0\u00a0 \u00a07.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a04,441,395 \u00a03.52% \u00a0\u00a04,295,439 \u00a03.66% \u00a03.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a02,612,015 \u00a02.07% \u00a0\u00a02,373,348 \u00a02.02% \u00a010.1%\nDepreciation and amortization \u00a0\u00a0413,406 \u00a00.33% \u00a0\u00a0351,219 \u00a00.30% \u00a017.7%\nLitigation and opioid-related expenses \u00a0\u00a028,519 \u00a0\u00a0 \u00a0\u00a084,725 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a080,109 \u00a0\u00a0 \u00a0\u00a033,140 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0113,684 \u00a0\u00a0 \u00a0\u00a023,499 \u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a03,247,733 \u00a02.57% \u00a0\u00a02,870,877 \u00a02.45% \u00a013.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,193,662 \u00a00.95% \u00a0\u00a01,424,562 \u00a01.21% \u00a0(16.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(22,048) \u00a0\u00a0 \u00a0\u00a0(6,120) \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0110,125 \u00a0\u00a0 \u00a0\u00a0106,288 \u00a0\u00a0 \u00a03.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,105,585 \u00a00.88% \u00a0\u00a01,324,394 \u00a01.13% \u00a0(16.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0201,202 \u00a0\u00a0 \u00a0\u00a0319,733 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "original_text": "\u00a0 \u00a0Six Months\nEnded \nMarch 31,\n2023 \u00a0% of\nRevenue \u00a0Six Months\nEnded \nMarch 31,\n2022 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$126,304,037 \u00a0\u00a0 \u00a0$117,348,256 \u00a0\u00a0 \u00a07.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0121,862,642 \u00a0\u00a0 \u00a0\u00a0113,052,817 \u00a0\u00a0 \u00a07.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a04,441,395 \u00a03.52% \u00a0\u00a04,295,439 \u00a03.66% \u00a03.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a02,612,015 \u00a02.07% \u00a0\u00a02,373,348 \u00a02.02% \u00a010.1%\nDepreciation and amortization \u00a0\u00a0413,406 \u00a00.33% \u00a0\u00a0351,219 \u00a00.30% \u00a017.7%\nLitigation and opioid-related expenses \u00a0\u00a028,519 \u00a0\u00a0 \u00a0\u00a084,725 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a080,109 \u00a0\u00a0 \u00a0\u00a033,140 \u00a0\u00a0 \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0113,684 \u00a0\u00a0 \u00a0\u00a023,499 \u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a03,247,733 \u00a02.57% \u00a0\u00a02,870,877 \u00a02.45% \u00a013.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,193,662 \u00a00.95% \u00a0\u00a01,424,562 \u00a01.21% \u00a0(16.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(22,048) \u00a0\u00a0 \u00a0\u00a0(6,120) \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0110,125 \u00a0\u00a0 \u00a0\u00a0106,288 \u00a0\u00a0 \u00a03.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,105,585 \u00a00.88% \u00a0\u00a01,324,394 \u00a01.13% \u00a0(16.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0201,202 \u00a0\u00a0 \u00a0\u00a0319,733 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "page_label": "10", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "1bb47096-a02d-4d23-85cc-7b9438626f38": {"node_ids": ["b2960218-5cc7-4893-a326-eb062e7d6b5c", "283efd3c-6c39-43e4-aa17-28f15cb63d7e", "01c3d115-1cd7-41df-a191-cd67779d1837"], "metadata": {"window": "Net income \u00a0\u00a0904,383 \u00a00.72% \u00a0\u00a01,004,661 \u00a00.86% \u00a0(10.0)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a010,764 \u00a0\u00a0 \u00a0\u00a0(7,542) \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$915,147 \u00a00.72% \u00a0$997,119 \u00a00.85% \u00a0(8.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.50 \u00a0\u00a0 \u00a0$4.77 \u00a0\u00a0 \u00a0(5.7)%\nDiluted \u00a0$4.46 \u00a0\u00a0 \u00a0$4.71 \u00a0\u00a0 \u00a0(5.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0203,188 \u00a0\u00a0 \u00a0\u00a0208,900 \u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0\u00a0205,306 \u00a0\u00a0 \u00a0\u00a0211,580 \u00a0\u00a0 \u00a0(3.0)%\n________________________________________ \n 1 Includes a $79.3 million LIFO expense and a $49.9 million gain from antitrust litigation settlements in the six months ended March\n31, 2023.  Includes a $60.7 million LIFO credit in the six months ended March 31, 2022.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,295,442 \u00a0$1,734,923 \u00a0$560,519 \u00a0$512,130 \u00a0$83,917 \u00a0$7,189 \u00a0$435,402 \u00a0$2.13 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02 \u00a0\u00a0\u2014 \u00a0\u00a0(2) \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n11", "original_text": "Net income \u00a0\u00a0904,383 \u00a00.72% \u00a0\u00a01,004,661 \u00a00.86% \u00a0(10.0)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a010,764 \u00a0\u00a0 \u00a0\u00a0(7,542) \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$915,147 \u00a00.72% \u00a0$997,119 \u00a00.85% \u00a0(8.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.50 \u00a0\u00a0 \u00a0$4.77 \u00a0\u00a0 \u00a0(5.7)%\nDiluted \u00a0$4.46 \u00a0\u00a0 \u00a0$4.71 \u00a0\u00a0 \u00a0(5.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0203,188 \u00a0\u00a0 \u00a0\u00a0208,900 \u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0\u00a0205,306 \u00a0\u00a0 \u00a0\u00a0211,580 \u00a0\u00a0 \u00a0(3.0)%\n________________________________________ \n 1 Includes a $79.3 million LIFO expense and a $49.9 million gain from antitrust litigation settlements in the six months ended March\n31, 2023. ", "page_label": "11", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "cf471dd7-da88-4f99-af33-033da7024c63": {"node_ids": ["d33315da-1936-4a5b-8462-3ddd7374d822", "c81751d0-3240-4f8c-ad5c-1e9d3a917823"], "metadata": {"window": "Turkey highly\ninflationary impact \u00a0\u00a04,855 \u00a0\u00a0\u2014 \u00a0\u00a04,855 \u00a0\u00a04,455 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a04,455 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a054,270 \u00a0\u00a0\u2014 \u00a0\u00a054,270 \u00a0\u00a054,270 \u00a0\u00a012,676 \u00a0\u00a0\u2014 \u00a0\u00a041,594 \u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(140,114) \u00a0\u00a0140,114 \u00a0\u00a0140,114 \u00a0\u00a032,727 \u00a0\u00a0(984) \u00a0\u00a0106,403 \u00a0\u00a00.52 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,813) \u00a0\u00a015,813 \u00a0\u00a015,813 \u00a0\u00a03,693 \u00a0\u00a0\u2014 \u00a0\u00a012,120 \u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(59,113) \u00a0\u00a059,113 \u00a0\u00a059,113 \u00a0\u00a013,808 \u00a0\u00a0\u2014 \u00a0\u00a045,305 \u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(97,444) \u00a0\u00a097,444 \u00a0\u00a097,444 \u00a0\u00a022,763 \u00a0\u00a0\u2014 \u00a0\u00a074,681 \u00a0\u00a00.37 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0(0.03) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(2,182) \u00a0\u00a0(3,244) \u00a0\u00a0\u2014 \u00a0\u00a01,062 \u00a0\u00a00.01 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,354,567 \u00a0$1,422,439 \u00a0$932,128 \u00a0$875,494 \u00a0$166,342 \u00a0$6,205 \u00a0$715,357 \u00a0$3.50 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP\n% change vs.  prior\nyear \u00a0\u00a06.2 % \u00a0\u00a09.4 % \u00a0\u00a01.7 % \u00a0\u00a00.9 % \u00a0\u00a0(8.5) % \u00a0\u00a0 \u00a0\u00a04.7 % \u00a0\u00a08.7 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.62% \u00a03.71%\nOperating expenses \u00a02.73% \u00a02.24%\n12", "original_text": "Turkey highly\ninflationary impact \u00a0\u00a04,855 \u00a0\u00a0\u2014 \u00a0\u00a04,855 \u00a0\u00a04,455 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a04,455 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a054,270 \u00a0\u00a0\u2014 \u00a0\u00a054,270 \u00a0\u00a054,270 \u00a0\u00a012,676 \u00a0\u00a0\u2014 \u00a0\u00a041,594 \u00a0\u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(140,114) \u00a0\u00a0140,114 \u00a0\u00a0140,114 \u00a0\u00a032,727 \u00a0\u00a0(984) \u00a0\u00a0106,403 \u00a0\u00a00.52 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(15,813) \u00a0\u00a015,813 \u00a0\u00a015,813 \u00a0\u00a03,693 \u00a0\u00a0\u2014 \u00a0\u00a012,120 \u00a0\u00a00.06 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(59,113) \u00a0\u00a059,113 \u00a0\u00a059,113 \u00a0\u00a013,808 \u00a0\u00a0\u2014 \u00a0\u00a045,305 \u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(97,444) \u00a0\u00a097,444 \u00a0\u00a097,444 \u00a0\u00a022,763 \u00a0\u00a0\u2014 \u00a0\u00a074,681 \u00a0\u00a00.37 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0(0.03) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(2,182) \u00a0\u00a0(3,244) \u00a0\u00a0\u2014 \u00a0\u00a01,062 \u00a0\u00a00.01 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$2,354,567 \u00a0$1,422,439 \u00a0$932,128 \u00a0$875,494 \u00a0$166,342 \u00a0$6,205 \u00a0$715,357 \u00a0$3.50 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP\n% change vs. ", "page_label": "12", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b636a6e5-91b7-4a50-a4de-05c19f686131": {"node_ids": ["ffec9053-89ae-4749-84bb-8e08ccfe98cb", "e4201620-ede3-440b-a0f5-370d8338a563", "2f5b229c-1b24-4b23-8182-15e70925eff9"], "metadata": {"window": "Operating income \u00a00.88% \u00a01.47%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$2,235,080 \u00a0$1,454,923 \u00a0$780,157 \u00a0$728,189 \u00a0$172,944 \u00a0$(7,231) \u00a0$548,014 \u00a0$2.59 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(1,835) \u00a0\u00a0\u2014 \u00a0\u00a0(1,835) \u00a0\u00a0(1,835) \u00a0\u00a0(427) \u00a0\u00a0\u2014 \u00a0\u00a0(1,408) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(16,059) \u00a0\u00a0\u2014 \u00a0\u00a0(16,059) \u00a0\u00a0(16,059) \u00a0\u00a0(3,897) \u00a0\u00a0\u2014 \u00a0\u00a0(12,162) \u00a0\u00a0(0.06) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(77,952) \u00a0\u00a077,952 \u00a0\u00a077,952 \u00a0\u00a018,431 \u00a0\u00a0(1,764) \u00a0\u00a057,757 \u00a0\u00a00.27 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(52,090) \u00a0\u00a052,090 \u00a0\u00a052,090 \u00a0\u00a05,298 \u00a0\u00a0\u2014 \u00a0\u00a046,792 \u00a0\u00a00.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated deal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(11,790) \u00a0\u00a011,790 \u00a0\u00a011,790 \u00a0\u00a02,797 \u00a0\u00a0\u2014 \u00a0\u00a08,993 \u00a0\u00a00.04 \u00a0\n13", "original_text": "Operating income \u00a00.88% \u00a01.47%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n", "page_label": "13", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8fd675f3-8941-48c4-9952-f93521529497": {"node_ids": ["c4dd5f83-63f5-41b8-885c-a297b9053d44", "6bda1993-ed92-46d4-ae44-f7e48089d5ed", "f2c538db-35f4-4ca7-8999-7a047397e60c"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(12,515) \u00a0\u00a012,515 \u00a0\u00a012,515 \u00a0\u00a02,969 \u00a0\u00a0\u2014 \u00a0\u00a09,546 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(7,900) \u00a0\u00a06,840 \u00a0\u00a014,740 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,737 \u00a0\u00a0(8,329) \u00a0\u00a0\u2014 \u00a0\u00a011,066 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,217,186 \u00a0$1,300,576 \u00a0$916,610 \u00a0$867,379 \u00a0$181,886 \u00a0$(2,155) \u00a0$683,338 \u00a0$3.22\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2023 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,441,395 \u00a0$3,247,733 \u00a0$1,193,662 \u00a0$1,105,585 \u00a0$201,202 \u00a0$10,764 \u00a0$915,147 \u00a0$4.46 \u00a0\n14", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(12,515) \u00a0\u00a012,515 \u00a0\u00a012,515 \u00a0\u00a02,969 \u00a0\u00a0\u2014 \u00a0\u00a09,546 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(7,900) \u00a0\u00a06,840 \u00a0\u00a014,740 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,737 \u00a0\u00a0(8,329) \u00a0\u00a0\u2014 \u00a0\u00a011,066 \u00a0\u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,217,186 \u00a0$1,300,576 \u00a0$916,610 \u00a0$867,379 \u00a0$181,886 \u00a0$(2,155) \u00a0$683,338 \u00a0$3.22\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net.\n", "page_label": "14", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "48d70c4d-35c4-4c7e-87a8-e96b3b10a00d": {"node_ids": ["514a09e2-e25a-4c16-a035-e1d20f5f9c8a"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0(49,899) \u00a0\u00a0\u2014 \u00a0\u00a0(49,899) \u00a0\u00a0(49,899) \u00a0\u00a0(11,657) \u00a0\u00a0\u2014 \u00a0\u00a0(38,242) \u00a0\u00a0(0.19) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a08,439 \u00a0\u00a0\u2014 \u00a0\u00a08,439 \u00a0\u00a08,441 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a08,441 \u00a0\u00a00.04 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a079,320 \u00a0\u00a0\u2014 \u00a0\u00a079,320 \u00a0\u00a079,320 \u00a0\u00a018,529 \u00a0\u00a0\u2014 \u00a0\u00a060,791 \u00a0\u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(211,992) \u00a0\u00a0211,992 \u00a0\u00a0211,992 \u00a0\u00a049,522 \u00a0\u00a0(2,142) \u00a0\u00a0160,328 \u00a0\u00a00.78 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(28,519) \u00a0\u00a028,519 \u00a0\u00a028,519 \u00a0\u00a06,662 \u00a0\u00a0\u2014 \u00a0\u00a021,857 \u00a0\u00a00.11 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(80,109) \u00a0\u00a080,109 \u00a0\u00a080,109 \u00a0\u00a018,714 \u00a0\u00a0\u2014 \u00a0\u00a061,395 \u00a0\u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(113,684) \u00a0\u00a0113,684 \u00a0\u00a0113,684 \u00a0\u00a026,557 \u00a0\u00a0\u2014 \u00a0\u00a087,127 \u00a0\u00a00.42 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0(0.03) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-\ncustomer note\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(1,148) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(1,148) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(6,639) \u00a0\u00a0(11,608) \u00a0\u00a0\u2014 \u00a0\u00a04,969 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,479,255 \u00a0$2,813,429 \u00a0$1,665,826 \u00a0$1,564,301 \u00a0$297,921 \u00a0$8,622 \u00a0$1,275,002 \u00a0$6.21 2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n15", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from antitrust\nlitigation settlements \u00a0\u00a0(49,899) \u00a0\u00a0\u2014 \u00a0\u00a0(49,899) \u00a0\u00a0(49,899) \u00a0\u00a0(11,657) \u00a0\u00a0\u2014 \u00a0\u00a0(38,242) \u00a0\u00a0(0.19) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary impact \u00a0\u00a08,439 \u00a0\u00a0\u2014 \u00a0\u00a08,439 \u00a0\u00a08,441 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a08,441 \u00a0\u00a00.04 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a079,320 \u00a0\u00a0\u2014 \u00a0\u00a079,320 \u00a0\u00a079,320 \u00a0\u00a018,529 \u00a0\u00a0\u2014 \u00a0\u00a060,791 \u00a0\u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0(211,992) \u00a0\u00a0211,992 \u00a0\u00a0211,992 \u00a0\u00a049,522 \u00a0\u00a0(2,142) \u00a0\u00a0160,328 \u00a0\u00a00.78 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and opioid-\nrelated expenses \u00a0\u00a0\u2014 \u00a0\u00a0(28,519) \u00a0\u00a028,519 \u00a0\u00a028,519 \u00a0\u00a06,662 \u00a0\u00a0\u2014 \u00a0\u00a021,857 \u00a0\u00a00.11 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and integration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(80,109) \u00a0\u00a080,109 \u00a0\u00a080,109 \u00a0\u00a018,714 \u00a0\u00a0\u2014 \u00a0\u00a061,395 \u00a0\u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(113,684) \u00a0\u00a0113,684 \u00a0\u00a0113,684 \u00a0\u00a026,557 \u00a0\u00a0\u2014 \u00a0\u00a087,127 \u00a0\u00a00.42 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nForeign currency gain \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(5,663) \u00a0\u00a0(0.03) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of non-\ncustomer note\nreceivable \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(1,148) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(1,148) \u00a0\u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(6,639) \u00a0\u00a0(11,608) \u00a0\u00a0\u2014 \u00a0\u00a04,969 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-GAAP \u00a0$4,479,255 \u00a0$2,813,429 \u00a0$1,665,826 \u00a0$1,564,301 \u00a0$297,921 \u00a0$8,622 \u00a0$1,275,002 \u00a0$6.21 2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n15", "page_label": "15", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "16633cac-2032-419d-bcd9-3517fad60db4": {"node_ids": ["4d342622-e2a9-471c-bf4b-697b73edcf49", "b91fc4e4-df44-40ac-8686-2845c88e8437", "1c8420ff-9425-4b71-89b1-88f6b8449771", "3b98622f-0457-493a-bc54-28a5a554dba6", "5e470302-a3ed-4351-a6cb-5c72e106ce5b"], "metadata": {"window": "Adjusted Non-GAAP\n% change vs.  prior\nyear \u00a0\u00a05.8 % \u00a0\u00a09.6 % \u00a0\u00a0\u2014 % \u00a0\u00a00.1 % \u00a0\u00a0(9.7) % \u00a0 \u00a0\u00a03.8 % \u00a0\u00a06.9 % \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.52% \u00a03.55%\nOperating expenses \u00a02.57% \u00a02.23%\nOperating income \u00a00.95% \u00a01.32%\n________________________________________ \n 1 Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net. \n  2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "original_text": "Adjusted Non-GAAP\n% change vs. ", "page_label": "16", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ffab077b-dbe7-4d72-b99b-ca6b09c298f2": {"node_ids": ["f9d502b2-0c38-40d5-980d-f6b357eeeca7", "8abab408-129a-4391-a888-3557d4315c97", "8bd0b50d-e4d7-41d4-9e5e-4ad0215b9db1"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(84,725) \u00a0\u00a084,725 \u00a0\u00a084,725 \u00a0\u00a011,210 \u00a0\u00a0\u2014 \u00a0\u00a073,515 \u00a0\u00a00.35 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(33,140) \u00a0\u00a033,140 \u00a0\u00a033,140 \u00a0\u00a07,716 \u00a0\u00a0\u2014 \u00a0\u00a025,424 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(23,499) \u00a0\u00a023,499 \u00a0\u00a023,499 \u00a0\u00a05,471 \u00a0\u00a0\u2014 \u00a0\u00a018,028 \u00a0\u00a00.09 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a04,946 \u00a0\u00a04,946 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a04,946 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(18,979) \u00a0\u00a06,840 \u00a0\u00a025,819 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(2,570) \u00a0\u00a0(17,204) \u00a0\u00a0\u2014 \u00a0\u00a014,634 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$4,232,866 \u00a0$2,567,109 \u00a0$1,665,757 \u00a0$1,563,019 \u00a0$330,039 \u00a0$(4,256) \u00a0$1,228,724 \u00a0$5.81 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.66% \u00a03.61%\nOperating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net. \n  2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\n17", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(84,725) \u00a0\u00a084,725 \u00a0\u00a084,725 \u00a0\u00a011,210 \u00a0\u00a0\u2014 \u00a0\u00a073,515 \u00a0\u00a00.35 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\ndeal and\nintegration\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0(33,140) \u00a0\u00a033,140 \u00a0\u00a033,140 \u00a0\u00a07,716 \u00a0\u00a0\u2014 \u00a0\u00a025,424 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRestructuring and\nother expenses \u00a0\u00a0\u2014 \u00a0\u00a0(23,499) \u00a0\u00a023,499 \u00a0\u00a023,499 \u00a0\u00a05,471 \u00a0\u00a0\u2014 \u00a0\u00a018,028 \u00a0\u00a00.09 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a04,946 \u00a0\u00a04,946 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a04,946 \u00a0\u00a00.02 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(18,979) \u00a0\u00a06,840 \u00a0\u00a025,819 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(2,570) \u00a0\u00a0(17,204) \u00a0\u00a0\u2014 \u00a0\u00a014,634 \u00a0\u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$4,232,866 \u00a0$2,567,109 \u00a0$1,665,757 \u00a0$1,563,019 \u00a0$330,039 \u00a0$(4,256) \u00a0$1,228,724 \u00a0$5.81 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.66% \u00a03.61%\nOperating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________ \n 1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Income, Net. \n ", "page_label": "17", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "18c50b95-a0e6-4159-abc8-a85289142737": {"node_ids": ["e2cadb71-ec5d-46c6-899e-d084ceb78d1d", "9d7d54a3-dc4a-4996-aa6f-76c884f758c1", "c2e6fb57-7441-4946-bea5-4460bdf1bf2d", "b44e530d-e562-49b3-908c-9110fd21d718"], "metadata": {"window": "Regarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$56,693,456 \u00a0$50,942,763 \u00a011.3%\nInternational Healthcare Solutions \u00a0\u00a06,764,935 \u00a0\u00a06,777,691 \u00a0(0.2)%\nIntersegment eliminations \u00a0\u00a0(1,186) \u00a0\u00a0(1,008) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$63,457,205 \u00a0$57,719,446 \u00a09.9%\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$756,137 \u00a0$729,542 \u00a03.6%\nInternational Healthcare Solutions \u00a0\u00a0175,991 \u00a0\u00a0187,068 \u00a0(5.9)%\nTotal segment operating income \u00a0\u00a0932,128 \u00a0\u00a0916,610 \u00a01.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(4,855) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(54,270) \u00a0\u00a016,059 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(140,114) \u00a0\u00a0(77,952) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,813) \u00a0\u00a0(52,090) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(59,113) \u00a0\u00a0(11,790) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(97,444) \u00a0\u00a0(12,515) \u00a0\u00a0\n18", "original_text": "Regarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "18", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "25d07277-3739-4196-bfcd-8f796d392da4": {"node_ids": ["8657904c-114f-429c-b8f2-ef46c033eebe", "47fd3b06-3139-4ecf-a53f-53eed305d51b", "eb6990ef-f748-4f48-8f7e-89fe735989be"], "metadata": {"window": "Operating income \u00a0$560,519 \u00a0$780,157 \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.74% \u00a0\u00a02.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.40% \u00a0\u00a01.44% \u00a0\u00a0\nOperating income \u00a0\u00a01.33% \u00a0\u00a01.43% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.88% \u00a0\u00a011.15% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.28% \u00a0\u00a08.39% \u00a0\u00a0\nOperating income \u00a0\u00a02.60% \u00a0\u00a02.76% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.62% \u00a0\u00a03.87% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.73% \u00a0\u00a02.52% \u00a0\u00a0\nOperating income \u00a0\u00a00.88% \u00a0\u00a01.35% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.71% \u00a0\u00a03.84% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.24% \u00a0\u00a02.25% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.47% \u00a0\u00a01.59% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (in thousands) \n (unaudited)\n19", "original_text": "Operating income \u00a0$560,519 \u00a0$780,157 \u00a0(28.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "19", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8fcc4cbd-0eac-491e-a5b1-e4b4e05c1251": {"node_ids": ["3d6d9744-4328-48d7-98f2-e765d82db6ef", "923071aa-73c5-4598-b2c4-52931edb8a36", "8bd9556b-5d6e-4198-b7b5-09785b79add0"], "metadata": {"window": "\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$112,930,035 \u00a0$103,922,410 \u00a08.7%\nInternational Healthcare Solutions \u00a0\u00a013,376,213 \u00a0\u00a013,427,473 \u00a0(0.4)%\nIntersegment eliminations \u00a0\u00a0(2,211) \u00a0\u00a0(1,627) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$126,304,037 \u00a0$117,348,256 \u00a07.6%\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,328,553 \u00a0$1,298,629 \u00a02.3%\nInternational Healthcare Solutions \u00a0\u00a0337,273 \u00a0\u00a0367,128 \u00a0(8.1)%\nTotal segment operating income \u00a0\u00a01,665,826 \u00a0\u00a01,665,757 \u00a0\u2014%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a01,835 \u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(8,439) \u00a0\u00a0\u2014 \u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(79,320) \u00a0\u00a060,738 \u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(211,992) \u00a0\u00a0(157,458) \u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(28,519) \u00a0\u00a0(84,725) \u00a0\u00a0\nAcquisition-related deal and integration expenses \u00a0\u00a0(80,109) \u00a0\u00a0(33,140) \u00a0\u00a0\nRestructuring and other expenses \u00a0\u00a0(113,684) \u00a0\u00a0(23,499) \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0(4,946) \u00a0\u00a0\nOperating income \u00a0$1,193,662 \u00a0$1,424,562 \u00a0(16.2)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20", "original_text": "\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a0\u00a02023 \u00a0\u00a02022 \u00a0% Change\nU.S. ", "page_label": "20", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "098c5ca1-2c88-4bec-a459-b6f22556d52e": {"node_ids": ["5bff4d05-67f4-4ce1-89f4-e93e90db1346", "0ee887a4-8828-4837-8f2a-f08691c364f2", "c11240c0-51d3-4d62-8a94-a8d2989a6729"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.60% \u00a0\u00a02.64% \u00a0\u00a0\nOperating expenses \u00a0\u00a01.42% \u00a0\u00a01.39% \u00a0\u00a0\nOperating income \u00a0\u00a01.18% \u00a0\u00a01.25% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.53% \u00a0\u00a011.12% \u00a0\u00a0\nOperating expenses \u00a0\u00a09.01% \u00a0\u00a08.38% \u00a0\u00a0\nOperating income \u00a0\u00a02.52% \u00a0\u00a02.73% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.52% \u00a0\u00a03.66% \u00a0\u00a0\nOperating expenses \u00a0\u00a02.57% \u00a0\u00a02.45% \u00a0\u00a0\nOperating income \u00a0\u00a00.95% \u00a0\u00a01.21% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55% \u00a0\u00a03.61% \u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23% \u00a0\u00a02.19% \u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.32% \u00a0\u00a01.42% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0 March 31, \u00a0September 30,\n21", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "21", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "368884fa-8c24-4580-9d20-e4b1e224b1ed": {"node_ids": ["5a968815-008f-4b6d-8342-c72bcee134b9"], "metadata": {"window": "\u00a0 \u00a02023 \u00a0\u00a02022\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,539,406 \u00a0$3,388,189\nAccounts receivable, net \u00a019,491,097 \u00a0\u00a018,452,675\nInventories \u00a016,955,245 \u00a0\u00a015,556,394\nRight to recover assets \u00a01,480,545 \u00a0\u00a01,532,061\nPrepaid expenses and other \u00a0523,348 \u00a0\u00a0660,439\nTotal current assets \u00a039,989,641 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,149,937 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a014,518,383 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0228,524 \u00a0\u00a0237,571\nOther long-term assets \u00a01,879,698 \u00a0\u00a01,761,661\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $58,766,183 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $42,734,822 \u00a0$40,192,890\nOther current liabilities \u00a02,069,996 \u00a0\u00a02,214,592\nShort-term debt \u00a0266,279 \u00a0\u00a01,070,473\nTotal current liabilities \u00a045,071,097 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,666,532 \u00a0\u00a04,632,360\n22", "original_text": "\u00a0 \u00a02023 \u00a0\u00a02022\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,539,406 \u00a0$3,388,189\nAccounts receivable, net \u00a019,491,097 \u00a0\u00a018,452,675\nInventories \u00a016,955,245 \u00a0\u00a015,556,394\nRight to recover assets \u00a01,480,545 \u00a0\u00a01,532,061\nPrepaid expenses and other \u00a0523,348 \u00a0\u00a0660,439\nTotal current assets \u00a039,989,641 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,149,937 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a014,518,383 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0228,524 \u00a0\u00a0237,571\nOther long-term assets \u00a01,879,698 \u00a0\u00a01,761,661\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $58,766,183 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $42,734,822 \u00a0$40,192,890\nOther current liabilities \u00a02,069,996 \u00a0\u00a02,214,592\nShort-term debt \u00a0266,279 \u00a0\u00a01,070,473\nTotal current liabilities \u00a045,071,097 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,666,532 \u00a0\u00a04,632,360\n22", "page_label": "22", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "552c9223-006f-4978-9615-5ff41f28d8d1": {"node_ids": ["bbc1e5b9-4452-463f-8125-8a4f650a3355"], "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0272,292 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,741,795 \u00a0\u00a01,620,413\nOther long-term liabilities \u00a01,055,255 \u00a0\u00a0976,583\nAccrued litigation liability \u00a05,448,075 \u00a0\u00a05,461,758\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0511,137 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $58,766,183 \u00a0$56,560,616\nAMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0Six Months Ended\nMarch 31,\n\u00a0 \u00a02023 \u00a0\u00a02022\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $904,383 \u00a0$1,004,661\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0527,840 \u00a0\u00a0423,420\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(861,202) \u00a0\u00a0(527,521)\nInventories \u00a0(1,413,515) \u00a0\u00a0(215,479)\nAccounts payable \u00a02,391,172 \u00a0\u00a0598,411\nOther, net \u00a0(209,090) \u00a0\u00a0(153,496)\nNet cash provided by operating activities \u00a01,339,588 \u00a0\u00a01,129,996\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(178,581) \u00a0\u00a0(209,343)\n23", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0272,292 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,741,795 \u00a0\u00a01,620,413\nOther long-term liabilities \u00a01,055,255 \u00a0\u00a0976,583\nAccrued litigation liability \u00a05,448,075 \u00a0\u00a05,461,758\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0511,137 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $58,766,183 \u00a0$56,560,616\nAMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0Six Months Ended\nMarch 31,\n\u00a0 \u00a02023 \u00a0\u00a02022\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $904,383 \u00a0$1,004,661\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0527,840 \u00a0\u00a0423,420\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(861,202) \u00a0\u00a0(527,521)\nInventories \u00a0(1,413,515) \u00a0\u00a0(215,479)\nAccounts payable \u00a02,391,172 \u00a0\u00a0598,411\nOther, net \u00a0(209,090) \u00a0\u00a0(153,496)\nNet cash provided by operating activities \u00a01,339,588 \u00a0\u00a01,129,996\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(178,581) \u00a0\u00a0(209,343)\n23", "page_label": "23", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "42c6c531-bc0a-4846-8dee-a086f06147b8": {"node_ids": ["eef444bc-bb42-4857-98f7-8d51aad2c7bc", "cbb30748-962e-4282-903e-1160d57593f0", "beda0a27-823d-4e70-85e2-209790d00459"], "metadata": {"window": "Cost of acquired companies, net of cash acquired 1 \u00a0(1,409,681) \u00a0\u00a0(124,158)\nOther, net \u00a0(11,633) \u00a0\u00a0(3,663)\nNet cash used in investing activities \u00a0(1,599,895) \u00a0\u00a0(337,164)\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(685,101) \u00a0\u00a0(208,790)\nPurchases of common stock 2 \u00a0(807,214) \u00a0\u00a0(11,396)\nExercises of stock options \u00a031,712 \u00a0\u00a072,973\nCash dividends on common stock \u00a0(201,479) \u00a0\u00a0(197,923)\nEmployee tax withholdings related to restricted share vesting \u00a0(67,954) \u00a0\u00a0(35,200)\nOther, net \u00a0(3,355) \u00a0\u00a0(4,251)\nNet cash used in financing activities \u00a0(1,733,391) \u00a0\u00a0(384,587)\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a088,822 \u00a0\u00a0(5,055)\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within assets\nheld for sale \u00a0(1,904,876) \u00a0\u00a0403,190\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0(516)\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,904,876) \u00a0\u00a0402,674\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3 \u00a03,593,539 \u00a0\u00a03,070,128\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3 $1,688,663 \u00a0$3,472,802\n________________________________________\n1 Includes $1,406.3 million for the acquisition of PharmaLex. \n  2 Includes $28.4 million of purchases in September 2022 that cash settled in October 2022. \n  3 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n24", "original_text": "Cost of acquired companies, net of cash acquired 1 \u00a0(1,409,681) \u00a0\u00a0(124,158)\nOther, net \u00a0(11,633) \u00a0\u00a0(3,663)\nNet cash used in investing activities \u00a0(1,599,895) \u00a0\u00a0(337,164)\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(685,101) \u00a0\u00a0(208,790)\nPurchases of common stock 2 \u00a0(807,214) \u00a0\u00a0(11,396)\nExercises of stock options \u00a031,712 \u00a0\u00a072,973\nCash dividends on common stock \u00a0(201,479) \u00a0\u00a0(197,923)\nEmployee tax withholdings related to restricted share vesting \u00a0(67,954) \u00a0\u00a0(35,200)\nOther, net \u00a0(3,355) \u00a0\u00a0(4,251)\nNet cash used in financing activities \u00a0(1,733,391) \u00a0\u00a0(384,587)\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a088,822 \u00a0\u00a0(5,055)\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within assets\nheld for sale \u00a0(1,904,876) \u00a0\u00a0403,190\nLess: Increase in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0(516)\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,904,876) \u00a0\u00a0402,674\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 3 \u00a03,593,539 \u00a0\u00a03,070,128\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 3 $1,688,663 \u00a0$3,472,802\n________________________________________\n1 Includes $1,406.3 million for the acquisition of PharmaLex. \n ", "page_label": "24", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ee046645-a402-466b-bb1a-bb5f0f792a30": {"node_ids": ["3bd1824e-1d27-4e6f-a619-d37f0aff50dc", "cb547f50-97a8-4e90-aebf-636289a27e38", "48034cb2-dd85-4d2c-baff-c2d776e3119f", "0acfc997-ba63-4a15-9a2c-e9aa3d3a5452", "de202494-c94f-4af4-a438-26f66d13da97", "b71e5118-d76f-47fd-958b-ee4d12cd83a3", "cd076787-9e8c-49e5-89ec-fc2e53dc6d75", "6ce1ed0f-4c05-4137-905d-9a5074082f61", "7f19e3c6-d67b-4d4e-ba48-ca198e3ba775", "cac545f6-e45a-4d17-b33d-5acda567295b", "02a982a6-3c49-489d-94e3-6b51a086f508", "88adbd8f-4b47-4beb-8f5c-a97614f4f38c", "5a15de15-ef42-404b-b43e-8ddaffda031e", "09265200-330a-4ec5-8582-5dd90953f47c", "675a98fa-7930-4554-8629-212e8fb751d3", "149a6d34-fb26-463f-9202-51826495a1ed", "f5391c3f-27ed-42ad-b330-d43be4e7a941", "95ebc054-9b60-4e84-a4d6-00fb0323b2c6", "e81820cb-8bdb-4624-ad2a-103b7839eb5f", "fc499630-bb64-4ac3-acc3-34e9d5abb2e4", "8be5db23-7493-4ac3-aedb-84cff14f8063"], "metadata": {"window": "\u00a0 \u00a0March 31, \n2023 \u00a0September\n30, \n2022 \u00a0March 31, \n2022 \u00a0September\n30, \n2021\nCash and cash equivalents \u00a0$1,539,406 \u00a0$3,388,189 \u00a0$2,960,759 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a087,740 \u00a0\u00a0144,980 \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a061,517 \u00a0\u00a060,370 \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,688,663 \u00a0$3,593,539 \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "\u00a0 \u00a0March 31, \n2023 \u00a0September\n30, \n2022 \u00a0March 31, \n2022 \u00a0September\n30, \n2021\nCash and cash equivalents \u00a0$1,539,406 \u00a0$3,388,189 \u00a0$2,960,759 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a087,740 \u00a0\u00a0144,980 \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a061,517 \u00a0\u00a060,370 \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,688,663 \u00a0$3,593,539 \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "25", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a987d23b-8858-4688-baaf-029e2c3bd9be": {"node_ids": ["dc5e9606-cf52-4384-8e32-f5e88271c1de", "cf19bdd2-48a8-4a6d-bacd-87c814b4e41c", "c35762f9-d1d9-4a9f-bbea-e81d30f019fd", "20713742-60f5-4f4c-b86a-b7be54d26e82", "2cdbe09c-0a5e-47bc-9ee4-ea983b1e2bb3", "3d75522d-4d17-4d32-bd6e-57bc5ce4ce5e", "e3bcaeac-10b7-42cd-8451-8659894b0d96", "f93c21b1-db84-4a30-ba7c-929c8688fc05", "f9fe768f-31e3-481c-adc8-99d9ef943842", "1117b6e6-8db1-4a12-8519-0f952d735a34", "aaeb1452-24fa-4708-be4e-1eb1683d928a", "0774fa4d-38cb-4855-a576-98ca28aca4d3", "303a2539-fb13-4145-9619-915e4ef9ce1b", "381fa99f-09bb-4b27-bcc5-2b1e4949219e", "07608cd4-15d9-4686-8f00-14fadc66b6b5", "acc19a3f-8a0e-48a8-bc11-6f2ab1c2eea8", "0d8e64ce-dfeb-4eff-9175-b72950e0452e", "3a7b5840-dc0f-4484-bfd4-54f37a1bae36", "f09e9ad0-49be-4e3a-8dbf-6680f8bf620b", "a405dff4-a395-4fad-a622-042253319e18", "095eb7e6-b986-467f-a0bd-ad4f8d898f86"], "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable, a foreign currency gain, and the gain (loss) on the currency remeasurement of the deferred tax\nasset relating to Swiss tax reform are excluded from adjusted income before income taxes because these amounts are\nunusual, non-operating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors\nbecause it facilitates the calculation of the Company\u2019s adjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "26", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0424d274-5fca-4e18-8a4d-973d57f1117e": {"node_ids": ["dd812978-96ad-4d91-9f78-556450ed5596", "1d38f63d-7b2c-46e2-a3f6-b23b70a2bc23", "d6275d57-0f30-485b-8937-78d333327af0", "a32c172d-d905-463e-a71c-55e3040c8457", "1a367bfe-4315-4db3-ba2b-83401b7f4c64", "a7c01f88-ed76-4605-9a3f-d0c57e7c275f", "49ea5a94-dc1d-4d55-b7c0-52e173fca5b8", "06cb0dbc-6b7a-4e8b-9432-a00e1b45b12d", "023ce815-ae13-40ab-a1df-1c9d8d31dc39", "2cdcf985-051c-4433-8d3f-395748d61003"], "metadata": {"window": "GAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. ", "original_text": "GAAP financial measure. ", "page_label": "27", "file_name": "CEN-Q2-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 235409, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}